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Abstract	  
	  
Mutations	   in	   the	   skeletal	   muscle	   sarcoplasmic	   reticulum	   calcium	   release	   channel	  
(RYR1)	   have	   been	   identified	   in	   association	   with	   malignant	   hyperthermia	   (MH)	   and	  
exertional	   heat	   stroke	   (EHS).	   	   MH	   is	   a	   pharmacogenetic	   disorder	   in	   which	  
hypermetabolism	   is	   triggered	   upon	   exposure	   to	   volatile	   anaesthetics.	   	  MH	   has	   long	  
been	   linked	   with	   EHS,	   a	   life	   threatening	   increase	   in	   body	   temperature	   caused	   by	  
strenuous	   exercise	   in	   warm	   climates	   with	   both	   conditions	   being	   caused	   by	   a	  
deregulation	  of	  skeletal	  muscle	  calcium	  homeostasis.	  	  The	  availability	  of	  genetic	  testing	  
in	  MH	  is	  limited	  to	  variants	  that	  have	  been	  proven	  to	  alter	  calcium	  handling	  in	  vitro.	  
In	   this	   thesis,	   data	   on	   the	   functional	   consequences	   of	   seven	  RYR1	   variants	   found	   in	  
association	  with	  MH	  are	  presented,	  one	  of	  which	  has	  also	  been	   identified	   in	  an	  EHS	  
patient.	   	   Site-­‐directed	  mutagenesis	  was	  used	   to	   introduce	   the	  variants	   into	  a	  human	  
RYR1	  cDNA	  clone	  before	  expressing	  wild	  type	  and	  mutant	  constructs	  in	  HEK293	  cells.	  	  
Six	   of	   the	   variants,	   including	   the	   EHS	   mutation,	   were	   found	   to	   have	   an	   increased	  
sensitivity	   to	   caffeine	   as	   evidenced	   through	   a	   significant	   decrease	   in	   EC50	   as	  well	   as	  
exaggerated	   calcium	   release	   at	   low	   doses	   of	   caffeine	   as	   compared	   to	   wild	   type	  
controls.	   	   For	   one	   variant,	   p.D3986E,	   an	   increase	   in	   RYR1	   expression	   was	   required	  
before	   the	   phenotype	   resembled	   the	   other	   RYR1	   variants,	   hinting	   at	   a	   more	  
complicated	  role	  in	  MH	  for	  this	  variant.	  
The	   functional	  data	  presented	   in	   this	   thesis	   is	   supportive	  of	   the	  addition	  of	   six	  RYR1	  
variants	  onto	  the	  genetic	  diagnostic	  panel	  for	  MH,	  increasing	  the	  availability	  of	   initial	  
genetic	   testing	   by	   19%.	   	   Furthermore,	   the	  work	   presented	   further	   supports	   the	   link	  
between	  MH	  and	  EHS	  through	  the	  presence	  of	  a	  common	  RYR1	  variant	  proven	  to	  alter	  
calcium	  handling.	  	  Finally,	  data	  obtained	  for	  the	  p.D3986E	  variant	  lays	  the	  foundation	  
for	  future	  studies	  aiming	  to	  identify	  genetic	  modifiers	  of	  the	  MH	  phenotype.	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Chapter	  One -­‐	  Introduction	  
1.1	  First	  reported	  case	  of	  malignant	  hyperthermia	  
Malignant	   hyperthermia	   (MH)	   is	   a	   rare,	   pharmacogenetic	   disorder	   in	  which	   volatile,	  
inhalational	   anaesthetics	   and	  depolarising	  muscle	   relaxants	   trigger	   a	   hypermetabolic	  
reaction	  in	  susceptible	  individuals.	   	  The	  first	  case	  of	  MH	  was	  reported	  in	  a	  previously	  
healthy	  21-­‐year-­‐old	  male	  who	  underwent	  surgery	  to	  repair	  a	  fractured	  tibia	  and	  fibula	  
(Denborough	  et	  al.,	  1962).	  	  The	  patient	  reported	  that	  a	  number	  of	  his	  family	  had	  died	  
during	   surgery	  when	   anaesthetised	  using	   ether.	   	   The	   surgery	  went	   ahead	   cautiously	  
using	  halothane	  instead,	  however,	  ten	  minutes	   into	  the	  operation,	  the	  patient	  began	  
having	  what	  would	  soon	  become	  recognised	  as	  an	  MH	  crisis.	   	  The	  blood	  pressure	  of	  
the	   patient	   dropped,	   his	   pulse	   rose	   and	   temperature	   increased	   rapidly,	   the	   surgery	  
was	  concluded	  quickly,	  the	  use	  of	  halothane	  was	  discontinued	  and	  aggressive	  cooling	  
procedures	   commenced	   resulting	   in	   the	   recovery	   of	   the	   patient	   over	   a	   period	  of	   90	  
minutes.	  	  	  
	  
1.2	  Symptoms	  and	  treatment	  of	  MH	  
In	  the	  years	  since	  the	  first	  reported	  case,	  the	  pathogenesis	  of	  an	  MH	  crisis	  has	  become	  
better	   defined.	   	   Early	   clinical	   features	   include	   masseter	   spasm,	   tachypnoea	   and	  
tachycardia,	   which	   are	   often	   followed	   by	   an	   increase	   in	   temperature,	   cyanosis	   and	  
generalised	  muscle	  rigidity.	  	  Additional	  symptoms	  include	  an	  increased	  creatine	  kinase	  
level,	  rhabdomyolysis,	  hyperkalaemia,	  hypoxaemia,	  metabolic	  and	  respiratory	  acidosis	  
and,	  if	  not	  treated	  promptly,	  death	  (Hopkins,	  2000).	   	  The	  number,	  severity	  and	  onset	  
of	  symptoms	  that	  manifest	  during	  an	  MH	  crisis	  vary	  between	  patients	  and	  are	  partly	  
dependent	  on	   the	  duration	  of	  anaesthesia,	   type	  of	  anaesthetic	  used	  and	   the	  patient	  
themselves.	  	  Additionally,	  previous,	  uneventful	  anaesthesia	  is	  not	  an	  indicator	  of	  being	  
unsusceptible	   to	   MH;	   in	   some	   instances	   an	   MH	   reaction	   occurs	   after	   several	  
anaesthetics	  with	  triggering	  drugs.	  	  During	  an	  MH	  crisis,	  the	  most	  frequently	  observed	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sign	   is	   respiratory	   acidosis.	   	   There	   are	   a	   median	   of	   four	   clinical	   signs	   present	   with	  
hypercarbia,	   masseter	   spasm	   and	   tachycardia	   the	   most	   common	   first	   signs	   of	   a	  
reaction,	   which,	   in	   many	   cases,	   begin	   less	   than	   a	   minute	   after	   the	   induction	   of	  
anaesthesia	  (Larach	  et	  al.,	  2010).	  	  
The	   symptoms	   triggered	   by	   an	   MH	   episode	   can	   be	   attributed	   to	   a	   deregulation	   of	  
calcium	   homeostasis	   in	   skeletal	   muscle	   (MacLennan	   and	   Phillips,	   1992,	   Ryan	   et	   al.,	  
1994,	  Hopkins,	  2000).	  MH-­‐inducing	  anaesthetics	   trigger	  uncontrolled	  calcium	  release	  
from	   the	   sarcoplasmic	   reticulum	   (SR)	   of	   the	   muscle	   cells	   resulting	   in	   muscle	  
contracture	   and	   the	   associated	   muscle	   rigidity	   observed	   in	   MH	   patients.	   	   Cellular	  
systems	   for	   the	   sequestration	   of	   calcium	   are	   eventually	   overwhelmed.	   Adenosine	  
triphosphate	   (ATP)	   is	   required	   to	  pump	   intracellular	   calcium	  back	   into	   the	  SR	  stores.	  	  
As	   this	   happens,	   it	   is	   broken	   down	   into	   adenosine	   diphosphate	   and	   inorganic	  
phosphate	  which	   stimulates	  glycolysis	   and	  oxidative	  phosphorylation.	   	   The	  depletion	  
of	   ATP	   during	   this	   process	   also	   stimulates	   the	   respiratory	   systems	   to	   produce	  more	  
ATP,	  further	  increasing	  metabolism.	  	  Hypermetabolic	  activity	  results	  in	  respiratory	  and	  
lactic	   acidosis	   and	   an	   excess	   of	   heat	   production	  which	   feeds	   back	   causing	   a	   further	  
increase	  in	  metabolic	  activity.	  
To	   date,	   the	   only	   commercially	   available	   drug	   to	   tackle	   an	   MH	   reaction	   during	  
anaesthesia	   is	   dantrolene	   (Kolb	   et	   al.,	   1982).	   	   Dantrolene	   dramatically	   reverses	   the	  
symptoms	   of	   patients	   undergoing	   an	  MH	   crisis	   during	   anaesthesia	  whilst	   possessing	  
relatively	   little	   side	   effects.	   	   Dantrolene	   prevents	   an	   MH	   reaction	   through	   the	  
reduction	   of	   the	   baseline	   resting	   calcium	   level	   of	   muscle	   fibres,	   which	   in	   MH	  
susceptible	  muscle	  is	  elevated	  above	  a	  wild	  type	  level	  (Lopez	  et	  al.,	  1985a,	  Lopez	  et	  al.,	  
1985b,	  Lopez	  et	  al.,	  1988).	   	  Following	  the	   introduction	  of	  dantrolene,	  mortality	   rates	  
from	  MH	   dropped	   from	   75%	   of	   patients	   experiencing	   an	  MH	   crisis	   to	   around	   2-­‐3%	  
(Jurkat-­‐Rott	   et	   al.,	   2000).	   	   Nevertheless,	   a	   reliable	   way	   of	   screening	   patients	  
preoperatively	  for	  MH	  is	  not	  available,	  unless	  the	  family	  is	  already	  under	  investigation	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by	  an	  MH	  unit	  and	  MH	  therefore,	  still	  presents	  a	  serious	  threat	  to	  otherwise	  healthy	  
patients	  undergoing	  general	  anaesthesia.	  
	  
1.3	  The	  in	  vitro	  contracture	  test	  
The	   in	   vitro	   contracture	   test	   (IVCT)	   is	   the	   current	   gold	   standard	   method	   used	   to	  
diagnose	   susceptibility	   to	   MH	   in	   which	   muscle	   biopsy	   specimens	   are	   exposed	   to	  
incremental	  doses	  of	  caffeine	  and	  halothane	  as	  a	  diagnostic	  indicator	  of	  probands	  and	  
their	   families	   who	   have	   suffered	   an	  MH	   crisis	   (Kalow,	   1970,	   Ellis	   et	   al.,	   1971).	   The	  
European	   Malignant	   Hyperthermia	   Group	   (EMHG)	   uses	   a	   standardised	   protocol	   for	  
three	   procedures	   carried	   out	   on	   viable	   muscle	   specimens	   of	   patients	   under	  
investigation	   for	   MH	   (Ellis,	   1984).	   	   Static	   tests	   for	   both	   caffeine	   and	   halothane	   are	  
performed	   by	   exposing	   muscle	   specimens	   to	   incremental	   concentrations	   of	   the	  
stimulant	  (0.25mM	  to	  4mM	  for	  caffeine	  and	  0.5%	  volume	  per	  volume	  (v/v)	  to	  2%	  v/v	  
for	  halothane).	  	  Successive	  concentrations	  are	  added	  after	  the	  specimen	  has	  reached	  a	  
contracture	   plateau	   from	   the	   previous	   stimulation	   (Figure	   1.1).	   	   In	   the	   dynamic	  
halothane	  test,	  a	  muscle	  specimen	  is	  exposed	  to	  the	  same	  incremental	  concentrations	  
of	   halothane	   but	   they	   are	   added	   at	   the	   end	   of	   a	   cycle	   consisting	   of	   stretching	   the	  
muscle	  at	  a	  rate	  of	  4mm	  per	  minute	  for	  90	  seconds,	  holding	  the	  muscle	  at	  this	  tension	  
and	   releasing	   at	   the	   same	   speed.	   	   A	   positive	   diagnosis	   of	   an	  MH	   susceptible	   (MHS)	  
individual	  is	  made	  on	  the	  basis	  of	  the	  muscle	  samples	  giving	  a	  sustained	  contracture	  of	  
0.2g	  at	  or	  below	  2mM	  caffeine	  or	  2%	  halothane	   for	  all	   tests.	   	  An	  MH	  normal	   (MHN)	  
diagnosis	  is	  given	  if	  this	  criterion	  is	  not	  met.	  	  A	  third	  diagnosis	  of	  MH	  equivocal	  is	  given	  
if	   the	   contracture	   is	  met	   for	   only	   one	   of	   the	   caffeine	   or	   halothane	   tests	   (MHEc	   and	  
MHEh	  respectively).	  	  	  
The	  malignant	  hyperthermia	  association	  of	  the	  United	  States	  (MHAUS)	  uses	  a	  different	  
protocol	   for	   the	   diagnosis	   of	   MH	   termed	   the	   caffeine/halothane	   contracture	   test	  
(CHCT)	   but	   still	   takes	   advantage	   of	   the	   sensitivity	   of	   MH	   muscle	   to	   halothane	   and	  
caffeine	   (Rosenberg,	   1989,	  Melton	   et	   al.,	   1989,	   Larach,	   1989).	   	   The	   CHCT	   involves	   a	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single	  exposure	  to	  3%	  halothane	  as	  well	  as	  incremental	  doses	  of	  caffeine	  similar	  to	  the	  
EMHG	   IVCT.	   A	   positive	   diagnosis	   is	   given	   when	   the	   muscle	   specimen	   reacts	   with	   a	  
minimal	   contracture	  of	  0.5g	  at	   a	   concentration	  of	  3%	   for	  halothane	  or	  0.2g	  at	  2mM	  
caffeine.	  	  	  
An	   additional	   test,	   which	   can	   be	   optionally	   included	   as	   part	   of	   the	   EMHG	   IVCT	  
protocol,	   is	   the	  ryanodine	  test	   (Hopkins	  et	  al.,	  1991b).	   	  This	   involves	  the	  exposure	  of	  
fresh	   muscle	   specimens	   to	   ryanodine,	   a	   plant	   alkaloid	   that	   shows	   dose	   dependent	  
responses	  in	  normal	  skeletal	  muscle	  from	  both	  rats	  and	  pigs	  (Sutko	  et	  al.,	  1997).	  	  The	  
muscle	  specimen	  is	  held	  in	  a	  bath	  containing	  1µM	  of	  Krebs	  solution.	  	  A	  positive	  test	  is	  
one	  in	  which	  a	  contraction	  is	  observed	  in	  the	  presence	  of	  ryanodine.	  
	  
1.4	  The	  genetics	  of	  MH	  
1.4.1	  Porcine	  stress	  syndrome	  
Pigs	  suffer	  a	  similar	  reaction	  to	  human	  MH,	  called	  porcine	  stress	  syndrome	  (PSS)	  when	  
exposed	   to	   high	   levels	   of	   stress	   encountered	   before	   slaughter	   as	   well	   as	   with	  MH-­‐
triggering	  drugs	  (Otsu	  et	  al.,	  1994,	  Mitchell	  and	  Heffron,	  1982).	  	  Similarly	  to	  MH,	  PSS	  is	  
caused	  by	  a	  deregulation	  of	  calcium	  homeostasis	  in	  skeletal	  muscle,	  more	  specifically	  a	  
hypersensitive	   gating	   of	   the	   calcium	   release	   channel	   of	   skeletal	   muscle	   (O'Brien,	  
1986b,	  O'Brien,	  1986a).	  	  Isolation	  of	  a	  partial	  fragment	  of	  the	  skeletal	  muscle	  calcium	  
release	   channel,	   the	   type	   1	   ryanodine	   receptor	   (RYR1)	  mapped	   the	   gene	   to	   porcine	  
chromosome	   6p11-­‐q21	   (Harbitz	   et	   al.,	   1990),	   a	   region	   of	   synteny	   with	   human	  
chromosome	  19.	   	  Linkage	  studies	  from	  multiple	  human	  multi-­‐generation	  MH	  families	  
with	  markers	  across	  chromosome	  19	  and	  within	  RYR1	  itself	  located	  the	  disease	  gene	  to	  
chromosome	  19q12-­‐13.2	   firmly	  establishing	  RYR1	   as	   the	  primary	   candidate	   locus	   for	  
MH	   (McCarthy	  et	  al.,	   1990,	  MacLennan	  et	  al.,	   1990).	   	   Similarly	   to	   the	   search	   for	   the	  
disease	  loci,	  the	  first	  MH	  mutation	  was	  identified	  in	  PSS	  (Fujii	  et	  al.,	  1991,	  Otsu	  et	  al.,	  
1991).	   A	   C>T	   transition	   at	   nucleotide	   residue	   1843	   resulting	   in	   an	   amino	   acid	  
substitution	  of	  arginine	  to	  cysteine	   is,	   to	  date,	   the	  only	  RYR1	  variant	  associated	  with	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PSS.	  	  The	  human	  equivalent	  mutation	  was	  found	  to	  cosegregate	  with	  MH	  susceptibility	  
in	  a	  large	  Canadian	  family	  (Gillard	  et	  al.,	  1991).	  
	  
	  
Figure	  1.1	  –	  Static	  halothane	  IVCT	  traces	  
(A)	  Representative	  trace	  of	  a	  negative	  diagnosis	  for	  MH.	  	  Upon	  the	  addition	  of	  0.5%-­‐2%	  halothane	  (indicated	  on	  
the	  x-­‐axis),	  no	  increase	  in	  muscle	  tension	  is	  observed.	  	  (B)	  Representative	  trace	  of	  a	  positive	  diagnosis	  for	  MH.	  	  
Upon	  the	  addition	  of	  0.5%-­‐2%	  halothane	  (indicated	  on	  the	  x-­‐axis),	  a	  continuous	  increase	  in	  muscle	  tension	  is	  
observed.	  	  The	  next	  dose	  of	  halothane	  is	  added	  as	  the	  muscle	  tension	  begins	  to	  plateau	  after	  the	  addition	  of	  the	  
previous	  dose.	  	  Image	  of	  diagnostic	  traces	  kindly	  provided	  by	  Dr.	  P.	  J.	  Halsall.	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1.4.2	  The	  type	  1	  ryanodine	  receptor	  (RYR1)	  
1.4.2.1	  Structure	  and	  function	  of	  RYR1	  
RYR1	  is	  the	  SR	  calcium	  release	  channel	  in	  skeletal	  muscle	  and	  is	  one	  of	  three	  ryanodine	  
receptor	  isoforms	  in	  humans,	  with	  RYR2	  being	  the	  primary	  isoform	  of	  smooth	  muscle	  
and	  RYR3	  being	  expressed	  in	  the	  brain.	  	  The	  RYR1	  gene	  spans	  160	  kilobase	  pairs	  (kb)	  of	  
deoxyribose	  nucleic	  acid	  (DNA)	  on	  chromosome	  19q13.2	  and	  contains	  106	  exons	  with	  
a	   total	   of	   15,391	   base	   pairs	   (bp)	   of	   coding	   sequence	   (Phillips	   et	   al.,	   1996).	   	   The	  
resultant	   5,038	   amino	   acid	   RYR1	   protein	   functions	   as	   a	   homotetramer	   with	   each	  
subunit	   having	   a	   mass	   of	   563	   kilodaltons	   (kDa),	   making	   it	   the	   largest	   ion	   channel	  
known	  and	  one	  of	  the	  largest	  proteins	  in	  the	  human	  body.	  	  Early	  predictions	  based	  on	  
sequence	   motifs	   of	   the	   RYR1	   protein	   suggested	   a	   structure	   that	   is	   primarily	  
cytoplasmic	  at	  the	  N-­‐terminal	  end	  followed	  by	  8	  transmembrane	  domains	  and	  a	  much	  
smaller	  C-­‐terminal	  cytoplasmic	  region	  (Figure	  1.2)	  (Du	  et	  al.,	  2002).	   	  Subsequent	  cryo-­‐
electron	  microscopy	  experiments	   revealed	  a	  mushroom-­‐like	   structure	  with	  over	  80%	  
of	  the	  mass	  in	  the	  cytoplasm	  (Ludtke	  et	  al.,	  2005,	  Serysheva	  et	  al.,	  2005,	  Samso	  et	  al.,	  
2005).	   	  Upon	   activation,	   RYR1	  undergoes	   a	   large	   conformational	   change	   resulting	   in	  
channel	   opening.	   	   Protein	   structures	   of	   open	   and	   closed	   states	   of	   the	   RYR1	   protein	  
indicate	   that	   upon	   activation,	   the	   inner	   helices	   of	   the	   transmembrane	   domains	  
undergo	  a	  conformational	  change	  by	  rotating	  to	  expand	  the	  diameter	  of	   the	  calcium	  
pore,	  allowing	  calcium	  release	  (Serysheva	  et	  al.,	  1999,	  Samso	  et	  al.,	  2009).	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Figure	  1.2	  –	  Schematic	  representation	  of	  one	  subunit	  of	  the	  RYR1	  protein	  tetramer	  
The	  majority	  of	  RYR1	  is	  in	  the	  cytoplasm	  followed	  by	  a	  total	  of	  8	  transmembrane	  (TM)	  regions	  between	  amino	  
acids	  4277	  and	  4953	  before	  another,	  much	  smaller	  cytosolic	  region	  at	  the	  C-­‐terminus	  of	  the	  protein.	  	  The	  calcium	  
pore	  is	  predicted	  to	  lie	  between	  TM7	  and	  8.	  Based	  on	  information	  in	  Du	  et	  al.	  (2002).	  
	  
	  
Allosteric	   gating	   of	   RYR1	   during	   excitation-­‐contraction	   (EC)	   coupling	   is	   primarily	  
triggered	  through	   interactions	  of	   the	  N-­‐terminal	  cytoplasmic	   region	  with	   the	  skeletal	  
muscle	  voltage	  sensors,	  the	  alpha-­‐1	  subunit	  (CaV1.1)	  of	  the	  dihydropyridine	  receptors	  
(DHPRs)	  (Figure	  1.3).	  	  	   	   	  After	  transmission	  of	  an	  action	  potential	  from	  the	  motor	  end	  
plate	   of	   a	   neuron	   to	   the	   sarcolemmal	   membrane,	   a	   wave	   of	   depolarisation	   travels	  
along	   the	   membrane	   and	   down	   the	   transverse	   tubules	   (T-­‐Tubules)	   to	   the	   DHPRs.	  	  
CaV1.1	   detects	   the	   voltage	   change,	   which	   causes	   a	   conformational	   change	   in	   the	  
protein,	  in	  particular	  a	  projection	  of	  a	  region	  called	  the	  II-­‐III	  loop	  to	  into	  the	  cytoplasm	  
of	   the	   muscle	   fibre	   to	   directly	   interact	   with	   RYR1	   causing	   channel	   opening	   and	  
subsequent	  muscle	  contraction	  (Cherednichenko	  et	  al.,	  2004).	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Figure	  1.3	  –	  Schematic	  showing	  excitation-­‐contraction	  coupling	  in	  skeletal	  muscle.	  	  	  
(A)	  Skeletal	  muscle	  at	  rest.	  	  The	  majority	  of	  cellular	  calcium	  (Ca2+)	  is	  in	  the	  sarcoplasmic	  reticulum	  stores.	  	  (B)	  
When	  an	  action	  potential	  arrives	  at	  the	  motor	  end	  plate	  the	  signal	  is	  transmitted	  to	  the	  sarcolemmal	  membrane	  
and	  travels	  down	  the	  T-­‐Tubules	  to	  the	  DHPR.	  	  Electrical	  stimulation	  of	  the	  DHPR	  causes	  the	  II-­‐III	  loop	  to	  project	  
across	  the	  cytoplasm	  to	  interact	  with	  RYR1	  in	  the	  sarcoplasmic	  reticulum	  membrane.	  	  This	  interaction	  results	  in	  
the	  opening	  of	  RYR1	  allowing	  calcium	  to	  flood	  into	  the	  cytosol,	  subsequently	  leading	  to	  muscle	  contraction.	  	  (C)	  
After	  stimulation	  the	  sarco(endo)plasmic	  reticulum	  calcium	  ATPase	  (SERCA)	  pump	  actively	  transports	  calcium	  
ions	  back	  into	  the	  sarcoplasmic	  reticulum	  stores.	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1.4.2.2	  Mutations	  in	  RYR1	  associated	  with	  MH	  
Whilst	  only	  one	  mutation	  to	  date	  has	  been	  found	  in	  association	  with	  PSS,	  244	  variants	  
in	  RYR1	  are	  currently	  listed	  on	  the	  EMHG	  website	  (www.emhg.org).	  	  Of	  these	  variants	  
approximately	  36%	  are	  unique	  to	  the	  family	  in	  which	  they	  were	  found,	  however,	  in	  the	  
UK	  the	  p.G2434R	  variant	  accounts	  for	  almost	  half	  of	  MH	  cases	  and	  is	  also	  recurrent	  in	  
the	   US	   (Sei	   et	   al.,	   2004,	   Robinson	   et	   al.,	   2006).	   	   The	   frequency	   of	   particular	   RYR1	  
variants	   varies	   throughout	   the	   world	   with	   the	   second	   most	   common	   UK	   variant,	  
p.T2206M,	  being	  particularly	  prevalent	  in	  Germany	  (Brandt	  et	  al.,	  1999),	  whereas	  the	  
p.R2336H	  and	  p.V2168M	  variants	  are	  common	  in	  Switzerland	  (Girard	  et	  al.,	  2001b)	  and	  
the	  p.R614C	  variant	  recurrent	  in	  Italy	  and	  Canada	  (Gillard	  et	  al.,	  1991,	  Robinson	  et	  al.,	  
2003b).	   	  Whilst	   in	   these	  countries	  many	  of	   the	  MH	  cases	   can	  be	  attributed	   to	   these	  
variants,	  in	  Japan,	  China,	  Taiwan,	  Australia	  and	  New	  Zealand	  the	  majority	  of	  reported	  
cases	  of	  MH	  are	  due	  to	  variants	  unique	  to	  the	  families	  (Davis	  et	  al.,	  2002,	  Oyamada	  et	  
al.,	  2002,	  Yeh	  et	  al.,	  2005).	  	  Despite	  there	  being	  106	  reported	  cases	  in	  which	  the	  RYR1	  
variant	  identified	  is	  unique	  to	  that	  family,	  half	  of	  all	  MH	  cases	  reported	  up	  to	  2006,	  for	  
which	  an	  RYR1	  variant	  has	  been	  identified,	  have	  been	  found	  to	  be	  associated	  with	  the	  
p.R164C,	  p.G341R,	  p.R614C,	  p.R2163H,	  p.V2168M,	  p.T2206M,	  p.R2434H	  and	  p.R2458H	  
variants	   (Robinson	  et	   al.,	   2006).	  However,	  with	  MH	  being	  a	   rare	  disease,	  only	   a	   few	  
centres	   in	   the	  world	   specialise	   in	  mutation	   screening	   for	  MH	  and	   the	   frequencies	  of	  
certain	   variants	  may	   be	   biased	   by	   centres	   that	   have	   established	   thorough	   screening	  
programmes.	  	  As	  diagnostics	  of	  MH	  moves	  into	  next	  generation	  sequencing	  to	  identify	  
RYR1	   variants,	   variants	   previously	   thought	   to	   be	   unique	   to	   certain	   families	   may	   be	  
identified	  at	  a	  higher	  frequency.	  
	  
1.4.2.2.1	  Types	  of	  mutation	  found	  in	  RYR1	  associated	  with	  MH	  
The	   overwhelming	   majority	   of	   genetic	   variants	   in	   RYR1	   associated	   with	   MH	   are	  
missense	  mutations	  present	  in	  heterozygous	  form	  (Robinson	  et	  al.,	  2006).	  	  There	  are,	  
however,	  a	  number	  of	  cases	  in	  which	  patients	  are	  reported	  to	  be	  homozygous	  for	  the	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same	  variant	  as	  well	  several	  cases	  of	  compound	  heterozygous	  individuals,	  in	  which	  two	  
mutant	  alleles	  were	   inherited	  from	  two	  MHS	  parents	   (Lynch	  et	  al.,	  1997,	  Monnier	  et	  
al.,	  2002).	   	  As	  well	  as	  missense	  variants,	   there	  have	  been	  two	  reports	  of	  deletions	   in	  
RYR1	   associated	  with	  MH,	   one	   resulting	   in	   the	   absence	   of	   one	   amino	   acid	   from	   the	  
protein	  and	  the	  other	  resulting	  in	  a	  premature	  stop	  codon	  150	  amino	  acids	  before	  the	  
end	  of	  the	  protein	  (Sambuughin	  et	  al.,	  2001a,	  Robinson	  et	  al.,	  2006).	  	  The	  single	  amino	  
acid	  deletion	  results	  in	  a	  larger	  than	  normal	  electrically	  evoked	  contracture	  during	  IVCT	  
diagnosis	  hinting	  at	  a	  disruption	  of	  normal	  EC	  coupling.	  	  There	  are	  no	  functional	  data	  
available	  for	  the	  deletion	  mutation	  that	  results	   in	  a	  premature	  stop	  codon,	  however,	  
as	  it	  has	  been	  identified	  in	  conjunction	  with	  MH	  it	  appears	  to	  suggest	  that	  the	  level	  of	  
RYR1	  expression	   is	   critical	   for	  normal	   function	  and	  a	  defect	   in	   the	   level	  of	  wild	   type	  
RYR1	  expression	  may	  be	  pathogenic	  in	  some	  instances	  of	  MH.	  
	  
1.4.2.2.2	  Expression	  levels	  of	  RYR1	  and	  its	  role	  in	  MH	  pathogenesis	  
The	   exact	   effect	   of	   a	   differential	   level	   of	  wild	   type	   and	  mutant	  RYR1	   expression	   on	  
susceptibility	  to	  MH	  is	  not	  known.	  	  Evidence	  from	  other	  RYR1	  related	  myopathies	  such	  
as	  central	  core	  disease	  (CCD)	  and	  multiminicore	  disease	  (MmD)	  has	  suggested	  that	  a	  
decrease	  in	  RYR1	  expression	  may	  be	  responsible	  for	  the	  associated	  muscle	  weakness.	  	  
In	   core	   myopathies,	   monoallelic	   expression	   of	   a	   paternal	   RYR1	   variant	   has	   been	  
associated	  with	  a	  severe	  form	  of	  CCD	  (Zhou	  et	  al.,	  2006a).	  	  Additionally,	  a	  cryptic	  splice	  
site	  mutation	   in	  RYR1,	  which	  results	   in	  a	  drastic	  decrease	  of	  RYR1	   in	  skeletal	  muscle,	  
has	  been	  found	  in	  association	  with	  a	  severe	  form	  of	  MmD	  (Monnier	  et	  al.,	  2003).	  	  To	  
date,	  there	  is	  limited	  data	  on	  MH	  cases	  with	  RYR1	  expression	  level	  defects.	  	  There	  has	  
been	   a	   suggestion	   that	   in	   patients	   carrying	   RYR1	   variants	   associated	   with	   MH,	   an	  
upregulation	  of	  the	  wild	  type	  allele	  is	  evident,	  possibly	  as	  a	  compensatory	  mechanism	  
against	   the	  hypersensitivity	   and	   leakiness	  of	   the	  mutant	  RYR1	   channel	   (Grievink	  and	  
Stowell,	   2010).	   	   Recently,	   it	   has	   been	   suggested	   that	   epigenetic	   allelic	   silencing	  may	  
play	  a	  role	  in	  the	  overall	  inheritance	  of	  MH	  as	  affected	  fathers	  have	  significantly	  fewer	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affected	   daughters	   than	   sons	   however,	   there	   is	   no	   evidence	   to	   suggest	   that	   MH	  
pathogenesis	  is	  a	  result	  of	  allelic	  silencing	  of	  wild	  type	  RYR1	  in	  susceptible	  individuals	  
(Robinson	  et	  al.,	  2009).	  
Increasing	   the	   expression	   level	   of	  wild	   type	  RYR1	   in	  myotubes	  does	  not	   significantly	  
alter	   the	   caffeine	   sensitivity	  of	   the	   cells,	   nor	  does	   it	  have	  an	   impact	  on	   the	  baseline	  
resting	   calcium	   level	   present	   in	   the	   cytoplasm	   of	   the	   cells	   (Perez	   et	   al.,	   2005).	  	  
Interestingly	   however,	   a	   similar	   increase	   in	   RYR3	   expression	   results	   in	   a	   significant	  
increase	  in	  sensitivity	  to	  caffeine	  that	  is	  in	  line	  with	  an	  increase	  in	  resting	  calcium	  level.	  	  
MHS	   individuals	   have	   an	   elevated	  baseline	   resting	   calcium	   level	   associated	  with	  MH	  
mutations	   (Yang	  et	  al.,	  2007,	  Eltit	  et	  al.,	  2012a),	  which,	  upon	  correction	   to	  wild	   type	  
levels,	  reduces	  the	  sensitivity	  of	  mutant	  cells	  to	  channel	  activators	  (Lopez	  et	  al.,	  2005).	  	  
Although	  there	  is	  no	  data	  to	  date	  examining	  the	  effect	  of	  the	  expression	  level	  of	  wild	  
type	   or	   mutant	   RYR1	   on	   a	   higher	   resting	   calcium	   background,	   fluctuations	   in	  
expression	   of	   these	   alleles	   may,	   at	   least	   in	   part,	   explain	   the	   variability	   of	   the	  
penetrance	   and	   severity	   of	   an	  MH	   crisis	   in	   susceptible	   individuals	   upon	   exposure	   to	  
anaesthesia.	  	  Recently,	  a	  gene	  dosage	  effect	  has	  been	  observed	  in	  p.T4826I	  RYR1	  mice	  
with	  a	  clear	  rank	  order	  in	  severity	  of	  the	  observed	  phenotype	  (Barrientos	  et	  al.,	  2012).	  	  
Homozygous	  muscle	   fibres	  were	  significantly	  more	  affected	  than	  heterozygous	   fibres	  
suggesting	  that,	  for	  at	  least	  some	  variants,	  expression	  levels	  and	  gene	  dose	  of	  mutant	  
RYR1	  alleles	  may	  contribute	  to	  the	  severity	  of	  an	  MH	  reaction.	  	  
	  
1.4.2.2.3	  Mutation	  hot-­‐spots	  associated	  with	  MH	  
Since	   the	  discovery	  of	   the	   first	  mutation	   in	  RYR1,	   screening	  projects	   of	  MH	  patients	  
have	  continued	  to	  add	  to	  the	  list	  of	  potentially	  causative	  variants.	  	  Early	  in	  this	  search,	  
the	  idea	  of	  mutation	  hot	  spots	  focussed	  screening	  projects	  onto	  small	  sections	  of	  RYR1	  
as	  a	  means	  to	  offset	  the	  difficulties	  of	  screening	  a	  15kb	  gene.	  	   Initially,	  two	  mutation	  
hot	  spots	  were	  described,	  one	  at	  the	  N-­‐terminal	  region	  spanning	  from	  the	  cysteine	  at	  
residue	   35	   to	   the	   arginine	   at	   residue	   614	   and	   one	   in	   the	   central	   region	   of	   RYR1	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covering	  a	  region	  of	  315	  amino	  acids	  between	  two	  arginine	  residues	  at	  positions	  2163	  
and	  2458	  (Jurkat-­‐Rott	  et	  al.,	  2000)	   (Figure	  1.4).	   	  A	   third	  hot	  spot	  was	  proposed	  after	  
the	  discovery	  of	  an	  RYR1	  variant	  in	  the	  C-­‐terminal	  region	  of	  the	  gene	  from	  the	  valine	  
residue	  at	  position	  4583	  to	  the	  glutamine	  at	  position	  4934	  (Lynch	  et	  al.,	  1999,	  Davis	  et	  
al.,	  2003).	  	  As	  sequencing	  technologies	  have	  improved,	  screening	  projects	  of	  the	  RYR1	  
gene	  have	  begun	  to	  identify	  a	  vast	  number	  of	  variants	  associated	  with	  MH,	  causing	  the	  
boundaries	  of	  the	  three	  mutation	  hot	  spots	  to	  expand	  to	  cover	  almost	  40%	  of	  the	  RYR1	  
coding	  sequence	  (Carpenter	  et	  al.,	  2009c).	  	  Robinson	  et	  al.	  (2006)	  outlined	  the	  spread	  
of	  mutations	   across	  RYR1	   indicating	   that	  no	  particular	  hot	   spot	  existed	  and	   that	   the	  
original	  theory	  was	  based	  on	  sequencing	  bias.	  	  	  
	  
	  
Figure	  1.4	  –	  The	  evolution	  of	  the	  RYR1	  mutation	  hot	  spot	  
Since	  the	  discovery	  of	  the	  first	  RYR1	  variant,	  screening	  projects	  were	  focussed	  on	  the	  areas	  in	  which	  variants	  had	  
already	  been	  found.	  	  This	  led	  to	  the	  postulation	  of	  a	  hot	  spot	  theory	  of	  MH.	  	  Originally	  only	  two	  hot	  spots	  (MHS1	  
and	  MHS2)	  at	  the	  N-­‐terminal	  region	  and	  central	  region	  of	  RYR1	  were	  proposed.	  	  This	  was	  subsequently	  expanded	  
to	  three	  hot	  spots	  upon	  the	  discovery	  of	  a	  variant	  in	  the	  C-­‐terminal	  portion	  of	  RYR1	  (MHS3).	  	  The	  proposed	  hot	  
spots	  have	  grown	  and	  now	  encompass	  almost	  40%	  of	  the	  entire	  coding	  sequence.	  	  
	  
	   13	  
1.5	  RYR1	  variants	  and	  their	  role	  in	  the	  pathogenesis	  of	  MH	  
1.5.1	  Structural	  defects	  in	  the	  RYR1	  protein	  
Variants	   in	   RYR1	   confer	   a	   hypersensitivity	   to	   activation	   and	   a	   passive	   calcium	   leak	  
resulting	   in	   a	   higher	   baseline	   resting	   calcium	   level	   (Tong	   et	   al.,	   1997,	   Tong	   et	   al.,	  
1999a,	   Yang	   et	   al.,	   2007,	   Yang	   et	   al.,	   2003).	   	   The	   mechanism	   by	   which	   missense	  
mutations	   in	   the	   large	   calcium	   channel	   can	   result	   in	   hypersensitive	   gating	   upon	  
stimulation	   is	   not	   entirely	   known.	   	   Early	   theories	   based	   on	   the	   idea	   of	   interacting	  
domains	  of	  the	  RYR1	  protein	  suggested	  that	  mutations	  result	  in	  a	  reduced	  stability	  of	  
these	   interactions	   leading	   to	   hypersensitivity	   and	   calcium	   leak	   (Yamamoto	   et	   al.,	  
2000).	  	  The	  hypothesis	  states	  that	  the	  gating	  of	  RYR1	  is	  dependent	  on	  the	  stability	  of	  
interacting	  domains	  in	  the	  large	  cytoplasmic	  N-­‐terminal	  region	  and	  central	  regions	  of	  
RYR1,	  roughly	  corresponding	  to	  the	  mutation	  hot	  spots	  suggested	  to	  exist	  in	  RYR1.	  	  
The	  advancement	  of	  protein	  structure	  technologies	  has	  enabled	  several	  mutations	  to	  
be	  mapped	  onto	  the	  structure	  of	  RYR1	  and	  caused	  an	  expansion	  of	  the	  early	  theories	  
of	   interdomain	   interactions.	   	   Mutations	   in	   RYR1	   appear	   to	   cluster	   around	   known	  
phosphorylation	  sites,	  regions	  of	  both	  intra-­‐	  and	  interdomain	  interactions	  and	  regions	  
that	   result	   in	   thermal	   instability	  of	   the	  native	  protein	   (Lobo	  and	  Van	  Petegem,	  2009,	  
Tung	  et	  al.,	  2010,	  Yuchi	  et	  al.,	  2012).	  	  Whilst	  the	  effect	  of	  a	  number	  of	  mutations	  may	  
be	   accounted	   for	   through	   the	   breakdown	   of	   internal	   interactions	   within	   RYR1	   it	  
appears	  unlikely	  that	  there	  is	  a	  model	  that	  fits	  all	  variants	  associated	  with	  MH.	  	  There	  
is	  evidence	  to	  suggest	  that	  certain	  mutations	  may	  not	  only	  affect	  the	  basic	  stability	  of	  
RYR1	  but	  also	  affect	  the	  proper	  functioning	  of	  Cav1.1	  (Esteve	  et	  al.,	  2010,	  Bannister	  et	  
al.,	  2010).	  	  Mutations	  in	  RYR1	  not	  only	  result	  in	  hypersensitivity	  of	  RYR1	  but	  also	  have	  
consequences	   for	   signalling	   to	   the	   DHPR	   for	   calcium	   entry	   into	   the	   muscle	   fibre.	  	  
Furthermore,	   the	   increased	   open	   probability	   of	   RYR1	   results	   in	   a	   retrograde	  
interaction	   with	   the	   DHPR,	   priming	   it	   for	   activation	   at	   lower	   voltages	   through	  
depolarisation.	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1.5.2	  Physiological	  defects	  caused	  by	  mutations	  in	  RYR1	  associated	  with	  MH	  
As	   well	   as	   resulting	   in	   structural	   defects	   in	   RYR1	   that	   affect	   signalling	   to	   and	   from	  
regulatory	  proteins	   involved	   in	  EC	  coupling,	  variants	   in	  RYR1	  appear	  to	  affect	  normal	  
skeletal	   muscle	   physiological	   processes	   that,	   when	   defective,	   may	   result	   in	   an	  
exacerbation	  of	  the	  MH	  phenotype	  upon	  triggering.	  
	  
1.5.2.1	  Store	  operated	  calcium	  entry	  
Store	  operated	   calcium	  entry	   (SOCE)	   is	   the	  process	  by	  which	   calcium	  enters	   the	   cell	  
after	   prolonged	   SR	   store	   depletion	   (Smyth	   et	   al.,	   2010)	   and	   works	   through	   the	  
interaction	   of	   two	   proteins,	   Orai1	   and	   STIM1.	   	   Orai1	   is	   a	   calcium	   release-­‐activated	  
channel	   (CRAC)	   localised	   in	   the	   plasma	   membrane	   that	   allows	   calcium	   entry	   upon	  
depletion	   of	   the	   SR	   stores.	   	   Activation	   of	   the	   Orai1	   CRAC	   is	   mediated	   through	   a	  
redistribution	  of	  STIM1	  in	  the	  SR	  membrane	  as	  a	  response	  to	  store	  depletion.	  	  STIM1	  is	  
a	   calcium	   sensing	   protein	   that	   is	   normally	   localised	   throughout	   the	   SR	   membrane,	  
however,	  upon	  depletion	  of	  the	  SR	  stores	  translocates	  to	  form	  punctate	  structures	  at	  
areas	   of	   the	   SR	   close	   to	   the	   plasma	  membrane	   allowing	   interaction	  with	   Orai1	   and	  
subsequent	  calcium	  entry	  (Figure	  1.5).	  	  	  
When	   MHN	   muscle	   fibres	   are	   exposed	   to	   MH-­‐triggering	   anaesthetics	   little	   or	   no	  
calcium	  is	  released	  from	  the	  SR	  stores,	  however,	  when	  MHS	  muscle	  fibres	  are	  exposed	  
to	  clinically	  relevant	  concentrations	  of	  halothane,	  sufficient	  calcium	  depletion	  from	  the	  
SR	  is	  achieved	  to	  activate	  SOCE	  (Duke	  et	  al.,	  2010).	  	  	  The	  additional	  calcium	  entry	  from	  
the	   intracellular	   space	   coupled	   with	   exaggerated	   calcium	   release	   from	   the	   SR	   may	  
contribute	   to	   the	   pathological	   increase	   in	   calcium	   associated	   with	   MH	   and	   partly	  
explain	  how	  an	  MH	  episode	  is	  maintained	  during	  anaesthesia.	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1.5.2.2	  Excitation-­‐coupled	  calcium	  entry	  
Excitation-­‐coupled	  calcium	  entry	  (ECCE)	  is	  a	  second	  mode	  of	  calcium	  entry	  in	  skeletal	  
muscle	   and	  occurs	   as	   a	   response	   to	  prolonged	  membrane	  depolarisation	  but,	   unlike	  
SOCE,	   ECCE	   is	   not	   dependent	   on	   store	   depletion	   for	   activation	   (Rosenberg,	   2009).	  	  	  
ECCE	  requires	  the	  interaction	  of	  RYR1	  and	  DHPR	  to	  permit	  the	  entry	  of	  calcium,	  most	  
likely	  through	  Cav1.1	  (Cherednichenko	  et	  al.,	  2004,	  Hurne	  et	  al.,	  2005,	  Bannister	  et	  al.,	  
2009)	  (Figure	  1.6).	  	  Mutations	  in	  RYR1	  associated	  with	  MH	  and	  in	  particular	  CCD	  show	  
an	   increase	   in	   ECCE	  which	   can	   be	   reversed	  with	   treatment	   with	   dantrolene,	   which,	  
similarly	   to	   SOCE	   may	   contribute	   to	   the	   prolonging	   of	   the	   MH	   phenotype	  
(Cherednichenko	  et	  al.,	  2008,	  Treves	  et	  al.,	  2011).	  
	  
1.5.2.3	  Sensitivity	  to	  calcium	  activation	  and	  magnesium	  inhibition	  
It	   has	   long	   been	   established	   that	   calcium	   has	   the	   ability	   to	   induce	   further	   calcium	  
release	  from	  ryanodine	  receptors.	  	  Whilst	  this	  calcium-­‐induced	  calcium	  release	  (CICR)	  
has	  a	  more	  prominent	   role	   in	   cardiac	  and	   smooth	  muscle	  EC	   coupling	   through	  RYR2	  
(Collier	  et	  al.,	  2000),	  RYR1	   is	  also	   sensitive	   to	  CICR	   (Endo,	  2009).	   	   In	   the	  presence	  of	  
physiological	   amounts	   of	  magnesium	   in	   the	   intracellular	   environment,	   CICR	   through	  
RYR1	  is	  inhibited.	  	  A	  reduction	  in	  magnesium	  and	  an	  increase	  in	  cytosolic	  calcium	  have	  
the	   ability	   to	   activate	   wild	   type	   RYR1.	   	   Additionally,	   reducing	   the	   amount	   of	  
magnesium	  causes	  normal	  muscle	  to	  be	  more	  sensitive	  to	  known	  MH	  triggers	  caffeine,	  
halothane	  and	  sevoflurane.	   	  MHS	  muscle	  has	  a	  more	  dramatic	  sensitivity	  to	  all	   these	  
activators	   in	   the	   presence	   of	   reduced	   magnesium	   but	   also	   when	   exposed	   to	  
physiological	   concentrations	   of	  magnesium	   (Kawana	   et	   al.,	   1992,	  Owen	   et	   al.,	   1997,	  
Duke	  et	  al.,	  2004,	  Duke	  et	  al.,	  2006,	  Duke	  et	  al.,	  2003,	  Duke	  et	  al.,	  2002).	  	  Furthermore,	  
a	  reduction	  in	  magnesium	  also	  makes	  MHN	  muscle	  more	  sensitive	  to	  store	  depletion	  
and	  the	  associated	  calcium	  entry	  through	  the	  SOCE	  mechanism,	  a	  reaction	  that	  is	  once	  
again	  more	  exaggerated	  in	  MHS	  fibres	  (Duke	  et	  al.,	  2010).	  
	   16	  
	  
Figure	  1.5	  –	  Schematic	  of	  the	  store	  operated	  calcium	  entry	  mechanism.	  
(A)	  Skeletal	  muscle	  at	  rest.	  	  STIM1	  molecules	  are	  present	  throughout	  the	  sarcoplasmic	  reticulum	  and	  Orai1	  
channels	  are	  present	  in	  the	  sarcolemmal	  membrane.	  (B)	  Store	  depletion	  triggers	  the	  rearrangement	  of	  STIM1	  
molecules	  to	  distinct	  regions	  close	  to	  the	  sarcolemmal	  membrane	  to	  allow	  interaction	  with	  Orai1	  channels	  that	  
undergo	  a	  similar	  rearrangement.	  	  STIM1	  molecules	  under	  oligomerisation	  and	  elongate	  to	  allow	  the	  interaction	  
with	  Orai1.	  	  (C)	  Interaction	  of	  STIM1	  and	  Orai1	  facilitates	  calcium	  entry	  from	  the	  extracellular	  space.	  	  Based	  on	  
information	  from	  Lewis	  (2007),	  and	  Smyth	  et	  al.	  (2010)	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Figure	  1.6	  –	  Schematic	  of	  the	  excitation-­‐coupled	  calcium	  entry	  mechanism	  in	  skeletal	  muscle.	  
(A)	  Skeletal	  muscle	  at	  rest.	  	  The	  majority	  of	  the	  cellular	  calcium	  is	  in	  the	  sarcoplasmic	  reticulum	  stores.	  	  There	  is	  
also	  calcium	  present	  both	  in	  the	  cytoplasm	  and	  in	  the	  extracellular	  space.	  (B)	  Depolarisation	  of	  the	  sarcolemmal	  
membrane	  results	  in	  excitation-­‐contraction	  coupling	  through	  interaction	  between	  the	  DHPR	  and	  RYR1	  calcium	  
channels.	  	  (C)	  Prolonged	  depolarisation	  results	  in	  calcium	  entry	  through	  the	  DHPR	  from	  the	  extracellular	  space.	  
Based	  on	  information	  from	  Rosenberg	  (2009).	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1.6	  Additional	  conditions	  associated	  with	  mutations	  in	  RYR1	  
As	   well	   as	   MH,	   mutations	   in	   RYR1	   have	   been	   associated	   with	   a	   number	   of	  
neuromuscular	   disorders	   including	   MmD	   (Ferreiro	   et	   al.,	   2002),	   nemaline	   rod	  
myopathy	   (Monnier	   et	   al.,	   2000),	   King-­‐Denborough	   syndrome	   (Dowling	   et	   al.,	   2011)	  
and	  centronuclear	  myopathy	  (Jungbluth	  et	  al.,	  2012,	  Wilmshurst	  et	  al.,	  2010).	  	  	  Whilst	  
the	  contribution	  of	  RYR1	  to	  these	  conditions	  appears	  to	  be	  largely	  heterogeneic,	  RYR1	  
is	   the	   main	   locus	   responsible	   for	   CCD	   and	   is	   increasingly	   being	   associated	   with	   a	  
physiological	   episode	   that	   shares	  many	   common	   features	   with	  MH;	   exertional	   heat	  
stroke	  (EHS).	  
	  
1.6.1	  Central	  Core	  Disease	  
CCD	  is	  a	  minimally	  progressive,	  congenital	  myopathy	  characterised	  histopathologically	  
through	  the	  presence	  of	  amorphous	  areas	  known	  as	  cores	  that	  lack	  oxidative	  enzymes	  
and	  mitochondria	   (Robinson	   et	   al.,	   2006).	   	   Common	   clinical	   features	   include	  muscle	  
atrophy,	   generalised	   lower	   limb	  weakness	   and	   floppy	   infant	   syndrome	  however,	   the	  
spectrum	   of	   clinical	   features	   of	   CCD	   is	   wide,	   with	   some	   patients	   being	   largely	  
asymptomatic	   despite	   the	   presence	   of	   cores	   and	   others	   being	   severely	   affected	  
through	  acute	  muscle	  weakness	  (Shuaib	  et	  al.,	  1987,	  Quinlivan	  et	  al.,	  2003).	  	  	  
Despite	   the	   seemingly	   contrasting	   symptoms	   associated	  with	   the	   two	   disorders,	   the	  
link	   between	   CCD	   and	  MH	   has	   long	   been	   established	   (Denborough	   et	   al.,	   1973).	   	   A	  
number	  of	  RYR1	  mutations	  have	  been	  associated	  with	  CCD	  either	  in	  conjunction	  with	  
MH	   or,	   in	   some	   cases,	   independent	   of	  MH	   (Quane	   et	   al.,	   1993,	   Zhang	   et	   al.,	   1993,	  
Lynch	  et	  al.,	  1999,	  Robinson	  et	  al.,	  2006).	  	  Whilst	  the	  hot-­‐spot	  theory	  of	  MH	  has	  largely	  
been	  quashed	  it	  does	  appear	  as	  though	  the	  third	  mutation	  hot	  spot	  at	  the	  C-­‐terminal	  
region	  of	  RYR1	  is	  the	  main	  area	  for	  mutations	  in	  CCD	  (Monnier	  et	  al.,	  2001,	  Davis	  et	  al.,	  
2003).	   	   This	   is	  perhaps	  not	   surprising	  as	  mutations	   in	   the	   calcium	  pore	  of	  RYR1	  may	  
explain	   the	   large	   amount	   of	   calcium	   leak	   associated	   with	   CCD	   and	   the	   resultant	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myopathy,	   however,	   similarly	   to	   MH,	   mutations	   associated	   with	   CCD	   are	   being	  
identified	  across	  RYR1	  (Shepherd	  et	  al.,	  2004).	  
Like	  MH,	   CCD	   is	   associated	   with	   elevated	   resting	   calcium	   attributed	   to	   passive	   leak	  
through	   RYR1.	   	   In	   CCD	   patients	   this	   leak	   appears	   to	   be	   more	   severe,	   leading	   to	  
myopathy,	   however,	   the	   hypersensitivity	   of	   RYR1	   is	   maintained	   leading	   to	   both	  
phenotypes	   (Tong	   et	   al.,	   1997).	   	   This	   calcium	   leak	   is	   attributed	   to	   an	   increased	  
hypersensitivity	   of	   RYR1	   to	   activation	  when	   not	   challenged	  with	   traditional	   agonists	  
and	   when	   exposed	   to	   volatile	   anaesthetics	   an	   MH	   reaction	   is	   still	   triggered.	   	   An	  
alternative	  molecular	  mechanism	   for	   the	  onset	  of	  CCD	  has	  also	  been	  established	   for	  
cases	  not	   linked	   to	  MH	   termed	  excitation-­‐contraction	  uncoupling	   (Dirksen	  and	  Avila,	  
2002)	  (Figure	  1.7).	  	  In	  a	  number	  of	  cases	  of	  CCD	  that	  have	  not	  been	  linked	  to	  MH,	  there	  
is	  an	  apparent	  uncoupling	  of	  the	  DHPRs	  and	  RYR1	  during	  EC	  coupling	  leading	  to	  severe	  
myopathy.	   	   In	   homozygous	   form	   in	   vitro,	   RYR1	   mutations	   associated	   with	   this	  
mechanism	  results	  in	  completely	  abolished	  EC	  coupling	  which	  is	  only	  partially	  restored	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Figure	  1.7	  –	  Mechanisms	  that	  lead	  to	  the	  central	  core	  disease	  pathogenesis	  
(A)	  Normal	  skeletal	  muscle	  at	  rest	  (left)	  and	  during	  depolarisation	  (right).	  	  At	  rest,	  the	  majority	  of	  cellular	  calcium	  
is	  in	  the	  sarcoplasmic	  reticulum	  stores.	  	  Upon	  depolarisation,	  interaction	  between	  RYR1	  and	  the	  DHPR	  causes	  
calcium	  release	  from	  the	  sarcoplasmic	  reticulum	  stores.	  	  (B)	  Leaky	  RYR1	  channels	  at	  rest	  (left)	  and	  during	  
depolarisation	  (right).	  	  Leaky	  RYR1	  channels	  causes	  there	  to	  be	  a	  higher	  cytoplasmic	  calcium	  level	  resulting	  in	  a	  
reduced	  amount	  of	  calcium	  release	  upon	  depolarisation	  resulting	  in	  muscle	  weakness	  and	  myopathy.	  	  (C)	  
Excitation-­‐contraction	  uncoupling.	  	  Upon	  depolarisation,	  no	  calcium	  release	  is	  observed	  as	  coupling	  between	  the	  
DHPR	  and	  RYR1	  is	  abolished.	  	  This	  phenotype	  is	  less	  severe	  when	  in	  heterozygous	  form.	  	  Based	  on	  information	  
from	  Avila	  et	  al.	  (2001).	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1.6.2	  Exertional	  heat	  stroke	  
EHS	  is	  a	  form	  of	  heat	  stroke	  associated	  with	  vigorous	  exercise	  in	  warm	  climates	  such	  as	  
military	  training	  programmes	  and	  mass	  participant	  events	  such	  as	  marathons	  (Hopkins,	  
2007).	  	  When	  triggered,	  susceptible	  individuals	  experience	  excessive	  increases	  in	  body	  
temperature	  as	  well	  as	  significant	  central	  nervous	  system	  dysfunction.	  	  There	  has	  long	  
been	  a	  suggested	  link	  between	  MH	  and	  EHS	  based	  on	  the	  similarity	  in	  the	  symptoms	  of	  
both	  conditions	  as	  well	  as	  reports	  of	  several	  individuals	  who	  suffer	  an	  EHS	  reaction	  and	  
are	   subsequently	   tested	  MHS	   through	   the	   IVCT	   (Hopkins	   et	   al.,	   1991a,	   Hackl	   et	   al.,	  
1991,	  Kochling	  et	  al.,	  1998,	  Hopkins,	  2007,	  Muldoon	  et	  al.,	  2007,	  Muldoon	  et	  al.,	  2008).	  	  
Currently,	  members	  of	  the	  British	  military	  who	  suffer	  repeated	  EHS	  episodes	  and	  fail	  
heat	   tolerance	   tests	   are	   referred	   to	   the	   UK	   MH	   diagnostic	   centre	   for	   testing.	  	  
Furthermore,	  both	  porcine	  (Mitchell	  and	  Heffron,	  1982,	  Otsu	  et	  al.,	  1994)	  and	  murine	  
models	   of	   MH	   (Chelu	   et	   al.,	   2006,	   Yang	   et	   al.,	   2006)	   are	   induced	   into	   the	  
hypermetabolic	   reaction	   associated	   with	   MH	   through	   exposure	   to	   an	   increase	   in	  
ambient	  temperature	  to	  42°C	  
The	   phenotypic	   link	   has,	   in	   recent	   years	   been	   supported	   through	   genetic	   data	  
emerging	   in	   EHS	   cases	   as	   well	   as	   other	   heat-­‐related	   illnesses	   such	   as	   exertional	  
rhabdomyolysis	   (Table	  1.1).	   	  Davis	  et	  al.	   (2002)	  and	  Wappler	  et	  al.	   (2001)	  reported	  a	  
total	  of	   six	   independent	   families	  possessing	  RYR1	   variants	  associated	  with	  exertional	  
rhabdomyolysis	  and	  MH.	  	  Furthermore,	  there	  have	  been	  recent	  reported	  cases	  of	  fatal	  
stress-­‐induced	  MH	  associated	  with	  RYR1	  variants	  in	  two	  children	  (Groom	  et	  al.,	  2011).	  	  
Whilst	  these	  conditions	  are	  related	  to	  MH	  and	  EHS,	  there	  has,	  to	  date,	  been	  only	  one-­‐
reported	   case	   where	   an	   EHS	   reaction	   has	   been	   categorically	   linked	   to	   an	   RYR1	  
mutation	  and	  previous	  MH	  family	  history	  (Tobin	  et	  al.,	  2001).	   	  A	  12-­‐year	  old	  boy	  had	  
suffered	  an	  MH	  reaction	  during	  anaesthesia	  and	  subsequently	  recovered	  without	  any	  
further	   complications.	   	   However,	   the	   boy	   died	   several	   months	   later	   of	   a	   clear	   EHS	  
episode	  whilst	  playing	  football.	  	  Genetic	  analysis	  of	  the	  boy	  and	  his	  family	  revealed	  the	  
presence	  of	  the	  p.R163C	  variant	  that	  has	  been	  previously	  associated	  with	  MH	  as	  well	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as	   being	   proven	   causative	   in	   functional	   experiments	   (Tong	   et	   al.,	   1997,	   Yang	   et	   al.,	  
2003).	  
	  
Nucleotide	  change	   Amino	  acid	  change	   Reference	  
487	  C>T	   R163C	   Tobin	  et	  al.	  (2001)	  
487	  C>T	   R163C	   	  
Wappler	  et	  al.	  (2001)	  1021	  G>A	   G341R	  
7297	  G>A	   L2433I	  
1201	  C>T	   R401C	   Davis	  et	  al.	  (2002)	  	  
11947	  C>T	   R3983C	   Groom	  et	  al.	  (2011)	  
13513	  G>C	   D4505H	  
Table	  1.1	  –	  Genetic	  variants	  in	  RYR1	  associated	  with	  exertional	  heat	  stroke	  and	  exertional	  rhabdomyolysis	  
The	  number	  of	  RYR1	  variants	  associated	  with	  exertional	  heat	  illnesses	  is	  steadily	  increasing.	  	  To	  date,	  only	  one	  
variant,	  the	  p.R163C	  has	  been	  definitively	  linked	  to	  both	  an	  MH	  and	  EHS	  episode	  in	  the	  same	  family.	  
	  
Whilst	  there	  is	  no	  treatment	  available	  for	  EHS	  aside	  from	  aggressive	  cooling	  measures,	  
recently	   a	   compound	   has	   been	   shown	   to	   protect	   against	   EHS	   in	  RYR1	   mutant	  mice	  
(Lanner	   et	   al.,	   2012).	   	   5-­‐aminoimidazole-­‐4-­‐carboxamide	   ribonucleoside	   (AICAR)	   is	   an	  
adenosine	   analogue	   that	   is	   readily	   taken	   up	   into	   cells	   and	   mimics	   the	   effect	   of	  
adenosine	  monophosphate	  (AMP)	  in	  the	  activation	  of	  AMP	  kinase	  (AMPK).	  	  AMPK	  is	  an	  
energy	  sensor	  that	  is	  activated	  upon	  an	  increase	  in	  AMP	  and	  inhibited	  in	  the	  presence	  
of	   high	   ATP	   (Merrill	   et	   al.,	   1997).	   	   Activation	   of	   AMPK	   increases	   the	   amount	   of	  
metabolic	   enzymes	   present	   in	   skeletal	   muscle,	   specifically	   GLUT-­‐4	   and	   hexokinase	  
(Holmes	  et	  al.,	  1999,	  Winder	  and	  Hardie,	  1999,	  Winder	  et	  al.,	  2000).	  	  AMPK	  activity	  is	  
elevated	   in	   individuals	   who	   have	   undergone	   endurance	   exercise	   training	   but	   it	   has	  
recently	  been	  shown	  that	  when	  AICAR	  is	  administered	  over	  a	  period	  of	  time,	  exercise	  
endurance	  and	  the	  associated	  increase	  in	  mitochondrial	  enzymes	  is	  increased	  even	  in	  
sedentary	  mice	  (Corton	  et	  al.,	  1995,	  Pold	  et	  al.,	  2005,	  Narkar	  et	  al.,	  2008).	  
Prophylactic	  treatment	  of	  an	  MH	  mouse	  expressing	  an	  RYR1	  variant	  with	  AICAR	  is	  fully	  
protective	  against	  the	  EHS	  phenotype.	  	  Whilst	  AMPK	  is	  known	  to	  be	  protective	  of	  cells	  
against	   heat	   shock,	   the	   actual	   method	   by	   which	   AICAR	   protects	   against	   the	   EHS	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episode	   is	   through	  a	  direct	   interaction	  with	  RYR1	   resulting	   in	   a	   reduction	  of	   calcium	  
leak	  from	  the	  mutant	  channel	  (Lanner	  et	  al.,	  2012).	  	  Treatment	  with	  AICAR	  was	  unable	  
to	   protect	   against	   anaesthesia	   induced	  MH	   suggesting	   that	   the	   volatile	   anaesthetic	  
overwhelms	  the	  ability	  of	  AICAR	  to	  reduce	  calcium	  leak	  from	  RYR1.	  
	  
1.7	  Genetic	  heterogeneity	  of	  MH	  
Despite	   the	   number	   of	   missense	   variants	   in	   RYR1	   associated	   with	   MH,	   there	   are	   a	  
number	   of	   families	   in	   which	   no	   mutation	   has	   been	   identified.	   	   Furthermore,	   initial	  
studies	  searching	  for	  the	  genetic	  locus	  responsible	  for	  MH,	  as	  well	  as	  identifying	  RYR1	  
as	  the	  primary	  locus	  for	  MH,	  found	  several	  families	  in	  which	  no	  linkage	  was	  observed	  
to	  chromosome	  19	  through	  microsatellite	  and	  single	  nucleotide	  polymorphisms	  (SNPs)	  
(Deufel	  et	  al.,	  1992,	  Levitt	  et	  al.,	  1992,	  Iles	  et	  al.,	  1992).	  	  Additionally,	  5%	  of	  MH	  cases	  
in	   which	   a	   previously	   identified	   variant	   is	   present	   show	   genotype/phenotype	  
discordance	   when	   correlated	   with	   IVCT	   data	   (Deufel	   et	   al.,	   1995,	   Fagerlund	   et	   al.,	  
1997,	   Robinson	   et	   al.,	   2003b),	   suggesting	   the	   possibility	   of	   further	   genetic	   loci	  
associated	   with	  MH	   as	   potential	   modifiers	   of	   the	  MH	   phenotype.	   This	   is	   supported	  
through	   the	   work	   of	   Robinson	   et	   al.	   (2003a)	   who	   showed	   that	   multiple	   interacting	  
gene	  products	  contribute	  to	  the	  MH	  phenotype	  in	  patients	  with	  and	  without	  identified	  
RYR1	  mutations.	  
	  
1.7.1	  The	  alpha	  1	  subunit	  of	  the	  dihydropyridine	  receptor	  (CaV1.1)	  
Aside	  from	  RYR1,	   six	  additional	   loci	  have	  been	  associated	  with	  MH	  in	  various	   linkage	  
studies	   and	  mutation	   screens	   and	   two	   strong	   additional	   candidate	   genes	   have	   been	  
proposed	  (Table	  1.2).	   	  The	  most	   important	  of	  these	  is	  the	  gene	  encoding	  the	  alpha	  1	  
subunit	  of	  the	  DHPR	  (CACNA1S)	  coding	  for	  the	  Cav1.1	  protein	  (Robinson	  et	  al.,	  1997).	  	  	  
Screening	  of	  CACNA1S	  in	  MH	  patients	  has,	  to	  date,	  identified	  two	  potentially	  causative	  
variants	  (Monnier	  et	  al.,	  1997,	  Carpenter	  et	  al.,	  2009b)	  and	  functional	  analysis	  of	  these	  
variants	  in	  dysgenic	  (CACNA1S	  null)	  myotubes	  show	  an	  increased	  sensitivity	  to	  caffeine	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and	  potassium	  chloride	   (KCl)	  as	  well	  as	  causing	  a	  decrease	   in	   the	  ability	  of	  Cav1.1	   to	  
negatively	   regulate	  RYR1	   indicating	   the	   functional	   relevance	  of	   these	   variants	   to	   the	  
MH	  reaction	  (Weiss	  et	  al.,	  2004,	  Eltit	  et	  al.,	  2012a).	  	  
	  
Chromosome	  position	   Gene	  
19q13.1	   Type	  I	  ryanodine	  receptor	  (RYR1)	  
1q32	   Alpha	   1	   subunit	   of	   the	   dihydropyridine	  
receptor	  (CACNA1S)	  
19p13.3	   Junctional	   sarcoplasmic	   reticulum	  protein	  
(JSRP1)	  
17q	   Unknown	  
7q	   Unknown	  
3q	   Unknown	  
5p	   Unknown	  
Table	  1.2	  –	  List	  of	  genes	  and	  genetic	  loci	  associated	  with	  MH	  
A	  total	  of	  7	  genetic	  loci	  have	  been	  linked	  to	  MH.	  	  Mutations	  have	  been	  identified	  in	  three	  genes	  have	  been	  
identified	  as	  potential	  causative	  factors	  in	  MH.	  	  The	  most	  important	  of	  these	  genes	  is	  RYR1,	  which	  accounts	  for	  
half	  of	  all	  MH	  cases.	  	  	  Two	  variants	  have	  been	  found	  in	  CACNA1S	  and	  proven	  to	  alter	  calcium	  homeostasis.	  	  Two	  
mutations	  have	  been	  identified	  in	  JSRP1	  but	  their	  functional	  consequences	  still	  remain	  unclear.	  	  Four	  loci	  in	  the	  
genome	  have	  also	  been	  identified	  in	  linkage	  studies	  but	  with	  no	  candidate	  gene	  or	  mutations	  identified	  to	  date.	  
 
 
1.7.2	  Junctional	  sarcoplasmic	  reticulum	  protein	  (JP-­‐45)	  
A	   third	   candidate	   gene	  was	   identified	   through	   a	   sequencing	   screen	   of	   a	   number	   of	  
genes	  known	  to	  be	   involved	   in	  EC	  coupling	  and	  calcium	  regulation	   in	  skeletal	  muscle	  
(Althobiti	   et	   al.,	   2009).	   	   Two	   variants	   have	   been	   identified	   in	   the	   junctional	  
sarcoplasmic	  reticulum	  protein	  (JSRP1),	  coding	  for	  an	   integral	  membrane	  protein	  (JP-­‐
45)	   that	   co-­‐localises	  with	   RYR1	   at	   the	   junctional	   triad	   and	   interacts	  with	   Cav1.1	   and	  
calsequestrin,	  a	  calcium	  binding	  protein	  in	  the	  terminal	  cisternae	  of	  the	  SR	  (Anderson	  
et	  al.,	  2003,	  Althobiti	  et	  al.,	  2009).	   	  Unpublished	  observations	   from	  our	   laboratory	   in	  
human	  embryonic	  kidney	   (HEK293)	  cells	  co-­‐transfected	  with	  RYR1	  and	  wild	   type	  and	  
mutant	   JSRP1	   constructs	   suggest	   the	   variants	   confer	   an	   increased	   sensitivity	   to	  
caffeine,	   however,	   expression	   of	   the	   variants	   in	   JSRP1	   null	   myotubes	   resulted	   in	   a	  
decreased	   sensitivity	   to	   KCl	   (Yasuda	   et	   al.,	   2013).	   	   The	   conflicting	   functional	   data	  
emphasises	   that	   the	   role	   of	   these	   variants	   in	  MH	  pathogenesis	   is	   unclear,	   however,	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having	  been	   identified	   in	   a	   large	  number	  of	  MHN	   individuals	   it	   is	   likely	   that	   if	   these	  
variants	  do	  contribute	  to	  MH	  it	  is	  only	  in	  a	  modifier	  role	  to	  a	  more	  severe	  MH-­‐causing	  
variant.	  
	  
As	  well	  as	  distinct	  candidate	  genes,	  linkage	  studies	  have	  identified	  several	  genetic	  loci	  
for	  which	  no	  obvious	  candidate	  gene	  has	  been	  identified	  (Levitt	  et	  al.,	  1991,	  Iles	  et	  al.,	  
1994,	  Sudbrak	  et	  al.,	  1995,	  Robinson	  et	  al.,	  1997).	  	  Regions	  of	  chromosome	  3q,	  5p,	  7q	  
and	  17q	  have	  all	  been	  identified	  in	  linkage	  studies	  as	  regions	  that	  may	  possess	  genes	  
of	   interest	   for	  MH.	   	  The	  alpha	  sub	  unit	  of	   the	  skeletal	  muscle	  sodium	  channel	  was	  a	  
putative	   candidate	   for	   the	   17q	   region	   due	   to	   its	   function	   in	   skeletal	   muscle	   EC	  
coupling;	   however,	   no	   mutation	   was	   identified	   in	   the	   families	   linked	   to	   this	   region	  
(Olckers	  et	  al.,	  1992).	  	  Similarly,	  the	  alpha	  2-­‐delta	  subunit	  of	  the	  DHPR	  was	  localised	  to	  
7q	  but	  with	  no	  mutation	  present	  in	  the	  linked	  family	  (Schleithoff	  et	  al.,	  1999).	  	  
	  
1.8	  Genetic	  diagnosis	  of	  MH	  
One	  of	  the	  main	  focuses	  of	  MH	  research	  in	  recent	  years	  has	  been	  the	  development	  of	  
a	  genetic	  diagnostic	  panel	   for	  MH.	   	  The	   IVCT	   involves	  an	   invasive	  muscle	  biopsy	  that	  
leaves	  patients	   in	  discomfort	  for	  several	  weeks	  after	  the	  procedure	  and	  permanently	  
scarred.	  	  Furthermore,	  in	  the	  UK,	  there	  is	  only	  one	  national	  diagnostic	  centre	  at	  which	  
the	   IVCT	  can	  be	  carried	  out	  meaning	  that	  patients	  have	  to	   travel,	   in	  some	   instances,	  
hundreds	   of	   miles	   to	   be	   tested.	   	   On	   occasion	   this	   has	   to	   be	   done	   as	   a	   matter	   of	  
emergency	  to	  ascertain	  the	  risk	  of	  MH	  before	  the	  patient	  can	  undergo	  another	  urgent	  
operation.	   	  Additionally,	   the	   IVCT	   is	  not	  universally	  available	   to	  all	  patients	  at	   risk	  of	  
MH	  as	  the	  biopsy	  can	  only	  be	  carried	  out	  on	  patients	  10	  years	  old	  and	  over.	   	   In	  such	  
cases,	  testing	  of	  the	  parents	  can	  only	  rule	  out	  the	  possibility	  of	  MH	  if	  both	  the	  mother	  
and	  father	  test	  negative.	  	  Studies	  aimed	  at	  elucidating	  the	  functional	  consequences	  of	  
missense	  variants	  identified	  in	  MH	  patients	  have	  demonstrated	  that,	  at	  least	  in	  some	  
cases,	   the	  use	  of	   genetic	   testing	   is	   a	  plausible	  method	  of	  diagnosis.	   	   The	  process	  by	  
which	  genetic	  diagnosis	  can	  be	  used	  is	  outlined	  in	  Figure	  1.8.	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Treves	   et	   al.	   (1994)	   were	   the	   first	   to	   engineer	   the	   swine	   MH	   mutation	   into	  
recombinant	   RYR1	   and	   ascertain	   the	   effect	   on	   calcium	   homeostasis	   in	   an	   in	   vitro	  
system.	  	  Mutant	  RYR1	  was	  proven	  to	  cause	  an	  abnormal	  increase	  in	  calcium	  transients	  
when	   challenged	  with	   the	   channel	   agonist	   4-­‐chloro-­‐m-­‐creosol	   (4-­‐CmC).	   	   	   Tong	   et	   al.	  
(1997)	   subsequently	   expanded	   this	   study	   into	   a	   comprehensive	   pharmacological	  
analysis	   of	   15	   MH-­‐associated	   RYR1	   variants	   in	   HEK293	   cells.	   	   All	   variants	   under	  
investigation	  were	   found	   to	   possess	   an	   increased	   sensitivity	   to	   caffeine,	   4-­‐CmC	   and	  
halothane.	   	   Furthermore,	   MHS	   myotubes	   have	   been	   shown	   to	   have	   an	   increased	  
affinity	   of	   [3H]	   Ryanodine	   binding	   when	   exposed	   to	   channel	   agonists	   indicating	   an	  
increased	  open-­‐state	  channel	  in	  MHS	  patients	  (Richter	  et	  al.,	  1997).	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Figure	  1.8	  –	  Flowchart	  outlining	  the	  current	  process	  for	  the	  diagnosis	  of	  MH	  
Upon	  referral	  for	  MH	  testing,	  the	  proband	  that	  experienced	  a	  suspected	  MH	  reaction	  is	  offered	  the	  IVCT	  to	  
confirm	  the	  MH	  diagnosis.	  	  If	  the	  proband	  died	  or	  is	  too	  young	  for	  MH	  testing	  a	  close	  relative	  is	  offered	  the	  IVCT	  
to	  confirm	  the	  MH	  diagnosis.	  	  If	  the	  MH	  diagnosis	  is	  confirmed,	  the	  patient	  is	  added	  to	  the	  genetic	  screening	  
panel	  to	  test	  for	  the	  presence	  of	  known	  causative	  MH-­‐associated	  mutations	  in	  RYR1.	  	  If	  no	  mutation	  is	  identified	  
all	  family	  members	  are	  offered	  an	  IVCT	  for	  MH	  diagnosis.	  	  If	  a	  mutation	  is	  identified,	  all	  subsequent	  family	  
members	  are	  offered	  genetic	  screening	  for	  MH	  before	  the	  need	  for	  an	  IVCT.	  	  If	  the	  mutation	  is	  not	  identified	  in	  
the	  family	  members	  MH	  is	  not	  ruled	  out	  and	  the	  IVCT	  is	  required	  to	  confirm	  the	  MHN	  diagnosis.	  	  If	  the	  familial	  
mutation	  is	  identified	  an	  MHS	  diagnosis	  can	  be	  made	  without	  the	  need	  for	  the	  IVCT.	  	  Based	  on	  information	  in	  
Urwyler	  et	  al.	  (2001)	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1.8.1	  EMHG	  guidelines	  for	  inclusion	  onto	  the	  genetic	  diagnostic	  panel	  for	  MH	  
With	  this	  molecular	  genetic	  data	  in	  mind,	  the	  EMHG	  developed	  a	  set	  of	  guidelines	  that	  
need	  to	  be	  fulfilled	  for	  missense	  mutations	  in	  RYR1	  to	  be	  added	  to	  a	  genetic	  diagnostic	  
panel	  (Urwyler	  et	  al.,	  2001,	  Robinson	  and	  Hopkins,	  2001).	  	  Genetic	  variants	  identified	  
in	   RYR1	   must	   be	   characterised	   on	   a	   genetic	   and	   functional	   level.	   	   Genetic	  
characterisation	   involves	   examining	   the	   change	   at	   both	   a	   DNA	   and	   protein	   level	   by	  
considering	  any	  aspects	  of	  evolutionary	  conservation	  in	  the	  region	  of	  the	  gene	  affected	  
and	  any	  potential	  structural	  or	  protein	  charge	  differences	  that	  may	  occur	  as	  a	  result	  of	  
the	   amino	   acid	   substitution.	   	   In	   practice	   this	   involves	   aligning	  RYR1	   DNA	   sequences	  
from	  different	   species	   and	   the	  different	  human	  RYR	   isoforms	   to	   see	   if	   the	  base	   and	  
amino	   acid	   affected	   lies	   in	   an	   evolutionary	   conserved	   region.	   	   	   The	   variant	  must	   be	  
found	  to	  co-­‐segregate	  with	  MH	  in	  at	  least	  two	  pedigrees	  as	  well	  as	  being	  absent	  from	  
at	   least	   200	   control	   chromosomes	   to	   ensure	   that	   the	   variant	   is	   a	   non-­‐pathogenic	  
polymorphism.	   	   Other	   attempts	   to	   characterise	   potential	  MH	  mutations	   involve	   the	  
use	   of	   various	   bioinformatic	   resources	   to	   predict	   what,	   if	   any,	   change	   of	   protein	  
structure	  may	  occur	  as	  a	  result	  of	  the	  variant.	  	  	  Prediction	  software	  must	  be	  used	  with	  
caution.	   	   Due	   to	   the	   size	   of	   RYR1,	   there	   is	   limited	   structural	   data	   available	   and	  
predictions	   are	   based	   on	   computer	   algorithms	   based	   on	   motifs	   from	   other	   genes.	  	  
Generating	  a	   reliable	  prediction	  of	  where	  exactly	  an	  RYR1	   variant	   lies	  on	   the	  overall	  
protein	  structure	  and	  also	  predicting	  what	  effect,	  if	  any	  that	  will	  have	  on	  function	  may	  
not	   be	   possible.	   Genetic	   characterisation	   is	   a	   first	   step	   in	   evaluating	   the	   potential	  
seriousness	  of	  any	  change	  in	  RYR1	  found	  in	  MH	  patients;	  however,	  the	  genetics	  of	  MH	  
has	   been	   proven	   to	   be,	   at	   times,	   extremely	   complex	   so	   until	   functional	   assays	   are	  
carried	  out,	  genetic	  information	  is	  just	  auxiliary.	  	  	  
	  
1.8.1.1	  Functional	  characterisation	  of	  genetic	  variants	  using	  ex	  vivo	  samples	  
Functional	   characterisation	   of	  RYR1	   variants	   can	   be	   performed	   in	   one	   of	   two	  ways.	  	  
The	   first	   of	  which	   is	   the	   use	   of	  ex	   vivo	   samples	   of	   known	   genotypes	   obtained	   from	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patients	   undergoing	   MH	   testing.	   	   The	   majority	   of	   such	   experiments	   have	   utilised	  
primary	   myoblasts	   obtained	   from	   muscle	   biopsy	   specimens	   surplus	   to	   diagnostic	  
requirements.	   	   Additionally,	   some	   groups	   have	   obtained	   B-­‐lymphocytes	   from	   the	  
blood	   of	   patients	   under	   investigation	   (Wehner	   et	   al.,	   2002,	   Sei	   et	   al.,	   1999).	   	  When	  
using	  such	  methods,	  members	  of	  the	  family	  under	  investigation	  both	  with	  and	  without	  
the	  RYR1	  variant	  must	  be	  tested	  to	  assign	  causality	  to	  the	  variant.	  	  However,	  because	  
the	  genetic	  background	  in	  these	  cases	  is	  not	  defined,	  the	  contribution	  of	  an	  unknown	  
genetic	  variant	  cannot	  be	  ruled	  out.	  	  To	  counteract	  this,	  the	  guidelines	  state	  that	  such	  
experiments	  must	  be	  performed	  on	  material	  obtained	  from	  at	  least	  two	  independent	  
families	   with	   the	   same	   mutation,	   however,	   recent	   evidence	   has	   hinted	   at	   the	  
possibility	  of	  patients	  carrying	  the	  same	  RYR1	  variant	  possessing	  a	  shared	  high-­‐risk	  MH	  
haplotype	  (Carpenter	  et	  al.,	  2009a).	  	  	  It	  is	  unknown	  whether	  in	  these	  circumstances	  the	  
shared	  haplotype	  of	  MH	  patients	  would	  possess	  a	  second,	  potentially	  causative	  variant	  
which	  could	  diagnose	  the	  wrong	  mutation	  in	  the	  family.	  
Additionally,	   the	   use	   of	   such	   material	   for	   functionally	   characterising	   MH	   mutations	  
essentially	  provides	  no	  new	  information	  on	  top	  of	  the	   IVCT.	   	  The	  assay	  can	  ascertain	  
whether	  the	  cells	  are	  responding	  in	  an	  MHS	  or	  MHN	  manner	  but	  to	  conclude	  that	  this	  
is	   because	   of	   the	   presence	   of	   one	   RYR1	   variant	   may	   not	   be	   accurate.	   	   	   The	  
identification	  of	  the	  first	  RYR1	  variants	  prompted	  mutation-­‐screening	  experiments	  to	  
focus	   on	   ‘hot	   spots’	   of	   the	   coding	   sequence	   in	   which	   variants	   had	   previously	   been	  
identified.	   	   Currently,	   most	   MH	   centres	   genotype	   patients	   by	   focussing	   on	   these	  
regions	  to	  screen	  for	  previously	  identified	  variants.	  	  Very	  few	  studies	  have	  carried	  out	  
comprehensive	  sequencing	  of	  RYR1	   to	  rule	  out	  the	  presence	  of	  any	  other	  variants	   in	  
the	  patients.	   	   	  This	   is	  highlighted	   in	  several	   reported	  cases	  of	  patients	  carrying	  more	  
than	   one	   missense	   variant	   potentially	   responsible	   for	   MH.	   	   Patients	   have	   been	  
identified	   carrying	   two	   mutant	   alleles	   of	   RYR1	   as	   either	   homozygous	   for	   the	   same	  
variant,	  compound	  heterozygous	  for	  two	  RYR1	  variants	   inherited	  from	  two	  unrelated	  
MHS	  parents	  and	  compound	  heterozygous	  with	  a	  variant	   in	  both	  RYR1	  and	  CACNA1S	  
(Lynch	   et	   al.,	   1997,	  Monnier	   et	   al.,	   2002).	   	   If	  ex	   vivo	  experiments	   are	   to	   be	   used	   in	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functional	   experiments	   it	   is	   vitally	   important	   that	   it	   is	   certain	   that	   the	   variant	  under	  
investigation	   is	   the	  only	  potentially	   causative	  MH	  variant	   in	   the	  patient.	   	  Having	   this	  
knowledge	   is	   highly	   unlikely	   unless	   the	   patient	   has	   undergone	   whole	   genome	  
sequencing	  meaning	  that	  ex	  vivo	  experiments	  are	  still	  problematic.	  
	  
1.8.1.2	  Functional	  analysis	  of	  genetic	  variants	  in	  in	  vitro	  expression	  systems	  
The	   second	   method	   described	   in	   the	   EMHG	   guidelines	   is	   the	   use	   of	   recombinant	  
complimentary	  DNA	   (cDNA)	   clones	   transfected	   into	   in	   vitro	   systems	   such	   as	  HEK293	  
cells.	   	   	   The	   defined	   genetic	   background	   of	   the	   cellular	   systems	   employed	   in	   such	  
experiments	   ensures	   that	   the	   results	   obtained	   can	  only	  be	   accredited	   to	   the	   variant	  
under	   investigation.	   	   	   The	  difficulties	  associated	  with	  producing	   recombinant	  mutant	  
RYR1	  clones	  are	  offset	  with	  the	  power	  of	  the	  analysis	  to	  confirm	  the	  causative	  nature	  
of	   the	   variant	   under	   investigation.	   	   	   To	   date,	   the	  majority	   of	   variants	   approved	   for	  
genetic	   diagnosis	   of	   MH	   have	   been	   functionally	   characterised	   using	   these	   methods	  
with	  HEK293	  cells	  being	  the	  primary	  expression	  system	  used	  (Tong	  et	  al.,	  1997,	  Tong	  et	  
al.,	   1999a,	   Sato	   et	   al.,	   2010).	   	  Whilst	   HEK293	   have	   consistently	   shown	   an	   increased	  
sensitivity	   of	   MH	   variants	   to	   channel	   agonists	   such	   as	   caffeine	   and	   halothane,	  
questions	   remain	   over	   their	   suitability	   as	   a	   functional	   system	   for	   MH.	   	   The	   lack	   of	  
expression	  of	  any	  of	   the	  RYR	   isoforms	   in	  HEK293	  cells	   is	  one	  of	   the	  reasons	  for	  their	  
use	   in	   functional	   studies	   (Rossi	   et	   al.,	   2002),	   however,	   such	  non-­‐muscle	   cell	   systems	  
also	   lack	   the	  expression	  of	  key	   triadic	  proteins	   such	  as	   the	  DHPR	  subunits	   that	  RYR1	  
relies	   on	   for	   normal	   function	   in	   skeletal	   muscle	   (Nakai	   et	   al.,	   1996).	   	   Additionally,	  
HEK293	   cells	   do	   not	   possess	   the	   highly	   organised	   cellular	   structure	   and	   specialised	  
organelles	  of	  skeletal	  muscle	  such	  as	  the	  T-­‐tubules	  and	  SR.	  
The	   primary	   reason	   for	   the	   use	   of	   non-­‐native	   cell	   types	   such	   as	   HEK293	   cells	   for	  
functional	  studies	  of	  RYR1	  variants	  is	  the	  ease	  of	  which	  they	  are	  transfected	  with	  cDNA	  
constructs	  compared	  with	  muscle	  cells.	   	   It	   is	  widely	  acknowledged	  that	  as	  the	  size	  of	  
the	   plasmid	   being	   transfected	   increases,	   the	   overall	   efficiency	   drops	   dramatically	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(Kreiss	  et	  al.,	  1999,	  Yin	  et	  al.,	  2005).	   	   In	  spite	  of	  this,	   transfection	  efficiencies	  of	  over	  
20kb	   plasmids	   containing	   RYR1	   into	   HEK293	   cells	   remain	   sufficiently	   high	   for	   the	  
reliable	   analysis	   of	  RYR1	   variants.	   	  Muscle	   cells,	   specifically	   differentiated	  myotubes	  
are	  difficult	  to	  transfect	  with	  small	  plasmids	  and,	  as	  the	  size	  of	  the	  construct	  increases,	  
transfection	  efficiencies	  have	  been	  seen	  to	  rapidly	  decline	  to	  efficiencies	  approaching	  
0%	  (Wang	  et	  al.,	  2000,	  Campeau	  et	  al.,	  2001,	  Neuhuber	  et	  al.,	  2002).	  	  	  
	  
1.8.1.2.1	  Development	  of	  a	  muscle-­‐like	  in	  vitro	  expression	  system	  for	  functional	  
experiments	  and	  differences	  with	  non-­‐native	  cell	  types	  
A	  highly	  efficient	  system	  of	  carrying	  out	   in	  vitro	   studies	   in	  muscle-­‐like	  cells	  has	  been	  
developed	   utilising	   type	   1	   human	   herpes	   simplex	   virus	   (HSV-­‐1)	   (Cunningham	   and	  
Davison,	  1993,	  Fraefel	  et	  al.,	  1996,	  Moore	  et	  al.,	  1998,	  Wang	  et	  al.,	  2000,	  Yang	  et	  al.,	  
2003).	   	   	   A	   set	   of	   five	   cosmids	   representing	   the	   entire	   HSV-­‐1	   genome	   minus	   the	  
packaging	  and	  cleavage	  signals	  required	  to	  produce	  virions	  was	  produced	  and	  paired	  
with	  a	  modified	  pUC	  vector	  containing	  the	  missing	  signals	  and	  a	  gene	  of	  interest.	  	  The	  
co-­‐transfection	   of	   the	   cosmids	   and	   expression	   vector	   resulted	   in	   HSV-­‐1	   virions	  
containing	  only	  the	  gene	  of	  interest	  and	  has	  been	  used	  to	  deliver	  RYR1	  at	  efficiencies	  
of	   up	   to	   90%	   into	   dyspedic	   (RYR	   functional	   knock-­‐out)	  muscle	   cells.	   	   The	   functional	  
consequences	   of	   6	   previously	   characterised	   RYR1	   variants	   were	   assessed	   using	   this	  
system.	   	   In	   addition	   to	   an	   increase	   in	   sensitivity	   to	   caffeine,	   halothane	   and	   4-­‐CmC,	  
mutant	  myotubes	   also	   displayed	  defects	   in	   EC	   coupling	  when	  depolarised	   using	   KCl.	  	  
Whilst	   there	   were	   no	   differences	   observed	   between	   HEK293	   cells	   and	   1B5	   cells	   in	  
terms	  of	   the	   sensitivity	  of	   expressed	  RYR1	  variants,	   evidence	   suggests	   there	  may	  be	  
some	  differences	  in	  the	  resting	  intracellular	  calcium	  level	  generated	  when	  variants	  are	  
expressed.	  
Muscle	  fibres	  from	  both	  MH	  swine	  (Lopez	  et	  al.,	  1987a)	  and	  MHS	  patients	  (Lopez	  et	  al.,	  
1987b,	   Lopez	   et	   al.,	   1992)	   have	   a	   statistically	   significantly	   increased	   resting	   calcium	  
when	   compared	   to	   wild	   type	   controls.	   	   The	   elevated	   resting	   calcium	   has	   been	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implicated	  as	  a	  causative	  factor	  of	  the	  MH	  episode	  and	  a	  reduction	  in	  which	  results	  in	  
a	   decrease	   in	   sensitivity	   of	  muscle	   fibres	   to	  MH-­‐triggering	   drugs	   (Lopez	   et	   al.,	   2000,	  
Lopez	  et	  al.,	  2005).	   	   In	   spite	  of	   this,	   the	   resting	  calcium	  of	  MH	  variants	  expressed	   in	  
HEK293	  cells	  appears	  to	  be	  no	  different	  to	  that	  of	  wild	  type	  transfected	  cells	  (Tong	  et	  
al.,	  1999b).	   	  Whilst	  this	  hints	  at	  a	  fundamental	  difference	  in	  the	  cellular	  environment	  
of	  myotubes	  and	  HEK293	  cells,	  the	  discrepancy	  may	  be	  due	  to	  the	  method	  employed.	  
The	   experiments	   involving	   muscle	   fibres	   and	   dyspedic	   myotubes	   utilise	   calcium-­‐
sensitive	  microelectrodes	   that	   are	   calibrated	  before	   and	  after	   each	  measurement	   to	  
ensure	  the	  maximum	  possible	  sensitivity	  and	  accuracy	  of	  the	  measurements.	  	  The	  use	  
of	  the	  electrodes	  requires	  a	  large	  cytoplasmic	  region	  for	  injection,	  which	  is	  not	  readily	  
visible	   in	  HEK293	  cells,	  which	  are	   largely	  nuclear.	   	  Resting	  calcium	  measurements	  on	  
HEK293	  cells	  and	  other	  non-­‐muscle	  cell	   types	  have	  used	   the	   ratiometric	  calcium	  dye	  
fura-­‐2.	   	   The	   overall	   sensitivity	   of	   fura-­‐2	   is	   much	   lower	   than	   calcium-­‐sensitive	  
microelectrodes	  and,	   in	   some	  cases,	  MH	  variants	   that	  have	  been	  proven	   to	  confer	  a	  
higher	   resting	  calcium	   level	   in	  myotubes	  have	  been	   found	   to	  be	  no	  different	   to	  wild	  
type	   in	  HEK293	  cells.	   	   Similarly,	  when	   fura-­‐2	  has	  been	  used	   in	  myotubes,	  not	  all	  MH	  
variants	  have	  been	  shown	  to	  have	  a	  higher	  resting	  calcium	  level	  (Wehner	  et	  al.,	  2002).	  	  
In	   HEK293	   cells,	   only	   resting	   calcium	   levels	   with	   CCD	   associated	   mutations	   are	  
detectable	   as	   being	   higher	   than	  wild	   type	   (Tong	   et	   al.,	   1999b).	   	  Whilst	   it	   cannot	   be	  
ruled	  out	  that	  the	  variation	  observed	  is	  due	  to	  discrepancies	  between	  individual	  RYR1	  
variants,	  the	  likelihood	  is	  that	  the	  differences	  observed	  are	  due	  to	  either	  an	  inherent	  
difference	   between	   the	   two	   expression	   systems	   or	  methods	   utilised.	   	  Whatever	   the	  
reason,	   resting	   calcium	   data	   obtained	   in	   HEK293	   cells	   remains	   unreliable	   and	  
problematic.	  
	  
1.8.1.3	  Knowledge	  gained	  from	  non-­‐native	  cell	  types	  
Despite	  the	  potential	  limitations	  associated	  with	  carrying	  out	  functional	  experiments	  in	  
non-­‐native	   cell	   types,	   HEK293	   cells	   and	   B-­‐lymphocytes	   have	   been	   used	   to	   generate	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useful	   information	  on	   the	   pathogenesis	   of	  MH.	   	   Additionally,	   the	  majority	   of	   the	   31	  
listed	  causative	  variants	  on	  the	  EMHG	  website	  have	  been	  functionally	  characterised	  in	  
non-­‐native	   cellular	   systems.	   	  HEK293	   cells	   expressing	  wild	   type	  RYR1	   have	   a	   greater	  
propensity	   of	   store	   overload	   induced	   calcium	   release	   (SOICR)	  when	   luminal	   calcium	  
concentrations	  are	  increased	  (Jiang	  et	  al.,	  2008).	  	  This	  effect,	  however,	  is	  more	  severe	  
in	   HEK293	   cells	   expressing	   a	   mutant	   RYR1	   construct	   (Figure	   1.9).	   	   As	   discussed	  
previously,	  RYR1	  mutations	  confer	  a	  higher	  baseline	  resting	  calcium	  level,	  coupled	  with	  
the	   exaggerated	   calcium	   entry	   mechanisms	   associated	   with	   an	   MH	   phenotype,	   the	  
high	   levels	   of	   calcium	   being	   pumped	   back	   into	   the	   SR	   could	   be	   the	   reason	   for	   this	  
SOICR.	   	   Furthermore,	   there	   is	   evidence	   to	   suggest	   that	   the	   sarco(endo)plasmic	  
reticulum	   calcium	   ATPase	   (SERCA)	   pump,	   responsible	   for	   calcium	   reuptake	   after	  
calcium	  release	  is	  overactive	  in	  cells	  expressing	  RYR1	  variants	  (Tong	  et	  al.,	  1999b).	  
B-­‐lymphocytes	   isolated	   from	   patients	   known	   to	   be	   carrying	   RYR1	   variants	   have	  
previously	   been	   used	   for	   ex	   vivo	   functional	   experiments	   as	   they	   express	   RYR1	   and	  
respond	   to	   channel	   agonists	   such	   as	   caffeine	   and	   4-­‐CmC	   (Sei	   et	   al.,	   1999).	   	   The	  
exaggerated	   calcium	   release	   associated	   with	   the	   MHS	   phenotype	   induces	   a	   higher	  
level	   of	   Il-­‐1β,	   a	   pyrogenic	   cytokine	   that	   induces	   temperature	   increases,	   which	   may	  
partly	  explain	  the	  rapid	  increase	  in	  temperature	  observed	  during	  an	  MH	  crisis	  (Girard	  
et	  al.,	  2001a).	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Figure	  1.9	  –	  Schematic	  of	  store	  overload-­‐induced	  calcium	  release	  from	  the	  sarcoplasmic	  reticulum	  through	  wild	  
type	  and	  mutant	  RYR1	  
(A)	  The	  amount	  of	  calcium	  present	  in	  the	  sarcoplasmic	  reticulum	  is	  indicated	  in	  blue.	  	  At	  rest,	  wild	  type	  RYR1	  has	  
a	  high	  threshold	  for	  store	  overload-­‐induced	  calcium	  release	  that,	  although	  lowered	  when	  exposed	  to	  volatile	  
anaesthetics,	  does	  not	  cause	  a	  significant	  amount	  of	  calcium	  release.	  	  (B)	  Conversely,	  mutant	  RYR1	  lowers	  the	  
resting	  threshold	  for	  store	  overload-­‐induced	  calcium	  release	  to	  a	  level	  similar	  to	  that	  of	  wild	  type	  RYR1	  during	  
exposure	  to	  volatile	  anaesthetics.	  	  This	  threshold	  is	  further	  reduced	  through	  exposure	  to	  triggering	  anaesthetics	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1.9	  Project	  Outline	  
The	  primary	  goals	  of	  this	  research	  project	  are	  as	  follows:	  
• To	  functionally	  characterise	  six	  common	  variants	   in	   the	  RYR1	  gene	  associated	  
with	  MH;	  
• To	  develop	  a	  robust	  and	  reliable	  method	  of	  creating	  variants	  in	  RYR1	  cDNA;	  
• To	  express	  the	  genetic	  variants	  generated	   in	  this	  project	   in	  both	  HEK293	  cells	  
and	  1B5	  cells	  to	  evaluate	  the	  use	  of	  non-­‐native	  cell	  types	  in	  functional	  studies;	  
• To	   examine	   the	   effect	   of	   increased	   or	   decreased	   RYR1	   expression	   on	   the	  
sensitivity	  of	  the	  wild	  type	  and	  mutant	  channels	  to	  activation;	  
• To	  functionally	  characterise	  a	  genetic	  variant	  identified	  in	  RYR1	  associated	  with	  
both	  MH	  and	  EHS.	  
	  
1.9.1	  Functional	  characterisation	  of	  genetic	  variants	  associated	  with	  MH	  
Despite	  the	  large	  number	  of	  genetic	  variants	  in	  the	  RYR1	  gene	  associated	  with	  MH	  and	  
found	   in	   patients	   known	   to	   be	   susceptible	   to	  MH,	   only	   31	   are	   available	   for	   genetic	  
diagnosis	  worldwide.	  	  This	  means	  that	  the	  majority	  of	  patients	  undergoing	  testing	  for	  
MH	   are	   still	   reliant	   on	   the	   IVCT,	   an	   invasive	   procedure	   that	   leaves	   the	   patients	   in	  
discomfort	   for	   several	   weeks	   and	   permanently	   scarred.	   	   Furthermore,	   St	   James’s	  
Hospital	   in	   Leeds	   is	   the	   only	   certified	  MH	   diagnostic	   centre	   in	   the	  UK	  meaning	   that	  
patients	  often	  have	  to	  travel	  hundreds	  of	  miles	   for	  diagnosis.	   	   	  The	  expansion	  of	   the	  
genetic	   diagnostic	   panel	   is	   vitally	   important	   to	  MH	   patients	   not	   only	   in	   the	   UK	   but	  
worldwide.	   	   The	   primary	   goal	   of	   this	   research	   project	   is	   to	   assess	   the	   functional	  
consequences	  of	  several	  common	  variants	  in	  RYR1	  that	  have	  been	  found	  in	  association	  
with	  MH.	  	  The	  functional	  data	  obtained	  on	  the	  genetic	  variants	  in	  this	  project	  will	  be	  
used	   to	   support	   their	   inclusion	  onto	   the	   genetic	   diagnostic	   panel	   for	  MH	  as	   per	   the	  
EMHG	  guidelines.	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1.9.2	   Evaluation	   of	   the	   use	   of	   non-­‐native	   cell	   types	   for	   functional	   experiments	   of	  
RYR1	  variants	  
The	  most	   ideal	  method	   for	   performing	   these	   experiments	   is	   in	   recombinant	   in	   vitro	  
systems	  using	  cDNA	  clones.	  	  In	  this	  project,	  a	  human	  RYR1	  cDNA	  clone	  will	  be	  used	  for	  
functional	  studies.	  	  Due	  to	  the	  size	  of	  the	  RYR1	  cDNA,	  subclones	  will	  be	  made	  to	  make	  
plasmid	  sizes	  more	  suitable	   for	  site-­‐directed	  mutagenesis.	   	  Upon	  confirmation	  of	   the	  
successful	   introduction	   of	   the	   mutation,	   full-­‐length	   RYR1	   cDNA	   constructs	   will	   be	  
reassembled	  and	  expressed	  in	  HEK293	  cells	  for	  functional	  experiments.	  	  	  Currently,	  the	  
use	  of	  these	  non-­‐native	  cell	  types	  is	  acceptable	  in	  the	  EMHG	  guidelines	  for	  functionally	  
assessing	  the	  consequences	  of	  genetic	  variants	   in	  RYR1	  despite	  the	   lack	  of	  the	  highly	  
specialised	  cellular	  structure	  of	  myotubes	  or	  the	  expression	  of	  key,	  regulatory	  proteins	  
of	  RYR1.	  	  Therefore,	  the	  RYR1	  variants	  generated	  in	  this	  project	  will	  also	  be	  expressed	  
in	   dyspedic	   myotubes,	   simulating	   a	   more	   native	   cellular	   environment	   for	   RYR1.	  	  
Directly	   comparing	   the	   results	  obtained	   in	  HEK293	   cells	   and	  1B5	  dyspedic	  myotubes	  
will	  form	  the	  framework	  for	  a	  thorough	  evaluation	  of	  the	  use	  of	  non-­‐native	  cell	  types	  
for	  functional	  studies	  of	  RYR1	  variants.	  
	  
1.9.3	  Evaluation	  of	  RYR1	  expression	  level	  on	  caffeine	  sensitivity	  of	  transfected	  cells	  
There	   is	  evidence	  to	  suggest	   that,	  at	   least	   in	  core	  myopathies,	   there	   is	  a	  decrease	   in	  
wild	   type	   RYR1	   expression	   through	   allelic	   silencing	   (Zhou	   et	   al.,	   2006a,	   Zhou	   et	   al.,	  
2006b).	  	  Silencing	  of	  wild	  type	  RYR1	  effectively	  increases	  the	  expression	  of	  the	  mutant	  
allele	   resulting	   in	   a	   severe	   core	  myopathy	   phenotype.	   	   In	  MH	   patients,	   it	   has	   been	  
found	   that	   there	   is	   an	   upregulation	   of	   the	  wild	   type	  RYR1	   allele	   as	   a	   compensatory	  
mechanism	   to	   counteract	   the	   hypersensitivity	   of	   the	   mutant	   allele	   as	   well	   as	   the	  
passive	   calcium	   leak	   associated	   with	   MH	   mutations	   (Grievink	   and	   Stowell,	   2010).	  	  
There	  is	  no	  evidence	  to	  suggest	  that	  an	  upregulation	  of	  the	  wild	  type	  RYR1	  allele	  is	  a	  
contributor	  to	  the	  MH	  phenotype	  however,	  experiments	  increasing	  the	  expression	  of	  
RYR3	   resulted	   in	   both	   an	   increase	   in	   the	   baseline	   resting	   calcium	   level	   and	   caffeine	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sensitivity.	   	   It	   has	   been	   shown	   that	   reducing	   the	   resting	   calcium	   level	   of	   cells	  
expressing	   RYR1	   mutations	   also	   results	   in	   a	   reduction	   in	   sensitivity	   to	   caffeine	   and	  
other	  triggering	  agents.	  	  To	  date,	  there	  have	  been	  no	  studies	  aimed	  at	  examining	  the	  
effect	   of	   an	   increase	   in	   mutant	   RYR1	   expression	   on	   the	   caffeine	   sensitivity	   of	  
transfected	  cells.	   	   In	   this	  project,	   the	  RYR1	  variants	  generated	  will	  be	  shuttled	   into	  a	  
pTUNE	  inducible	  expression	  vector	  allowing	  tight	  regulation	  of	  RYR1	  expression.	  
	  
1.9.4	  Functional	  characterisation	  of	  a	  genetic	  variant	  associated	  with	  MH	  and	  EHS	  
It	   is	  becoming	  increasingly	  apparent	  that	  the	   link	  between	  MH	  and	  EHS	  is	  more	  than	  
just	  phenotypic	  similarities.	  	  A	  number	  of	  RYR1	  variants	  are	  emerging	  associated	  with	  
multiple	   exertional	   heat	   illnesses	   such	   as	   exertional	   rhabdomyolysis	   and	   EHS.	  	  
Recently,	  our	   laboratory	  exome	  sequenced	  a	  number	  of	   families	   in	  which	  no	  genetic	  
variant	  had	  been	  identified	  as	  potentially	  causative	  of	  MH.	  	  One	  of	  the	  RYR1	  variants	  
identified	  was	  also	  found	  in	  an	  EHS	  patient	  that	  had	  previously	  tested	  negative	  for	  MH	  
through	  the	  IVCT.	  	  In	  this	  project,	  functional	  analysis	  will	  be	  carried	  out	  on	  this	  variant	  
to	   examine	   its	   association	   with	   both	   the	   MH	   and	   EHS	   phenotype	   observed	   in	   the	  
patients.	   	   Furthermore,	   experiments	   will	   be	   performed	   using	   AICAR,	   the	   compound	  
recently	  found	  to	  be	  entirely	  protective	  of	  heat-­‐induced	  MH	  in	  murine	  models.	  
	  
1.9.5	  Clinical	  relevance	  of	  the	  project	  goals	  
Functional	  analysis	  of	   the	  genetic	  variants	   in	  RYR1	   as	  part	  of	   this	   thesis	  will	   increase	  
the	   availability	   of	  mutations	   approved	   for	   genetic	   diagnosis	   for	  MH	   by	   22.5%.	   	   The	  
variants	  selected	  for	  functional	  analysis	  have	  been	  found	  in	  a	  total	  of	  43	  families	  in	  the	  
UK	  and	  make	  up	  27%	  of	  the	  families	  that	  have	  an	  as	  yet	  uncharacterised	  RYR1	  variant	  
in	   the	   UK	  MH	   population.	   	   A	   number	   of	   individuals	   in	   these	   families	   are	   yet	   to	   be	  
tested	  for	  MH,	  approval	  of	  these	  variants	  for	  genetic	  diagnosis	  would	  negate	  the	  need	  
for	  these	  individuals	  and	  any	  future	  identified	  families	  to	  undergo	  the	  IVCT.	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It	  is	  becoming	  increasingly	  evident	  that	  the	  link	  between	  MH	  and	  EHS	  is	  strengthening.	  	  
Both	  phenotypic	  and	  genotypic	  data	  provide	  a	  strong	  argument	  for	  MH	  and	  EHS	  being	  
different	  manifestations	  of	  the	  same	  molecular	  defects	  in	  patients	  with	  one	  or	  both	  of	  
these	   conditions.	   	   Functional	   analysis	   of	   the	   EHS	   variant	   will	   contribute	   to	   the	  
understanding	  of	  the	  two	  disorders	  and	  support	  the	  current	  standard	  of	  MH	  testing	  for	  
all	  EHS	  sufferers.	  	  Expanding	  the	  knowledge	  of	  the	  molecular	  causes	  of	  an	  EHS	  episode	  
is	  of	  particular	   importance	   to	   the	  armed	  services	  due	   to	   the	  volume	  of	  EHS	  patients	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Chapter	  Two -­‐	  Materials	  and	  Methods	  
	  
2.1	  Molecular	  cloning	  
During	   this	   project	   an	   extensive	   cloning	   strategy	   was	   designed	   to	   facilitate	   the	  
introduction	   of	   missense	   mutations	   into	   the	   RYR1	   coding	   sequence.	   	   The	   starting	  
material	  was	   human	  RYR1	   cDNA	   in	   a	   pcDNA3.1	   +	   expression	   vector	   (pcRYR1)	  which	  
was	   a	   gift	   from	  Dr.	   Kathryn	   Stowell’s	   laboratory	   in	   New	   Zealand	   (Sato	   et	   al.,	   2010).	  	  
Subclones	  were	  created	  from	  pcRYR1	  for	  mutagenesis	  and	  the	  entire	  coding	  sequence	  
was	   shuttled	   into	   two	   additional	   expression	   vectors	   for	   further	   experiments.	  	  
Subclones	   of	   RYR1	   were	   constructed	   in	   pBluescript	   II	   SK	   +	   (Agilent	   technologies;	  
Wokingham,	   UK).	   	   Due	   to	   the	   limited	   number	   of	   unique	   restriction	   sites	   in	   pcRYR1,	  
non-­‐directional	   cloning	   was	   required	   to	   shuttle	   RYR1	   into	   a	   pHSVPrPUC	   expression	  
vector	  (Wang	  et	  al.	  (2000);	  Vector	  was	  a	  gift	  from	  Professor	  Paul	  Allen’s	  laboratory	  in	  
Boston,	   MA,	   USA)	   to	   facilitate	   the	   packaging	   of	   RYR1	   into	   HSV-­‐1	   virions	   and	  
subsequent	   expression	   in	  myotubes.	   	   Furthermore,	   a	   two-­‐step	   cloning	   strategy	  was	  
developed	   to	   shuttle	   RYR1	   into	   a	   pTUNE	   inducible	   expression	   vector	   (Deans	   et	   al.	  
(2007);	   OriGene;	   Wembley,	   UK)	   to	   examine	   the	   effect	   of	   expression	   level	   of	   RYR1	  
mutants	  on	  caffeine	  sensitivity.	  	  The	  cloning	  strategies	  are	  described	  in	  more	  detail	  in	  
chapter	  3	  but	  the	  various	  molecular	  biology	  techniques	  used	  to	  carry	  out	  the	  strategy	  
are	   described	   below.	   	   All	   plasmids	   used	   in	   this	   project	   contained	   an	   ampicillin	  
resistance	  gene	  for	  bacterial	  selection.	  	  All	  the	  expression	  vectors	  used	  also	  possessed	  
a	  neomycin	  resistance	  gene	  conferring	  resistance	  to	  the	  antibiotic	  G418	  for	  eukaryotic	  
cell	  line	  selection.	  
	  
2.1.1	  Restriction	  endonuclease	  digests	  
Restriction	  endonuclease	  digestion	  was	  used	  to	  obtain	  cDNA	  fragments	  for	  subcloning	  
and	   a	   diagnostic	  means	   to	   confirm	   successful	   ligation	   and	   starting	   plasmid	  material.	  	  
One	   or	   multiple	   enzymes	   (New	   England	   Biolabs	   (NEB);	   Hitchin,	   UK	   or	   Fermentas;	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Loughborough,	  UK)	  were	  used	  according	  to	  manufacturer’s	  instructions	  or,	  in	  the	  case	  
of	  double	  digests,	  reactions	  were	  set	  up	  as	  recommended	  by	  the	  NEB	  and	  Fermentas	  
double	   digest	   calculator	   websites	   (available	   at	  
http://www.neb.com/nebecomm/DoubleDigestCalculator.asp#.T8Nk8-­‐2KPKc	   and	  
http://www.fermentas.com/en/tools/doubledigest	  respectively).	  
	  
2.1.1.1	  Removing	  overhangs	  
DNA	   overhangs	   generated	   by	   restriction	   digestion	   were	   removed	   using	   DNA	  
polymerase	   I	   (Klenow	   fragment)	   (NEB).	   	   Digested	   DNA	  was	   gel	   purified	   (see	   section	  
2.1.3)	   before	   incubation	   of	   purified	   DNA	   with	   1	   unit	   of	   the	   Klenow	   fragment	   per	  
microgram	  of	  DNA	  and	  33µM	  each	  dNTP	  (NEB)	  for	  15	  minutes	  at	  25°C.	   	  The	  reaction	  
was	   stopped	  with	  ethylenediaminetetraacetic	   acid	   (EDTA)	  at	   a	   final	   concentration	  of	  
10mM.	   	   Additionally,	   the	   Klenow	   fragment	   was	   heat	   inactivated	   at	   75°C	   for	   20	  
minutes.	  	  	  
	  
2.1.2	  Gel	  extraction	  
Gel	   extraction	   was	   performed	   to	   retrieve	   cDNA	   fragments	   with	   the	   intention	   of	  
subcloning	   into	   shuttle	   vectors	   or	   for	   the	   reconstruction	   of	   full-­‐length	   cDNA	   clones.	  	  	  
The	  bands	  of	   interest	  were	  separated	  by	  electrophoresis	   (see	  section	  2.2.13)	  excised	  
from	  a	  0.7%	  low	  melting	  point	  (LMP)	  agarose	  (Fisher	  Scientific;	  Loughborough,	  UK)	  gel	  
using	   an	   individual	   sterile	   scalpel	   each	   before	   purifying	   the	   DNA	   using	   the	   QIAGEN	  
QIAEX	  II	  kit	  (Manchester,	  UK)	  according	  to	  manufacturer’s	  instructions.	  	  	  
	  
2.1.3	  Ligation	  
Fragments	   to	   be	   subcloned	   were	   ligated	   with	   T4	   DNA	   ligase	   (NEB).	   	   Purified	   DNA	  
fragments	  were	  incubated	  with	  200	  units	  of	  ligase	  at	  16°C	  overnight	  at	  a	  molar	  ratio	  of	  
3:1	  (insert:vector)	  in	  which	  the	  total	  amount	  of	  DNA	  never	  exceeded	  100ng.	  	  Ligation	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mixes	  were	  heat	  inactivated	  at	  65°C	  for	  15	  minutes.	  	  If	  only	  one	  restriction	  enzyme	  was	  
used	   to	   generate	   the	   DNA	   fragments	   or	   the	   two	   enzymes	   produced	   compatible	  
overhangs,	   the	   vector	   sample	   was	   pre-­‐treated	   with	   Antarctic	   phosphatase	   (NEB)	   to	  
prevent	  religation	  of	  the	  fragments.	  	  Restriction	  endonuclease	  enzymes	  that	  produced	  
a	  5’	  extension	  were	  incubated	  with	  2.5	  units	  of	  Antarctic	  phosphatase	  for	  15	  minutes	  
at	  37°C.	   	  For	  enzymes	  that	  produced	  blunt	  ends,	  digested	   fragments	  were	   incubated	  
for	  1	  hour	  at	  37°C.	  
	  
2.1.4	  Transformation	  of	  E.coli	  
XL10	  Gold	  ultracompetent	  Escherichia	  coli	  (E.coli)	  (Agilent	  technologies)	  were	  used	  for	  
bacterial	   transformation.	   	   Cells	   and	   DNA	   were	   defrosted	   on	   ice	   before	   adding	   β-­‐
mercaptoethanol	  to	  a	  final	  concentration	  of	  4%	  v/v	  to	  a	  100µl	  aliquot	  of	  cells.	  	  	  	  	  50ng	  
of	   plasmid	  DNA	  was	  mixed	   gently	  with	   50µl	   of	   XL10	  Gold	   cells	   in	   a	   pre-­‐chilled	   14ml	  
falcon	  tube	  and	  placed	  on	   ice	   for	  30	  minutes.	   	  The	  mixture	  was	  heat	  shocked	   for	  30	  
seconds	  at	  42°C	  in	  a	  water	  bath	  and	  placed	  back	  on	  ice	  for	  2	  minutes.	  	  900µl	  of	  super	  
optimal	  broth	  with	  catabolite	  repression	  (SOC)	  medium	  (1%	  w/v	  tryptone,	  0.25%	  w/v	  
yeast	   extract,	   4.28mM	   sodium	   chloride	   (NaCl),	   2.5mM,	   10mM	   magnesium	   chloride	  
(MgCl2),	  20mM	  magnesium	  sulphate	  (MgSO4),	  20mM	  glucose,	  pH	  7)	  was	  added	  to	  the	  
mixture	  before	  placing	  them	  in	  a	  37°C	  shaking	  incubator	  for	  1	  hour.	  100µl	  of	  the	  E.coli	  
and	   SOC	   mixture	   was	   then	   plated	   onto	   Luria-­‐Bertani	   (LB)	   agar	   plates	   (0.5%	   w/v	  
tryptone,	   0.25%	   w/v	   yeast	   extract,	   171mM,	   0.75%	   w/v	   agar)	   containing	   50µg/ml	  
ampicillin	  and	  incubated	  overnight	  at	  37°C.	  	  	  
When	  transforming	  XL10	  Gold	  cells	  after	  ligation,	  the	  same	  procedure	  was	  carried	  out,	  
however,	  after	  incubation	  with	  SOC	  medium,	  the	  E.coli	  were	  pelleted	  and	  resuspended	  
in	   100µl	   of	   SOC	   medium	   and	   plated	   onto	   the	   LB	   agar	   plates	   containing	   50µg/ml	  
ampicillin.	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2.1.5	  Overnight	  cultures	  
Overnight	   bacterial	   cultures	  were	   established	   for	   a	   number	   of	   bacterial	   colonies	   on	  
plates	   containing	   potentially	   successfully	   ligated	   subclones	   and	   full-­‐length	   plasmid	  
constructs.	   	   Initially,	  mini-­‐prep	   cultures	  were	   set	   up	   to	   screen	   for	   successful	   ligation	  
followed	   by	  maxi-­‐prep	   cultures	   to	   produce	   large	   quantities	   of	   plasmid	   DNA	   for	   the	  
transfection	  experiments.	  
	  
2.1.5.1	  Mini-­‐prep	  overnight	  cultures	  	  
Single	  bacterial	  colonies	  were	  picked	  for	  overnight	  cultures	  using	  an	  individual	  sterile	  
inoculation	  loop.	  	  Colonies	  were	  placed	  into	  14ml	  falcon	  tubes	  with	  4ml	  of	  LB	  medium	  
containing	  50µg/ml	  ampicillin.	  	  Tubes	  were	  placed	  in	  a	  shaking	  incubator	  overnight	  at	  
37°C	  .	  
	  
2.1.5.2	  Maxi-­‐prep	  overnight	  cultures.	  	  	  
A	   single	   bacterial	   colony	  was	   picked	   using	   an	   individual	   sterile	   inoculation	   loop	   and	  
placed	   into	   4ml	   of	   LB	   broth	   containing	   50µg/ml	   ampicillin	   as	   a	   starter	   culture.	   	   The	  
tubes	  were	  placed	   in	  a	   shaking	   incubator	  at	  37°C	   for	  8	  hours.	   	   	   For	   cDNA	  constructs	  
200µl	   of	   the	   starter	   culture	  was	   diluted	   into	   100ml	   of	   LB	   broth	   containing	   50µg/ml	  
ampicillin	  and	  placed	   in	  a	  37°C	   shaking	   incubator.	   	   For	   cosmid	  DNA,	  500µl	  of	   starter	  
culture	  was	  used	   to	   inoculate	  250ml	  of	   super	  optimal	  broth	   (SOB)	  broth	   (1%	  weight	  
per	   volume	   (w/v)	   tryptone,	   0.25%	   w/v	   yeast	   extract,	   4.28mM	  NaCl,	   2.5mM,	   10mM	  
MgCl2,	  pH	  7)	  containing	  50µg/ml	  ampicillin.	  
	  
2.1.6	  Glycerol	  stocks	  
Glycerol	  stocks	  were	  made	  of	  all	  cultures	  of	  interest.	  	  500µl	  of	  bacteria	  taken	  from	  the	  
overnight	  cultures	  was	  mixed	  1:1	  with	  30%	  glycerol	   in	  a	  2ml	  cryo-­‐tube	  to	  create	  15%	  
glycerol	  stocks.	  	  Cultures	  were	  flash	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  	  Any	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stocks	  that	  were	  tested	  and	  proved	  negative	  for	  the	  plasmid	  of	  interest	  were	  allowed	  
to	   defrost	   before	   being	   treated	   with	   1%	   virkon	   overnight	   according	   to	   the	   local	  
biological	  safety	  regulations.	  
	  
2.1.7	  Plasmid	  DNA	  extraction	  
As	  discussed	  in	  section	  2.1.6,	  overnight	  cultures	  were	  established	  for	  bacterial	  colonies	  
of	   interest.	   	   The	   mini-­‐prep	   plasmid	   DNA	   extraction	   was	   performed	   to	   an	   in-­‐house	  
protocol	  whereas	  maxi-­‐prep	  plasmid	  DNA	  extractions	  were	  performed	  using	  a	  QIAGEN	  
EndoFree	  maxi-­‐prep	  kit.	  	  Both	  protocols	  used	  an	  alkaline	  lysis	  method	  for	  plasmid	  DNA	  
extraction.	  
	  
2.1.7.1	  Mini-­‐prep	  plasmid	  DNA	  extraction	  	  
Bacterial	  cultures	  grown	  overnight	  in	  14ml	  falcon	  tubes	  were	  centrifuged	  at	  1,500	  x	  g	  
for	  10	  minutes	  at	  4°C.	   	  The	  supernatant	  was	  discarded.	   	  Pellets	  were	  resuspended	   in	  
200µl	  of	  ice-­‐cold	  resuspension	  buffer	  (50mM	  glucose,	  20mM	  Tris,	  10mM	  EDTA,	  pH	  8)	  
by	  vortexing.	  	  400µl	  of	  room	  temperature	  lysis	  buffer	  (0.2M	  sodium	  hydroxide	  (NaOH)	  
1%	  w/v	  Sodium	  dodecyl	  sulphate	  (SDS))	  was	  added.	  	  The	  tubes	  were	  inverted	  several	  
times	  to	  ensure	  thorough	  mixing	  and	  placed	  on	  ice	  for	  no	  more	  than	  5	  minutes.	  	  After	  
the	  incubation	  time	  300µl	  of	  neutralisation	  buffer	  (3M	  potassium	  acetate,	  pH	  5.5)	  was	  
added.	  	  The	  tubes	  were	  inverted	  several	  times	  to	  ensure	  thorough	  mixing	  to	  neutralise	  
the	  reaction.	  	  All	  samples	  were	  centrifuged	  at	  full	  speed	  in	  a	  microcentrifuge	  at	  4°C	  for	  
10	   minutes.	   	   The	   supernatant	   was	   transferred	   to	   a	   fresh	   1.5ml	   centrifuge	   tube	  
containing	   0.7	   volumes	   of	   100%	   isopropanol.	   	   The	   samples	   were	   mixed	   gently	   and	  
centrifuged	  at	  full	  speed	  in	  a	  microcentrifuge	  at	  4°C	  for	  45	  minutes.	  	  The	  supernatant	  
was	  discarded	  and	  the	  pellet	  was	  washed	  with	  1ml	  of	  70%	  ethanol	  by	  centrifuging	  at	  
full	   speed	   in	   a	   microcentrifuge	   at	   4°C	   for	   10	   minutes.	   	   The	   supernatant	   was	   again	  
discarded	  and	  the	  pellet	  was	  allowed	  to	  air	  dry	  for	  10	  minutes.	  	  Once	  the	  pellet	  was	  a	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bright	   white	   colour	   it	   was	   redissolved	   in	   50µl	   of	   Tris	   EDTA	   (TE)	   buffer	   (10mM	   Tris,	  
1mM	  EDTA).	  	  DNA	  pellets	  were	  allowed	  to	  dissolve	  at	  4°C	  before	  being	  quantified	  and	  
stored	  at	  -­‐20°C	  long	  term.	  
	  
2.1.7.2	  Maxi-­‐prep	  plasmid	  DNA	  extraction	  
Maxi-­‐prep	   plasmid	   DNA	   extraction	   was	   carried	   out	   using	   the	   QIAGEN	   EndoFree	  
plasmid	   maxi	   kit	   with	   a	   modified	   protocol.	   	   DNA	   eluted	   from	   the	   QIAGEN	   tip	   was	  
precipitated	   with	   0.7	   volumes	   of	   room	   temperature	   isopropanol	   and	   centrifuged	   at	  
1,500	   x	   g	   for	   90	  minutes	   at	   4°C	   followed	   by	  washing	   the	   DNA	   pellet	   with	   5ml	   70%	  
ethanol	   and	   centrifuging	   at	   1,500	   x	   g	   for	   90	   minutes	   at	   4°C.	   	   The	   DNA	   pellet	   was	  
allowed	  to	  dry	  for	  30	  minutes	  before	  being	  resuspended	  in	  100µl	  TE	  buffer.	  
	  
2.1.8	  DNA	  quantification	  
DNA	   was	   quantified	   using	   either	   gel	   electrophoresis	   or	   a	   Nanodrop	   1000	  
spectrophotometer.	  	  For	  gel	  electrophoresis	  quantification	  samples	  were	  run	  on	  a	  1%	  
agarose	  gel	  (see	  section	  2.1.13).	  	  Linear	  DNA	  samples	  were	  run	  with	  a	  DNA	  MassRuler	  
ladder	  of	   known	  band	   concentrations	   for	   comparison.	   	   For	   the	  Nanodrop	  1µl	   of	   the	  
DNA	   to	   be	   measured	   was	   placed	   on	   the	   spectrophotometer	   stage	   and	   absorbance	  
reads	  were	   taken.	   	  DNA	  quantity	  was	  measured	  as	  compared	   to	  a	  blank	  sample	  and	  
DNA	  quality	  read	  was	  measured	  by	  dividing	  the	  absorbance	  at	  260	  nanometres	   (nm)	  




When	   plasmid	   DNAs	   were	   linearised	   for	   stable	   transfection	   of	   HEK293	   cells	   (see	  
section	  2.2.6)	  or	  after	  PacI	  digestion	  of	  the	  cosmid	  DNA	  set	  for	  HSV-­‐1	  packaging	  (see	  
section	  2.2.8),	  they	  were	  purified	  of	  protein	  using	  a	  phenol:chloroform	  method.	   	  The	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restriction	  digest	  reaction	  was	  made	  up	  to	  600µl	  using	  TE	  buffer.	  	  An	  equal	  volume	  of	  
25:24:1	   phenol:chloroform:isoamyl	   alcohol	   (Fisher	   Scientific)	   was	   added	   and	   mixed	  
thoroughly.	  	  Samples	  were	  centrifuged	  at	  full	  speed	  in	  a	  microcentrifuge	  for	  1	  minute.	  	  
The	   aqueous	   phase	   was	   gently	   removed	   ensuring	   that	   the	   interphase	   was	   not	  
disturbed	   and	  placed	   into	   a	   fresh	   1.5ml	   centrifuge	   tube.	   0.1	   volumes	   of	   3M	   sodium	  
acetate	  (pH	  5.5)	  and	  0.7	  volumes	  of	  100%	  isopropanol	  were	  added	  to	  the	  samples	  and	  
mixed	   gently.	   	   Samples	   were	   stored	   at	   -­‐80°C	   for	   2	   hours	   or	   -­‐20°C	   overnight	   to	  
precipitate	   the	   DNA.	   	   The	   precipitated	   samples	   were	   centrifuged	   at	   full	   speed	   in	   a	  
microcentrifuge	  at	  4°C	  for	  30	  minutes.	   	  The	  supernatant	  was	  discarded	  and	  the	  DNA	  
pellet	   was	   washed	   with	   1ml	   of	   70%	   ethanol	   by	   centrifugation	   at	   full	   speed	   in	   a	  
microcentrifuge	  at	  4°C	  for	  15	  minutes.	  	  The	  supernatant	  was	  again	  discarded	  and	  the	  
pellet	   was	   allowed	   to	   air	   dry	   for	   10	   minutes	   before	   redissolving	   in	   20µl	   of	   TE.	   	   As	  
phenol	   is	   toxic	   to	   the	   cells	   being	   used,	   purity	   of	   the	   samples	  were	   analysed	   using	   a	  
Nanodrop	   1000	   (see	   section	   2.1.9).	   	   Phenol	   and	   protein	   contamination	   produced	   a	  
characteristic	   shift	   to	   the	   left	   on	   the	   Nanodrop	   plots	   resulting	   in	   a	   decrease	   in	   the	  
260/280	  ratios.	  	  If	  this	  shift	  was	  seen	  the	  DNA	  was	  reprecipitated	  using	  0.1	  volumes	  of	  
3M	  sodium	  acetate	  (pH	  5.5)	  and	  0.7	  volumes	  of	  100%	  isopropanol	  overnight	  at	  -­‐20°C	  
before	  washing	  the	  pellet	  again	  as	  before.	  	  This	  process	  was	  repeated	  until	  no	  phenol	  
contamination	  was	  seen	  on	  the	  Nanodrop	  plots.	  
	  
2.1.10	  Polymerase	  chain	  reaction	  
Polymerase	   chain	   reaction	   (PCR)	   was	   used	   to	   amplify	   regions	   of	   RYR1	   cDNA	   for	  
confirmation	  of	  successful	  ligations	  and	  mutagenesis.	  	  PCR	  products	  were	  sent	  for	  DNA	  
sequencing	   (see	   section	   2.1.14).	   	   PCR	   cycling	   reactions	   were	   carried	   out	   using	  
Thermoprime	  Taq	  polymerase	   (Thermo	  Scientific;	  Loughborough,	  UK)	  on	  a	  GeneAmp	  
2700	   thermocycler.	   	   The	   PCR	   reactions	   contained	   10x	   Taq	   reaction	   buffer,	   20pmol	  
each	  primer,	  0.25mM	  each	  dNTP,	  1mM	  MgCl2,	  2.5	  units	  of	  Taq	  polymerase	  and	  100ng	  
of	   template	   DNA	   in	   a	   total	   reaction	   volume	   of	   25µl.	   	   Oligonucleotide	   primers	   were	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designed	   using	   Primer	   3	   (http://frodo.wi.mit.edu/)	   to	   be	   between	   15	   and	   25	  
nucleotides	   long	   with	   a	   melting	   temperature	   of	   60°C	   and	   obtained	   from	   IDT	  
technologies	   (Leuven,	   Belgium).	   	   Cycling	   conditions	   were	   specifically	   optimised	   for	  
each	   reaction	   with	   an	   annealing	   temperature	   of	   58°C	   as	   a	   starting	   point.	   	   On	   rare	  
occasions	   when	   58°C	   was	   an	   unsuitable	   annealing	   temperature	   for	   PCR,	   an	  
optimisation	   reaction	  was	   carried	  out	  on	  a	  DNAEngine	  Peltier	   gradient	   thermocycler	  
with	   a	   gradient	   of	   annealing	   temperatures	   ranging	   from	   50°C	   to	   58°C	   to	   obtain	   the	  
optimal	  annealing	  temperature.	  	  A	  list	  of	  primers	  used	  in	  this	  project	  for	  the	  screening	  
of	  the	  various	  subclones	  is	  given	  in	  Table	  2.1	  
	  
	  
Primer	  name	   Primer	  sequence	  (5’-­‐3’)	   Target	  
pBSrev	   ATTAATGCAGCTGGCACGAC	   5’	  subclone	  SpeI	  restriction	  
site	  	  SC11	   ATGGCATGGCCATACAGG	  
5scHindfor	   GGCCTCTTCGCTATTACGC	   5’	  subclone	  HindIII	  
restriction	  site	  5scHindrev	   AGGACATCGAGGAGATGGTG	  
pBSfor	   GTCCCATTCGCCATTCAG	   3’	  subclone	  Acc65I	  
restriction	  site	  SC31	   GCGGTTCCTCACCAAAGTG	  
pBSrev	   ATTAATGCAGCTGGCACGAC	   3’	  subclone	  XbaI	  restriction	  
site	  	  SC42	   CATGGCTTCGAGACTCAC	  
pTUNE_BspEIfor	   GCATCAGAGCAGCCGATT	   pTUNE	  plasmid	  
endogenous	  BspEI	  site	  pTUNE_BspEIrev	   GCGCCACCTTCTACTCCTC	  
pTUNEfor	   TCGCTGATTTGTGTAGGGGA	   XhoI/Acc65I	  restriction	  site	  
in	  pTUNE	  subclone	  pTUNESCrev	   GGATGGCCTCTTCGATGG	  
pTUNESCFLfor	   CCAAGTGCTTCATCTGTGGA	   SalI/BsiWI	  restriction	  site	  in	  
pTUNE	  subclone	  pTUNErev	   CGGGAATTCGTCGACTGG	  
pTUNEFLfor	   ACATTCTGCGCGTTGCTAGT	   SpeI/NheI	  restriction	  in	  full-­‐
length	  pTUNERYR1	  pTUNErev	   CGGGAATTCGTCGACTGG	  
pHSVfor	   GTCCTCGTCGATAAGCTTGC	   5’	  end	  of	  RYR1	  in	  full-­‐length	  
pHSVRYR1	  RYR1HSVrev	   GGCGGAGTTGTTACGACATT	  
RYR1HSVfor	   AGCACAACCTGGCCAATTAC	   3’	  end	  of	  RYR1	  in	  full-­‐length	  
pHSVRYR1	  pHSVrev	   GGGCATCTCTACCTCAGTGC	  
Table	  2.1	  –	  Primers	  to	  screen	  for	  successful	  generation	  of	  the	  various	  subclones	  created	  in	  this	  project	  
Listed	  are	  all	  the	  primers	  used	  to	  screen	  potential	  subclones	  generated	  for	  the	  various	  cloning	  steps	  in	  this	  
project.	  	  Primers	  were	  designed	  to	  create	  a	  PCR	  product	  over	  the	  restriction	  sites	  used	  for	  ligation.	  	  A	  PCR	  product	  
would	  only	  be	  generated	  if	  ligation	  had	  been	  successful.	  
	   47	  
2.1.11	  MEGAWHOP	  
Mega	   primer	   PCR	   of	   whole	   plasmid	   (MEGAWHOP)	   was	   used	   for	   site-­‐directed	  
mutagenesis	   to	   introduce	   specific	   single	   nucleotide	   missense	   mutations	   into	   RYR1	  
cDNA	   constructs.	   	   MEGAWHOP	   mutagenesis	   utilises	   a	   mega	   primer	   system	   in	  
conjunction	  with	  the	  QuikChange	  mutagenesis	  protocol	  (Figure	  2.1).	  	  MEGAWHOP	  was	  
originally	  developed	  for	  the	  introduction	  of	  random	  mutations	  into	  cDNA	  libraries	  but	  
has	  been	  successfully	  used	  in	  the	  site-­‐directed	  mutagenesis	  of	  large	  plasmid	  constructs	  
(Miyazaki,	   2003,	   Sato	   et	   al.,	   2010,	   Sato	   et	   al.,	   2013).	   	   Forward	   mutagenic	   primers	  
between	  20	  and	  35	  nucleotides	   long	  were	  designed	  with	  the	  desired	  mutation	  in	  the	  
middle,	   allowing	   strong	   binding	   to	   the	   template	  DNA	   at	   either	   side	   of	   the	  missense	  
change.	   	   This	   was	   partnered	   with	   a	   reverse	   wild	   type	   primer	   between	   15	   and	   20	  
nucleotides	  long,	  resulting	  in	  a	  PCR	  product	  of	  200	  to	  800	  bp.	  	  This	  first	  round	  of	  PCR	  
generated	   a	   mutated	   double	   stranded	   PCR	   product,	   which,	   after	   confirmation	   of	  
successful	  introduction	  of	  the	  missense	  change	  via	  sequencing	  (see	  section	  2.1.14)	  was	  
used	  as	  a	  pair	  of	  mutagenic	  mega	  primers.	  	  Whole	  plasmid	  DNA	  replication	  was	  carried	  
out	   using	   Pfu	   ultra	   DNA	   polymerase	   (Agilent	   Technologies)	   according	   to	   the	  
QuikChange	   system	   but	   with	   the	   mega	   primers	   generated	   in	   the	   first	   mutagenesis	  
step.	   	  The	  PCR	  reaction	  was	  digested	  with	  the	  DpnI	  restriction	  enzyme,	  removing	  the	  
Dam+	  methylated	  template	  DNA,	   leaving	  only	  unmethylated,	   replicated	  PCR	  product.	  	  	  
The	  PCR	  product	  was	  then	  transformed	  into	  XL10	  Gold	  E.coli	  and	  grown	  on	  LB	  plates	  
containing	   ampicillin	   (see	   section	   2.1.5)	   before	   plasmid	   DNA	   extraction	   (see	   section	  
2.1.8.1)	   and	   PCR	   screening	   for	   successful	   mutagenesis.	   	   The	   primers	   used	   for	  
mutagenesis	  and	  subsequent	  screening	  are	  listed	  in	  Table	  2.2.	  
The	  mega-­‐primer	  generating	  PCR	  was	  carried	  out	  using	  10x	  Taq	  polymerase	  reaction	  
buffer,	   20pmol	   of	   each	   primer,	   0.25mM	   each	   dNTP,	   1mM	   MgCl2,	   2.5	   units	   of	   Taq	  
polymerase,	  100ng	  of	  template	  DNA	  in	  a	  total	  volume	  of	  25µl.	  	  The	  cycling	  conditions	  
were	  an	  initial	  denaturation	  step	  of	  95°C	  for	  5	  minutes	  followed	  by	  25	  cycles	  of	  95°C	  
for	   30	   seconds,	   58°C	   for	   30	   seconds	   and	   72°C	   for	   45	   seconds	   followed	   by	   a	   final	  
extension	  step	  of	  72°C	  for	  7	  minutes.	  
	   48	  
Whole	  plasmid	  PCR	  followed	  using	  5x	  Pfu	  ultra	  polymerase	  reaction	  buffer,	  200ng	  of	  
mega	  primers,	  0.25mM	  each	  dNTP,	  2mM	  MgCl2,	  2.5	  units	  of	  Pfu	  ultra	  DNA	  polymerase	  
and	  100ng	  of	   template	  DNA	   in	  a	   total	  volume	  of	  50µl.	   	  The	   reaction	   included	  a	   final	  
concentration	  of	   6%	   (v/v)	   of	  Quiksolution	   from	   the	  Agilent	  mutagenesis	   kit.	   	   Cycling	  
conditions	  consisted	  of	  an	   initial	  denaturation	  step	  of	  95°C	  for	  1	  min	   followed	  by	  18	  
cycles	  of	  95°C	  for	  50	  seconds,	  53°C	  for	  50	  seconds	  and	  68°C	  for	  2	  minutes	  per	  kb	  of	  
template	  DNA	  followed	  by	  a	  final	  extension	  step	  of	  7	  minutes	  at	  68°C.	  
	  
2.1.12	  Electrophoresis	  
DNA	   gel	   electrophoresis	   was	   performed	   using	   0.7%-­‐2%	   agarose	   depending	   on	   the	  
product	  sizes	  expected	  containing	  0.5µg/ml	  ethidium	  bromide.	   	  Gels	  were	  made	  and	  
run	  in	  1x	  Tris-­‐acetic	  acid-­‐EDTA	  (TAE)	  buffer	  (40mM	  Tris,	  20mM	  acetic	  acid,	  1mM	  EDTA)	  
and	   allowed	   to	   set	   before	   loading	   samples	   and	   subjecting	   it	   to	   an	   electric	   current.	  	  
DNA	  samples	  were	  electrophoresed	  for	  between	  20	  minutes	  and	  1	  hour	  at	  100-­‐150v	  
depending	  on	  the	  product	  sizes	  expected.	  	  Products	  were	  visualized	  using	  ultra	  violet	  
(UV)	   light	   in	   a	   UGenius	   Gene	   Flash	   gel	   doc	   system.	   	   When	   PCR	   products	   or	   digest	  
fragments	   were	   required	   for	   gel	   extraction,	   DNA	   samples	   were	   run	   on	   a	   0.7%	   LMP	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   Primer	  sequence	  (5’-­‐3’)	   Target	  
subclone	  Mutation	   p.D1056H	  (c.3166	  G>C)	  
Mutagenic	  primer	  (forward)	   AACATCGAGCCTCCTCACCAGGAGCCCAGT	   	  
5’	  PCR	  screening	  primer	  (forward)	   AGAAAATGGGCACAACGTG	  
Reverse	  primer	  (both	  reactions)	   GTCGATCATACAGCCAACGA	  
	   	   	  
Mutation	   p.R2336H	  (c.7007	  G>A)	   	  
3’	  Mutagenic	  primer	  (forward)	   TACCTGGACTTCCTGCACTTTGCTGTCTTCGTCAA	  
PCR	  screening	  primer	  (forward)	   GAGCTGGCCTTGGCATT	  
Reverse	  primer	  (both	  reactions)	   TGCCGGCTTGGATTAGAT	  
	   	   	  
Mutation	   p.R2355W	  (c.7063	  C>T)	   	  
3’	  Mutagenic	  primer	  (forward)	   ACGCCAATGTGGTGGTGTGGCTGCTCATCCGGAA	  
PCR	  screening	  primer	  (forward)	   GAGCTGGCCTTGGCATT	  
Reverse	  primer	  (both	  reactions)	   TGCCGGCTTGGATTAGAT	  
	   	   	  
Mutation	   p.E3104K	  (c.9310	  G>A)	   	  
3’	  Mutagenic	  primer	  (forward)	   CTCGGAGGACATCAAGAAGATGGTGGAGAA	  
PCR	  screening	  primer	  (forward)	   GAGTCTCTCTCTTTGGGACA	  
Reverse	  primer	  (both	  reactions)	   CAGCTGCGGCTCCAGGAA	  
	   	   	  
Mutation	   p.D3986E	  (c.11958	  	  C>G)	   	  
3’	  Mutagenic	  primer	  (forward)	   AGTCGCCTATGGGAGGCAGTGGTGGGATT	  
PCR	  screening	  primer	  (forward)	   CTACTCGGGCAAGGATGTCATT	  
Reverse	  primer	  (both	  reactions)	   CTTCTGGAAGTCCTTCTTGGAGAT	  
	   	   	  
Mutation	   p.G3990V	  (c.11969	  G>T)	   	  
3’	  Mutagenic	  primer	  (forward)	   ACGCAGTGGTGGTATTCCTGCACGTGTT	  
PCR	  screening	  primer	  (forward)	   CTACTCGGGCAAGGATGTCATT	  
Reverse	  primer	  (both	  reactions)	   CTTCTGGAAGTCCTTCTTGGAGAT	  
	   	   	  
Mutation	   p.V4849I	  (c.14545	  G>A)	   	  
3’	  Mutagenic	  primer	  (forward)	   GGCGGTGGTCATCTACCTGTACA	  
PCR	  screening	  primer	  (forward)	   TACCTGGGCTGGTATATGGTGATGT	  
Reverse	  primer	  (both	  reactions)	   GCACTTGGTCTCCATATCCTCCTT	  
Table	  2.2	  –	  List	  of	  primers	  used	  for	  mutagenesis	  and	  mutation	  site	  screening	  
Primers	  used	  for	  mutagenesis	  are	  listed	  in	  the	  table.	  	  A	  total	  of	  seven	  RYR1	  variants	  were	  targeted	  in	  the	  
subclones.	  	  Mutagenic	  forward	  primers	  (with	  the	  missense	  change	  highlighted	  in	  red)	  were	  paired	  with	  a	  reverse	  
primer	  to	  generate	  mutagenic	  mega	  primers	  that	  were	  subsequently	  used	  for	  whole	  plasmid	  mutagenesis.	  	  Upon	  
screening	  for	  successful	  mutagenesis	  the	  PCR	  screening	  primers	  were	  paired	  with	  the	  same	  reverse	  primer	  used	  
for	  the	  generation	  of	  the	  mega	  primers	  to	  screen	  over	  the	  mutation	  site.	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Figure	  2.1	  –	  MEGAWHOP	  mutagenesis.	  	  	  
(A)	  	  Mutagenic	  mega	  primers	  were	  created	  using	  a	  mutagenic	  forward	  primer	  of	  around	  30	  nucleotides	  in	  length	  
which	  was	  paired	  with	  a	  wild	  type	  reverse	  primer	  of	  20	  nucleotides	  to	  create	  a	  mutated	  PCR	  product	  of	  between	  
200	  and	  800bp.	  	  The	  mega	  primers	  were	  sent	  for	  sequencing	  to	  confirm	  the	  presence	  or	  absence	  of	  the	  desired	  
mutation.	  	  (B)	  Mutagenic	  mega	  primers	  were	  used	  for	  whole	  plasmid	  PCR	  to	  introduce	  the	  desired	  mutation	  into	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2.1.13	  Sequencing	  
DNA	   sequencing	  was	   performed	  on	   PCR	   products	   generated	   spanning	  mutation	   and	  
ligation	   sites	   to	   confirm	   successful	   mutagenesis	   and	   cloning	   respectively.	   	   PCR	  
products	  to	  be	  sequenced	  were	  purified	  by	  incubating	  with	  exosap-­‐IT	  (Affymetrix;	  High	  
Wycombe,	   UK)	   at	   37°C	   for	   30	   minutes	   using	   the	   manufacturers	   recommended	  
concentration	   and	   then	   heat	   inactivated	   at	   80°C	   for	   15	   minutes.	   	   Samples	   were	  
sequenced	  using	  the	  BigDye	  Terminator	  kit	  (Applied	  Biosystems).	  	  Purified	  PCR	  product	  
was	   mixed	   with	   1.6pmol	   of	   the	   primer	   used	   to	   generate	   the	   PCR	   product	   and	   the	  
BigDye	   components	   according	   to	  manufacturers	   recommendations.	   	   The	   sequencing	  
reaction	  was	  carried	  out	  on	  an	  Applied	  Biosystems	  Gene	  Amp	  2700	  thermocycler	  with	  
cycling	   conditions	   consisting	   of	   an	   initial	   denaturation	   step	   of	   96°C	   for	   5	   minutes	  
followed	   by	   30	   cycles	   of	   96°C	   for	   30	   seconds,	   58°C	   for	   20	   seconds	   and	   60°C	   for	   4	  
minutes.	  	  	  Sequenced	  products	  were	  precipitated	  with	  3M	  sodium	  acetate	  (pH	  5.5)	  and	  
resuspended	  in	  Hi-­‐Di	  formamide	  (Life	  Technologies;	  Paisley,	  UK).	  	  Resuspended	  pellets	  
were	  sent	  to	  the	  Leeds	  Institute	  of	  Molecular	  Medicine	  in-­‐house	  sequencing	  service	  for	  
sequence	  reading	  using	  an	  ABI3103xl	  genetic	  analyser	  (Life	  Technologies).	  	  Base	  calling	  
was	   performed	   by	   the	   service	   using	   Sequence	   Analysis	   v5.2	   and	   sequencing	   results	  
were	   examined	   in	   4peaks	   sequencing	   software	   (available	   to	   download	   at	  
http://nucleobytes.com/index.php/4peaks).	  
	  
2.2	  Materials	  for	  cell	  culture	  
In	   this	   project,	   various	   cell	   lines	  were	   used.	   	   HEK293	   cells	  were	   the	   primary	   in	   vitro	  
expression	  system	  used	   for	   functional	  experiments	   (LGC	  Standards;	  Teddington,	  UK).	  	  
1B5	   Myoblasts	   were	   differentiated	   into	   myotubes	   for	   functional	   experiments	   in	  
muscle-­‐like	  cells.	  	  2-­‐2	  cells	  were	  used	  for	  HSV-­‐1	  viral	  packaging	  (see	  section	  2.2.8)	  (The	  
1B5	  and	  2-­‐2	  cell	   lines	  were	  a	  gift	   from	  Professor	  Paul	  D	  Allen’s	   laboratory	   in	  Boston,	  
MA,	  USA	  as	  was	  the	  cosmid	  set	  used	  for	  viral	  packaging).	  A	  C2C12	  mouse	  myoblast	  cell	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line	   was	   used	   as	   a	   positive	   control	   for	   immunocytochemistry	   (Sigma-­‐Aldrich;	   Poole,	  
UK)	  (see	  section	  2.2.8.3.1).	  	  	  
	  
2.2.1	  Defrosting	  the	  cell	  lines	  
2ml	  cryo	  tubes	  containing	  a	  frozen	  aliquot	  of	  the	  cells	  required	  were	  defrosted	  quickly	  
by	  placing	  the	  tubes	  into	  a	  37°C	  water	  bath.	  	  Defrosted	  cells	  were	  placed	  into	  a	  50ml	  
falcon	   tube	   containing	   preheated	   growth	  medium	   and	   centrifuged	   for	   5	  minutes	   at	  
400	  x	  g.	  	  The	  cell	  pellet	  was	  resuspended	  in	  10ml	  of	  growth	  medium	  (see	  section	  2.2.2	  
for	  the	  growth	  medium	  of	  each	  cell	  line)	  and	  plated	  onto	  a	  10cm	  tissue	  culture	  dish.	  	  
	  
2.2.2	  Maintenance	  of	  cells	  
Cells	  were	  maintained	  in	  the	  growth	  medium	  recommended	  by	  the	  supplier	  or	  lab	  of	  
origin	  (Life	  Technologies).	  	  HEK293	  cells	  and	  C2C12	  cells	  were	  maintained	  in	  Dulbecco’s	  
Modified	  Essential	  Medium	  (DMEM)	  containing	  4.5g/L	  glucose,	   for	  stably	  transfected	  
HEK293	  cells,	  the	  growth	  medium	  was	  supplemented	  with	  0.5mg/ml	  G418.	  	  1B5	  cells	  
were	  maintained	   in	   DMEM	   containing	   1g/L	   D-­‐glucose	   and	   pyruvate.	   	   2-­‐2	   Cells	  were	  
maintained	   in	   DMEM	   containing	   4.5g/L	   glucose,	   25mM	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐
piperazineethanesulfonic	  acid	  (HEPES)	  and	  0.5mg/ml	  G418	  (Sigma-­‐Aldrich).	  	  All	  growth	  
media	  was	   supplemented	  with	   10%	   fetal	   bovine	   serum	   (FBS)	   (Biosera;	   Uckfield,	   UK)	  
and	  10-­‐units/ml	  penicillin	  and	  10µg/ml	  streptomycin	  solution	  (Life	  Technologies).	  
	  
2.2.3	  Passaging	  the	  cell	  lines	  
Growth	  medium	  was	  removed	  from	  the	  plates	  containing	  cells.	  	  The	  cells	  were	  washed	  
with	  phosphate-­‐buffered	  saline	  (PBS)	  (Life	  Technologies)	  pre-­‐heated	  to	  37°C	  before	  a	  
thin	  covering	  of	  0.25%	  Trypsin-­‐EDTA	  (T/E)	  (Life	  Technologies)	  was	  applied.	  	  The	  plates	  
were	  incubated	  at	  37°C	  for	  5	  minutes.	  	  Confirmation	  that	  the	  cells	  were	  detached	  from	  
the	  plate	  was	  seen	  under	  the	  light	  microscope.	  	  5ml	  of	  PBS	  was	  used	  to	  gently	  detach	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any	   remaining	  cells	  before	   transferring	   the	  cells	   to	  a	  50ml	   tube	   that	   contained	  15ml	  
PBS.	   	   Tubes	   were	   centrifuged	   at	   400	   x	   g	   for	   5	   minutes	   to	   pellet	   the	   cells.	   	   The	  
supernatant	   was	   discarded	   and	   the	   pellet	   was	   resuspended	   in	   10ml	   of	   growth	  
medium.	   	   The	   desired	   amount	   of	   suspension	   was	   added	   to	   new	   plates	   with	   fresh	  
growth	  medium	  in.	  
	  
2.2.4	  Freezing	  the	  cell	  lines	  
When	   cells	   were	   required	   for	   freezing	   the	   same	   procedure	   was	   carried	   out	   as	   for	  
passaging	   the	  cells	  up	  until	   they	  were	  pelleted	  and	  the	  supernatant	  discarded.	   	  Cells	  
were	   resuspended	   in	   the	   desired	   amount	   of	   freezing	   medium	   (full	   growth	   medium	  
with	  10%	  dimethyl	  sulphoxide	  (DMSO;	  Sigma	  Aldrich).	   	  2ml	  aliquots	  were	  placed	  into	  
cryotubes.	   	   The	   tubes	   were	   put	   in	   a	   ‘cool	   cell’	   freezing	   device	   (Sanyo-­‐Biomedical;	  
Loughborough,	  UK)	  and	  stored	  overnight	  at	  -­‐80°C	  to	  allow	  the	  cells	  to	  freeze	  slowly	  at	  
1°C	  per	  minute.	  	  The	  following	  day	  cells	  were	  taken	  to	  liquid	  nitrogen	  stores	  for	  long-­‐
term	  storage.	  
	  
2.2.5	  Cell	  counting	  
Cells	  were	  counted	  using	  a	  haemocytometer.	  	  Cells	  were	  passaged	  as	  described	  above	  
until	  the	  pelleting	  step.	  	  The	  cell	  pellets	  were	  resuspended	  in	  the	  required	  amount	  of	  
growth	  medium.	   	   10µl	  was	   added	   to	   the	  haemocytometer	   and	   all	   cells	  within	   the	   4	  
large	  corner	  squares	  were	  counted.	  	  The	  average	  cell	  number	  from	  the	  4	  squares	  was	  
equivalent	  to	  the	  amount	  of	  cells	  x	  104	  per	  ml	  of	  medium.	  	  The	  desired	  number	  of	  cells	  
was	  then	  plated	  onto	  the	  next	  tissue	  culture	  vessel.	  
	  
2.2.5.1	  Trypan	  blue	  viability	  stain	  
An	  antibiotic	  kill	  curve	  was	  established	  to	  determine	  the	  correct	  amount	  of	  selection	  
pressure	  to	  add	  to	  transfected	  cells.	   	  5	  x	  104	  HEK293	  cells	  were	  plated	   in	  TC25	  flasks	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and	   allowed	   to	   adhere	   to	   the	   vessel.	   	   24	   hours	   later,	   growth	   medium	   containing	  
varying	  levels	  of	  G418	  antibiotic	  were	  added	  to	  the	  cells	  (0mg/ml,	  0.5mg/ml,	  1mg/ml	  
and	  1.5mg/ml).	   	  Trypan	  blue	  viability	   staining	  was	  carried	  out	  every	  2	  days	  after	   the	  
addition	  of	  antibiotics	  to	  see	  how	  effectively	  G418	  was	  killing	  the	  cells.	  	  	  
Cells	  were	  passaged	  as	  described	  in	  section	  2.2.3	  up	  until	  the	  pelleting	  step.	  	  The	  cell	  
pellets	  were	  resuspended	  in	  200µl	  of	  PBS.	  	  An	  equal	  volume	  of	  0.4%	  w/v	  trypan	  blue	  
(Acros	   Organics;	   Geel,	   Belgium)	   was	   added	   to	   each	   cell	   suspension	   and	   allowed	   to	  
incubate	   at	   room	   temperature	   for	   5	  minutes.	   	   After	   incubation,	   10µl	   of	   the	  mixture	  
was	  added	  to	  a	  haemocytometer	  and	  visualised	  under	  a	  light	  microscope.	  	  Dead	  cells	  
took	  up	  the	  dye	  and	  therefore	  appeared	  dark	  blue	  whereas	  living	  cells	  remained	  white.	  	  
The	   total	   numbers	   of	   cells	   were	   counted	   and	   the	   percentage	   of	   dead	   cells	   was	  
calculated	  and	  plotted	   in	  a	  graph.	   	  When	  carrying	  out	   stable	   transfection	  of	  HEK293	  
cells,	  trypan	  blue	  viability	  staining	  was	  carried	  out	  after	  the	  initial	  selection	  of	  10	  days	  
to	   ensure	   that	   mock-­‐transfected	   cells	   were	   dead	   and	   transfected	   cells	   showed	  
resistance	  to	  the	  antibiotic	  (see	  section	  2.2.6).	  
	  
2.2.6	  Stable	  transfection	  of	  HEK293	  cells	  
Stable	  transfection	  of	  pcRYR1	  constructs	  into	  HEK293	  cells	  was	  performed	  to	  establish	  
cell	   lines	   expressing	   RYR1	   at	   high	   levels	   for	   caffeine-­‐induced	   calcium	   release	  
experiments.	  	  Prior	  to	  transfection,	  cells	  were	  plated	  into	  24-­‐well	  tissue	  culture	  plates	  
in	   antibiotic-­‐free	   growth	   medium	   and	   were	   allowed	   to	   grow	   to	   90%	   confluence.	  	  
Purified,	   linear	   plasmid	   DNA	   was	   diluted	   in	   50µl	   of	   Opti-­‐MEM	   (Life	   Technologies)	  
ensuring	  that	  800ng	  of	  DNA	  was	  present	  per	  transfection.	  	  2µl	  of	  Lipofectamine-­‐2000	  
(LF2000;	  Life	  Technologies)	  was	  also	  diluted	   in	  50µl	  of	  Opti-­‐MEM.	   	  The	  two	  mixtures	  
were	   allowed	   to	   incubate	   at	   room	   temperature	   for	   5	  minutes	  before	   combining	   the	  
two.	  	  The	  tubes	  were	  mixed	  gently	  and	  incubated	  at	  room	  temperature	  for	  20	  minutes	  
to	  allow	  the	  formation	  of	  DNA-­‐lipid	  complexes.	  	  After	  the	  incubation	  time,	  100µl	  of	  the	  
complexes	  were	  dropped	   into	  each	  well.	   	   The	  plate	  was	  gently	   rocked	   several	   times	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and	  placed	  in	  a	  37°C	  incubator	  with	  5%	  CO2.	  	  24	  hours	  post-­‐transfection	  cells	  were	  split	  
1:10	   and	   plated	   into	   10cm	   plates	   containing	   fresh	   growth	  medium.	   	   48	   hours	   after	  
transfection,	  antibiotic	  selection	  pressure	  was	  added	  to	  the	  growth	  medium	  (1mg/ml	  
G418).	  
Cells	  were	  allowed	   to	  grow	   in	   the	  high	   selection	  growth	  medium	   for	  10	  days	  before	  
carrying	   out	   trypan	   blue	   viability	   staining	   (see	   section	   2.2.5.1).	   	   If	  mock	   transfected	  
cells	  had	  a	  much	  higher	  dead	  cell	  count	  than	  transfected	  cells	  they	  were	  discarded	  and	  
the	   transfected	   cells	  were	   transferred	   to	   a	  new,	   lower	   selection	  pressure	   (0.8mg/ml	  
G418)	   and	   allowed	   to	   grow	   for	   a	   further	   10	   days.	   	   If	   mock	   transfected	   cells	   had	   a	  
similar	  dead	  cell	  count	  to	  transfected	  cells,	  high	  selection	  pressure	  was	  maintained	  for	  
a	   further	   10	   days	   and	   tested	   again	   using	   trypan	   blue.	   	   Cells	   were	   always	   split	   1:10	  
when	  70%	  confluence	  was	  reached.	  
After	  20	  days	  of	  selection	  the	  fastest	  growing	  cells	  were	  selected	  to	  take	  forward	  with	  
the	   remaining	   plates	   being	   frozen	   as	   back	   ups	   (see	   section	   2.2.4).	   	   The	   selection	  
pressure	  was	  dropped	  to	  0.5mg/ml	  G418.	  	  The	  cells	  were	  split	  and	  diluted	  enough	  to	  
ensure	  that	   individual	  colonies	  of	  cells	  had	  space	  to	  grow.	   	  Colonies	  were	  allowed	  to	  
grow	   for	   7	   days	   before	   the	   fastest	   growing	   were	   individually	   picked	   using	   a	   10ml	  
pipette	  and	  placed	  into	  a	  well	  each	  in	  a	  6-­‐well	  plate.	  	  The	  cells	  were	  allowed	  to	  grow	  
for	  a	  further	  7	  days	  before	  the	  fastest	  growing	  well	  was	  selected	  as	  the	  stable	  clone.	  
	  
2.2.7	  Transient	  transfection	  of	  HEK293	  cells	  
Transient	   transfection	   of	   pcRYR1	   constructs	   was	   also	   performed.	   	   Additionally,	  
transient	  transfection	  of	  pTUNERYR1	  plasmids	  was	  carried	  out	  due	  to	  the	  absence	  of	  a	  
suitable	  antibiotic	  selection	  gene	  after	  cloning.	  	  Transient	  transfection	  of	  plasmids	  into	  
HEK293	   cells	   was	   carried	   out	   prior	   to	   calcium	   release	   measurements	   (48	   hours	   for	  
pcRYR1	   constructs	   and	   72	   hours	   for	   pTUNERYR1	   constructs).	   	   The	   96-­‐well	   opti-­‐clear	  
plates	  used	  for	  transfection	  and	  calcium	  release	  measurements	  were	  pre-­‐coated	  with	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Entactin-­‐Collagen	   IV-­‐Laminin	   (ECL)	   (Millipore;	   Watford,	   UK)	   extracellular	   matrix	  
proteins	   to	   allow	   greater	   adhesion	   to	   the	   plate	   during	   the	   calcium	   release	  
experiments.	  	  The	  wells	  that	  would	  eventually	  contain	  cells	  were	  coated	  with	  ECL	  at	  a	  
final	  concentration	  of	  20µg/ml	  for	  1	  hour	  at	  37°C.	  	  	  	  5	  x	  104	  HEK293	  cells	  were	  plated	  
into	  each	  well	  of	  a	  96-­‐well	  plate	  and	  allowed	  to	  adhere	  overnight.	  	  The	  following	  day	  
DNA	  transfection	  was	  carried	  out.	  	  200ng	  of	  the	  desired	  construct	  and	  0.5µl	  of	  LF2000	  
was	  diluted	  with	  25µl	  of	  Opti-­‐MEM	  each	  and	  allowed	  to	  incubate	  at	  room	  temperature	  
for	  10	  minutes.	  	  Following	  the	  incubation	  period	  the	  DNA	  and	  LF2000	  were	  combined	  
and	   mixed	   gently	   and	   left	   at	   room	   temperature	   for	   20	   minutes	   to	   allow	   DNA:lipid	  
complex	   formation.	   	   After	   the	   incubation	   period,	   50µl	   of	   DNA:lipid	   complexes	  were	  
added	  to	  each	  well	  to	  be	  transfected.	  	  The	  plate	  was	  rocked	  gently	  several	  times	  and	  
placed	  in	  a	  5%	  CO2	  incubator	  for	  48	  hours	  prior	  to	  calcium	  release	  measurements.	  
	  
2.2.7.1	  pTUNERYR1	  expression	  induction	  
The	  pTUNE	  expression	  vector	  allows	  for	  inducible	  expression	  through	  a	  process	  based	  
on	   the	   lac	   operon	   (Figure	   2.2).	   	   In	   the	   switched	   off	   state,	   expression	   of	   RYR1	   is	  
inhibited	   by	   the	   constitutive	   expression	   of	   LacI	   proteins	   that	   bind	   to	   operator	   sites	  
directly	  upstream	  of	  a	  cytomegalovirus	  (CMV)	  promoter	  and	  Rous	  sarcoma	  virus	  (RSV)	  
promoter	  blocking	  transcription	  from	  both.	  	  The	  RSV	  promoter	  drives	  expression	  of	  the	  
gene	   of	   interest	   which,	   when	   blocked	   by	   LacI	   proteins	   results	   in	   limited,	   if	   any,	  
expression	   of	   the	   gene	   of	   interest.	   	   The	   CMV	   promoter	   drives	   expression	   of	   TetR	  
proteins	  which,	  when	  blocked	  results	  in	  the	  expression	  of	  a	  small	  hairpin	  ribose	  nucleic	  
acid	  (shRNA)	  that	  binds	  to	  the	  3’	  untranslated	  region	  of	  the	  gene	  of	  interest	  blocking	  
any	   residual	   gene	   expression.	   	   In	   the	   presence	   of	   Isopropyl-­‐β-­‐thiogalactopyranoside	  
(IPTG)	   (Cell	  Signalling	  Technology;	  Hitchin,	  UK),	   LacI	  expression	   is	  blocked	  preventing	  
the	  binding	  of	  these	  proteins	  upstream	  of	  the	  CMV	  and	  RSV	  promoters.	  	  This	  results	  in	  
expression	  of	  the	  gene	  of	  interest	  and	  absence	  of	  expression	  of	  the	  shRNA.	  	  Expression	  
can	  be	  fine	  tuned	  depending	  on	  the	  amount	  of	  IPTG	  added	  to	  the	  cell	  culture	  medium.	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HEK293	   cells	   transfected	   with	   pTUNERYR1	   constructs	   were	   allowed	   to	   sit	   in	   the	  
transfection	   mix	   for	   6	   hours	   before	   changing	   the	   medium	   to	   standard	   HEK293	   cell	  
growth	  medium	  containing	  the	  desired	  amount	  of	  IPTG.	  	  Fresh	  medium	  was	  added	  to	  
the	   transfected	   cells	   every	   24	   hours	   until	   caffeine-­‐induced	   calcium	   release	  
measurements	   or	   cell	   viability	   assays	   were	   carried	   out,	   in	   the	   case	   of	   pTUNERYR1	  
transfected	   cells,	   experiments	   were	   performed	   72	   hours	   post-­‐transfection.	   	   For	  
standard	   dose-­‐response	   experiments,	   an	   IPTG	   induction	   level	   of	   25µM	  was	   selected	  
based	  on	  information	  from	  Deans	  et	  al.	  (2007).	  	  A	  higher	  (250µM)	  and	  lower	  (2.5µM)	  
dose	  of	  IPTG	  was	  used	  to	  tune	  RYR1	  expression	  in	  later	  experiments.	  
	  
Figure	  2.2	  –	  Induction	  of	  pTUNERYR1	  constructs	  
(A)	  Repression	  of	  RYR1	  expression.	  	  A	  constitutively	  expressed	  LacI	  protein	  binds	  to	  LacO	  sites	  preventing	  the	  
transcription	  of	  the	  TetR	  protein	  as	  well	  as	  preventing	  RYR1	  expression	  from	  the	  RSV	  promoter.	  	  The	  TetO	  
promoter	  is	  free	  to	  transcribe	  a	  shRNA	  that	  binds	  to	  a	  target	  in	  the	  3’	  untranslated	  region	  of	  RYR1	  preventing	  any	  
expression	  that	  may	  pass	  through	  the	  initial	  LacI	  block.	  	  (B)	  Activation	  of	  gene	  expression	  using	  IPTG.	  	  IPTG	  
prevents	  the	  LacI	  proteins	  binding	  to	  LacO	  sites	  allowing	  expression	  of	  the	  TetR	  protein,	  which	  prevents	  the	  
shRNA	  binding	  to	  its	  target.	  	  Without	  a	  LacI	  protein	  bound	  to	  the	  LacO	  site	  and	  shRNA	  to	  its	  target,	  RYR1	  
expression	  can	  occur	  without	  being	  blocked.	  	  Redrawn	  from	  Deans	  et	  al	  2008.	  
	  
	  
2.2.7.1.1	  Treatment	  with	  AICAR	  
Some	   HEK293	   cells	   transfected	   with	   pTUNERYR1	   constructs	   were	   pre-­‐treated	   with	  
AICAR	  (Cell	  Signalling	  Technology)	  to	  examine	  its	  effect	  on	  caffeine	  sensitivity.	  	  In	  these	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experiments	   cells	   were	   incubated	   with	   1mM	   AICAR	   in	   the	   normal	   growth	   medium	  
containing	   the	   desired	   amount	   of	   IPTG	   to	   maintain	   RYR1	   expression.	   	   Cells	   were	  
treated	   with	   AICAR	   overnight	   prior	   to	   the	   caffeine-­‐induced	   calcium	   release	  
experiments	  or	  cell	  viability	  assays.	  
	  
2.2.8	  HSV-­‐1	  viral	  packaging	  
pHSVRYR1	   constructs	   generated	   through	   the	   cloning	   steps	   in	   this	   project	   were	  
packaged	   into	  HSV-­‐1	  virions	  according	   to	  previously	   reported	  protocols	   (Wang	  et	  al.,	  
2000,	  Yang	  et	  al.,	  2003),	  which	  are	  described	  below.	  
	  
2.2.8.1	  Preparation	  of	  2-­‐2	  cells	  and	  viral	  packaging	  
Monkey	  Vero	  2-­‐2	  cells	  were	  passaged	  in	  cell	  culture	  until	  there	  were	  ten	  10cm	  dishes	  
reaching	   confluence	   per	   pHSVRYR1	   construct	   to	   be	   packaged.	   	   The	   day	   before	   viral	  
packaging,	  3	  x	  106	  cells	  were	  plated	  onto	  each	  plate	  to	  be	  transfected.	  	  Viral	  packaging	  
was	  carried	  out	  on	  10	  plates	  for	  each	  construct.	  	  Co-­‐transfection	  of	  plasmid	  DNA	  and	  
cosmid	  DNAs	  containing	  the	  entire	  HSV-­‐1	  genome	  minus	  the	  viral	  packaging	  signal	  was	  
carried	  out	  to	  produce	  HSV-­‐1	  virions	  (Figure	  2.3	  A).	  	  The	  cosmid	  DNA	  set	  was	  produced	  
by	  Fraefel	  et	  al.	  (1996)	  and	  then	  modified	  by	  Wang	  et	  al.,(2000).	  	  Each	  of	  the	  5	  cosmid	  
DNAs	  were	  transfected	  at	  an	  equal	  molar	  ratio	  based	  on	  the	  size	  of	  each	  cosmid	  with	  
no	  more	  than	  1.2µg	  of	  any	  cosmid	  being	  used.	  	  1.2µg	  of	  the	  largest	  cosmid	  was	  added	  
to	  each	  plate.	  	  The	  concentration	  of	  each	  other	  cosmid	  in	  the	  mix	  was	  based	  on	  their	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Cosmid	   Size	  (bp)	   %	  of	  the	  largest	  cosmid	   Amount	  of	  DNA	  per	  plate	  transfected	  (µg)	  
6	   39,165	   98%	   1.176	  
14	   36,032	   90.7%	   1.08	  
28	   39,706	   -­‐	   1.2	  
48	   35,977	   90.6%	   1.08	  
56	   35,710	   89%	   1.07	  
	   	   	   Total:	  5.4	  
Table	  2.3	  –	  Ratios	  of	  each	  cosmid	  required	  for	  HSV-­‐1	  viral	  packaging.	  
Each	  of	  the	  five	  cosmids	  used	  for	  HSV-­‐1	  viral	  packaging	  needed	  to	  be	  co-­‐transfected	  at	  equal	  molar	  ratios.	  	  
Because	  each	  cosmid	  is	  different	  in	  size	  the	  amount	  of	  DNA	  in	  µg	  required	  to	  reach	  an	  equal	  molar	  ratio	  is	  
different.	  	  A	  maximum	  of	  6µg	  of	  cosmid	  DNA	  was	  required	  for	  each	  10cm	  dish	  transfected.	  	  Cosmid	  28	  was	  the	  
largest	  and	  the	  rest	  were	  calculated	  as	  a	  percentage	  of	  the	  largest	  to	  calculate	  the	  amount	  of	  DNA	  required	  
compared	  to	  the	  largest.	  	  1.2µg	  of	  DNA	  was	  used	  as	  the	  maximum	  amount	  of	  DNA	  for	  each	  cosmid.	  	  
	  
For	   each	   plate	   to	   be	   transfected	   the	   following	   reactions	   were	   set	   up;	   1.5µg	   of	   the	  
plasmid	  DNA	  construct	  (containing	  the	  HSV-­‐1	  packaging	  signals)	  was	  diluted	  with	  750µl	  
of	  Opti-­‐MEM.	   	   Cosmid	  DNA	   (containing	   the	   rest	   of	   the	  HSV-­‐1	   genome)	  mix	   totalling	  
5.4µg	  of	  cosmid	  DNA	  containing	  the	  entire	  HSV	  genome	  minus	  the	  packaging	  signals	  
were	  added.	  	  An	  equal	  volume	  of	  µl	  of	  PLUS	  reagent	  (Life	  Technologies)	  to	  µg	  of	  DNA	  
was	   added	   to	   the	  mixture,	  mixed	   gently	   and	   incubated	   at	   room	   temperature	   for	   10	  
minutes.	   	   At	   the	   same	   time,	   for	   each	   plate	   to	   be	   transfected,	   50µl	   of	   LF2000	   was	  
diluted	   in	   750µl	   of	   Opti-­‐MEM	   and	   incubated	   for	   10	   minutes	   at	   room	   temperature.	  	  
After	   the	   incubation	   period,	   the	   LF2000/Opti-­‐MEM	  mixture	  was	   added	   drop-­‐wise	   to	  
each	   plasmid	  DNA	   construct,	  mixed	   by	   inversion	   several	   times	   before	   an	   incubation	  
period	  of	  45	  minutes	  at	  room	  temperature.	  	  Each	  plate	  to	  be	  transfected	  was	  washed	  
3	  times	  with	  Opti-­‐MEM	  before	  the	  addition	  of	  8ml	  of	  transfection	  mix	  to	  each	  plate.	  	  
Plates	   were	   placed	   in	   a	   37°C	   and	   humidified	   5%	   CO2	   incubator	   for	   2.5	   days	   before	  
harvesting	  of	  the	  HSV-­‐1	  virions.	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Figure	  2.3	  –	  Strategy	  used	  to	  package	  pHSVRYR1	  constructs	  into	  HSV-­‐1	  virions	  
(A)	  Co-­‐transfection	  of	  the	  5	  cosmids	  and	  pHSVRYR1	  plasmid	  into	  2-­‐2	  cells.	  	  Cells	  are	  transfected	  and	  allowed	  to	  
remain	  in	  culture	  for	  2.5	  days	  to	  ensure	  high	  levels	  of	  HSV-­‐1	  within	  the	  cells	  upon	  harvesting.	  	  (B)	  Harvesting	  the	  
HSV-­‐1	  virions.	  	  Cells	  are	  pooled	  and	  harvested	  using	  a	  combination	  of	  freeze	  thawing	  and	  sonication	  to	  break	  
open	  the	  cells,	  freeing	  the	  HSV-­‐1	  virions.	  	  (C)	  Titration	  of	  the	  HSV-­‐1	  virions	  using	  2-­‐2	  cells	  to	  determine	  the	  viral	  
titre	  obtained	  in	  the	  2.5	  days	  of	  viral	  packaging.	  	  (D)	  After	  the	  viral	  titre	  has	  been	  determined,	  suitable	  amounts	  
of	  virions	  can	  be	  used	  to	  transduce	  dyspedic	  1B5	  cells	  to	  allow	  the	  expression	  of	  RYR1	  and	  subsequent	  calcium	  
release	  experiments.	  	  
	  
	  
2.2.8.2	  Harvesting	  HSV-­‐1	  virions	  
The	  following	  harvesting	  procedure	  was	  carried	  out	  for	  each	  construct	  being	  packaged	  
(Figure	  2.3	  B).	  	  Cells	  from	  each	  of	  the	  plates	  that	  were	  co-­‐transfected	  with	  the	  cosmid	  
DNA	   set	   and	   pHSVRYR1	   constructs	   were	   harvested	   with	   a	   cell	   scraper.	   	   Cells	  
transfected	  with	  each	  pHSVRYR1	   construct	  were	  pooled	   into	  a	  50ml	   falcon	   tube	  and	  
placed	  on	  ice	  for	  10	  minutes.	  	  Each	  tube	  was	  centrifuged	  at	  1,400	  x	  g	  for	  10	  minutes.	  	  
All	  but	  2ml	  of	   the	  supernatant	  was	  transferred	  to	  a	   fresh	  50ml	  falcon	  tube	  and	  flash	  
frozen	   in	  a	  dry-­‐ice	  ethanol	  bath.	   	  The	  majority	  of	   the	  packaged	  virions	  are	  contained	  
within	  the	  cells	  but	  the	  supernatant	  contains	  some	  virions	  and	  was	  frozen	  as	  back	  up	  
stock	  of	  virions.	  	  The	  remaining	  cell	  pellet	  was	  resuspended	  in	  the	  2ml	  supernatant	  left	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over	  and	  transferred	   into	  a	  14ml	   tube.	   	  The	  suspended	  cells	  were	  put	   through	  three	  
freeze/thaw	  cycles	  in	  a	  dry-­‐ice	  ethanol	  bath	  followed	  by	  thawing	  in	  a	  37°C	  water	  bath.	  	  
After	  the	  3	  cycles,	  cells	  were	  subjected	  to	  sonication	  at	  20%	  output	  for	  a	  total	  period	  
of	  20	  seconds	  in	  2-­‐second	  bursts.	   	  Sonicated	  cells	  were	  then	  centrifuged	  at	  1,400	  x	  g	  
for	   15	  minutes.	   	   The	   supernatant	  was	   transferred	   into	   100µl	   aliquots	   of	   virions	   and	  
flash	  frozen	  in	  a	  dry-­‐ice	  ethanol	  bath.	  	  Frozen	  virions	  and	  supernatants	  were	  stored	  at	  -­‐
80°C	  until	  needed.	  
	  
2.2.8.3	  Preparation	  of	  2-­‐2	  cells	  for	  HSV-­‐1	  virion	  titration	  
1	  X	  105	  Vero	  2-­‐2	  cells	  were	  plated	  onto	  a	  24-­‐well	  plate	  and	  cultured	  overnight.	   	  The	  
following	  day,	  1µl,	  5µl	  and	  20µl	  of	  harvested	  virions	  were	  diluted	  in	  DMEM	  containing	  
2%	  FBS	   to	  a	   total	  volume	  of	  250µl.	   	   The	  Vero	  2-­‐2	  cell	  growth	  medium	  was	   removed	  
and	  replaced	  with	  the	  250µl	  virion	  mixture	  and	  cultured	  overnight	  at	  37°C	  and	  5%	  CO2.	  	  
The	   following	   day,	   the	   virion	   mixture	   was	   replaced	   with	   standard	   2-­‐2	   cell	   growth	  
medium	  and	  cultured	  for	  a	  further	  24	  hours	  before	  being	  fixed	  with	  ice	  cold	  methanol	  
for	  20	  minutes	  at	  -­‐20°C.	  	  Fixed	  cells	  were	  washed	  with	  4°C	  PBS	  and	  stored	  at	  4°C	  until	  
required	  for	  titration	  using	  immunostaining	  (see	  section	  2.2.8.5)	  (Figure	  2.3C).	  
	  
2.2.8.4	  Preparation	  of	  1B5	  cells	  for	  HSV-­‐1	  virion	  titration	  
1B5	   Cells	   were	   differentiated	   on	   a	   96-­‐well	   Opti-­‐clear	   plate	   as	   described	   in	   section	  
2.2.8.6.	  	  Midway	  through	  the	  4-­‐day	  differentiation	  period,	  the	  differentiation	  medium	  
was	   removed	  and	   replaced	  with	  one	   containing	  either	  20µl,	   50µl	   or	   100µl	   virions	   in	  
growth	  medium	  with	  DMEM	  containing	  2%	  FBS	  to	  a	  total	  volume	  of	  150µl.	  	  Cells	  were	  
incubated	   in	   this	   medium	   overnight	   in	   an	   incubator	   at	   37°C	   and	   5%	   CO2	   before	  
replacing	   the	   medium	   with	   differentiation	   medium	   and	   incubation	   in	   the	   hypoxic	  
incubator	   for	   a	   further	   24	   hours	   prior	   to	   titration	   using	   caffeine-­‐induced	   calcium	  
release	  (Figure	  2.3D).	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2.2.8.5	  Immunocytochemistry	  assay	  
Fixed	  cells	  were	  washed	  with	  4°C	  PBS	  and	  blocked	  overnight	   in	  PBS	  with	  5%	  	  normal	  
Goat	   serum	   (NGS)	   (Life	   Technologies)	   at	   4°C.	   	   The	   following	   day,	   cells	  were	  washed	  
three	   times	   in	   PBS	  before	   the	  primary	   anti-­‐RYR1	  antibody	   (34C)	   (Sigma	  Aldrich)	  was	  
incubated	  with	  the	  cells	  at	  a	  concentration	  of	  1µg/ml	  diluted	  in	  PBS	  with	  5%	  NGS	  for	  2	  
hours	  at	  4°C.	   	  The	  cells	  were	  then	  washed	  with	  4°C	  PBS	  three	  times	  before	  adding	  a	  
goat-­‐anti-­‐mouse	   secondary	   antibody	   with	   Cy3	   conjugate	   (Jackson	   Immunoresearch;	  
Newmarket,	  UK)	  at	  a	  dilution	  of	  1:3000	  in	  PBS	  with	  5%	  NGS	  for	  1	  hour	  at	  4°C.	   	  After	  
secondary	   antibody	   staining,	   the	   cells	   were	   washed	   three	   times	   in	   4°C	   PBS	   before	  
being	   covered	  with	   300mM	   4',	   6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI;	   Life	   Technologies)	  
nucleic	  acid	  stain	  for	  5	  minutes	  and	  washing	  a	  further	  three	  times	  in	  4°C	  PBS.	  	  The	  cells	  
were	  then	  coated	  in	  4°C	  PBS	  prior	  to	  detection.	  
Fluorescence	  was	  detected	  using	  the	  Delta	  Vision	  wide	  field	  deconvolution	  microscope	  
in	  the	  University	  of	  Leeds,	  Faculty	  of	  Biological	  Sciences	  bio-­‐imaging	  facility.	  	  A	  60x	  oil	  
immersion	  lens	  was	  used	  to	  detect	  Cy3	  fluorescence	  using	  a	  filter	  set	  with	  excitation	  at	  
555/28nm	  and	  detection	  at	  617/73.	  	  DAPI	  staining	  was	  detected	  using	  a	  filter	  set	  with	  
excitation	   at	   360/40nm	   and	   emission	   at	   457/50nm.	   	   Images	  were	   overlaid	   together	  
and	  saved	  to	  file	  using	  SoftWoRx	  v3.3.6	  image	  acquisition	  software.	  
	  
2.2.8.6	  Differentiation	  of	  1B5	  cells	  and	  C2C12	  cells	  
1B5	  and	  C2C12	  cells	  were	  plated	  onto	  a	  96-­‐well	  Opti-­‐clear	  plate	  pre-­‐coated	  with	  ECL	  as	  
described	  in	  section	  2.2.7	  and	  allowed	  to	  grow	  to	  70%	  confluence	  before	  switching	  to	  
a	  differentiation	  medium	  containing	  2%	  heat-­‐inactivated	  horse	  serum	  (Sigma-­‐Aldrich)	  
as	  well	  as	  transferring	  the	  plate	  to	  a	  hypoxic	  incubator	  containing	  5%	  CO2	  and	  5%	  O2	  at	  
37°C.	   	   Cells	   were	   allowed	   to	   grow	   for	   4	   days	   in	   the	   hypoxic	   incubator	   to	   fully	  
differentiate	   myoblasts	   into	   myotubes.	   	   Complete	   differentiation	   was	   observed	  
through	   the	   presence	   of	   elongated	   and	   multinucleated	   myotubes	   under	   the	   light	  
microscope.	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2.2.9	  Transfection	  of	  1B5	  cells	  
Conventional	   transfection	   of	   1B5	   cells	   was	   also	   performed	   using	   LF2000	   and	   Xfect	  
polymer	   (Clonetech;	   Paris,	   France).	   	   LF2000	   transfections	  were	   performed	   using	   the	  
same	   reaction	   as	   described	   in	   section	   2.2.7.	   	   Transfections	   with	   the	   Xfect	   polymer	  
were	  performed	  to	  manufacturer’s	   instructions;	  briefly,	  400ng	  of	  DNA	  per	  well	   to	  be	  
transfected	  was	   diluted	   to	   25µl	  with	   the	   Xfect	   buffer.	   	   0.2µl	   per	   transfection	   of	   the	  
Xfect	  polymer	  was	  diluted	  to	  25µl	  with	  the	  Xfect	  buffer.	   	  Both	  tubes	  were	  combined	  
and	   vortexed	   at	   a	   medium	   speed	   for	   10	   seconds	   before	   a	   10-­‐minutes	   room	  
temperature	   incubation.	   	   Following	   the	   incubation,	   the	  50µl	  mix	  was	   added	   to	   each	  
well	  to	  be	  transfected.	  
Transfections	  using	  each	  method	  were	  performed	  at	  different	  differentiation	   stages.	  	  
Transfections	  were	  performed	  before	  a	  3-­‐day	  and	  4-­‐day	  differentiation	  step.	  	  For	  these	  
transfections,	   1B5	   cells	  were	   plated	   onto	   a	   96-­‐well	   Opti-­‐clear	   plate	   pre-­‐coated	  with	  
ECL	  24	  hours	  prior	  to	  transfection.	  	  Transfections	  were	  performed	  as	  described	  above.	  	  
Cells	   were	   allowed	   to	   sit	   in	   the	   transfection	   mixes	   for	   6	   hours	   before	   having	   the	  
medium	  changed	  to	  1B5	  differentiation	  medium	  (see	  section	  2.2.8.6)	  and	  being	  placed	  
in	   the	   hypoxic	   incubator	   for	   the	   desired	   differentiation	   period.	   	   Alternatively,	   cells	  
were	  transfected	  midway	  through	  a	  4-­‐day	  differentiation	  period.	  	  In	  this	  case,	  1B5	  cells	  
were	   plated	   onto	   a	   96-­‐well	   Opti-­‐clear	   plate	   pre-­‐coated	   with	   ECL.	   	   24	   hours	   after	  
plating,	   the	  plate	  was	  transferred	  to	  the	  hypoxic	   incubator	   for	  2	  days.	   	  Transfections	  
were	  then	  performed	  as	  described	  above.	  	  Cells	  were	  allowed	  to	  sit	  in	  the	  transfection	  
mixes	   for	   6	   hours	   in	   the	   5%	   CO2	   incubator	   before	   having	   the	  medium	   changed	   and	  
being	  placed	  back	  into	  the	  hypoxic	  incubator	  for	  a	  further	  2	  days	  of	  differentiation.	  
	  
2.3	  Protein	  
HEK293	   cells	  were	   seeded	   onto	   a	   6-­‐well	   plate	   to	   perform	   transient	   transfections	   to	  
obtain	  cells	  expressing	  RYR1	  for	  protein	  extraction	  and	  subsequent	  detection.	   	  When	  
the	   cells	   reached	   80%	   confluence	   they	   were	   transfected	   with	   the	   various	   cDNA	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constructs	   used	   in	   this	   project.	   	   Transfections	   were	   performed	   using	   the	   same	  
procedure	   described	   in	   section	   2.2.7	   however,	   4µg	   of	   each	   plasmid	  was	   transfected	  
and	  diluted	  in	  250µl	  of	  Opti-­‐MEM.	  	  Similarly,	  the	  amount	  of	  LF2000	  was	  increased	  to	  
10µl	   per	   transfection	   diluted	   in	   250µl	   of	   Opti-­‐MEM.	   	   For	   the	   pcRYR1	   transient	  
experiments,	  cells	  were	  transfected	  and	  allowed	  to	  grow	  for	  48	  hours	  before	  protein	  
extraction.	   	   For	   the	  pTUNERYR1	   transfections,	   cells	  were	   transfected	  and	   induced	   to	  
the	  desired	  level	  using	  IPTG	  (see	  section	  2.2.7.1)	  before	  protein	  was	  harvested	  after	  a	  
total	  incubation	  time	  of	  72	  hours.	  	  These	  culture	  times	  were	  consistent	  with	  the	  times	  
allowed	   before	   calcium	   measurements	   were	   carried	   out	   (see	   section	   2.2.7.1).	   	   For	  
stable	  HEK293	  cell	  lines,	  cells	  were	  plated	  onto	  a	  10cm	  tissue	  culture	  dish	  and	  allowed	  
to	  grow	  to	  sub-­‐confluence	  prior	  to	  protein	  extraction.	  	  
	  
2.3.1	  Protein	  extraction	  
Cells	  were	  cooled	  on	  ice	  and	  washed	  once	  with	  4°C	  PBS.	  	  Cells	  were	  covered	  in	  4°C	  PBS	  
for	  a	  second	  time	  and	  loosened	  from	  the	  plate	  surface	  using	  a	  cell	  scraper.	  	  Cells	  were	  
collected	  and	  placed	  in	  a	  50ml	  falcon	  tube	  and	  cooled	  on	  ice	  for	  5	  minutes.	  	  Following	  
the	  cooling	  step	  the	  cells	  were	  centrifuged	  at	  1,600	  rpm	  for	  15	  minutes	  to	  pellet	  the	  
cells.	  	  Cell	  pellets	  were	  resuspended	  in	  100µl	  of	  cell	  lysis	  buffer	  (100mM	  Tris,	  0.5%	  v/v	  
triton	  x-­‐100,	  1%	  protease	  cocktail	  inhibitor).	  	  Resuspended	  cell	  pellets	  were	  incubated	  
at	   37°C	   for	   10	   minutes	   before	   centrifuged	   at	   10,000	   x	   g	   for	   15	   minutes.	   	   The	  
supernatant	  was	  transferred	  to	  a	  fresh	  1.5ml	  centrifuge	  tube	  and	  stored	  at	  -­‐20°C	  until	  
needed.	  
	  
2.3.2	  Protein	  quantification	  using	  a	  Bradford	  assay	  
A	   Bradford	   assay	   to	   quantify	   the	   protein	   samples	   was	   performed	   on	   the	   Nanodrop	  
1000	   machine.	   	   Protein	   standards	   were	   made	   from	   bovine	   serum	   albumin	   (BSA)	  
(BioFX;	   Cambridge,	   UK)	   powder	   at	   concentrations	   of	   0.1mg/ml,	   0.5mg/ml,	   1mg/ml,	  
4mg/ml	  and	  8mg/ml	  by	  diluting	  the	  appropriate	  amount	  of	  BSA	  in	  distilled	  water.	  	  10µl	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of	  each	  of	  the	  protein	  standards	  and	  samples	  to	  be	  measured	  were	  mixed	  with	  200µl	  
of	  Bradford	  reagent	  (Bio-­‐Rad)	  and	  incubated	  at	  room	  temperature	  for	  10	  minutes.	  	  The	  
Nanodrop	   machine	   was	   blanked	   using	   2µl	   of	   Bradford	   reagent	   containing	   no	   BSA	  
before	  measuring	  2µl	  each	  of	  the	  protein	  standards	  in	  triplicate	  to	  generate	  a	  standard	  
curve.	   	  Following	  the	  generation	  of	  the	  standard	  curve,	  2µl	  of	  each	  sample	  extracted	  
was	  measured	  on	   the	  Nanodrop	  with	  concentrations	  being	  calculated	   relative	   to	   the	  
standard	  curve.	  
	  
2.3.3	  Protein	  detection	  
2.3.3.1	  Polyacrylamide	  gel	  electrophoresis	  
4%-­‐8%	   polyacrylamide	   gels	   were	   made	   according	   to	   the	   recipe	   given	   in	   Table	   2.4.	  	  
50µg	  of	  each	  protein	  sample	  was	  diluted	  to	  15µl	  in	  deionised	  water.	  	  A	  mixture	  of	  10%	  
β-­‐mercaptoethanol	   (Sigma-­‐Aldrich)	   in	   Laemmli	   loading	   buffer	   (v/v)	   (Bio-­‐Rad)	   was	  
made,	  mixed	  1:1	  with	  the	  protein	  sample	  and	  incubated	  at	  95°C	  for	  10	  minutes.	  	  After	  
the	  boiling	  step,	   the	  samples	  were	  placed	  on	   ice	   for	  10	  minutes	  before	   loading	  onto	  
the	   polyacrylamide	   gel.	   	   A	   mini-­‐protean	   protein	   electrophoresis	   tank	   was	   set	   up	  
according	  to	  the	  manufacturers	  instructions	  (Bio-­‐Rad).	  	  The	  internal	  chamber	  was	  filled	  
with	  1x	  tris-­‐glycine-­‐SDS	  (TGS)	  buffer	  (25mM	  Tris,	  190mM	  glycine	  0.1%	  w/v	  SDS)	  as	  was	  
half	  of	  the	  external	  tank.	  	  A	  total	  of	  30µl	  of	  the	  protein	  sample	  mix	  was	  added	  to	  each	  
well	   with	   one	  well	   possessing	   a	   Precision	   Plus	   protein	   ladder	   (Bio-­‐Rad).	   All	   samples	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   4%	  stacking	  gels	   8%	  resolving	  gels	  
Deionised	  water	   2.816ml	   10.584ml	  
Polyacrylamide	  mix	  (40%)	   400µl	   4ml	  
Tris	  (pH	  8.8)	  (1.5M)	   700µl	   -­‐	  
Tris	  (pH	  6.8)	  (0.7M)	   -­‐	   5ml	  
SDS	  (10%)	   40µl	   200µl	  
Ammonium	  persulphate	  (10%)	   40µl	   200µl	  
Tetramethylethylnediamine	   4µl	   16µl	  
Table	  2.4	  –	  Recipe	  for	  the	  polyacrylamide	  gels	  made	  in	  this	  project	  
8%	  resolving	  gels	  were	  made	  and	  poured	  into	  the	  gel	  cast	  and	  allowed	  to	  set	  for	  30	  minutes	  with	  an	  overlay	  of	  
0.1%	  SDS	  before	  the	  addition	  of	  the	  4%	  stacking	  gel	  mix.	  	  The	  stacking	  gel	  was	  allowed	  30	  minutes	  to	  set	  with	  a	  
comb	  in	  prior	  to	  electrophoresis.	  
	  
2.3.3.2	  Western	  blotting	  
Prior	   to	   the	   completion	   of	   electrophoresis,	   a	   total	   of	   6	   squares	   of	   3mm	  Whatman	  
blotting	  paper	  were	  cut	  to	  the	  same	  size	  as	  the	  gel.	  	  A	  piece	  of	  polyvinylidene	  fluoride	  
(PVDF)	   membrane	   was	   also	   cut	   to	   the	   same	   size	   as	   the	   gel.	   	   The	   membrane	   was	  
activated	   in	   100%	  methanol	   for	   2	  minutes	   before	   being	  washed	   in	   TGS	   buffer.	   	   The	  
western	  blot	  was	  set	  up	  so	  that	  the	  gel	  and	  the	  membrane	  were	  sandwiched	  between	  
3	  pieces	  of	  Whatman	  paper	  each	  and	  blotted	  overnight	  at	  4°C	  and	  30	  volts	  with	  gentle	  
mixing	  of	  the	  buffer	  with	  a	  magnetic	  flea.	  	  The	  blot	  was	  run	  in	  tris-­‐glycine	  (TG)	  buffer	  
(25mM	  Tris,	  190mM	  glycine).	  	  The	  following	  day,	  the	  membrane	  and	  gel	  was	  checked	  
for	  complete	  protein	  transfer	  as	  indicated	  by	  the	  largest	  band	  of	  the	  pre	  stained	  ladder	  
being	  visible	  on	  the	  membrane	  but	  absent	  from	  the	  gel.	  	  The	  membrane	  was	  blocked	  
for	  1	  hour	  in	  5%	  milk	  in	  tris-­‐buffered	  saline	  (TBS)	  with	  tween	  (TBST)	  buffer	  (50mM	  Tris,	  
150mM	  NaCl	  1%	  v/v	   tween)	  with	  gentle	  agitation.	   	  For	  RYR1	  detection	  a	  34C	  mouse	  
anti-­‐RYR1	  primary	  antibody	  was	  diluted	  1:5000	  in	  5%	  milk	  in	  TBST.	   	  For	  alpha-­‐tubulin	  
detection	   a	   mouse	   primary	   anti-­‐alpha-­‐tubulin	   antibody	   (Sigma-­‐Aldrich)	   was	   also	  
diluted	   1:5000	   in	   5%	  milk	   in	   TBST.	   	   The	  membrane	  was	   incubated	  with	   the	   primary	  
antibodies	   for	   2	   hours	   at	   room	   temperature	   with	   constant	   agitation.	   	   Following	  
incubation	  with	   the	   primary	   antibodies	   the	  membrane	  was	   washed	   3	   times	   for	   ten	  
minutes	   each	   in	   5%	  milk	   in	   TBST	  before	   incubation	  with	   the	   secondary	   antibody.	   	   A	  
goat-­‐anti-­‐mouse	   secondary	   antibody	   with	   horseradish	   peroxidase	   (HRP)	   conjugate	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(Bio-­‐Rad)	  was	  diluted	  1:5000	  in	  5%	  milk	  in	  TBST	  and	  incubated	  with	  the	  membrane	  at	  
room	  temperature	   for	  1	  hour	  with	  constant	  agitation.	   	  Following	   the	   incubation,	   the	  
membrane	  was	  washed	  2	   times	  with	  5%	  milk	   in	  TBST	  and	  a	   final	  wash	   in	  5%	  milk	   in	  
TBS.	  
Chemiluminescence	  was	  detected	  using	   the	  North2South	  HRP	  detection	   kit	   (Thermo	  
Scientific).	  	  Equal	  volumes	  of	  the	  luminol	  enhancer	  and	  peroxide	  solutions	  were	  mixed	  
and	   placed	   onto	   the	  membrane	   and	   incubated	   at	   room	   temperature	   for	   5	  minutes	  
before	  protein	  detection	  in	  a	  ChemiDoc	  MP	  imaging	  system	  (Bio-­‐Rad).	  	  Exposure	  times	  
were	  calibrated	  for	  each	  sample	  to	  ensure	  that	  overexposure	  was	  avoided.	  
	  
2.3.3.3	  Western	  blot	  data	  analysis	  
Western	  blotting	   images	  were	  analysed	   in	   ImageLab	  software.	   	  RYR1	  expression	  was	  
quantified	  relative	  to	  the	  alpha-­‐tubulin	  expression	  and	  compared	  across	  all	  samples	  to	  
examine	   differences	   in	   RYR1	   expression	   in	   each	   of	   the	   transfected	   cell	   samples	   and	  
untransfected	  controls.	  	  Two-­‐tailed	  unpaired	  student’s	  t-­‐tests	  were	  performed	  on	  the	  
data	  obtained	  for	  each	  construct.	  
	  
2.4	  Caffeine-­‐induced	  calcium	  release	  experiments	  
HEK293	   cells	   transiently	   transfected	   with	   pcRYR1	   and	   pTUNERYR1	   constructs	   were	  
prepared	   on	   96-­‐well	   Opti-­‐clear	   plates	   suitable	   for	   caffeine-­‐induced	   calcium	   release	  
experiments	  as	  described	  above	  (see	  section	  2.2.7).	  	  Similarly,	  1B5	  cells	  either	  infected	  
with	  HSV-­‐1	  virions	  or	  transfected	  using	  LF2000	  or	  Xfect	  were	  also	  prepared	  on	  the	  96-­‐
well	  plates	  (see	  section	  2.2.9	  and	  2.2.10	  respectively).	  	  For	  stably	  transfected	  HEK293	  
cells,	   24	   hours	   prior	   to	   the	   caffeine-­‐induced	   calcium	   release	   assays,	   cells	   were	  
transferred	  onto	  96-­‐well	  Opti-­‐clear	  plates.	  	  	  
Plates	  destined	  for	  caffeine-­‐induced	  calcium	  release	  assays	  were	  washed	  three	  times	  
in	   imaging	   buffer	   (125mM	   NaCl,	   5mM	   KCl,	   2mM	   calcium	   chloride	   (CaCl2),	   1.2mM	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MgSO4,	  6mM	  glucose,	  25mM	  HEPES,	  pH	  7.4).	   	  After	  the	  washing	  steps	  the	  cells	  were	  
incubated	   with	   20µM	   Fluo-­‐4	   acetoxymethyl	   (AM)	   (Life	   Technologies),	   a	   fluorescent	  
calcium	  indicator,	  for	  20	  minutes	  at	  room	  temperature.	  	  Fluo-­‐4	  AM	  1mM	  stocks	  were	  
diluted	  to	  20µM	  in	  imaging	  buffer.	  	  	  During	  the	  incubation	  with	  Fluo-­‐4	  AM,	  a	  caffeine	  
dilution	  series	  was	  created	  as	  described	  in	  Table	  2.5.	  	  The	  reason	  for	  the	  differences	  in	  
caffeine	  series	  was	  due	  to	  the	  availability	  of	  the	  injection	  channels	  at	  the	  time	  of	  the	  
experiments.	   	   The	   incremental	   doses	   of	   caffeine	   were	   loaded	   into	   a	   syringe	   each	  
starting	   with	   the	   lowest	   concentration	   and	   working	   up	   to	   the	   maximum	   caffeine	  
concentration.	   	  For	  the	  1B5	  cell	  transfection	  experiments,	  20mM	  caffeine	  and	  40mM	  
KCl	  were	  used	  as	  agonists	  to	  examine	  the	  transfection	  efficiency.	  	  After	  incubation	  with	  
Fluo-­‐4	   AM,	   cells	   were	   washed	   a	   further	   three	   times	   in	   imaging	   buffer	   before	   the	  
commencement	   of	   the	   caffeine-­‐induced	   calcium	   release	   assay.	   	   The	   syringes	   were	  
attached	  to	  a	  central	  Perspex	  column	  via	  narrow	  tubing.	  	  The	  column	  was	  specifically	  
designed	  to	  fit	  in	  the	  well	  of	  a	  96-­‐well	  plate	  (Duke	  and	  Steele,	  2008)	  (Figure	  2.4).	  	  Each	  
syringe	  was	  individually	  primed	  to	  deliver	  a	  small,	  but	  excess	  amount	  of	  caffeine	  upon	  
activation	   to	   the	   cells.	   	   The	   syringes	   were	   under	   computer	   control	   so	   that	   a	  
standardised	  dose	  was	  delivered	  every	  40	  seconds,	  however,	  the	  delivery	  of	  the	  next	  
caffeine	  dose	  was	  manually	  delayed	  until	  the	  previous	  calcium	  release	  event	  triggered	  
by	  the	  caffeine	  had	  finished.	  	  The	  cells	  being	  measured	  were	  constantly	  perfused	  with	  
imaging	   buffer	  meaning	   applied	   caffeine	   doses	  were	   instantly	   removed	   to	   eliminate	  
the	   possibility	   of	   multiple	   calcium	   release	   events	   due	   to	   prolonged	   exposure	   to	  
caffeine.	   	   The	   apparatus	   was	   set	   up	   and	   the	   plate	   placed	   on	   the	   stage	   of	   a	   Nikon	  
Eclipse	  TE3000	   inverted	  confocal	  microscope	  and	  visualised	  with	  a	  40x	  oil	   immersion	  
Fluor	  objective.	  	  Upon	  stimulation	  with	  caffeine,	  cells	  responded	  by	  releasing	  calcium,	  
which	   was	   visualised	   as	   a	   temporary	   increase	   in	   fluorescence	   that	   was	   ultimately	  
sequestered	  back	  into	  the	  cellular	  stores	  through	  excitation	  at	  488nm	  and	  detection	  at	  
520nm.	  	  The	  entire	  duration	  of	  the	  experiment	  was	  recorded	  as	  a	  Z-­‐stack	  with	  Image	  
Pro	  Plus	  software	  with	  1	  image	  taken	  per	  second.	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Figure	  2.4	  –	  Confocal	  microscope	  set	  up	  for	  calcium	  release	  measurements.	  
A	  maximum	  of	  seven	  syringes	  were	  loaded	  with	  incremental	  doses	  of	  caffeine.	  	  The	  syringes	  were	  attached	  to	  a	  
central	  Perspex	  column	  via	  narrow	  tubing.	  	  The	  column	  was	  specifically	  designed	  to	  fit	  into	  the	  well	  of	  the	  96-­‐well	  
plates	  used	  in	  this	  project.	  	  The	  syringes	  are	  under	  computer	  control	  so	  that	  the	  caffeine	  doses	  are	  added	  
sequentially	  to	  the	  cells	  in	  a	  standardised	  fashion.	  	  A	  constant	  perfusion	  of	  imaging	  buffer	  means	  that	  as	  soon	  as	  
the	  caffeine	  has	  been	  added	  to	  the	  cells	  it	  is	  removed.	  	  Increases	  in	  fluorescence	  associated	  with	  calcium	  release	  
is	  detected	  via	  confocal	  microscopy	  and	  recorded	  as	  a	  z-­‐stack.	  
	  
	  



























































Table	  2.5	  –	  Agonist	  concentrations	  used	  for	  the	  calcium	  release	  assays	  in	  this	  project	  
Various	  caffeine	  concentrations	  were	  used	  throughout	  the	  project	  based	  on	  the	  availability	  of	  the	  injection	  
channels	  attached	  to	  the	  confocal	  microscope.	  	  For	  the	  1B5	  titration	  experiment,	  only	  three	  caffeine	  
concentrations	  were	  selected	  to	  get	  induced	  calcium	  release	  at	  low	  and	  high	  concentrations	  of	  caffeine	  to	  
ascertain	  the	  infection	  efficiency.	  	  For	  the	  1B5	  cell	  transfection	  experiments,	  KCl	  was	  also	  used	  as	  an	  agonist.	  	  A	  
single	  high	  dose	  (40mM)	  of	  KCl	  was	  used	  with	  20mM	  caffeine	  to	  induce	  calcium	  release.	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2.5	  Data	  analysis	  
The	   videos	   generated	   from	   confocal	   microscopy	   were	   analysed	   in	   ImageJ	   software.	  	  
The	   fluorescence	  data	  obtained	   from	   ImageJ	  analysis	  was	   imported	   into	   the	  Prism	  6	  
statistical	  package	  for	  subsequent	  statistical	  analysis	  and	  graph	  production.	  
	  
2.5.1	  ImageJ	  
The	   z-­‐stack	   videos	   created	   were	   analysed	   using	   ImageJ	   software	   (available	   to	  
download	   at	   http://rsbweb.nih.gov/ij/).	   	   Any	   uneven	   background	   fluorescence	   was	  
removed	   using	   the	   software.	   	   To	   remove	   any	   effects	   of	   cell	   density	   adding	   to	   the	  
fluorescence	   data,	   regions	   of	   interest	   were	   selected	   by	   highlighting	   areas	   that	  
responded	   to	   low	   doses	   (1mM-­‐2mM)	   of	   caffeine,	   as	   untransfected	   cells	   did	   not	  
produce	   a	   calcium	   release	   event	   at	   these	   concentrations.	   	   This	   was	   particularly	  
important	  for	  transient	  transfection	  experiments	  where	  not	  all	  cells	  were	  expected	  to	  
respond	  to	  caffeine.	  	  Cells	  seen	  to	  be	  reacting	  to	  caffeine	  stimulation	  were	  highlighted,	  
creating	  a	  data	  sheet	  of	  their	  levels	  of	  fluorescence	  over	  time.	  	  All	  the	  cells	  reacting	  in	  
the	  given	  field	  of	  view	  were	  highlighted	  and	  measurements	  were	  taken.	   	  Each	  of	  the	  
dose-­‐response	  experiments	  were	  measured	  and	   the	   fluorescence	  data	  was	   imported	  
into	   Prism	   6	   statistics	   package	   (available	   to	   download	   at	  
http://www.graphpad.com/prism/).	  	  	  
	  
2.5.2	  Dose-­‐response	  analysis	  
The	  fluorescence	  data	  was	  imported	  to	  Prism	  and	  normalised	  with	  0%	  defined	  as	  the	  
fluorescence	   level	   before	   the	   addition	   of	   any	   caffeine	   and	   100%	   as	   the	   peak	  
fluorescence	  achieved	  during	  the	  dose-­‐response	  experiments.	  	  	  The	  fluorescence	  level	  
achieved	  after	  each	  dose	  of	  caffeine	  was	  taken	  for	  each	  experiment	  and	  plotted	  on	  a	  
log	   x-­‐axis	   to	   construct	   a	  dose-­‐response	   curve.	   	   The	  non-­‐linear	   regression	   function	   in	  
Prism	  6	  was	  used	  to	  fit	  a	  curve.	   	  The	  dose	  required	  to	  produce	  half	  of	  the	  maximum	  
response	  (the	  EC50)	  was	  taken	  from	  the	  fitted	  dose-­‐response	  curve.	  	  In	  some	  cases,	  the	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dose	  required	  to	  produce	  10%	  and	  25%	  of	  the	  maximum	  response	  was	  also	  calculated	  
(the	  EC10	  and	  EC25	  respectively).	  
	  
2.5.3	  Area	  under	  the	  curve	  measurements	  
Each	   dose-­‐response	   experiment	   was	   also	   subjected	   to	   area	   under	   the	   curve	   (AUC)	  
measurements	  for	  each	  caffeine	  concentration	  that	  produced	  a	  calcium	  release	  event.	  	  
The	  baseline	  for	  measurements	  was	  independently	  set	  for	  each	  caffeine	  concentration	  
and	  each	  experiment.	  
	  
2.5.4	  Statistical	  analysis	  
Unpaired	   Student’s	   t-­‐tests	   were	   carried	   out	   between	   each	   construct	   measured	   to	  
determine	   if	   there	   were	   any	   statistically	   significant	   differences	   between	   the	   dose-­‐
responses	  and	  AUC	  measurements	  taken.	  	  As	  there	  is	  evidence	  to	  suggest	  some	  RYR1	  
variants	   result	   in	   a	   decrease	   in	   caffeine	   sensitivity	   as	   well	   as	   the	   more	   common	  
increase	   in	   caffeine	   sensitivity,	   two-­‐tailed	   statistical	   tests	   were	   performed	   for	   the	  
dose-­‐response	   and	   AUC	   experiments.	   	   For	   the	   experiments	   involving	   pre-­‐treatment	  
with	   AICAR,	   one-­‐tailed	   statistical	   tests	   were	   performed	   as	   a	   decrease	   in	   caffeine	  
sensitivity	  was	  expected	  in	  these	  cases.	  	  Similarly,	  for	  experiments	  aimed	  at	  examining	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Chapter	  Three -­‐	  Selection	  and	  cloning	  of	  RYR1	  variants.	  
	  
3.1	  Introduction	  
3.1.1	  EHMG	  guidelines	  
Since	   the	   introduction	   of	   the	   EMHG	  guidelines	   in	   2001	   that	   outlined	   the	   process	   by	  
which	  missense	  variants	  in	  the	  RYR1	  gene	  can	  be	  added	  to	  a	  genetic	  diagnostic	  panel,	  
only	  31	  mutations	  have	  been	  functionally	  characterised	  (Urwyler	  et	  al.,	  2001).	  	  This	  is,	  
at	  least	  in	  part,	  due	  to	  the	  difficulties	  associated	  with	  cloning	  and	  manipulating	  a	  gene	  
the	  size	  of	  RYR1.	  	  The	  guidelines	  outline	  two	  methods	  by	  which	  functional	  studies	  can	  
be	  carried	  out.	  	  The	  first	  of	  these	  is	  to	  utilise	  ex	  vivo	  samples	  from	  patients	  who	  have	  
previously	   undergone	   a	  muscle	   biopsy	   to	   diagnose	  MH	   status.	   	  Whilst	   this	   is	   of	   no	  
benefit	   to	   the	   patients	   who	   have	   already	   been	   diagnosed,	   functional	   data	   obtained	  
from	   samples	   of	   known	   genotype	   can	   contribute	   to	   their	   inclusion	   on	   the	   genetic	  
diagnostic	  panel	  for	  MH.	  	  However,	  due	  to	  potential	  problems	  with	  having	  samples	  of	  
an	   unknown	   genetic	   background,	   the	   presence	   of	   additional	   causal	   variants	  
contributing	  to	  the	  functional	  results	  cannot	  be	  ruled	  out.	  	  Multiple	  variants	  have	  been	  
found	   in	   some	   patients	   including	   two	   variants	   on	   the	   same	   allele,	   compound	  
heterozygosity	  and	  variants	   in	   two	  different	  genes	   (RYR1	   and	  CACNA1S)	   (Monnier	  et	  
al.,	   2002).	   	   Because	   of	   these	   complications,	   the	   guidelines	   require	   the	   studies	   to	   be	  
carried	   out	   in	   two	   independent	   families	   to	   rule	   out	   the	   contribution	   of	   genetic	  
background	   on	   the	   functional	   results.	   	   Although	   this	   eliminates	   the	   issue	   of	   genetic	  
background,	  some	  variants	  are	  found	  uniquely	  in	  one	  family	  meaning	  that	  there	  would	  
be	   no	   hope	   of	   these	   families	   ever	   having	   their	   MH	   status	   diagnosed	   genetically.	  	  
Worldwide,	   36%	   of	   all	   MH	   families	   possess	   a	   unique	   RYR1	   or	   CACNA1S	   variant,	  
meaning	   that	   these	   families	   would	   be	   unsuitable	   for	   genetic	   diagnosis	   using	   this	  
method.	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3.1.2	  Functional	  analysis	  of	  RYR1	  variants	  using	  recombinant	  methods	  
By	  far	  the	  most	  reliable	  method	  of	  functionally	  characterising	  genetic	  variants	  in	  RYR1	  
is	  to	  carry	  out	  experiments	  using	  cDNA	  clones.	  	  Such	  experiments	  remove	  the	  issue	  of	  
an	   unknown	   genetic	   background	   affecting	   the	   functional	   results	   and	   also	   allow	   the	  
possibility	  of	  families	  with	  unique	  genetic	  variants	  to	  have	  their	  variant	  characterised,	  
potentially	   leading	   to	   diagnosis	   before	   the	   need	   for	   a	   muscle	   biopsy.	   This	   method,	  
however,	   is	   not	   without	   difficulties	   itself.	   	   RYR1	   is	   one	   of	   the	   largest	   genes	   in	   the	  
human	   genome,	   spanning	   106	   exons	   and	   including	   over	   15kb	   of	   coding	   sequence	  
making	  molecular	   cloning	   extremely	   challenging.	   	   Conventional	  methods	   of	   working	  
with	   cDNA	   clones,	   in	   general,	   are	   not	   applicable	   to	   a	   construct	   of	   RYR1’s	   size.	  	  
Although	   some	   studies	   claim	   to	   be	   able	   to	   carry	   out	   site-­‐directed	   mutagenesis	   on	  
constructs	  of	  20kb,	   these	  are	  difficult	   to	   replicate	   in	   the	   laboratory.	   	  To	   improve	   the	  
efficiency	   of	   these	   experiments,	   RYR1	   first	   needs	   to	   be	   subcloned	   using	   unique	  
restriction	   sites	   to	   produce	   a	   plasmid	   of	   a	   reasonable	   size	   to	   facilitate	   successful	  
mutagenesis.	  	  The	  larger	  the	  gene,	  the	  fewer	  unique	  restriction	  sites	  are	  available	  for	  
subcloning	  and	  in	  the	  RYR1	  cDNA	  there	  are	  only	  14	  unique	  restriction	  sites,	  a	  number	  
that	   is	   further	   reduced	   when	   incorporated	   into	   an	   expression	   vector.	   Experiments	  
involving	  subcloning	  and	  mutagenesis	  of	  RYR1	  cDNA	  constructs	  to	  date,	  have	  required	  
elaborate	  cloning	  strategies	  to	  obtain	  the	  desired	  mutant	  constructs.	  	  
	  
3.1.3	  Subcloning	  RYR1	  
The	   earliest	   attempt	   at	   functionally	   characterising	   RYR1	   variants	   utilised	   a	   cloning	  
strategy	   involving	   the	   production	   of	   eleven	   subclones	   to	   introduce	   new	   unique	  
restriction	  sites	  for	  further	  subcloning	  and	  subsequent	  mutagenesis	  (Tong	  et	  al.,	  1997).	  	  
The	  mutations	  involved	  in	  this	  study	  were	  only	  separated	  by	  2kb	  of	  DNA.	  	  Subsequent	  
studies	   have	   all	   had	   similarly	   complicated	   cloning	   strategies	   to	   facilitate	   the	  
construction	  of	  wild	  type	  and	  mutant	  RYR1	  constructs	  (Du	  et	  al.,	  2001,	  Sambuughin	  et	  
al.,	  2001b,	  Yang	  et	  al.,	  2003).	  One	  of	   the	  primary	  aims	  of	   the	  work	  described	   in	   this	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chapter	  was	  to	  develop	  a	  cloning	  strategy	  that	  is	  as	  simplistic	  as	  possible	  given	  the	  size	  
of	  RYR1	  and	  the	   inherent	  complications	   involved	   in	  such	  cloning	  experiments.	   	  To	  do	  
this,	   a	  human	  RYR1	  clone	  was	  used	   that	  was	   kindly	  provided	  by	  Dr.	   Kathryn	  Stowell	  
(Sato	  et	  al.,	  2010).	  	  The	  majority	  of	  the	  previous	  functional	  work	  has	  been	  carried	  out	  
using	   a	   rabbit	   RYR1	   (RyR1)	   cDNA	   construct	   that,	   although	   having	   a	   high	   level	   of	  
homology	  with	  the	  human	  gene,	  is	  not	  identical	  (Table	  3.1).	  	  	  
	  
	   DNA	   Protein	  
Identity	   91.3%	   96.5%	  
Mismatches	   1,322	   175	  
Gaps	   39	   17	  
Table	  3.1	  –	  Differences	  between	  human	  and	  rabbit	  RYR1	  sequences.	  
The	  majority	  of	  functional	  work	  on	  RYR1	  variants	  has	  been	  carried	  out	  using	  a	  rabbit	  RyR1	  cDNA	  clone	  in	  spite	  of	  
the	  coding	  sequence	  being	  only	  91.3%	  identical	  to	  the	  human	  equivalent.	  	  When	  aligned	  using	  ClustalW2	  
(available	  at	  http://www.ebi.ac.uk/Tools/msa/clustalw2/)	  1,322	  mismatches	  are	  present	  between	  the	  human	  
and	  rabbit	  sequences	  with	  39	  gaps	  in	  the	  sequence.	  	  This	  is	  translated	  into	  a	  96.5%	  identity	  in	  the	  protein	  
sequence	  with	  175	  mismatched	  amino	  acids	  and	  17	  gaps	  in	  the	  sequence.	  
	  
	  
ClustalW2	   alignment	   of	   the	   protein	   and	   cDNA	   sequences	   for	   both	   the	   human	   and	  
rabbit	   constructs	   reveals	  96.5%	  and	  91.3%	   identity	   respectively.	   	  Although	   there	   is	  a	  
high	  percentage	  of	  identity	  between	  the	  sequences,	  the	  rabbit	  sequence	  has	  a	  total	  of	  
1,322	  mismatched	   nucleotides,	  which	   translates	   to	   175	   different	   amino	   acids	   in	   the	  
protein	   sequence	  with	   a	   total	   of	   17	   gaps	   in	   the	   sequence	  where	   amino	   acids	   in	   the	  
rabbit	  sequence	  are	  missing.	  	  In	  studies	  using	  rabbit	  clones,	  mutations	  ‘corresponding’	  
to	  the	  same	  mutation	  in	  the	  human	  gene	  are	  introduced.	  	  The	  use	  of	  a	  human	  clone	  in	  
these	   experiments	   makes	   the	   experiments	   more	   representative	   of	   the	   human	  
condition.	  
	  
3.1.4	  Native	  Vs.	  Non-­‐native	  environment	  
In	   spite	  of	   being	   structurally	   and	   functionally	   different	   to	   the	  native	   environment	  of	  
RYR1,	   HEK293	   cells	   have	   been	   the	   primary	   cellular	   system	   to	   carry	   out	   functional	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studies	   to	   date.	   	   HEK293	   cells	   do	   not	   have	   the	   structural	   architecture	   of	   mature	  
myotubes	  such	  as	  the	  T-­‐Tubules,	  which	  are	  a	  uniquely	  muscle	  cell	  structure	  essential	  
for	   excitation-­‐contraction	   coupling.	   	   Furthermore,	   the	   SR	   in	   myotubes	   is	   a	   highly	  
specialised	   version	   of	   the	   endoplasmic	   reticulum	   found	   in	   other	   cell	   types.	   	   HEK293	  
cells	  have	  traditionally	  been	  used	  due	  to	  the	  fact	  that	  they	  are	  easy	  to	  culture	  and	  easy	  
to	   transfect	   when	   compared	   to	   muscle	   cells,	   which	   are	   extremely	   difficult	   to	   work	  
with.	   	  Myoblasts	   need	   to	   be	   differentiated	   into	  myotubes	   to	   be	   functionally	   active.	  	  
Transfection	   of	  myoblasts	   has	   a	   low	  efficiency,	  which	   is	   exacerbated	  when	   trying	   to	  
transfect	   differentiating	   myoblasts	   or	   mature	   myotubes	   (Neuhuber	   et	   al.,	   2002).	  	  
Recently,	   a	   method	   of	   viral	   transduction	   using	   HSV-­‐1	   has	   been	   developed,	   which	  
boasts	   an	   extremely	   high	   efficiency	   of	   gene	   transfer	   when	   infecting	   differentiating	  
myotubes	   (Fraefel	   et	   al.,	   1996,	   Wang	   et	   al.,	   2000).	   	   To	   facilitate	   this	   method	   of	  
expression	   in	   myotubes,	   a	   specialised	   expression	   vector	   containing	   the	   HSV-­‐1	  
packaging	  signal	  and	  a	  viral	  promoter	  driving	  gene	  expression	  was	  developed.	  	  In	  this	  
study,	  wild	  type	  and	  mutant	  constructs	  will	  be	  transferred	  into	  this	  pHSVPrPUC	  vector	  
to	  allow	  viral	  packaging	  and	  expression	  of	  our	  constructs	  in	  myotubes.	  
	  
3.1.5	  Differential	  expression	  of	  RYR1	  constructs	  in	  cellular	  systems	  
Maintaining	   expression	   of	   RYR1	   is	   of	   paramount	   importance	   when	   examining	   the	  
functional	   consequences	   of	   different	   genetic	   variants.	   	   Transfection	   efficiencies	   of	  
large	   cDNA	   constructs	   are	   inevitably	   much	   lower	   than	   that	   of	   smaller	   constructs	  
(Campeau	  et	  al.,	  2001).	  	  This	  means	  that	  maintaining	  a	  consistently	  high	  level	  of	  RYR1	  
expression	   in	   cells	   successfully	   transfected	   is	   essential.	   	   A	   recent	   study	   has	  
demonstrated	   the	   importance	   of	   the	   expression	   levels	   of	  RYR1.	   	   Allele	   specific	   PCR	  
revealed	  that	  patients	  carrying	  known	  RYR1	  mutations	  had	  a	  higher	  level	  of	  expression	  
from	   the	   wild	   type	   allele,	   possibly	   as	   a	   compensatory	   mechanism	   for	   the	   mutated	  
allele	  (Grievink	  and	  Stowell,	  2010).	  	  This	  difference	  in	  expression	  was	  postulated	  to	  be	  
a	  partial	  explanation	  for	  the	  variability	  seen	  in	  patients	  with	  MH.	  	  Recent	  work	  looking	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at	   the	   increased	   expression	   of	  RYR1	   and	  RYR3	   in	   dyspedic	  myotubes	   has	   suggested	  
that	  an	  increased	  expression	  of	  wild	  type	  channels	  does	  not	  affect	  the	  sensitivity	  of	  the	  
channels	   to	  activating	  agents	   such	  as	   caffeine	  and	  KCl.	   	  Although	  an	   increased	  RYR1	  
expression	  had	  no	  effect	  on	  the	  excitability	  of	  the	  cells,	  an	  increase	  in	  RYR3	  resulted	  in	  
a	  statistically	  significant	  decrease	  in	  EC50	  of	  the	  cells.	  	  This	  was,	  in	  part,	  put	  down	  to	  the	  
increase	  in	  resting	  calcium	  associated	  with	  an	  increased	  RYR3	  expression.	  	  It	  has	  been	  
long	   established	   that	  mutants	   in	  RYR1	   cause	   an	   increase	   in	   the	   resting	   intracellular	  
calcium	  level	  of	  cells	  carrying	  these	  variants;	  however,	  no	  studies	  have	  examined	  the	  
increased	  expression	  of	  mutant	  RYR1	  alleles	  in	  cellular	  systems.	  	  Shuttling	  RYR1	  into	  an	  
inducible	   expression	   system	   will	   allow	   us	   to	   examine	   the	   effect	   of	   an	   increased	   or	  
decreased	  expression	  of	  RYR1	  on	  the	  excitability	  of	  the	  cells	  to	  channel	  agonists.	  
	  
3.2	  Aims	  of	  the	  chapter	  
The	  aims	  of	  this	  chapter	  are	  to	  select	  RYR1	  variants	  for	  functional	  studies	  in	  this	  thesis	  
based	  on	  the	  frequency	  at	  which	  they	  have	  been	  identified	   in	  the	  UK	  and	  worldwide	  
population.	  	  To	  facilitate	  the	  functional	  studies	  of	  these	  variants	  an	  additional	  goal	  is	  to	  
develop	  a	  robust,	  efficient	  and	  relatively	  simple	  cloning	  strategy	  that	  will	  allow	  for	  the	  
introduction	  of	  missense	  variants	   into	  a	  human	  RYR1	   cDNA	  construct.	   	   Furthermore,	  
wild	   type	  and	  mutant	  RYR1	   constructs	  will	  be	   shuttled	   into	  a	  pHSVPrPUC	  expression	  
vector	   that	   will	   allow	   RYR1	   to	   be	   packaged	   into	   HSV-­‐1	   virions	   for	   expression	   in	  
dyspedic	   myotubes.	   	   The	   constructs	   will	   also	   be	   transferred	   into	   an	   inducible	  
expression	  vector,	  allowing	  us	  to	  examine	  the	  effect	  of	  expression	  levels	  of	  wild	  type	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3.3	  Results	  
3.3.1	  Selection	  of	  RYR1	  variants	  for	  this	  project	  
There	   are	   currently	   158	   RYR1	   variants	   identified	   in	   the	   UK	   population	   that	   are	  
uncharacterised	  and	  therefore	  unavailable	   for	  genetic	  diagnosis	  of	  MH.	   	  The	  primary	  
selection	  criteria	  for	  variants	  used	  in	  this	  project	  was	  the	  frequency	  at	  which	  they	  have	  
been	   identified	   in	  the	  UK	  population	  apart	   from	  for	  the	  p.D1056H	  variant	  which	  was	  
added	  to	  the	  project	  after	  it	  was	  identified	  in	  an	  EHS	  patient	  who	  tested	  negative	  for	  
MH.	   	   The	   variant	  was	   found	   to	   segregate	  with	   disease	   in	   one	   additional	  MH	   family.	  	  
The	   seven	   variants	   listed	   in	   Table	   3.2	   account	   for	   35%	  of	   all	   families	   in	   the	  UK	   that	  
possess	  an	  as	  yet	  uncharacterised	  RYR1	  variant.	  	  
	  
Nucleotide	  change	   Amino	  acid	  change	   Families	  in	  the	  UK	   Total	  global	  families	  
c.3166	  G>C	   p.D1056H	   1	  (+1	  EHS)	   1	  (+1	  EHS)	  
c.7007	  G>A	   p.R2336H	   8	   15	  
c.7063	  C>T	   p.R2355W	   7	   9	  
c.9310	  G>A	   p.E3104K	   4	   4	  
c.11958	  C>G	   p.D3986E	   4	   4	  
c.11969	  G>T	   p.G3990V	   10	   10	  
c.14545	  G>A	   p.V4849I	   8	   12	  
Table	  3.2	  –	  List	  of	  variants	  chosen	  for	  this	  project.	  
The	  variants	  chosen	  for	  functional	  characterisation	  in	  this	  project	  account	  for	  43	  of	  the	  UK	  MH	  families	  that	  
possess	  an	  as	  yet	  uncharacterised	  variant.	  	  An	  additional	  13	  families	  worldwide	  have	  been	  found	  carrying	  one	  of	  
the	  variants	  in	  association	  with	  MH.	  	  The	  c.3166	  G>C,	  p.D1056H	  variant	  was	  added	  to	  the	  project	  after	  it	  emerged	  
it	  was	  identified	  in	  an	  EHS	  patient	  who	  had	  tested	  negative	  for	  MH.	  	  The	  variant	  was	  also	  found	  to	  segregate	  with	  
the	  MH	  phenotype	  in	  one	  additional	  family.	  	  Functional	  characterisation	  of	  these	  variants	  will	  increase	  the	  
genetic	  diagnostic	  panel	  for	  MH	  by	  22.5%.	  
	  
	  
All	  of	  the	  variants	  selected	  in	  this	  project	  are	  missense	  mutations	  resulting	  in	  a	  change	  
of	  amino	  acids	   in	  the	  RYR1	  protein	  chain	  (Table	  3.3).	   	  The	  potential	  severity	  of	  these	  
changes	   varies	   between	   each	   variant.	   	   The	   p.D3986E	   variant	   has	   the	  mildest	   amino	  
acid	   change	   with	   aspartic	   acid	   and	   glutamic	   acid	   both	   being	   acidic,	   polar	   and	  
hydrophilic	  meaning	   the	   substitution	  may	  be	  a	  mild	  one.	   	  Additionally,	   the	  p.V4849I	  
variant	  results	   in	  a	  similar	  substitution	  despite	  being	  found	   in	  12	  families	  worldwide.	  	  
The	  remaining	  variants	  all	  cause	  amino	  acid	  property	  changes	  meaning	  that	  the	  overall	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structure	   and	   function	  of	   the	  protein	  may	  be	   altered	  as	   a	   result	   of	   the	   substitution.	  	  
Furthermore,	   there	   is	   a	   high	   level	   of	   evolutionary	   conservation	   of	   all	   variants	   under	  
investigation	   in	  this	  project.	   	  The	  base	  mutated	   in	  human	  MH	  is	  maintained	  across	  a	  
number	  of	   species	  known	  to	  undergo	  similar	  MH	  reactions	  as	  well	  as	  closely	   related	  
species	   indicating	   the	   importance	   of	   the	   residue.	   	   The	   only	   discrepancy	   is	   that	   in	  
mouse	  RYR1,	  the	  cytosine	  residue	  that	  is	  mutated	  in	  the	  p.D3986E	  variant	  is	  a	  thymine,	  
however	  this	  does	  not	  effect	  the	  amino	  acid	  coded	  for	  in	  the	  wild	  type	  sequence.	  	  The	  
same	   difference	   is	   seen	   in	   human	   RYR2,	   however	   once	   again	   the	   amino	   acid	   is	  
maintained.	   	  Additionally,	   in	  human	  RYR3,	  the	  arginine	  residue	  that	   is	  effected	  in	  the	  
p.R2355W	  variant	  is	  a	  lysine	  residue.	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Table	  3.3	  –	  Amino	  acid	  properties	  of	  the	  variants	  selected	  for	  study	  in	  this	  project.	  
Five	  of	  the	  missense	  variants	  under	  investigation	  in	  this	  project	  result	  in	  a	  substitution	  of	  amino	  acid	  that	  has	  
significantly	  different	  properties.	  	  These	  substitutions	  may	  result	  in	  a	  change	  in	  the	  structure	  and	  therefore	  
function	  of	  the	  overall	  protein.	  	  Of	  the	  7	  selected	  variants,	  2	  possess	  no	  major	  changes	  (p.D3986E	  and	  p.V4849I).	  	  
However,	  these	  two	  variants	  have	  been	  identified	  in	  16	  families	  worldwide.	  	  Patients	  carrying	  the	  p.D3986E	  
variant	  have	  been	  found	  to	  have	  a	  significantly	  higher	  caffeine	  contracture	  compared	  to	  other	  RYR1	  variants	  
during	  the	  IVCT	  and	  the	  p.V4849I	  variant	  has	  been	  identified	  in	  a	  large	  number	  of	  both	  MH	  and	  CCD	  families	  
worldwide	  making	  both	  variants	  of	  interest	  in	  this	  project.	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An	  additional	  criterion	  for	  selection	  in	  this	  project	  is	  the	  co-­‐segregation	  of	  the	  variant	  
under	   investigation	   with	   the	   disease	   phenotype.	   	   All	   the	   variants	   selected	   for	   this	  
project	  segregate	  with	  the	  MH	  phenotype	  in	  all	  individuals	  available	  for	  genetic	  testing	  
and	   are	   therefore	   not	   considered	   to	   be	   polymorphisms.	   	   Finally,	   all	   of	   the	   variants	  
selected	  in	  this	  project	  have	  been	  found	  to	  be	  absent	  from	  a	  panel	  of	  200	  MHN	  control	  
UK	  chromosomes	  through	  routine	  diagnostic	  screening	  at	  the	  Leeds	  MH	  testing	  centre,	  
further	  reducing	  the	  possibility	  of	  the	  variants	  being	  non-­‐pathogenic.	  	  	  
	  
3.3.2	  Cloning	  using	  pcRYR1	  
The	   RYR1	   cDNA	   sequence	   in	   a	   pcDNA3.1	   expression	   vector	   results	   in	   a	   20,649bp	  
plasmid.	   	   This	   is	   too	   large	   for	   conventional	  methods	   of	  mutagenesis.	   	   To	   be	   able	   to	  
introduce	  missense	  variants	  into	  RYR1	  associated	  with	  MH	  and	  EHS	  pcRYR1	  needed	  to	  
be	   subcloned.	   	   The	   variants	   selected	   for	   functional	   experiments	   in	   this	   project	   are	  
mainly	  clustered	  in	  the	  3’	  half	  of	  RYR1,	  however,	  the	  p.D1056H	  variant	  is	  within	  the	  5’	  
end.	  	  Generating	  a	  3’	  subclone	  containing	  all	  of	  the	  sites	  for	  the	  six	  variants	  in	  this	  half	  
of	  RYR1	  was	  possible	  due	  to	  the	  unique	  restriction	  sites	  Acc65I	  and	  XbaI.	  	  However,	  the	  
creation	  of	  a	  5’	  subclone	  for	  the	  introduction	  of	  the	  p.D1056H	  variant	   into	  RYR1	  was	  
made	  more	  difficult	  due	  to	  the	  absence	  of	  any	  suitable	  restriction	  sites	  in	  the	  5’	  end	  of	  
RYR1.	  	  Cloning	  this	  variant	  required	  the	  shuttling	  of	  RYR1	  into	  a	  new	  expression	  vector.	  
	  
3.3.2.1	  Creation	  of	  the	  3’	  subclone	  of	  RYR1	  
pcRYR1	   was	   digested	  with	  Acc65I	   and	  XbaI	   resulting	   in	   a	   DNA	   fragment	   of	   8,248bp	  
which	  was	  gel	  purified.	  	  The	  larger	  12,401bp	  fragment	  remaining	  from	  XbaI	  and	  Acc65I	  
digestion	  was	  also	  gel	  purified	  and	  saved	  for	  later	  reconstruction	  of	  full-­‐length	  mutant	  
pcRYR1	  constructs.	  	  pBluescript	  II	  SK	  +	  was	  also	  digested	  with	  XbaI	  and	  Acc65I	  and	  gel	  
purified.	   	  The	  8,248bp	  RYR1	   fragment	  was	   ligated	  into	  the	  linear	  2,880bp	  pBluescript	  
sample	  to	  create	  a	  3’	  subclone	  of	  RYR1,	  11,128bp	  in	  length	  (Figure	  3.1).	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Figure	  3.1	  –	  Creation	  of	  the	  3’	  subclone	  of	  RYR1.	  	  	  
(A)	  The	  unique	  restriction	  sites	  Acc65I	  and	  XbaI	  were	  used	  to	  cut	  pcRYR1	  resulting	  in	  two	  fragments.	  	  One	  large	  
fragment	  of	  12,401bp	  containing	  the	  pcDNA	  expression	  vector	  and	  the	  5’	  end	  of	  RYR1	  was	  produced	  as	  well	  as	  a	  
smaller	  fragment	  of	  8,284bp	  containing	  the	  3’	  end	  of	  RYR1.	  	  Both	  fragments	  of	  DNA	  were	  gel	  purified;	  the	  smaller	  
fragment	  for	  subcloning	  and	  the	  larger	  fragment	  for	  reconstruction	  of	  full-­‐length	  pcRYR1	  constructs.	  	  (B)	  
pBluescript	  II	  SK	  +	  was	  cut	  with	  Acc65I	  and	  XbaI	  resulting	  in	  a	  linear	  product	  of	  2,880bp	  which	  was	  	  gel	  purified.	  	  
(C)	  The	  8,248bp	  fragment	  of	  RYR1	  from	  (A)	  was	  inserted	  into	  pBluescript	  to	  create	  the	  3’	  subclone	  of	  RYR1.	  
	  
	  
Ligation	  mixes	  were	   transformed	   into	   XL10	  Gold	   ultracompetent	  E.coli	   and	   bacterial	  
colonies	   were	   allowed	   to	   form	   on	   LB	   agar	   plates	   containing	   ampicillin.	   	   Bacterial	  
colonies	  were	  cultured	  for	  mini	  prep	  plasmid	  DNA	  extraction	  and	  were	  screened	  using	  
EcoRI	   restriction	   digestion	   for	   successful	   ligation.	   	   Positive	   samples	   produced	   DNA	  
bands	   at	   7,592bp,	   1,986bp	   and	   1,550bp	   (Figure	   3.2).	   	   PCR	  products	  were	   generated	  
over	  the	  Acc65I	  and	  XbaI	  cloning	  sites	  and	  sent	  for	  sequencing.	  	  The	  TCTAGA	  XbaI	  and	  
GGTACC	   Acc65I	   cloning	   sites	   were	   identified	   as	   well	   as	   the	   RYR1	   and	   pBluescript	  
sequence	  immediately	  flanking	  each	  site	  were	  confirmed	  from	  reference	  sequences	  	  
	  
	  
	   81	  
	  
Figure	  3.2	  –	  Digest	  and	  sequence	  confirmation	  of	  the	  3’	  subclone.	  
(A)	  	  Plasmid	  map	  of	  the	  3’	  subclone	  with	  EcoRI	  sites	  marked	  and	  expected	  DNA	  bands	  in	  the	  table	  below	  the	  map.	  	  
(B)	  	  Gel	  image	  of	  the	  3’	  subclone.	  	  Lane	  1	  is	  a	  3’	  subclone	  sample	  digested	  with	  EcoRI.	  DNA	  bands	  at	  7,592bp,	  
1986bp	  and	  1,550bp	  indicate	  successful	  ligation	  and	  creation	  of	  the	  3’	  subclone.	  	  Lane	  2	  is	  an	  undigested	  3’	  
subclone	  sample.	  	  Lane	  M	  is	  a	  DNA	  MassRuler	  ladder	  with	  relevant	  DNA	  band	  sizes	  marked.	  	  (C)	  PCR	  products	  
created	  with	  primers	  at	  either	  side	  of	  the	  ligation	  sites	  were	  sequenced.	  	  The	  GGTACC	  Acc65I	  and	  TCTAGA	  XbaI	  
sites	  are	  marked	  with	  the	  gold	  boxes.	  	  Sequences	  generated	  were	  aligned	  to	  reference	  sequence	  samples	  to	  




3.3.2.2	  Creation	  of	  the	  5’	  subclone	  of	  RYR1	  
There	  were	  no	  unique	   restriction	  sites	  at	   the	  5’	  end	  of	   the	  RYR1	   in	  pcRYR1	  meaning	  
that	  a	  5’	   subclone	  could	  not	  be	  created	   that	  would	  be	  able	   to	  be	   inserted	  back	   into	  
pcRYR1.	   	   However,	   a	   5’	   subclone	   of	  RYR1	   was	   created	   using	   one	   of	   three	   SpeI	   and	  
HindIII	  restriction	  sites	  that	  left	  the	  5’	  end	  of	  RYR1	  intact	  (Figure	  3.3).	  	  pcRYR1	  digested	  
with	   SpeI	   and	  HindIII	   produced	   DNA	   bands	   at	   9,601bp,	   4,692bp,	   4,292bp,	   1,311bp,	  
717bp	  and	  36bp.	  	  The	  9,601bp	  fragment	  produced	  when	  cutting	  pcRYR1	  with	  SpeI	  and	  
HindIII	  was	   gel	   purified.	   	   All	   the	   remaining	   DNA	   bands	   produced	  with	   this	   digestion	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were	  not	  purified	  as	  no	  reconstruction	  could	  be	  made	  from	  their	  products.	  	  pBluescript	  
II	  SK	  +	  was	  also	  cut	  with	  SpeI	  and	  HindIII,	  resulting	  in	  a	  linear	  product	  of	  2,922bp	  and	  
was	   gel	   purified.	   	   Both	   purified	   fragments	   were	   ligated	   together	   to	   produce	   a	   5’	  
subclone	  of	  RYR1,	  12,523bp	  in	  size.	   	  Ligation	  mixes	  were	  transformed	  into	  XL10	  Gold	  
ultracompetent	  cells	  and	  colonies	  potentially	  containing	  the	  5’	  subclone	  were	  cultured	  
for	   mini	   prep	   plasmid	   DNA	   extraction	   and	   screened	   using	   XhoI	   restriction	  
endonuclease	  to	  test	  for	  successful	  ligation	  (Figure	  3.4).	  	  Positive	  samples	  created	  DNA	  
bands	  at	  5,396bp,	  4,019bp,	  2,086bp	  and	  1,022bp.	  	  A	  PCR	  product	  was	  generated	  over	  
the	  two	  cloning	  sites	  and	  sent	  for	  sequencing	  to	  confirm	  successful	  ligation.	  	  Sequence	  
analysis	   confirmed	   the	   presence	   of	   the	   ACTAGT	   SpeI	   and	   AAGCTT	  HindIII	   restriction	  




Figure	  3.3	  –	  Creation	  of	  the	  5’	  subclone	  of	  RYR1.	  
(A)	  pcRYR1	  was	  cut	  with	  SpeI	  and	  HindIII	  resulting	  in	  8	  DNA	  bands.	  	  The	  largest	  band	  of	  9,601bp	  contained	  the	  5’	  
end	  of	  RYR1	  and	  was	  gel	  purified.	  	  The	  remaining	  bands	  were	  not	  gel	  purified,	  as	  it	  was	  not	  possible	  to	  
reconstruct	  full-­‐length	  pcRYR1	  from	  these	  pieces.	  	  (B)	  pBluescript	  II	  SK	  +	  was	  cut	  with	  SpeI	  and	  HindIII	  which	  
produced	  a	  linear	  product	  of	  2,922bp	  that	  was	  gel	  purified.	  	  (C)	  Both	  gel-­‐purified	  fragments	  were	  ligated	  together	  
to	  form	  a	  12,523bp	  plasmid	  resulting	  in	  the	  5’	  subclone	  of	  RYR1.	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Figure	  3.4	  –	  Digestion	  confirmation	  of	  the	  creation	  of	  the	  5’	  subclone	  of	  RYR1.	  	  
	  (A)	  Plasmid	  map	  of	  the	  5’	  subclone	  with	  XhoI	  sites	  labelled.	  	  	  The	  expected	  DNA	  bands	  are	  indicated	  in	  the	  table	  
below	  the	  map.	  	  	  (B)	  Gel	  image	  of	  the	  5’	  subclone	  cut	  with	  XhoI.	  	  Lane	  1	  contains	  the	  5’	  subclone	  digested	  with	  
XhoI	  resulting	  in	  DNA	  bands	  at	  5,396bp,	  4,019bp,	  2,086bp	  and	  1,022bp	  indicating	  successful	  ligation.	  	  Lane	  2	  is	  an	  
undigested	  5’	  subclone	  sample.	  	  Lane	  M	  is	  a	  MassRuler	  DNA	  ladder	  with	  the	  relevant	  DNA	  band	  sizes	  indicated.	  
(C)	  Sequence	  confirmation	  of	  the	  successful	  creation	  of	  the	  5’	  subclone.	  	  PCR	  products	  generated	  over	  the	  cloning	  
sites	  were	  sequenced	  in	  both	  directions	  to	  confirm	  ligation.	  	  The	  ACTAGT	  SpeI	  site	  and	  AAGCTT	  HindIII	  sites	  were	  
identified	  (gold	  boxes).	  	  The	  sequence	  immediately	  flanking	  these	  cloning	  sites	  was	  aligned	  to	  reference	  
sequences	  for	  RYR1	  and	  pBluescript	  to	  confirm	  successful	  ligation.	  
	  
	  
3.3.2.3	  MEGAWHOP	  site-­‐directed	  mutagenesis	  
The	  5’	   and	  3’	  RYR1	   subclones	  were	  used	  as	   templates	   for	  MEGAWHOP	   site-­‐directed	  
mutagenesis.	  	  Mega	  primers	  between	  200bp	  and	  800bp	  in	  length	  were	  generated	  and	  
sequenced	   in	   both	   directions	   to	   ensure	   that	   the	   desired	   mutation	   was	   introduced	  
successfully.	   	   After	   successful	   generation	   of	   the	   mega	   primers,	   mutagenic	   PCR	   was	  
performed	   followed	   by	   DpnI	   digestion	   and	   transformation	   into	   XL10	   Gold	  
ultracompetent	  cells.	  Colonies	  generated	  were	  counted	  and	  cultured	  overnight	   in	   LB	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broth	  for	  mini	  prep	  plasmid	  DNA	  extraction.	  	  Primers	  flanking	  the	  mutation	  sites	  were	  
designed	   and	   used	   to	   generate	   a	   PCR	   product	   that	   was	   sequenced	   to	   confirm	  
successful	  mutagenesis	  (Figure	  3.5).	  	  A	  total	  of	  34	  colonies	  were	  produced	  throughout	  
the	  mutagenesis	  experiments,	  18	  of	  which	  contained	  the	  mutation	  of	  interest	  resulting	  
in	   an	   overall	   mutagenesis	   efficiency	   of	   52.9%	   (Table	   1).	   	   The	   success	   of	   the	  
introduction	  of	   individual	  mutations	  ranged	  from	  100%	  of	  colonies	  screened	  (1/1	   for	  
p.D1056H	  and	  p.V4849I)	  to	  20%	  of	  colonies	  screened	  (1/5	  for	  p.R2336H).	  	  	  
	  
	  
Mutation	   Colonies	  screened	   Colonies	  positive	   %	  Success	  
p.D1056H	   1	   1	   100	  
p.R2336H	   5	   1	   20	  
p.R2355W	   12	   6	   50	  
p.E3104K	   6	   4	   66.6	  
p.D3986E	   4	   2	   40	  
p.G3990V	   5	   3	   60	  
p.V4849I	   1	   1	   100	  
TOTAL	   34	   18	   52.9	  
Table	  3.4	  –	  MEGAWHOP	  mutagenesis	  success	  rate.	  	  	  
An	  overall	  success	  rate	  of	  52.9%	  was	  observed.	  	  Individual	  mutagenesis	  success	  ranged	  from	  between	  20%	  and	  
100%.	  	  The	  number	  of	  bacterial	  colonies	  produced	  after	  the	  mutagenesis	  protocol	  ranged	  from	  1	  to	  12.	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Figure	  3.5	  –	  Sequence	  confirmation	  of	  successful	  mutagenesis.	  	  	  
PCR	  products	  were	  generated	  over	  each	  mutation	  site	  and	  sent	  for	  sequencing	  to	  confirm	  the	  introduction	  of	  the	  
desired	  mutation	  into	  the	  subclone	  of	  RYR1.	  	  	  Wild	  type	  sequences	  are	  in	  the	  right	  hand	  column;	  mutant	  
sequences	  are	  in	  the	  left	  hand	  column.	  	  The	  amino	  acid	  altered	  is	  indicated	  with	  a	  gold	  box.	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3.3.2.4	  Reconstruction	  of	  full-­‐length	  mutant	  pcRYR1	  constructs	  using	  the	  3’	  subclone	  
After	   confirmation	   of	   successful	   mutagenesis,	   the	  mutant	   3’	   subclone	   was	   cut	   with	  
Acc65I	   and	   XbaI	   producing	   a	   large	   DNA	   band,	   8,248bp	   in	   length	   containing	   the	  
mutated	   3’	   end	   of	   RYR1	   and	   a	   smaller	   band	   of	   2,880bp.	   The	   larger	   band	   was	   gel	  
purified.	  	  The	  12,401bp	  DNA	  fragment	  that	  was	  saved	  during	  the	  construction	  of	  the	  3’	  
subclone	  was	  used	  as	   the	  vector	   for	   ligation	  of	   the	  3’	  end	  of	  RYR1	  back	   into	  pcRYR1	  	  
(Figure	  3.6).	  	  	  
	  
	  
Figure	  3.6	  –	  Reconstruction	  of	  full-­‐length	  mutant	  pcRYR1	  constructs.	  	  	  
(A)	  Mutant	  3’	  subclones	  were	  digested	  with	  Acc65I	  and	  XbaI.	  The	  mutation	  site	  is	  indicated	  with	  the	  yellow	  circle.	  
The	  8,248bp	  fragment	  corresponding	  to	  the	  3’	  end	  of	  RYR1	  was	  gel	  purified.	  	  The	  2,880bp	  pBluescript	  vector	  DNA	  
was	  discarded.	  	  (B)	  The	  3’	  end	  of	  RYR1	  was	  re-­‐ligated	  back	  into	  pcRYR1	  using	  the	  12,401bp	  ‘vector’	  sequence	  
saved	  from	  the	  construction	  of	  the	  3’	  subclone	  to	  create	  a	  mutant	  pcRYR1	  construct.	  
	  
	  
The	   ligation	   products	   were	   transformed	   into	   XL10	   Gold	   Ultracompetent	   cells	   and	  
cultured	   overnight	   on	   LB	   agar	   plates	   containing	   ampicillin.	   	   Individual	   colonies	  were	  
selected	   and	   cultured	   overnight	   in	   LB	   broth	   for	   mini	   prep	   plasmid	   DNA	   extraction.	  	  
Extracted	  DNA	  samples	  were	  screened	  using	  HindIII	  to	  test	  for	  successful	  ligation	  and	  
reconstruction	   of	   pcRYR1	   constructs.	   	   Positive	   samples	   produced	   DNA	   bands	   at	  
15,046bp,	   4,292bp	   and	   1,311bp	   (Figure	   3.7).	   	   Full-­‐length	  mutant	   pcRYR1	   constructs	  
were	  generated	  for	  the	  variants	  p.R2336H,	  p.3104K,	  p.D3986E,	  p.G3990V	  and	  p.V4849I	  
(Figure	  3.8).	  	  PCR	  products	  were	  generated	  over	  the	  Acc65I	  and	  XbaI	  cloning	  sites	  and	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sequenced	  in	  both	  directions.	  	  The	  presence	  of	  the	  GGTACC	  Acc65I	  restriction	  site	  and	  
TCTAGA	  XbaI	  restriction	  site	  were	  confirmed	  as	  well	  as	  the	  presence	  of	  the	  sequence	  
of	  RYR1	  or	  pcDNA3.1	   immediately	  flanking	  both	  sites	  was	  from	  reference	  sequences.	  	  






Figure	  3.7	  –	  Digest	  and	  sequence	  confirmation	  of	  full-­‐length	  pcRYR1	  constructs	  
(A)	  Plasmid	  map	  of	  mutant	  pcRYR1	  with	  HindIII	  sites	  marked.	  	  The	  expected	  DNA	  bands	  produced	  through	  HindIII	  
digestion	  are	  marked	  in	  the	  table	  below	  the	  map.	  	  (B)	  Gel	  image	  of	  pcRYR1	  cut	  with	  HindIII.	  Lane	  1	  is	  a	  mutant	  
pcRYR1	  construct	  digested	  with	  HindIII.	  Lane	  2	  is	  an	  undigested	  mutant	  pcRYR1	  construct.	  	  Lane	  M	  is	  a	  MassRuler	  
DNA	  ladder	  with	  the	  relevant	  DNA	  band	  sizes	  marked.	  	  (C)	  PCR	  products	  were	  generated	  over	  both	  cloning	  sites	  
and	  sequenced	  to	  confirm	  successful	  ligation.	  	  The	  presence	  of	  the	  TCCGGA	  Acc65I	  site	  and	  TCTAGA	  XbaI	  site	  was	  
identified	  and	  aligned	  to	  references	  sequences	  to	  confirm	  successful	  ligation.	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Figure	  3.8	  –	  Successful	  reconstruction	  of	  pcRYR1	  constructs.	  	  	  
Gel	  image	  showing	  pcRYR1	  constructs	  digested	  with	  HindIII.	  	  Lanes	  1a	  and	  1b	  are	  wild	  type	  controls	  for	  HindIII	  
digestion	  of	  pcRYR1	  (a	  lane)	  and	  an	  undigested	  sample	  of	  pcRYR1	  (b	  lane).	  	  Lanes	  2-­‐6	  follow	  the	  same	  pattern	  and	  
represent	  the	  successfully	  reconstructed	  mutant	  pcRYR1	  samples	  generated.	  	  Lane	  M	  is	  a	  MassRuler	  DNA	  ladder	  
with	  the	  relevant	  DNA	  band	  sizes	  marked.	  
	  
	  
3.3.3	  Cloning	  in	  pHSVPrPUC	  
To	  use	   the	  HSV-­‐1	  method	  of	   infecting	  dyspedic	  myotubes	   the	  RYR1	   cDNA	  constructs	  
needed	  to	  be	  transferred	  from	  the	  pcDNA3.1	  expression	  vector	  into	  pHSVPrPUC.	  	  Due	  
to	  the	  large	  size	  of	  RYR1	  there	  were	  limited	  unique	  restriction	  sites	  in	  the	  plasmid	  and	  
there	  were	  no	  unique	  restriction	  sites	  at	  the	  5’	  end	  of	  the	  cDNA	  construct.	   	  The	  only	  
usable	  restriction	  sites	  to	  shuttle	  the	  RYR1	  cDNA	  sequence	  into	  pHSVPrPUC	  were	  two	  
SpeI	   restriction	   sites	   that	   flanked	  either	   side	  of	   the	   insert.	   	   The	  SpeI	   recognition	   site	  
(ACTAGT)	  produces	  a	  5’	  overhang	  of	  CTAG	  that	  is	  compatible	  with	  the	  XbaI	  	  (TCTAGA)	  
restriction	  site	  in	  the	  pHSVPrPUC	  polylinker.	  The	  limited	  number	  of	  restriction	  sites	  in	  
the	   pHSVPrPUC	   polylinker	   meant	   that	   there	   was	   no	   suitable	   method	   available	   for	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Figure	  3.9	  –	  pHSVRYR1	  cloning	  strategy.	  	  	  
(A)	  Wild	  type	  and	  mutant	  full-­‐length	  pcRYR1	  constructs	  were	  digested	  with	  SpeI	  producing	  DNA	  bands	  15,240bp,	  
4,962bp	  and	  717bp	  in	  length.	  	  The	  15,240bp	  fragment	  contained	  the	  entire	  RYR1	  coding	  sequence.	  	  The	  RYR1	  
cDNA	  fragment	  was	  gel	  purified.	  	  	  (B)	  pHSVPrPUC	  was	  linearised	  with	  XbaI	  and	  treated	  with	  Antarctic	  
phosphatase	  to	  prevent	  religation.	  	  The	  treated	  sample	  was	  gel	  purified.	  	  	  	  (C)	  Gel	  purified	  RYR1	  cDNA	  and	  
pHSVPrPUC	  vector	  were	  ligated	  together	  to	  produce	  a	  20,083bp	  plasmid	  for	  full-­‐length	  wild	  type	  or	  mutant	  
pHSVRYR1.	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Wild	  type	  and	  mutant	  pcRYR1	  constructs	  were	  digested	  with	  SpeI	  producing	  three	  DNA	  
fragments	   (Figure	  3.9).	   	  The	   largest	  was	  15,240bp	   in	   length	  and	  contained	  the	  entire	  
RYR1	  coding	  sequence.	  	  This	  fragment	  was	  gel	  purified	  with	  the	  remaining	  bands	  being	  
discarded.	  	  pHSVPrPUC	  was	  linearised	  using	  an	  XbaI	  site	  in	  the	  polylinker,	  treated	  with	  
Antarctic	  phosphatase	  to	  prevent	  religation	  and	  gel	  purified.	  	  The	  RYR1	  cDNA	  fragment	  
and	   linear	  pHSVPrPUC	  samples	  were	   ligated	   together	   to	  produce	  either	  wild	   type	  or	  
mutant	   pHSVRYR1	   samples.	   The	   ligation	   products	   were	   transformed	   into	   XL10	   Gold	  
Ultracompetent	   cells	   and	   cultured	   overnight	   on	   LB	   agar	   plates	   containing	   ampicillin.	  	  
Individual	   bacterial	   colonies	   were	   selected	   for	   overnight	   cultures	   in	   LB	   broth.	   	  Mini	  
prep	  plasmid	  DNA	  extraction	  was	  carried	  out	  before	  screening	  the	  DNA	  samples	  with	  a	  
HindIII	   digest	   to	   test	   for	   successful	   ligation	   of	   the	   pHSVRYR1	   samples	   (Figure	   3.10).	  	  
Positive	   samples	   produced	   DNA	   bands	   at	   9,625bp,	   4,855bp,	   4,292bp	   and	   1,311bp.	  	  	  
Because	  a	  non-­‐directional	  cloning	  method	  was	  used	  it	  was	  possible	  for	  the	  RYR1	  cDNA	  
to	  ligate	  in	  either	  orientation	  into	  pHSVPrPUC	  however,	  HindIII	  was	  able	  to	  successfully	  
discriminate	  between	  the	  two	  orientations.	  	  RYR1	  in	  the	  reverse	  orientation	  produces	  
DNA	  bands	  at	  14,420bp,	  4,292bp,	  1,311bp	  and	  60bp.	  	  	  	  
PCR	   products	   were	   generated	   over	   both	   cloning	   sites	   and	   sequenced	   in	   both	  
directions.	   	  Both	  the	  SpeI	  and	  XbaI	  sites	  were	  destroyed	  by	  the	  ligation	  resulting	  in	  a	  
TCTAGT	   site	   at	   the	   5’	   end	   of	  RYR1	   and	   a	   ACTAGA	   site	   at	   the	   3’	   end	   of	  RYR1.	   	   The	  
presence	   of	   these	   sites	   was	   confirmed	   via	   sequencing	   as	   well	   as	   aligning	   the	  
immediately	   flanking	   sequences	   of	   RYR1	   and	   pHSVPrPUC	   to	   reference	   sequences.	  	  
Positive	  bacterial	  colonies	  were	  identified	  for	  three	  constructs	  ligated	  into	  pHSVPrPUC	  
(wild	  type,	  p.R2336H	  and	  p.D3986E)	  (Figure	  3.11).	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Figure	  3.10	  –	  Digest	  and	  sequence	  confirmation	  of	  pHSVRYR1	  constructs.	  
(A)	  Plasmid	  map	  of	  pHSVRYR1	  with	  HindIII	  sites	  labelled	  and	  the	  expected	  DNA	  bands	  indicated	  in	  the	  table	  
below	  the	  map.	  	  (B)	  Gel	  image	  of	  wild	  type	  pHSVRYR1	  cut	  with	  HindIII.	  Lane	  1	  is	  a	  wild	  type	  pHSVRYR1	  construct	  
digested	  with	  HindIII.	  Lane	  2	  is	  an	  undigested	  pHSVRYR1	  sample.	  	  Lane	  M	  is	  a	  MassRuler	  DNA	  ladder	  with	  the	  
relevant	  DNA	  band	  sizes	  marked.	  	  The	  presence	  of	  the	  9,625bp,	  4,855bp,	  4,292bp	  and	  1,311bp	  fragments	  in	  lane	  
1	  indicate	  positive	  ligation	  and	  the	  successful	  generation	  of	  a	  pHSVRYR1	  construct.	  (C)	  The	  ligation	  of	  SpeI	  into	  
the	  compatible	  XbaI	  site	  produced	  an	  TCTAGT	  sequence	  at	  the	  5’	  end	  of	  RYR1	  and	  a	  ACTAGA	  site	  at	  the	  3’	  end	  of	  
RYR1.	  	  These	  sequences	  were	  identified	  and	  are	  marked	  with	  a	  gold	  box.	  	  The	  sequences	  immediately	  flanking	  











	   92	  
	  
Figure	  3.11	  –	  pHSVRYR1	  cDNA	  constructs	  generated	  in	  this	  study.	  	  	  
Wild	  type,	  p.R2336H	  and	  p.D3986E	  RYR1	  cDNA	  constructs	  were	  successfully	  ligated	  with	  pHSVPrPUC.	  Each	  ‘a’	  
lane	  is	  a	  pHSVRYR1	  construct	  digested	  with	  HindIII.	  	  Each	  ‘b’	  lane	  is	  an	  undigested	  pHSVRYR1	  sample.	  	  The	  ‘M’	  
lanes	  are	  MassRuler	  DNA	  ladders	  with	  the	  appropriate	  DNA	  band	  sizes	  marked	  on	  the	  left.	  
	  
	  
3.3.4	  Cloning	  in	  pTUNE	  
3.3.4.1	  Removal	  of	  the	  BspEI	  site	  from	  pTUNE	  
Unlike	   the	   cloning	   strategy	   for	   pHSVRYR1,	   there	   were	   sufficient	   restriction	   sites	  
available	  to	  shuttle	  RYR1	  from	  the	  two	  subclones	  in	  pBluescript	  II	  SK	  +	  to	  pTUNE	  using	  
a	  two-­‐step	  and	  directional	  cloning	  strategy.	  	  However,	  for	  this	  to	  work,	  an	  endogenous	  
BspEI	   restriction	   site	   first	   needed	   to	   be	   removed	   from	  pTUNE	   (Figure	   3.12).	   	   pTUNE	  
was	  digested	  with	  BspEI	   before	  blunting	  with	  Klenow	   fragment	  and	   religation	  of	   the	  
newly	  blunt	  ends.	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Figure	  3.12–	  Removal	  of	  an	  endogenous	  BspEI	  restriction	  site	  in	  pTUNE.	  	  	  
(A)	  pTUNE	  was	  linearised	  with	  BspEI	  and	  gel	  purified.	  	  (B-­‐D)	  Purified,	  linear	  DNA	  was	  incubated	  with	  Klenow	  
fragment	  at	  a	  concentration	  of	  1	  unit	  per	  microgram	  of	  DNA.	  	  Klenow	  fragment	  blunts	  the	  5’	  overhang	  created	  by	  
BspEI	  by	  filling	  in	  the	  3’	  recessed	  end	  with	  dNTPs	  supplied	  in	  the	  reaction	  resulting	  in	  a	  blunt	  TCCGG	  sequence	  at	  
one	  end	  and	  a	  CCGGA	  sequence	  at	  the	  other	  end.	  	  (E-­‐F)	  Blunt	  end	  ligation	  is	  carried	  out	  resulting	  in	  a	  plasmid	  that	  
has	  lost	  its	  BspEI	  restriction	  site.	  	  Sequence	  confirmation	  confirmed	  the	  successful	  blunting	  of	  BspEI	  with	  the	  
presence	  of	  a	  TCCGGCCGGA	  site	  where	  the	  BspEI	  site	  originally	  was.	  
	  
	  
Primers	  were	  designed	  flanking	  the	  endogenous	  BspEI	  restriction	  site.	  	  A	  PCR	  product	  
was	  generated	  and	  sequenced	  in	  both	  directions	  to	  confirm	  the	  successful	  blunting	  of	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3.3.4.2	  Creation	  of	  the	  pTUNE	  subclone	  
The	   3’	   subclone	   generated	   for	  MEGAWHOP	  mutagenesis	  was	   used	   to	   shuttle	   the	   3’	  
end	  of	  RYR1	   into	  pTUNE	  (Figure	  3.13).	   	  The	  3’	  subclone	  was	  cut	  with	  Acc65I	  and	  SalI	  
which	  generated	  DNA	  fragments	  8,168bp	  and	  2,960bp	  in	  length.	  	  The	  larger	  fragment	  
contained	   the	   entire	   3’	   end	   of	  RYR1	   and	  was	   gel	   purified.	   	   The	   smaller,	   pBluescript	  
fragment	   was	   discarded.	   	   pTUNE	   was	   double	   digested	   with	   BsiWI	   and	   XhoI	   which	  
produce	   compatible	   5’	   overhangs	   for	   Acc65I	   (CATG	   overhang)	   and	   SalI	   (AGCT	  
overhang)	   respectively.	   	   The	   linear	   pTUNE	   DNA	   was	   gel	   purified.	   	   The	   8,168bp	  
fragment	  representing	   the	  3’	  end	  of	  RYR1	  was	   ligated	   into	   the	  purified	   linear	  pTUNE	  
sample	  to	  create	  a	  20,297bp	  plasmid	  termed	  the	  pTUNE	  subclone.	  	  
	  
	  
Figure	  3.13	  –	  Construction	  of	  the	  pTUNE	  subclone.	  	  	  
(A)	  The	  3’	  subclone	  of	  RYR1	  was	  cut	  with	  Acc65I	  and	  SalI	  to	  produce	  an	  8,168bp	  fragment	  of	  RYR1.	  	  This	  fragment	  
was	  gel	  purified.	  	  The	  2,960bp	  fragment	  of	  pBluescript	  was	  discarded.	  (B)	  	  pTUNE	  was	  cut	  with	  BsiWI	  and	  XhoI	  
which	  produce	  compatible	  overhangs	  with	  Acc65I	  and	  SalI	  respectively	  and	  gel	  purified	  	  (C)	  	  These	  two	  fragments	  
were	  ligated	  together	  to	  produce	  the	  pTUNE	  subclone.	  	  This	  entire	  process	  was	  repeated	  for	  each	  mutant	  
construct	  present	  in	  the	  3’	  end	  of	  RYR1.	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Ligation	  products	  were	  transformed	  into	  XL10	  Gold	  Ultracompetent	  	  cells	  and	  cultured	  
overnight	   on	   LB	   agar	   plates	   containing	   ampicillin.	   	   Individual	   bacterial	   colonies	  were	  
selected	   and	   screened	   using	   the	   restriction	   enzyme	   XhoI	   (Figure	   3.14).	   	   Positive	  
samples	  produced	  a	  DNA	  band	  at	  16,005bp	  and	  4,292bp.	   	  Additionally,	  primers	  were	  
designed	  flanking	  the	  two	  cloning	  sites	  so	  that	  a	  PCR	  product	  could	  only	  be	  generated	  
if	  successful	  ligation	  had	  occurred.	  	  PCR	  products	  were	  generated	  over	  the	  cloning	  sites	  
of	   samples	   that	   tested	   positive	  with	  XhoI	  digestion	   and	  were	   sequenced	   to	   confirm	  





Figure	  3.14	  –	  Digest	  and	  sequence	  confirmation	  of	  pTUNE	  subclone	  constructs	  
(A)	  	  Plasmid	  map	  of	  the	  pTUNE	  subclone	  with	  XhoI	  restriction	  sites	  marked.	  	  Expected	  DNA	  bands	  are	  indicated	  in	  
the	  table	  below	  the	  map.	  (B)	  	  Gel	  image	  of	  a	  positive	  sample	  for	  wild	  type	  pTUNE	  subclone.	  	  Lane	  1	  is	  the	  wild	  
type	  pTUNE	  subclone	  digested	  with	  XhoI.	  	  Lane	  2	  is	  undigested	  pTUNE	  subclone.	  	  Lane	  M	  is	  a	  DNA	  MassRuler	  
marker	  with	  the	  relevant	  DNA	  band	  sizes	  marked.	  	  The	  presence	  of	  16,005bp	  and	  4,292bp	  bands	  in	  lane	  1	  
indicates	  successful	  ligation	  and	  creation	  of	  the	  pTUNE	  subclone.	  	  (C)	  The	  BsiWI	  and	  Acc65I	  restriction	  sites	  were	  
both	  destroyed	  to	  produce	  a	  CGTACC	  sequence.	  	  The	  SalI	  and	  XhoI	  restriction	  sites	  were	  both	  destroyed	  to	  
produce	  a	  GTCGAG	  sequence.	  	  The	  new	  sites	  are	  indicated	  with	  a	  gold	  box.	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Ligating	   together	   the	   BsiWI	   and	  Acc65I	   sites	   together	   destroyed	   both	   sequences	   to	  
produce	   a	   CGTACC	   site	   and	   ligating	   together	   the	   SalI	  and	  XhoI	   sites	   destroyed	   both	  
sequences	   to	   produce	   a	   GTCGAG	   sequence.	   	   These	   sites	   were	   identified	   in	   the	  
sequence	   files.	   	   The	   sequence	   imediately	   flanking	   each	   cloning	   site	   was	   aligned	   to	  
reference	   sequences	   to	   confirm	   succsesful	   ligation.	   	   Positive	   samples	   identified	  
through	   digestion	   and	   sequencing	   were	   identified	   for	   wild	   type,	   p.R2355W	   and	  




Figure	  3.15	  –	  Gel	  image	  of	  pTUNE	  subclone	  constructs	  successfully	  generated	  in	  this	  project.	  	  	  
Wild	  type,	  p.R2355W	  and	  p.D3986E	  pTUNE	  subclones	  were	  successful	  generated.	  	  The	  16,004bp	  and	  4,292bp	  
fragments	  indicate	  positive	  digests.	  	  	  ‘a’	  lanes	  are	  pTUNE	  subclone	  samples	  digested	  with	  XhoI.	  	  ‘b’	  lanes	  are	  




3.3.4.3	  Construction	  of	  full-­‐length	  pTUNERYR1	  constructs	  
Wild	  type	  and	  mutant	  pTUNE	  subclone	  samples	  were	  digested	  with	  NheI	  and	  BspEI	  to	  
produce	   a	   linear	   20,158bp	  DNA	  product	   that	  was	   gel	   purified.	   	   Digestion	  with	  BspEI	  
removed	  the	  small	  section	  of	  RYR1	   that	  contained	  the	  Acc65I	  site	  that	  had	  been	   lost	  
due	   to	   ligation	   into	   the	   compatible	  BsiWI	   restriction	   site.	   	   The	   5’	   subclone	   that	  was	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generated	   for	   MEGAWHOP	   mutagenesis	   was	   digested	   with	   SpeI	   and	   BspEI	   	   which	  
produced	  a	  DNA	  fragment	  of	  7,121bp	  and	  that	  included	  the	  entire	  5’	  end	  of	  RYR1	  not	  
represented	  in	  the	  pTUNE	  subclone	  as	  well	  as	  a	  5,402bp	  fragment	  containing	  the	  rest	  
of	   the	   5’	   end	   of	   RYR1	   and	   the	   pBluescript	   vector.	   	   The	   7,121bp	   fragment	   was	   gel	  
purified	  and	  the	  other	  fragment	  was	  discarded.	  	  The	  7,121bp	  gel	  purified	  sample	  was	  
ligated	  into	  the	  linear	  pTUNE	  subclone	  samples	  to	  generate	  27,279bp	  full-­‐length	  wild	  
type	  and	  mutant	  pTUNERYR1	  constructs	  (Figure	  3.16).	  	  	  
	  
	  
Figure	  3.16	  –	  Construction	  of	  full-­‐length	  pTUNERYR1	  constructs.	  	  	  
(A)	  Wild	  type	  and	  mutant	  5’	  subclone	  samples	  were	  digested	  with	  SpeI	  and	  BspEI	  to	  remove	  the	  first	  7kb	  of	  RYR1	  
and	  was	  gel	  purified.	  	  (B)	  Wild	  type	  and	  mutant	  pTUNE	  subclones	  were	  cut	  with	  NheI	  and	  BspEI	  and	  gel	  purified.	  	  
(C)	  3	  different	  pTUNERYR1	  constructs	  were	  produced.	  	  The	  wild	  type	  5’	  subclone	  fragment	  was	  ligated	  into	  the	  
wild	  type	  pTUNE	  subclone	  to	  create	  wild	  type	  pTUNERYR1.	  	  The	  mutant	  5’	  subclone	  fragment	  was	  ligated	  into	  the	  
wild	  type	  pTUNE	  subclone	  to	  create	  the	  p.D1056H	  pTUNERYR1	  construct	  and	  the	  wild	  type	  5’	  subclone	  fragment	  
was	  ligated	  into	  the	  mutant	  pTUNE	  subclone	  to	  create	  the	  p.R2355W	  and	  p.D3986E	  pTUNERYR1	  constructs.	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The	  wild	  type	  5’	  subclone	  was	  used	  to	  produce	  p.R2355W	  and	  p.D3986E	  pTUNERYR1	  
constructs	   and	   the	   p.D1056H	   mutated	   5’	   subclone	   was	   ligated	   into	   the	   wild	   type	  
pTUNE	   subclone	   to	   generate	   p.D1056H	   pTUNERYR1.	   	   Ligation	   products	   were	  
transformed	   into	  XL10	  Gold	  Ultracompetent	   	  cells	  and	  cultured	  overnight	  on	  LB	  agar	  
plates	  containing	  ampicllin.	   	   Individual	  bacterial	   colonies	  were	  selected	   for	  overnight	  
cultures	  and	  were	   subject	   to	  mini	  prep	  plasmid	  DNA	  extraction.	  Potential	   full-­‐length	  
pTUNERYR1	  DNA	  samples	  were	  digested	  with	  Acc65I	  which,	  when	  positive	  produced	  
DNA	  bands	  at	  20,220bp	  and	  7,054bp	  (Figure	  3.17).	  	  	  	  
	  
	  
Figure	  3.17	  –	  Digest	  and	  sequence	  confirmation	  of	  pTUNERYR1	  constructs.	  
(A)	  	  Plasmid	  map	  of	  pTUNERYR1	  with	  Acc65I	  sites	  marked	  and	  expected	  DNA	  bands	  indicated	  in	  the	  table	  below	  
the	  map.	  	  (B)	  	  Gel	  image	  of	  pTUNERYR1	  digested	  with	  Acc65I.	  	  Lane	  1	  is	  an	  undigested	  pTUNERYR1	  sample.	  	  Lane	  
2	  is	  pTUNERYR1	  digested	  with	  Acc65I.	  	  Lane	  M	  is	  a	  DNA	  MassRuler	  ladder	  with	  the	  relevant	  DNA	  band	  sizes	  
marked.	  	  The	  presence	  of	  20,220bp	  and	  7,054bp	  DNA	  bands	  in	  lane	  1	  indicates	  successful	  creation	  of	  full-­‐length	  
pTUNERYR1.	  	  (C)	  The	  NheI	  and	  SpeI	  sites	  were	  ligated	  together	  to	  produce	  a	  GCTAGT	  site,	  resulting	  in	  the	  
destruction	  of	  both	  original	  restriction	  sites.	  	  The	  BspEI	  site	  was	  left	  intact.	  	  Sequences	  immediately	  flanking	  each	  
cloning	  site	  were	  aligned	  to	  RYR1	  and	  pTUNE	  reference	  sequences	  to	  confirm	  ligation.	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Additionally,	   primers	   were	   designed	   that	   flanked	   each	   cloning	   site	   so	   that	   a	   PCR	  
product	   could	  only	   be	   generated	   if	   successful	   ligation	  had	  occurred.	   	   A	   PCR	  product	  
was	   generated	   over	   both	   cloning	   sites	   and	   sequenced	   in	   both	   directions	   to	   confirm	  
ligation.	  	  Ligation	  of	  compatible	  NheI	  and	  SpeI	  	  sites	  resulting	  in	  the	  destruction	  of	  both	  
restriction	   sites	   and	   the	   presence	   of	   a	   GCTAGT	   sequence.	   	   This	   sequence	   and	   the	  
TCCGGA	  BspEI	   sequence	  were	   identified.	   	   The	   sequences	   immediately	   flanking	   each	  
cloning	   site	   were	   also	   aligned	   against	   RYR1	   and	   pTUNE	   plasmid	   DNA	   reference	  
sequences.	   	   Full-­‐length	   pTUNERYR1	   constructs	   were	   successfully	   generated	   for	   wild	  
type,	  p.D1056H,	  p.R2355W	  and	  p.D3986E	  (Figure	  3.18).	  
	  
	  
Figure	  3.18	  –	  Full-­‐length	  pTUNERYR1	  constructs	  digested	  with	  Acc65I.	  	  	  
Wild	  type,	  p.D1056H,	  p.R2355W	  and	  p.D3986E	  pTUNERYR1	  constructs	  were	  successfully	  generated.	  	  ‘a	  lanes’	  are	  




In	   this	   chapter,	   seven	   RYR1	   variants	   were	   selected	   for	   experiments	   aimed	   at	  
elucidating	   their	   functional	   consequences.	   	   As	   part	   of	   this	   project,	   a	   comprehensive	  
cloning	  strategy	  needed	  to	  be	  devised	  coupled	  with	  a	  mutagenesis	  protocol	  as	  robust	  
and	   reliable	   as	   possible	   for	   such	   large	   plasmids.	   	   The	   work	   presented	   above	  meets	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these	   criteria	  with	   all	   seven	   variants	   successfully	   introduced	   into	   subclones	   of	  RYR1	  
before	  full-­‐length	  plasmid	  reconstructions	  in	  several	  eukaryotic	  expression	  vectors.	  
	  
3.4.1	  Selection	  of	  RYR1	  variants	  
Seven	  variants	  were	  selected	  that	  have	  been	   identified	   in	  over	  a	   third	  of	   the	  UK	  MH	  
population	  that	  possess	  an	  as	  yet	  uncharacterised	  RYR1	  variant.	  	  A	  total	  of	  46	  families	  
have	   been	   found	   to	   possess	   one	   of	   these	   variants	   and	   the	   successful	   functional	  
characterisation	   of	   these	   variants	   would	   increase	   the	   availability	   of	   initial	   genetic	  
diagnosis	   by	   22.5%	   worldwide,	   negating	   the	   need	   for	   the	   invasive	   muscle	   biopsy	  
associated	  with	  IVCT	  testing	  for	  MH.	  
Amongst	   the	   seven	   variants	   are	   two	   which	   might	   be	   predicted	   to	   have	   minimal	  
function	  consequences	  based	  on	  the	  properties	  of	  the	  amino	  acids	  that	  are	  substituted	  
in	   the	   MH	   patients.	   	   The	   p.D3986E	   variant	   has	   an	   extremely	   mild	   amino	   acid	  
substitution	  of	  glutamic	  acid	  to	  aspartic	  acid.	  	  Both	  amino	  acids	  are	  polar,	  hydrophilic	  
and	  acidic	  and	  differ	  only	  in	  the	  presence	  of	  an	  additional	  methylene	  group	  in	  glutamic	  
acid.	   	   Despite	   the	   seemingly	   mild	   change,	   the	   p.D3986E	   variant	   has	   been	   found	   in	  
association	  with	  MH	  in	  4	  UK	  families	  which,	  when	  the	  IVCT	  results	  are	  taken	  together	  
produce	  a	  significantly	  larger	  caffeine	  contracture	  than	  specimens	  carrying	  other	  RYR1	  
variants	  meaning	  it	  is	  still	  a	  good	  candidate	  for	  MH	  testing	  (Carpenter	  et	  al.,	  2009c).	  
The	  second	  variant,	  p.V4849I,	  again	  maintains	  acidity	  and	  hydrophobicity.	   	  However,	  
this	   variant,	   has	   been	   found	   in	   a	   large	  number	   of	   families	  worldwide	   in	   conjunction	  
with	  both	  MH	  and	  CCD.	   	  Data	  obtained	   from	   lymphoblastoid	  cells	   indicates	   that	   this	  
variant	   produces	   an	   elevated	   resting	   calcium	   concentration	   in	   cells	   expressing	   the	  
variant,	  consistent	  with	  both	  MH	  and	  CCD	  phenotypes	  (Ducreux	  et	  al.,	  2006).	   	  Based	  
on	  the	  frequency	  at	  which	  the	  variant	  has	  been	  identified	  as	  well	  as	  data	  obtained	  in	  
patient	  cells,	  the	  functional	  consequences	  of	  the	  p.V4849I	  variant	  are	  still	  of	  interest	  in	  
this	  project.	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Evolutionary	  conservation	  of	  the	  nucleotide	  and	  amino	  acid	  affected	  is	  also	  of	  interest	  
when	   selecting	   RYR1	   variants	   that	   may	   potentially	   be	   causative	   of	   MH.	   	   Across	   a	  
number	   of	   species	   that	   are	   closely	   related	   to	   humans	   or	   have	   been	   reported	   to	  
undergo	  a	  similar	  reaction	  to	  MH,	  all	  amino	  acids	  affected	  in	  the	  variants	  selected	  are	  
maintained	   indicating	   at	   least	   some	   importance	   of	   the	   residue	   in	   question.	  	  
Interestingly,	  the	  p.D3986	  and	  p.V4849	  residues	  that	  appeared	  to	  have	  a	  mild	  change	  
when	  mutated	  have	  been	   fully	  maintained	  not	  only	  across	  different	   species	  but	  also	  
across	   the	   three	   RYR	   isoforms	   in	   humans	   suggesting	   that	   the	   amino	   acid	   present	   is	  
important	  for	  the	  normal	  function	  of	  the	  protein.	  
The	  only	   residue	   that	  shows	  any	   form	  of	  variation	  between	  different	  RYR	  proteins	   is	  
the	  p.R2355	  residue	  that	  in	  human	  RYR2	  is	  a	  lysine	  residue.	  	  The	  change	  from	  arginine	  
to	   lysine	   is	   a	   relatively	  mild	  one	  with	  both	  amino	  acids	  being	  positively	   charged	  and	  
basic	  however,	  as	  discussed	  above	  this	  does	  not	  negate	  the	  possibility	  of	  a	  change	  of	  
function.	  	  However,	  as	  these	  two	  residues	  are	  present	  in	  the	  two	  wild	  type	  sequences,	  
it	  suggests	  that	  the	  change	  is	  a	  functional	  one	  relating	  to	  the	  slightly	  different	  roles	  of	  
RYR1	   and	   RYR2	   in	   the	   tissue	   in	   which	   they	   are	   primarily	   expressed.	   	   The	   p.R2355	  
residue	  is	  maintained	  across	  all	  the	  RYR1	  isoforms	  examined	  indicating	  the	  importance	  
of	  this	  residue	  and	  therefore	  its	  inclusion	  in	  this	  project.	  
The	  primary	  selection	  criterion	  for	  inclusion	  in	  this	  project	  was	  the	  frequency	  at	  which	  
the	   variant	   has	   been	   found	   in	   the	   UK	  MH	   population.	   	   The	   exception	   to	   this	   is	   the	  
p.D1056H	   RYR1	   variant,	   which	   was	   chosen	   for	   study	   in	   this	   project	   due	   to	   its	  
association	  with	  both	  MH	  and	  EHS.	   	   The	   variant	  was	   identified	   to	   co-­‐segregate	  with	  
disease	   in	  an	  MH	   family	  but	  upon	  subsequent	   screening	  of	   the	  UK	  MH	  population	   it	  
was	   also	   identified	   in	   an	   individual	   who	   suffered	   an	   EHS	   reaction	   and	   was	  
subsequently	  referred	  for	  MH	  testing.	  	  However,	  the	  EHS	  individual	  tested	  negative	  for	  
MH	   through	   the	   IVCT.	   	   There	   has	   long	   been	   a	   link	   between	  MH	   and	   EHS	   through	   a	  
shared	   phenotype	   and	  with	   increasing	   evidence	   of	   a	   genotypic	   link,	   experiments	   on	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the	   p.D1056H	   variant	   are	   of	   particular	   interest	   (Tobin	   et	   al.,	   2001,	   Hopkins,	   2007,	  
Muldoon	  et	  al.,	  2007,	  Muldoon	  et	  al.,	  2008).	  
	  
3.4.2	  Subcloning	  RYR1	  
The	  cloning	  work	  presented	  above	  represents	  a	  significant	  step	  forward	  in	  simplifying	  
the	  processes	  by	  which	  functional	  studies	  can	  be	  carried	  out	  using	  RYR1	  cDNA	  clones.	  	  
It	   is	   unfeasible	   to	   carry	   out	   conventional	   mutagenesis	   on	   a	   full-­‐length	   RYR1	   cDNA	  
construct	   and	   so	   the	   necessity	   to	   subclone	   certain	   sections	   of	  RYR1	   is	   unavoidable.	  	  
The	   first	  work	   aimed	   at	   functionally	   assessing	   a	   number	   of	   genetic	   variants	   in	  RYR1	  
associated	   with	   MH	   constructed	   eleven	   separate	   subclones	   of	   RYR1	   to	   carry	   out	  
mutagenesis	  on	  (Tong	  et	  al.,	  1997).	   	  This,	  however,	  was	  a	  large	  undertaking	  that	  first	  
needed	  the	  introduction	  of	  five	  new	  unique	  restriction	  sites	  into	  the	  cDNA	  sequence	  of	  
RYR1.	   	   Three	   large	   subclones	   of	  RYR1	  were	   created	   for	   the	   introduction	   of	   the	   new	  
restriction	  sites,	  one	  of	  which	  was	  then	  subcloned	  further	  after	  the	   introduction	  of	  a	  
new	   restriction	   site.	   	   The	   shuttle	   vectors	   used	   for	   these	   manipulations	   were	  
themselves	   modified	   to	   allow	   the	   subcloning	   of	   certain	   regions	   of	   RYR1.	   After	   the	  
introduction	   of	   the	   new	   restriction	   sites,	   an	   expression	   vector	   also	   had	   to	   be	  
manipulated	  to	  allow	  the	  full-­‐length	  RYR1	  construct	  to	  be	  inserted.	  	  Furthermore,	  this	  
work	  was	  carried	  out	  to	  facilitate	  the	  introduction	  variants	  that	  were	  only	  separated	  by	  
2kb	  of	  DNA.	  
Subsequent	  work	  has	  also	  required	  the	  creation	  of	  multiple	  step	  cloning	  strategies	  to	  
allow	  the	  introduction	  of	  genetic	  variants	  in	  RYR1.	  Sambuughin	  et	  al.	  (2001b)	  removed	  
one	   piece	   of	   RYR1	   directly	   from	   a	   full-­‐length	   construct	   but	   needed	   to	   insert	   the	  
mutated	   piece	   of	   DNA	   into	   one	   of	   three	   subclones	   which	   were	   then	   combined	   to	  
recreate	  a	  full-­‐length	  RYR1	  cDNA	  construct.	  	  Sato	  et	  al.	  (2010)	  used	  a	  similar	  strategy	  in	  
which	   full-­‐length	  RYR1	   was	   split	   into	   two	   large	   subclones	   before	   each	   being	   halved	  
again	  to	  create	  a	  total	  of	  four	  constructs.	  	  Mutagenesis	  was	  performed	  on	  one	  of	  the	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four	  smaller	  constructs	  before	  going	  through	  two	  reconstruction	  steps	   to	  create	   full-­‐
length	  mutants.	  
The	  cloning	  strategies	  used	  were	  in	  part	  necessary	  to	  produce	  a	  small	  enough	  subclone	  
to	  carry	  out	  site	  directed	  mutagenesis.	  	  	  The	  original	  functional	  study	  used	  plasmids	  no	  
larger	   than	   4.5kb	   in	   size.	   	   As	  mutagenesis	   protocols	   have	   advanced,	   the	   size	   of	   the	  
plasmid	  used	  as	  a	  template	  for	  mutagenesis	  has	  increased	  but	  never	  above	  10kb.	  	  The	  
MEGAWHOP	  mutagenesis	   protocol	   utilised	   in	   this	   study	   has	   allowed	  us	   to	   carry	   out	  
mutagenesis	   on	   plasmids	   12.5kb	   in	   size.	   	   This	   increase	   in	   size	   of	   template	   DNA	   has	  
facilitated	  the	  use	  of	  a	  one	  step	  subcloning	  strategy	  in	  which	  RYR1	  was	  split	  in	  half	  to	  
create	   a	   5’	   and	   a	   3’	   subclone.	   	   The	   possibility	   of	   carrying	   out	  mutagenesis	   on	   these	  
subclones	  means	  that	  individual	  strategies	  do	  not	  need	  to	  be	  developed	  for	  individual	  
genetic	   variants	   in	   RYR1.	   	   The	   mutation	   site	   will	   be	   present	   in	   either	   of	   the	   two	  
subclones	  and	  can	  be	  used	  for	  mutagenesis.	  	  The	  5’	  subclone	  has	  an	  overlap	  into	  the	  3’	  
subclone	  meaning	  that	  no	  area	  of	  RYR1	  is	  missed.	  	  Mutations	  in	  the	  3’	  end	  of	  RYR1	  can	  
be	  reconstructed	  into	  pcRYR1	  to	  create	  full-­‐length	  constructs	  however,	  due	  to	  the	  lack	  
of	  a	  unique	  restriction	  site	  at	  the	  5’	  end	  of	  RYR1,	  mutations	  in	  this	  subclone	  had	  to	  be	  
reconstructed	  into	  a	  new	  vector	  (pTUNE).	  	  The	  wild	  type	  3’	  end	  of	  RYR1	  was	  inserted	  
into	  pTUNE	  meaning	  that	  the	  need	  for	  only	  a	  one	  step	  cloning	  strategy	  is	  maintained.	  
	  
3.4.3	  Mutagenesis	  of	  RYR1	  subclones	  
The	  mutagenesis	   protocol	   had	   an	   overall	   efficiency	   of	   52.9%	   but	   ranged	   from	   20%-­‐
100%	  of	  colonies	  screened	  for	   individual	  mutations.	   	  This	  discrepancy	   is	   likely	  due	  to	  
variability	   in	  the	  stringency	  of	  the	  mutagenesis	  procedure.	   	  One	  such	  example	  would	  
be	   inconsistencies	   in	   DpnI	   digestion	   of	   the	   original	   template	   DNA.	   	   For	   variants	   in	  
which	   there	   were	   more	   colonies	   after	   transformation	   the	   success	   percentage	   was	  
lower.	   	   For	   both	   variants	   where	   only	   one	   colony	   formed	   after	   transformation	  
(p.D1056H	  and	  p.V4849I),	  that	  colony	  was	  positive	  for	  the	  mutation.	  	  Previous	  studies	  
fail	   to	   report	   their	   mutagenesis	   efficiency	   however	   it	   is	   widely	   accepted	   that	   as	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plasmid	  size	  increases	  the	  efficiency	  for	  any	  enzymatic	  process	  is	  reduced.	   	  A	  success	  
rate	   of	   over	   50%	   is	   considered	   good	   for	   a	   cDNA	   construct	   of	   the	   size	   of	  RYR1.	   	   The	  
development	  of	  a	  simple	  and	  robust	  method	  of	  generating	  mutant	  RYR1	  constructs	  is	  
not	   only	   of	   use	   to	   our	   group	   but	   other	   groups	  working	   on	   characterising	  mutations	  
identified	   in	   the	  MH	  population.	   	  Many	   variants	   identified	   in	   patients	   are	   unique	   to	  
their	   family.	   	   EMHG	   guidelines	   only	   allow	   variants	   to	   be	   added	   to	   the	   genetic	  
diagnostic	  panel	  of	  MH	  if	  experiments	  have	  been	  carried	  out	  on	  ex	  vivo	  samples	  from	  
two	   independent	   families	  meaning	   some	   variants	  may	   never	   be	   characterised	   using	  
this	  method.	  	  	  Making	  recombinant	  experiments	  more	  accessible	  to	  other	  laboratories	  
would	  aid	  the	  increase	  of	  the	  genetic	  diagnostic	  panel	  in	  the	  global	  MH	  population.	  
	  
3.4.4	  The	  requirement	  of	  multiple	  expression	  vectors	  
For	  simple	   functional	  experiments	   involving	  easily	   transfectable	  cells	  such	  as	  HEK293	  
cells	  the	  use	  of	  the	  pcDNA	  expression	  vector	   is	  sufficient.	   	  However,	   in	  this	  study	  we	  
wanted	   to	   be	   able	   to	   compare	   the	   functional	   consequences	   of	   variants	   in	   RYR1	   in	  
HEK293	   cells	   as	   well	   as	   in	   the	   more	   native	   1B5	   muscle-­‐like	   cells.	   	   Conventional	  
transfection	  methods	  are	  unsuitable	   for	  experiments	   in	  muscle	  cells.	   	  Small	  plasmids	  
have	   low	   transfection	   efficiency	   in	   muscle	   cells	   (Campeau	   et	   al.,	   2001)	   and	   when	  
coupled	  with	  a	  plasmid	  over	  20kb	   in	   size,	   the	  efficiency	  drops	   further.	   	  A	  method	   to	  
virally	   transduce	   the	  dyspedic	   1B5	   cells	   has	  been	  developed	  which	   allows	   functional	  
experiments	   to	   be	   carried	   out	   in	   a	  more	   native	   environment	   for	   RYR1	   (Yang	   et	   al.,	  
2003).	   	   The	  method	   involves	  packaging	  RYR1	   into	  HSV	  virions.	   	   To	  do	   this,	   the	  RYR1	  
cDNA	  needed	  to	  be	  transferred	  to	  the	  pHSVPrPUC	  vector	  that	  contains	  the	  packaging	  
signal	   for	   HSV	   capsid	   formation.	   	   Due	   to	   the	   size	   of	  RYR1,	   there	   are	   limited	   unique	  
restriction	  sites	  for	  shuttling	  over	  the	  cDNA	  sequence	  to	  the	  pHSVPrPUC	  vector.	   	  The	  
only	  method	  available	   in	  this	  study	  was	  to	  cut	  with	  SpeI	  which	  had	  three	  sites	   in	  the	  
pcRYR1	  vector.	  	  There	  were	  no	  SpeI	  sites	  in	  the	  RYR1	  cDNA	  sequence	  but	  one	  at	  either	  
end	   of	   the	   sequence	   and	   a	   further	   one	   in	   the	   vector	   sequence.	   	   SpeI	   produces	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compatible	  overhangs	  with	  XbaI.	  	  pHSVPrPUC	  was	  linearised	  using	  XbaI	  and	  RYR1	  was	  
non-­‐directionally	  cloned	  into	  pHSVPrPUC.	  	  This	  method	  was	  far	  from	  ideal	  as	  ligations	  
of	  such	  size	  are	  extremely	  inefficient.	  	  This	  was	  exacerbated	  by	  the	  fact	  that	  the	  RYR1	  
cDNA	   could	   insert	   into	   pHSVPrPUC	   in	   either	   direction	   further	   reducing	   the	   ligation	  
efficiency.	   	   Nevertheless,	   three	   constructs	   were	   successfully	   generated.	   	   Wild	   type,	  
p.R2336H	  and	  p.D3986E	  RYR1	  were	   introduced	   into	   the	  pHSVPrPUC	  vector.	   	  Getting	  
the	  wild	  type	  construct	  into	  pHSVPrPUC	  was	  essential	  for	  any	  subsequent	  comparisons	  
with	  mutant	  constructs.	  	  
Recent	  evidence	  has	  hinted	  at	   the	   importance	  of	  expression	   levels	  of	  RYR1	   alleles	   in	  
patients	  with	  MH	  (Grievink	  and	  Stowell,	  2010).	  	  This	  coupled	  with	  the	  desire	  to	  reliably	  
obtain	   specific	   levels	   of	  RYR1	  expression	   in	   cellular	   systems	   led	   to	   the	   idea	   to	   place	  
RYR1	   constructs	   into	   the	   pTUNE	   inducible	   expression	   vector	   (Deans	   et	   al.,	   2007).	  	  
Unlike	   most	   other	   inducible	   expression	   vectors,	   pTUNE	   functions	   as	   a	   single	   vector	  
which,	  when	  dealing	  with	  a	  construct	  the	  size	  of	  RYR1	  is	  ideal.	  	  The	  polylinker	  of	  pTUNE	  
had	   several	   restriction	   sites	   that	   had	   complimentary	   overhangs	   to	   several	   sites	   in	  
pcRYR1	  making	   the	   shuttling	  of	  RYR1	   into	  pTUNE	  easier	   than	   it	  was	   for	  pHSVPrPUC.	  	  
The	  strategy	  depended	  on	  BspEI	  to	  be	  a	  unique	  restriction	  site	  within	  RYR1	  meaning	  an	  
endogenous	   BspEI	   site	   needed	   to	   be	   removed	   before	   RYR1	   could	   be	   cloned	   into	  
pTUNE.	   	  The	  pTUNE	  BspEI	  site	  resided	  in	  the	  neomycin	  resistance	  gene	  meaning	  that	  
no	  stable	  pTUNERYR1	   clones	  would	  be	  able	   to	  be	  created.	  However,	  with	   the	  added	  
complication	  of	  needing	  to	   induce	  expression,	  only	  transient	  transfections	  of	  HEK293	  
cells	  were	  planned	  for	  these	  constructs.	  	  	  
	  
3.5	  Future	  work	  
The	  cloning	  work	  presented	  here	   represents	  a	   substantial	   step	   forward	   in	   increasing	  
the	  ease	  at	  which	   functional	  experiments	   for	  RYR1	   variants	   can	  be	   carried	  out.	   	   The	  
development	  of	  a	  highly	  efficient	  and	  robust	  mutagenesis	  method	  coupled	  with	  a	  one	  
step	  reassembly	  strategy	  means	  that	  the	  speed	  at	  which	  mutant	  RYR1	  constructs	  can	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be	   created	   is	   greatly	   increased.	   	   There	   are	   currently	   over	   200	   uncharacterised	  RYR1	  
variants	  that	  need	  to	  be	  functionally	  tested	  before	  they	  can	  be	  included	  on	  a	  genetic	  
diagnostic	  panel	  and	  decrease	   the	  need	   for	  a	  muscle	  biopsy.	   	   The	  development	  of	  a	  
production	   line	   of	  mutant	  RYR1	   variants	  would	   increase	   the	   efficiency	   at	  which	   the	  
variants	  can	  be	  added	  to	  the	  genetic	  diagnostic	  panel.	  
In	   spite	   of	   this,	   work	   can	   still	   be	   done	   to	   further	   improve	   the	   efficiency	   of	   the	  
production	  of	  mutant	  RYR1	  constructs.	   	  Currently,	  any	  variants	   in	  the	  5’	  end	  of	  RYR1	  
need	  to	  be	  reconstructed	  into	  the	  pTUNE	  inducible	  vector.	   	   Ideally,	  there	  would	  be	  a	  
unique	   restriction	   site	   at	   the	   5’	   end	   of	   RYR1	   that	   would	   facilitate	   the	   possibility	   of	  
introducing	  the	  mutated	  5’	  end	  of	  RYR1	  straight	  back	  into	  the	  pcDNA	  vector.	  	  Although	  
placing	  the	  5’	  end	  of	  RYR1	  into	  pTUNE	  is	  still	  a	  one	  step	  cloning	  strategy,	  the	  plasmid	  is	  
much	  larger	  than	  pcDNA	  and	  along	  with	  the	  need	  to	  induce	  the	  cells	  with	  high	  doses	  of	  
IPTG	  to	  generate	  expression	  of	  RYR1	   it	  would	  be	   less	  technically	  demanding	  to	  place	  
the	   variants	   into	   the	  pcRYR1	   construct.	   	   Future	  work	   could	   introduce	  a	  new,	  unique	  
restriction	  site	  into	  the	  pcDNA	  expression	  vector	  as	  well	  as	  at	  the	  5’	  end	  of	  RYR1	  in	  the	  
5’	   subclone	   meaning	   that	   the	   subclone	   could	   be	   recreated	   using	   the	   new	   site	   and	  
Acc65I.	  	  This	  would	  allow	  the	  introduction	  of	  the	  5’	  subclone	  directly	  into	  pcRYR1.	  
Another	  area	  that	  could	  be	   improved	   is	   the	  mutagenesis	  method.	   	  MEGAWHOP	  site-­‐
directed	  mutagenesis,	  although	  efficient	  and	  suitable	  for	   large	  plasmids,	   is	  still	  a	  PCR	  
based	  method	  that	  holds	  inherent	  risks	  of	  introducing	  additional,	  unwanted	  mutations	  
into	  the	  plasmid	  targeted.	   	  A	  technique,	  which	  could	  be	  used	   in	  such	  experiments,	   is	  
recombinogenic	  engineering	  (recombineering).	  	  This	  method	  is	  based	  on	  lambda	  Red-­‐
mediated	  homologous	  recombination.	  	  The	  technique	  was	  first	  developed	  to	  study	  the	  
gene	   functions	   of	   recently	   sequenced	   genes	   of	   unknown	   function	   derived	   from	   the	  
human	   genome	   project.	   	   	   The	   method	   has	   been	   used	   extensively	   in	   studying	   gene	  
function	   and	   expression	   patterns	   in	   the	   nematode	   worm,	   Caenorhabditis	   elegans	  
through	   the	   insertion	   of	   reporter	   constructs	   at	   the	   end	   of	   C-­‐terminal	   end	   of	   target	  
genes	  (Dolphin	  and	  Hope,	  2006).	  One	  of	  the	  biggest	  advantages	  of	  this	  technique	  is	  its	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potential	  for	  limitless	  size	  of	  constructs	  manipulated	  and	  although	  recombineering	  has	  
been	  primarily	  used	   for	   the	  addition	  of	   reporter	   constructs	   to	  genes	   the	  potential	   is	  
there	   to	   introduce	   single	   point	   mutations	   in	   a	   similar	   fashion	   to	   the	   MEGAWHOP	  
protocol	   developed	   here.	   	   The	   use	   of	   recombineering	  would	   eliminate	   the	   need	   for	  
unique	   restriction	   sites	   and	   laborious	   ‘cut	   and	   paste’	   methods	   of	   subcloning	   to	  
facilitate	   site-­‐directed	   mutagenesis	   as	   well	   as	   limit	   the	   amount	   of	   error	   introduced	  
through	  PCR	  based	  mutation	  strategies.	  
	  
3.6	  Conclusions	  
The	  work	  presented	  here	  provides	  a	  large	  step	  forward	  in	  the	  production	  of	  full-­‐length,	  
mutant	   RYR1	   cDNA	   constructs.	   	   By	   far	   the	   best	   ways	   of	   functionally	   characterising	  
RYR1	  variants	  are	  recombinant	  methods.	  	  Therefore,	  developing	  a	  robust,	  efficient	  and	  
simple	   cloning	   strategy	   that	   allows	   the	   relatively	   rapid	   creation	   of	   RYR1	   variants	   is	  
essential.	  	  In	  the	  10	  years	  prior	  to	  this	  work,	  only	  31	  RYR1	  variants	  have	  been	  accepted	  
as	  causative	  of	  MH	  and	  placed	  onto	  the	  genetic	  diagnostic	  panel.	   	  This	   is	   in	  no	  small	  
part	  due	   to	   the	  difficulties	  associated	  with	  working	  with	   large	  cDNA	  constructs.	   	  The	  
methods	  developed	  here	  have	  created	  7	  full-­‐length	  mutant	  RYR1	  constructs	  that,	  after	  
subsequent	  functional	  analysis	  can	  potentially	  increase	  the	  genetic	  diagnostic	  panel	  by	  
22.5%.	  	  These	  variants	  represent	  a	  total	  of	  46	  families	  in	  the	  UK	  that	  possess	  an	  as	  yet	  
uncharacterised	   missense	   RYR1	   variant.	   	   The	   addition	   of	   these	   variants	   to	   the	  
diagnostic	  panel	  for	  MH	  will	  improve	  the	  diagnostic	  procedure	  for	  people	  within	  these	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Chapter	  Four -­‐	  Functional	  analysis	  of	  genetic	  variants	  in	  the	  RYR1	  gene	  associated	  
with	  malignant	  hyperthermia	  in	  HEK293	  cells	  
	  
4.1	  Introduction	  
Since	  the	  introduction	  of	  the	  EMHG	  guidelines	  for	  the	  inclusion	  of	  RYR1	  and	  CACNA1S	  
variants	   onto	   the	   genetic	   diagnostic	   panel	   for	  MH,	   by	   far	   the	  most	   frequently	   used	  
method	  has	  been	  expressing	  recombinant	  RYR1	  variants	  in	  HEK293	  cells.	  	  Out	  of	  the	  31	  
mutations	  listed	  as	  causative	  on	  the	  EMHG	  website,	  85%	  have	  been	  tested	  in	  HEK293	  
cells.	   	   Recently,	   experiments	   involving	   dyspedic	   muscle-­‐like	   1B5	   cells	   have	   been	  
developed	  but	  currently	  they	  have	  only	  been	  used	  to	  confirm	  the	  causative	  nature	  of	  
MH	  mutations	   already	  on	   the	  diagnostic	   panel	   (Yang	  et	   al.,	   2003).	   	  Work	  on	  ex	   vivo	  
samples	  struggle	  to	  make	  it	  to	  the	  diagnostic	  panel	  for	  MH	  due	  to	  the	  limited	  number	  
of	  samples	  and	  families	  available	  for	  such	  studies	  and	  due	  to	  the	  problems	  associated	  
with	   working	   on	   a	   non-­‐defined	   genetic	   background	   they	   possess	   relatively	   little	  
scientific	  merit	  as	  a	  method	  of	  functionally	  assessing	  RYR1	  variants.	  
	  
4.1.1	  Variants	  in	  pcRYR1	  
Several	   of	   the	  most	   frequent	  RYR1	  variants	   found	   in	   association	  with	  MH	   in	   the	  UK	  
population	  were	  selected	  as	  candidates	  to	  be	  functionally	  characterised	  as	  described	  
in	   chapter	   3.	   	   Five	   of	   the	   variants,	   p.R2336H,	   p.E3104K,	   p.D3986E,	   p.G3990V	   and	  
p.V4849I	  were	  introduced	  into	  pcRYR1	  and	  account	  for	  a	  total	  of	  34	  UK	  families	  with	  
an	   as	   yet	   uncharacterised	   RYR1	   variant.	   	   The	   p.E3104K,	   p.D3986E	   and	   p.G3990V	  
variants	   have	   been	   identified	   exclusively	   in	   the	   UK	   whereas	   the	   p.R2336H	   and	  
p.V4849I	  variants	  have	  been	  found	  worldwide.	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4.1.1.1	  p.R2336H	  worldwide	  
The	   p.R2336H	   variant	   is	   particularly	   prevalent	   in	   the	  MH	   population	   of	   Switzerland	  
with	  one	  report	  suggesting	  it	  may	  be	  present	  in	  a	  similar	  frequency	  to	  the	  p.V2168M	  
variant	  which	   is	  the	  most	  common	  in	  Switzerland	  (Treves	  et	  al.,	  2011).	   	   Interestingly,	  
immortalised	   lymphoblastoid	   cells	   isolated	   from	   patients	   carrying	   this	   variant	   only	  
showed	  an	  increased	  sensitivity	  to	  4-­‐CmC	  but	  not	  caffeine	  (Levano	  et	  al.,	  2009).	  	  In	  this	  
case,	   cells	   from	   seven	   separate	   families	   were	   analysed,	   potentially	   removing	   any	  
worries	  of	  the	  genetic	  background	  playing	  a	  part	  in	  the	  seemingly	  wild	  type	  phenotype	  
when	  the	  cells	  were	  exposed	  to	  caffeine.	  	  However,	  lymphocytes	  are	  not	  a	  cell	  type	  in	  
which	  RYR1	  would	  carry	  out	  its	  primary	  function	  and	  questions	  remain	  over	  the	  use	  of	  
these	   cells	   as	   a	   representative	   system	   for	   these	   experiments,	   especially	   considering	  
the	  fact	  that	  this	  variant	  has	  been	  identified	  to	  cosegregate	  with	  the	  MH	  phenotype	  in	  
14	   families	  worldwide.	   	   The	  p.R2336H	   variant	   has	   also	  been	   implicated	   in	   a	   form	  of	  
non-­‐anaesthesia	   induced	  MH.	   	   A	   patient	   carrying	   both	   the	   p.R2336H	   variant	   and	   a	  
p.E209K	   variant	   experienced	   almost	   100	   episodes	   of	   generalised	   body	   rigidity	   and	  
muscle	  spasms	  in	  the	  absence	  of	  anaesthesia	  (Loke	  et	  al.,	  2007,	  Muldoon	  et	  al.,	  2008).	  	  
The	  p.E209K	  variant	  was	  dismissed	  as	   the	   causative	   factor	   in	   this	   case	  based	  on	   the	  
prediction	   of	   an	   in	   silico	   protein	   prediction	   program	   and	   p.R2336H	   accepted	   as	   the	  
cause.	   Whereas	   the	   p.R2336H	   variant	   has	   been	   implicated	   in	   a	   non-­‐anaesthesia	  
reaction,	  an	  additional	  variant	  at	  this	  codon,	  p.R2336C,	  has	  been	  found	  in	  association	  
with	  a	  recessive	  myopathy	  (Bevilacqua	  et	  al.,	  2011).	  	  A	  patient	  carrying	  a	  p.R2336C	  and	  
p.D4911L	   displayed	   axial	   and	   proximal	   muscle	   weakness	   along	   with	   impaired	  
respiratory	  function	  and	  poor	  spontaneous	  movements.	  	  It	  is	  not	  known	  whether	  this	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4.1.1.2	  p.V4849I	  worldwide	  
The	  p.V4849I	  variant	  has	  been	  identified	  in	  cases	  of	  CCD	  as	  well	  as	  MH.	  	  Monnier	  et	  al.	  
(2005)	  reported	  a	  case	  where	  only	  MH	  was	  found	  in	  the	  family	  carrying	  the	  p.V4849I	  
variant	  whereas,	   in	   the	  UK,	  6	  out	  of	   the	  8	   families	   that	  possess	   the	  p.V4849I	  variant	  
have	   CCD	   segregating	   with	   the	   variant	   in	   addition	   to	   MH.	   	   Jungbluth	   et	   al.	   (2002)	  
reported	   a	   family	   in	   which	   the	   p.V4849I	   variant	   had	   been	   identified	   in	   the	  
heterozygous	  state	  in	  both	  parents	  of	  a	  CCD	  affected	  child	  who	  carried	  the	  variant	  in	  
homozygous	   form.	   	   The	   parents	   were	   asymptomatic	   of	   CCD	   but	   unfortunately,	   no	  
family	   members	   were	   tested	   for	   MH	   susceptibility	   via	   the	   IVCT.	   	   Similarly	   to	   the	  
p.R2336H	  variant,	   immortalised	   lymphoblastoid	   cells	   isolated	   from	  both	  parents	   and	  
the	  CCD	  affected	  daughter	  did	  not	  display	  an	  increased	  sensitivity	  to	  4-­‐CmC	  (Ducreux	  
et	  al.,	   2006).	   	   This	  was,	  however,	   just	  one	   family	   tested	  using	  a	  non-­‐defined	  genetic	  
background	   and	   in	   a	   cellular	   system	   far	   removed	   from	   the	   normal	   environment	   of	  
RYR1.	  	  An	  elevated	  resting	  calcium	  level	  was	  seen,	  however,	  in	  the	  patients	  indicating	  
that	  this	  variant	  may,	  at	  least	  in	  part,	  contribute	  to	  the	  myopathy	  phenotype.	  
	  
4.1.2	  The	  variants	  in	  the	  UK	  population	  
Carpenter	  et	  al.	  (2009c)	  presented	  data	  for	  each	  of	  the	  variants	  under	  investigation	  in	  
this	   chapter	   in	   correlation	   with	   IVCT	   data	   obtained	   at	   the	   St	   James’s	   Hospital	   MH	  
diagnostic	  centre.	  	  All	  variants	  correlated	  with	  a	  strong	  MHS	  IVCT	  response.	  	  There	  was	  
some	   variability	   between	   the	   variants	   within	   the	   different	   parameters	   of	   the	   IVCT	  
procedure	   and	   the	   MH	   reaction	   experienced	   by	   patients	   carrying	   these	   variants.	  	  
Patients	   carrying	   the	   p.D3986E	   and	   p.G3990V	   variants	   were	   found	   to	   have	   a	  
significantly	   higher	   static	   caffeine	   contracture	   in	   the	   IVCT	   as	   compared	   to	   patients	  
carrying	  a	  known	  causative	  MH	  variant.	   	  Patients	  carrying	  the	  p.G3990V	  variant	  were	  
also	   associated	   with	   a	   more	   severe	   dynamic	   halothane	   IVCT	   response.	   Both	   the	  
p.R2336H	   and	   the	   p.D3986E	   variants	   were	   associated	   with	   a	   higher	   creatine	   kinase	  
value	  in	  MH	  probands.	  	  The	  p.E3104K	  variant	  was	  associated	  with	  a	  ryanodine	  binding	  
	   111	  
response	   close	   to	   wild	   type	   and	   an	   overall	   weaker	   response	   throughout	   the	   IVCT.	  	  
Although	   the	   p.V4849I	   variant	   was	   associated	   with	   both	   MH	   and	   CCD,	   the	   IVCT	  
response	   was	   not	   significantly	   different	   to	   any	   of	   the	   other	   variants	   under	  
investigation.	  	  	  
This	   variability	   observed	   between	   patients	   known	   to	   be	   carrying	   these	   variants	   and	  
their	  IVCT	  responses	  may	  represent	  one	  reason	  why	  some	  patients	  have	  a	  more	  severe	  
MH	  reaction,	  a	  quicker	  onset	  time	  and	  why	  some	  patients	  can	  undergo	  more	  than	  one	  
anaesthesia	   before	   experiencing	   an	   MH	   reaction.	   	   However,	   each	   of	   the	   patients	  
included	   in	   such	   studies	   also	   have	   unknown	   genetic	   factors	   contributing	   to	   this	  
variability.	  	  Comprehensive	  functional	  analysis	  of	  these	  genetic	  variants	  in	  recombinant	  
systems	   will	   allow	   greater	   conclusions	   to	   be	   drawn	   on	   the	   inherent	   variability	   of	  
different	  RYR1	  variants.	  
	  
4.2	  Aims	  of	  the	  chapter	  
The	  aims	  of	  this	  chapter	  were	  to	  functionally	  characterise	  common	  RYR1	  variants	  that	  
have	   consistently	   been	   identified	   in	   association	  with	  MH	   in	   the	  UK	  population.	   	   The	  
functional	  studies	  carried	  out	  will	  be	  the	  final	  step	  for	  placing	  these	  variants	  onto	  the	  
genetic	   diagnostic	   panel	   for	   MH,	   expanding	   the	   current	   availability	   for	   genetic	  
diagnosis	   by	   16.1%	  and	   reducing	   the	  need	   for	   a	  muscle	   biopsy	   for	   patients.	  HEK293	  
cells	  were	  selected	  as	  the	  expression	  system	  in	  this	  chapter	  to	  allow	  a	  robust,	  reliable	  
and	   reproducible	   method	   of	   transfection	   and	   subsequent	   measurements	   to	   be	  
established.	   	   The	  aim	  of	   this	  was	   to	  develop	  a	  protocol	   that	   can	  be	   readily	  used	   for	  
many	   other	   RYR1	   variants	   found	   associated	   with	   MH	   in	   the	   UK	   and	   worldwide	  
populations.	  	  Furthermore,	  obtaining	  data	  in	  HEK293	  cells	  is	  the	  first	  step	  of	  evaluating	  
their	   use	   in	   functional	   studies	   as	   a	   comparison	   point	   to	   data	   obtained	   in	   dyspedic	  
myotubes.	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4.3	  Results	  
4.3.1	  HEK293	  cells	  stably	  transfected	  with	  pcRYR1	  constructs	  
4.3.1.1	  Antibiotic	  kill	  curve	  
To	   determine	   the	   correct	   concentration	   of	   the	   selective	   antibiotic,	   G418,	   to	   use	   in	  
selecting	   stable	   HEK293	   cell	   lines	   transfected	   with	   wild	   type	   or	   mutant	   pcRYR1	  
constructs,	  an	  antibiotic	  kill	  curve	  was	  established	  (Figure	  4.1).	  
	  
Figure	  4.1	  –	  Antibiotic	  kill	  curve	  for	  HEK293	  cells	  exposed	  to	  G418	  over	  a	  period	  of	  10	  days.	  	  	  
(A)	  The	  percentage	  of	  cells	  that	  died	  after	  up	  to	  10	  days	  of	  exposure	  to	  G418.	  	  	  	  Measurements	  were	  taken	  every	  
2	  days.	  	  The	  higher	  the	  concentration	  of	  G418,	  the	  higher	  the	  percentage	  of	  cells	  that	  took	  up	  the	  trypan	  blue	  
viability	  stain	  and	  were	  therefore	  dead.	  	  After	  10	  days,	  98%	  of	  cells	  exposed	  to	  1.5mg/ml	  G418	  were	  dead.	  	  No	  
more	  than	  5%	  of	  cells	  were	  dead	  at	  any	  time	  point	  when	  the	  growth	  medium	  was	  free	  of	  antibiotics.	  	  	  (B)	  Cell	  
count	  of	  cells	  after	  exposure	  to	  G418.	  	  Cells	  with	  no	  antibiotic	  continued	  to	  grow	  freely.	  	  The	  higher	  the	  antibiotic	  
concentration,	  the	  slower	  the	  cells	  were	  able	  to	  proliferate.	  
	  
	  
Panel	   A	   shows	   the	   percentage	   of	   cells	   that	   took	   up	   the	   trypan	   blue	   dye	   and	   were	  
therefore	   dead.	   	   The	   higher	   the	   concentration	   of	   G418	   in	   the	   growth	  medium,	   the	  
more	   cells	   died	   throughout	   the	   10-­‐day	   experiment.	   	   After	   10	   days,	   98%	   of	   cells	  
exposed	  to	  1.5mg/ml	  G418	  took	  up	  the	  trypan	  blue	  viability	  stain	  indicating	  cell	  death	  
compared	  with	  89%	  and	  70%	  for	  cells	  exposed	  to	  1mg/ml	  G418	  and	  0.5mg/ml	  G418,	  
respectively.	   	   No	   more	   than	   5%	   of	   cells	   were	   dead	   when	   no	   antibiotic	   was	   in	   the	  
growth	  medium.	   	  Based	  on	  this,	  5%	  was	  taken	  as	  the	  background	  death,	  presumably	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caused	   by	   the	   resuspension	   procedure	   to	   mix	   the	   cells	   with	   trypan	   blue.	   	   Panel	   B	  
shows	  the	  cell	  count	  in	  each	  of	  the	  flasks	  measured	  throughout	  the	  experiment.	  	  Cells	  
exposed	  to	  no	  antibiotics	  grew	  the	  most	  prolifically.	  	  As	  the	  concentration	  of	  antibiotic	  
increased,	  the	  cell	  count	  at	  each	  time	  point	  measured	  decreased.	   	  The	  tissue	  culture	  
flasks	  were	  initially	  seeded	  with	  5	  x	  104	  HEK293	  cells.	  	  The	  flasks	  that	  were	  not	  exposed	  
to	   any	  G418	   reached	  a	   cell	   count	  of	   512	   x	   104.	   	   Cells	   exposed	   to	  0.5mg/ml	  of	  G418	  
grew	  to	  a	  cell	  count	  of	  448	  x	  104.	  	  Cells	  exposed	  to	  1mg/ml	  of	  G418	  reached	  304	  x	  104	  
cells/ml	  and	  cells	  exposed	  to	  1.5mg/ml	  similarly	  only	  managed	  to	  reach	  320	  x	  104	  cells	  
per	  ml	   over	   the	   10-­‐day	   time	   period.	   	   1mg/ml	   G418	  was	   the	   recommended	   starting	  
antibiotic	  concentration	  and	  based	  on	  the	  results	  obtained	  here,	  there	  was	  no	  reason	  
to	  diverge	  from	  this	  concentration	  for	  the	  stable	  transfection	  experiments.	  
	  
4.3.1.2	  Caffeine-­‐induced	  calcium	  release	  of	  stably	  transfected	  HEK293	  cells	  
Data	  obtained	  from	  confocal	  microscopy	  was	  saved	  as	  a	  z-­‐stack	  video	  and	  analysed	  in	  
ImageJ	  and	  fluorescence	  traces	  were	  plotted	  in	  Prism	  6	  statistics	  package	  (Figure	  4.2).	  	  
Cells	  were	  loaded	  with	  Fluo-­‐4	  AM	  as	  described	  in	  section	  2.4.	  	  Upon	  stimulation	  with	  
caffeine,	   calcium	   release	   was	   observed	   as	   a	   temporary	   increase	   in	   fluorescence	  
followed	   by	   a	   return	   to	   baseline	   as	   the	   Ca2+	   ions	   were	   sequestered	   back	   into	   the	  
stores.	  	  All	  cells	  responded	  at	  caffeine	  concentrations	  of	  between	  1mM	  and	  20mM.	  	  A	  
small	  proportion	  of	  untransfected	  HEK293	  cells	  responded	  to	  high	  doses	  of	  caffeine	  (8-­‐
20mM)	  (Figure	  4.3A).	  	  Because	  of	  this,	  ten	  independent	  experiments	  were	  analysed	  to	  
calculate	   a	   background	   rate	   of	   cells	   responding	   to	   caffeine	   that	  were	   untransfected	  
resulting	  in	  an	  average	  background	  rate	  of	  4.02%	  being	  calculated	  (Figure	  4.3B).	  	  Based	  
on	   the	   responses	   of	   untransfected	   cells,	   only	   cells	   that	   responded	   to	   low	   doses	   of	  
caffeine	   (1mM-­‐5mM)	   were	   selected	   on	   the	   videos	   for	   analysis.	   	   Any	   cells	   that	   only	  
responded	  to	  caffeine	  doses	  above	  5mM	  were	  not	  used	  for	  subsequent	  analysis.	  



















Figure	  4.2	  –	  Ca2+	  release	  from	  a	  HEK293	  cell	  upon	  stimulation	  with	  1mM	  caffeine.	  	  	  
(A)	  Fluorescence	  trace	  generated	  from	  a	  HEK293	  cell	  releasing	  Ca2+.	  	  (B)	  Time	  lapse	  image	  showing	  the	  same	  
HEK293	  cell	  releasing	  Ca2+	  upon	  stimulation	  with	  caffeine.	  	  Ca2+	  release	  is	  visualised	  as	  a	  temporary	  increase	  in	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Figure	  4.3	  –	  The	  response	  of	  untransfected	  HEK293	  cells	  to	  caffeine.	  	  	  
(A)	  Untransfected	  cells	  only	  responded	  to	  high	  doses	  of	  caffeine	  as	  seen	  by	  the	  temporary	  increase	  in	  
fluorescence	  observed	  after	  the	  addition	  of	  20mM	  caffeine	  in	  the	  above	  trace.	  	  (B)	  Ten	  independent	  experiments	  
were	  analysed	  giving	  an	  estimated	  background	  rate	  of	  4.02%	  of	  HEK293	  cells	  that	  responded	  to	  high	  doses	  of	  
caffeine	  (8mM-­‐20mM).	  
	  
Wild	  type	  cells	  never	  responded	  to	  0.5mM	  caffeine	  and	  only	  on	  rare	  occasions	  did	  the	  
mutants	   (Figure	   4.4).	   	   Each	   experiment	   was	   plotted	   as	   a	   normalised	   response	   with	  
100%	   being	   the	   peak	   fluorescence	   for	   each	   video	   and	   0%	   being	   the	   baseline	  
fluorescence	  before	   the	   addition	  of	   any	   caffeine.	   	  A	  maximum	   response	  was	  usually	  
observed	   at	   5mM	   caffeine	   for	   all	   constructs.	   	   On	   occasion,	  wild	   type	   and	   p.D3986E	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transfected	  cells	  only	  achieved	  a	  maximum	  response	  at	  20mM	  caffeine.	  	  p.R2336H	  and	  
p.G3990V	  often	  reached	  a	  maximum	  response	  at	  concentrations	  of	  caffeine	  as	  low	  as	  
2mM.	   	   Dose-­‐response	   curves	   were	   plotted	   on	   a	   log	   x-­‐axis.	   	   The	   peak	   fluorescence	  
produced	   from	   each	   caffeine	   concentration	   was	   taken	   before	   non-­‐linear	   regression	  
was	  used	  to	  fit	  a	  representative	  curve	  for	  all	  experiments	  (Figure	  4.5A-­‐C).	  	  	  
	  
	  
Figure	  4.4	  –	  Representative	  traces	  of	  HEK293	  cells	  stably	  transfected	  with	  wild	  type	  and	  mutant	  pcRYR1	  
constructs.	  	  	  
The	  response	  at	  each	  caffeine	  concentration	  is	  seen	  as	  a	  temporary	  increase	  in	  fluorescence.	  	  The	  red	  arrows	  
mark	  the	  time	  that	  each	  caffeine	  concentration	  was	  added	  to	  the	  well	  and	  instantly	  perfused	  off.	  	  Wild	  type	  
transfected	  cells	  never	  reached	  a	  maximum	  response	  before	  the	  addition	  of	  5mM	  caffeine.	  	  This	  was	  the	  same	  for	  
cells	  transfected	  with	  the	  p.D3986E	  variant,	  however,	  cells	  transfected	  with	  both	  the	  p.R2336H	  and	  p.G3990V	  
variants	  often	  reached	  a	  maximum	  response	  at	  caffeine	  concentrations	  as	  low	  as	  2mM.	  
	  
For	   cells	   transfected	   with	   p.R2336H	   and	   p.G3990V	   constructs,	   the	   fitted	   curve	   was	  
shifted	   to	   the	   left,	   indicating	   an	   increase	   in	   sensitivity	   to	   caffeine.	   	   Cells	   transfected	  
with	  p.D3986E	  had	  a	  curve	  that	  was	  very	  similar	   to	  the	  curve	  produced	  by	  wild	  type	  
cells.	   	   The	   dose	   at	   which	   half	   of	   the	   maximum	   response	   (EC50)	   was	   produced	   was	  
calculated	  from	  the	  curves	  generated	  in	  the	  Prism	  software	  package	  	  (Figure	  4.5D-­‐E).	  	  	  
Compared	   to	  cells	   stably	   transfected	  with	   the	  wild	   type	  pcRYR1	  construct	  where	   the	  
EC50	   was	   3.209mM	   (standard	   error	   of	   the	   mean	   (SEM)	   =	   0.259,	   95%	   confidence	  
intervals	  (CI)	  =	  2.443-­‐3.774),	  p.R2336H	  and	  p.G3990V	  transfected	  cells	  had	  an	  EC50	  that	  
was	   statistically	   significantly	   reduced	   to	   0.9101mM	   (SEM	   =	   0.092,	   95%	   CI	   =	   0.801-­‐
1.274;	   p=0.0003)	   and	   1.414mM	   (SEM	   =	   0.098,	   95%	   CI	   =	   1.118-­‐1.694;	   p=0.0001)	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respectively	  (n=6).	  	  The	  EC50	  of	  cells	  transfected	  with	  the	  p.D3986E	  construct	  was	  only	  
slightly	   reduced	   to	   2.857mM,	  which	  was	   not	   statistically	   significantly	   different	   from	  
that	  of	  wild	  type	  (SEM	  =	  0.1865,	  95%	  CI	  =	  2.225-­‐3.184;	  p=0.2339)	  (n=6).	  	  	  
The	   percentage	   of	   the	   maximum	   response	   was	   plotted	   for	   each	   construct	   at	   each	  
caffeine	  concentration	  (Figure	  4.5F).	  	  At	  1mM	  caffeine,	  cells	  transfected	  with	  p.R2336H	  
produced	  a	  response	  that	  was	  statistically	  significantly	  higher	  than	  any	  other	  construct	  
(wild	   type	   (p=0.001),	   p.D3986E	   (p=0.0004)	   and	   p.G3990V	   (p=0.0004).).	   p.D3986E	  
transfected	   cells	   produced	   a	   response	   that	   was	   statistically	   significantly	   higher	   than	  
wild	   type	   at	   1mM	   caffeine	   (p=0.046)	   whereas,	   as	   a	   percentage	   of	   its	   maximum,	  
p.G3990V	  produced	  a	   response	   that	  was	  not	  significantly	  different	   from	  wild	   type	  at	  
1mM	   caffeine	   (p=0.1554).	   	   At	   2mM	   all	   variants	   produced	   a	   statistically	   significantly	  
higher	   response	   as	   a	   percentage	   of	   their	   maximum	   as	   compared	   to	   wild	   type	  
(p.R2336H	   p<0.0001,	   p.D3986E	   p=0.0033,	   p.G3990V	   p<0.0001).	   	   However,	   the	  
p.D3986E	  response	  was	  significantly	  smaller	  than	  the	  p.R2336H	  and	  p.G3990V	  variants	  
(p<0.0001	  for	  both	  constructs).	  	  At	  5mM	  and	  20mM	  caffeine	  a	  maximum	  response	  had	  
been	   achieved	   for	   all	   constructs	  meaning	   that	   there	  were	   no	   significant	   differences	  
observed.	  	  For	  all	  analyses	  n=6.	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Figure	  4.5	  –	  Caffeine	  dose-­‐response	  for	  HEK293	  cells	  stably	  transfected	  with	  wild	  type	  and	  mutant	  pcRYR1	  
constructs.	  	  	  
(A-­‐C)	  Dose-­‐response	  curve	  for	  each	  variant	  stably	  transfected	  into	  HEK293	  cells	  plotted	  with	  wild	  type.	  	  Data	  
points	  are	  shown	  as	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  the	  mean.	  	  The	  curves	  for	  p.R2336H	  and	  
p.G3990V	  variants	  	  are	  shifted	  to	  the	  left	  indicating	  an	  increase	  in	  sensitivity	  to	  caffeine.	  	  The	  p.D3986E	  curve	  is	  
very	  similar	  to	  the	  wild	  type	  curve.	  (D-­‐E)	  EC50	  for	  each	  experiment.	  	  A	  two-­‐tailed	  student’s	  t-­‐test	  showed	  a	  
statistically	  significant	  reduction	  in	  EC50	  as	  compared	  to	  wild	  type	  for	  p.R2336H	  and	  p.G3990V.	  	  No	  statistical	  
significance	  was	  seen	  between	  wild	  type	  and	  p.D3986E.	  	  Box	  plots	  are	  shown	  as	  median,	  upper	  and	  lower	  
quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  (F)	  Graph	  showing	  the	  %	  maximal	  response	  produced	  at	  
each	  dose	  of	  caffeine	  for	  each	  construct.	  	  Data	  is	  presented	  as	  mean	  plus	  or	  minus	  the	  standard	  error	  of	  the	  
mean.	  	  A	  two-­‐tailed	  student’s	  t-­‐test	  showed	  a	  statistically	  significant	  increase	  in	  %	  of	  maximal	  response	  produced	  
at	  1mM	  caffeine	  for	  p.R2336H	  and	  p.D3986E.	  	  At	  2mM	  all	  variants	  had	  a	  significant	  increase	  in	  the	  %	  of	  the	  
maximal	  response	  produced.	  	  	  No	  significant	  difference	  was	  seen	  at	  20mM	  caffeine.	  *p<0.5,	  **p<0.01,	  
***p<0.001	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4.3.1.3	  EC10	  and	  EC25	  of	  cells	  transfected	  with	  the	  wild	  type	  and	  p.D3986E	  constructs	  
Due	  to	  cells	  transfected	  with	  p.D3986E	  constructs	  having	  an	  EC50	  similar	  to	  wild	  type	  
transfected	   cells	   but	   still	   producing	   a	   statistically	   significantly	   higher	   response	   as	   a	  
percentage	  of	   it’s	  maximum	  at	  1mM	  and	  2mM	  caffeine,	  EC10	  and	  EC25	  measurements	  
were	   taken	   from	   the	   same	  dose-­‐response	   curve	  generated	   in	   Figure	  4.5	  B	   (the	  dose	  
required	  to	  produce	  10%	  and	  25%	  of	  the	  maximum	  response	  respectively).	  	  p.D3986E	  
transfected	  cells	  had	  a	   statistically	   significantly	   lower	  EC10	   (1.58mM)	  as	  compared	   to	  
wild	   type	   (2.19mM;	   p=0.04).	   	   The	   EC25	   of	   p.D3986E	   transfected	   cells	   (2.15mM)	  was	  
considerably	   lower	   than	  wild	   type	   transfected	   cells	   (2.68mM)	  but	   this	   did	   not	   reach	  
statistical	  significance	  (p=0.07)	  (Figure	  4.6).	  	  For	  each	  measurement	  n=6.	  
	  
	  
Figure	  4.6	  –	  EC10	  and	  EC25	  calculations	  for	  cells	  stably	  transfected	  with	  wild	  type	  or	  p.D3986E	  pcRYR1	  constructs.	  	  	  
(A)	  Box	  plots	  representing	  EC10	  and	  EC25	  measurements	  for	  both	  constructs.	  	  Cells	  transfected	  with	  p.D3986E	  
constructs	  had	  a	  lower	  EC10	  and	  EC25	  compared	  to	  wild	  type.	  	  Box	  plots	  are	  shown	  as	  the	  median,	  the	  upper	  and	  
lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  	  (B)	  The	  EC10	  of	  p.D3986E	  transfected	  cells	  
(1.58mM)	  was	  statistically	  significantly	  lower	  than	  that	  of	  wild	  type	  transfected	  cells	  (2.19mM;	  p=0.04)	  The	  EC25	  
measurement	  for	  p.D3986E	  (2.15mM)	  was	  considerably	  lower	  than	  wild	  type	  (2.68mM)	  but	  this	  was	  not	  
significant	  (p=0.07).	  *	  p<0.05	  
	  
	  
4.3.1.4	  Area	  under	  the	  curve	  measurements	  of	  cells	  stably	  transfected	  with	  pcRYR1	  
constructs	  
AUC	   measurements	   were	   taken	   as	   an	   indirect	   measure	   of	   the	   quantity	   of	   calcium	  
being	   released	   at	   each	   caffeine	   concentration.	   	   To	   account	   for	   the	   variable	   baseline	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produced	   in	   each	   dose-­‐response	   experiment,	   AUC	   measurements	   were	   specifically	  
tailored	   for	   each	   individual	   experiment.	   	   No	   measurements	   were	   taken	   at	   0.5mM	  
caffeine	  as	  only	  a	  few	  experiments	  produced	  a	  response	  at	  that	  dose	  and	  wild	  type	  did	  
not	   respond	  at	  all	   (Figure	  4.7).	   	  At	  1mM	  caffeine,	  wild	   type	  transfected	  HEK293	  cells	  
produced	  24.81	  ±	  8.357	   fluorescence	  units	   (FU)	   (measurements	  were	   taken	  as	  mean	  
plus	  or	  minus	  the	  standard	  error	  of	  the	  mean).	   	  p.R2336H	  and	  p.G3990V	  transfected	  
cells	   produced	   587.1	   ±	   135.1	   FU	   and	   938.6	   ±	   180.7	   FU	   respectively	   which	   was	  
statistically	   significantly	   higher	   than	   the	  wild	   type	   response	   (p=0.0089	   and	  p=0.0039	  
respectively).	   	  Cells	   transfected	  with	  p.D3986E	  constructs	  produced	  a	  small	   response	  
that	   was	   not	   statistically	   significantly	   higher	   than	   wild	   type	   (237.6	   ±	   34.19	   FU;	  
p=0.1712).	   	   Similar	   responses	   were	   observed	   at	   2mM	   caffeine	   with	   wild	   type	  
producing	  a	  response	  of	  124.1	  ±	  57.1	  FU	  and	  p.R2336H	  and	  p.G3990V	  transfected	  cells	  
producing	   statistically	   significant	   increases	   in	   calcium	   releases	   of	   	   930.5	   ±	   122.5	   FU	  
(p=0.0172)	   and	   1326	   ±	   334.4	   FU	   (p=0.0165)	   respectively.	   	   Cells	   transfected	   with	  
p.D3986E	  constructs	  again	  responded	  in	  a	  similar	  way	  to	  wild	  type	  with	  a	  total	  calcium	  
release	  of	  350.5	  ±	  47.34	  FU	  which	  was	  not	  statistically	  significant.	  Furthermore,	  cells	  
transfected	   with	   p.R2336H	   and	   p.G3990V	   constructs	   produced	   a	   statistically	  
significantly	  higher	  response	  than	  cells	  transfected	  with	  the	  p.D3986E	  variant	  at	  both	  
1mM	  (p=0.0145	  and	  p=0.0054)	  and	  2mM	  caffeine	  (p=0.0176	  and	  p=0.0055).	  	  At	  5mM	  
and	   20mM	   caffeine	   no	   significant	   differences	   were	   observed	   between	   any	   of	   the	  
constructs	  under	  investigation.	  	  For	  each	  comparison	  n=6.	  
	   121	  
	  
	  
Figure	  4.7	  –	  Area	  under	  the	  curve	  measurements	  of	  HEK293	  cells	  stably	  transfected	  with	  pcRYR1	  constructs.	  	  	  
Box	  plots	  are	  shown	  as	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  At	  
1mM	  and	  2mM	  caffeine,	  p.R2336H	  and	  p.G3990V	  transfected	  cells	  produced	  a	  statistically	  significant	  increase	  in	  
calcium	  release	  as	  compared	  to	  both	  wild	  type	  and	  p.D3986E	  transfected	  cells.	  	  At	  these	  low	  doses	  of	  caffeine,	  
cells	  transfected	  with	  the	  p.D3986E	  variant	  did	  not	  produce	  a	  response	  that	  was	  significantly	  different	  from	  wild	  
type.	  	  At	  5mM	  and	  20mM	  caffeine,	  no	  significant	  difference	  was	  observed	  between	  any	  of	  the	  constructs	  under	  
investigation.	  *p<0.05,	  **p<0.01.	  
	  
4.3.2	  HEK293	  cells	  transiently	  transfected	  with	  pcRYR1	  constructs	  
4.3.2.1	  Caffeine-­‐induced	  calcium	  release	  from	  HEK293	  cells	  transiently	  transfected	  
with	  pcRYR1	  constructs	  
HEK293	   cells	  were	   transiently	   transfected	  with	  wild	   type	   pcRYR1	   and	   the	   constructs	  
with	   the	   variants	   p.E3104K,	   p.G3990V	   and	   p.V4849I	   introduced	   into	   them.	  	  
Transfected	  cells	  were	  exposed	  to	  0.5mM,	  1mM,	  2mM	  4mM,	  8mM	  and	  20mM	  caffeine	  
for	  p.E3104K	  and	  p.V4849I	   transfected	  cells	  and	  0.2mM,	  0.5mM,	  1mM,	  2mM,	  5mM,	  
10mM	  and	  20mM	  caffeine	  for	  p.G3990V	  transfected	  cells.	  	  Each	  experiment	  involving	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an	   RYR1	   variant	   was	   done	   in	   parallel	   with	   wild	   type	   transfected	   cells	   at	   the	   same	  
caffeine	   concentrations.	   Representative	   traces	   produced	   from	   each	   construct	   are	  
presented	  in	  Figure	  4.8.	   	  No	  cells	  responded	  to	  either	  0.2mM	  or	  0.5mM	  caffeine.	   	  All	  
cells	  responded	  to	  1mM	  caffeine	  but	  cells	  transfected	  with	  mutant	  pcRYR1	  constructs	  
tended	   to	   produce	   larger	   calcium	   transients.	   	   For	   cells	   transfected	   with	   p.E3104K	  
constructs	  this	  reached	  as	  high	  as	  60%	  of	  the	  maximum	  response.	   	  At	  2mM	  caffeine,	  
the	  majority	  of	  cells	  transfected	  with	  mutant	  pcRYR1	  constructs	  reached	  a	  maximum	  
response	  which	  was	  maintained	   through	   the	   remaining	  doses	  of	  caffeine.	   	  Wild	   type	  
transfected	   cells	   first	   reached	   a	  maximum	   at	   5mM	   caffeine	   with	   all	   cells	   producing	  
100%	  of	  the	  maximum	  response	  at	  8mM	  or	  10mM	  caffeine.	  
	  
	  
Figure	  4.8	  –	  Representative	  traces	  of	  caffeine-­‐induced	  calcium	  release	  of	  cells	   transiently	  transfected	  with	  wild	  
type	  and	  mutant	  pcRYR1	  cDNA	  constructs.	  	  	  
All	  three	  of	  the	  mutant	  pcRYR1	  constructs	  reached	  a	  maximum	  response	  before	  the	  equivalent	  wild	  type	  
experiment.	  	  All	  cells	  responded	  at	  1mM	  caffeine	  but	  this	  was	  always	  more	  exaggerated	  in	  the	  mutant	  
transfected	  cells.	  	  In	  some	  cases,	  the	  mutant	  cells	  reached	  a	  maximum	  response	  at	  caffeine	  concentrations	  as	  low	  
as	  2mM	  whereas	  it	  took	  either	  5mM	  or	  8mM	  caffeine	  to	  produce	  the	  same	  response	  in	  wild	  type	  transfected	  
cells.	  
	  
Traces	  obtained	  from	  confocal	  microscopy	  were	  normalised	  where	  100%	  was	  defined	  
as	   the	   peak	   fluorescence	   in	   the	   entire	   video	   and	   0%	  was	   the	   baseline	   fluorescence	  
before	  the	  addition	  of	  any	  caffeine.	  	  The	  peak	  fluorescence	  obtained	  after	  the	  addition	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of	   each	   caffeine	   concentration	   was	   taken	   and	   plotted	   on	   a	   log	   x-­‐axis.	   	   Non-­‐linear	  
regression	   was	   applied	   to	   construct	   dose-­‐response	   curves	   for	   each	   RYR1	   variant	   in	  
relation	  to	  wild	  type	  (Figure	  4.9A-­‐C).	  	  For	  each	  of	  the	  RYR1	  variants,	  the	  caffeine	  dose-­‐
response	  curve	  was	  shifted	  to	  the	  left	  indicating	  an	  increase	  in	  sensitivity	  to	  caffeine.	  	  
From	   these	  dose-­‐response	  curves,	   the	  EC50	  was	   calculated	   (Figure	  4.9D-­‐E).	   	  All	   three	  
variants	   transiently	   transfected	   into	   HEK293	   cells	   produced	   a	   statistically	   significant	  
decrease	  in	  EC50	  as	  compared	  to	  wild	  type.	  	  p.E3104K	  had	  an	  EC50	  of	  1.74mM	  (SEM	  =	  
0.287,	   95%	   CI	   =	   1.208-­‐2.615;	   p=0.0114	   compared	   to	   wild	   type	   (EC50	   for	   wild	   type	   =	  
4.099mM	  caffeine,	  SEM	  =	  0.776,	  95%	  CI	  =	  1.639-­‐5.949)	  n=7),	  p.G3990V	  had	  an	  EC50	  of	  
1.252mM	  (SEM	  =	  0.1562,	  95%	  CI	  =	  0.758-­‐1.625;	  p=0.0111;	  n=6)	  and	  p.V4849I	  had	  an	  
EC50	   of	   1.711	   (SEM	  =	   0.1693,	   95%	  CI	   =	   1.295-­‐2.213;	   p=0.0274;	   n=7).	   	  No	   statistically	  
significant	  difference	  was	  observed	  between	  any	  of	  the	  variants.	  	  
The	  percentage	  of	   the	  maximal	   response	  at	  each	  caffeine	  concentration	   is	  plotted	   in	  
Figure	  4.9F.	  	  At	  1mM	  caffeine,	  cells	  transfected	  with	  the	  p.G3990V	  construct	  produced	  
a	  statistically	  significantly	  higher	  percentage	  of	   its	  maximal	   response	  as	  compared	  to	  
wild	   type	   (P=0.01;	   n=6).	   	   Cells	   transfected	   with	   neither	   the	   p.E3104K	   or	   p.V4849I	  
variants	  produced	  a	  statistically	  significant	  higher	  percentage	  of	  its	  maximal	  response	  
at	   1mM	   (n=7).	   	   At	   2mM	   caffeine,	   cells	   transfected	   with	   both	   the	   p.G3990V	   and	  
p.V4849I	  constructs	  produced	  a	  response	  that	  was	  statistically	  significantly	  higher	  as	  a	  
percentage	  of	   its	  maximum	  as	   compared	   to	  wild	   type	   (p=0.0001,	  n=6	  and	  p=0.0074,	  
n=7	  respectively).	  	  The	  p.E3104K	  variant	  produced	  a	  response	  that	  was	  not	  statistically	  
significantly	  higher	   than	  wild	   type	  at	  1mM	  caffeine	  but	  was	   significantly	  higher	   than	  
wild	  type	  at	  2mM	  caffeine	  (p=0.0522;	  n=7).	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Figure	  4.9	  –	  Caffeine	  dose-­‐response	  for	  HEK293	  cells	  transiently	  transfected	  with	  wild	  type	  and	  mutant	  pcRYR1	  
constructs.	  	  	  
(A-­‐C)	  Dose-­‐response	  curve	  for	  each	  variant	  transiently	  transfected	  into	  HEK293	  cells	  plotted	  with	  wild	  type.	  	  The	  
curve	  for	  all	  three	  variants	  was	  shifted	  to	  the	  left	  indicating	  an	  increased	  sensitivity	  to	  caffeine.	  	  Points	  are	  mean	  
plus	  or	  minus	  the	  standard	  error	  of	  the	  mean.	  (D-­‐E)	  EC50	  for	  each	  experiment.	  	  Box	  plots	  are	  presented	  as	  the	  
median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  A	  two-­‐tailed	  student’s	  t-­‐test	  
showed	  a	  statistically	  significant	  reduction	  in	  EC50	  for	  each	  variant	  transiently	  transfected	  into	  HEK293	  cells	  as	  
compared	  to	  wild	  type.	  	  (F)	  Graph	  showing	  the	  percentage	  of	  the	  maximal	  response	  produced	  at	  1mM,	  2mM	  and	  
20mM	  caffeine	  for	  each	  variant.	  	  The	  data	  are	  presented	  as	  the	  mean	  plus	  or	  minus	  the	  standard	  error	  of	  the	  
mean.	  	  The	  p.G3990V	  variant	  produced	  a	  statistically	  significant	  higher	  %	  of	  its	  maximal	  response	  as	  compared	  to	  
wild	  type	  at	  1mM	  caffeine.	  	  Both	  the	  p.G3990V	  and	  p.V4849I	  produced	  a	  statistically	  significant	  higher	  
percentage	  of	  its	  maximal	  response	  as	  compared	  to	  wild	  type	  at	  2mM	  caffeine.	  	  No	  significant	  difference	  was	  
seen	  at	  20mM	  caffeine.	  	  	  *p<0.05,	  **	  p<0.01,	  ***p<0.001.	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At	   1mM	   caffeine,	   cells	   transiently	   transfected	  with	   p.G3990V	   constructs	   produced	   a	  
higher	  response	  as	  a	  percentage	  of	  its	  maximum	  as	  compared	  to	  cells	  transfected	  with	  
p.E3104K	   (p=0.0201;	   n=6).	   	   At	   20mM	   caffeine,	   cells	   transiently	   transfected	   with	   all	  
constructs	   had	   reached	   a	   maximum	   response	   and	   no	   significant	   difference	   was	  
observed	  between	  any	  of	  the	  constructs.	  
	  
4.3.2.2	  Area	  under	  the	  curve	  measurements	  of	  cells	  transiently	  transfected	  with	  
pcRYR1	  constructs	  
AUC	   measurements	   were	   taken	   at	   each	   caffeine	   concentration	   that	   produced	   a	  
response	  (Figure	  4.10).	  	  The	  baseline	  for	  each	  experiment	  was	  independently	  assessed	  
from	  each	  experiment.	  	  At	  1mM	  caffeine	  wild	  type	  produced	  a	  calcium	  release	  of	  80.95	  
±	   31.11	   FU.	   	   Cells	   transfected	   with	   p.E3104K,	   p.G3990V	   and	   p.V4849I	   pcRYR1	  
constructs	  produced	  a	  statistically	  significant	  increase	  in	  calcium	  release	  	  as	  compared	  
to	  wild	   type	   (202.8	   ±	   46.35	   FU;	   p=0.0374,	   486.6	   ±	   58.66	   FU;	   p=0.0001	   and	   587.1	   ±	  
63.09	   FU;	   p=0.0265	   respectively).	   	   The	   p.G3990V	   transfected	   cells	   also	   produced	   a	  
statistically	   significantly	   higher	   calcium	   release	   than	   p.E3104K	   and	   p.V4849I	  
transfected	   cells	   (p=0.0027	   and	   p=0.0115	   respectively).	   	   At	   2mM	   caffeine	   all	   three	  
RYR1	  variants	  produced	  a	  higher	  amount	  of	  calcium	  release	  as	  compared	  to	  wild	  type	  
transfected	  cells.	  	  Wild	  type	  cells	  released	  285.8	  ±	  100.8	  FU	  compared	  to	  641.7	  ±	  107.2	  
for	   p.E3104K,	   667.5	   ±	   76.46	   FU	   for	   p.G3990V	   and	   596.1	   ±	   101	   FU	   for	   p.V4849I	  
transfected	   cells.	   	   In	   each	   case	   this	  was	   a	   statistically	   significantly	   higher	   amount	   of	  
calcium	  release.	  	  At	  20mM	  caffeine,	  on	  average,	  cells	  transfected	  with	  mutant	  pcRYR1	  
constructs	  produced	  a	  higher	  amount	  of	  calcium	  release	  as	  compared	  to	  wild	  type,	  but	  
this	  was	  not	  statistically	  significant.	  	  In	  each	  comparison	  n=6.	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Figure	  4.10	  –	  Area	  under	  the	  curve	  measurements	  of	  pcRYR1	  constructs	  transiently	  transfected	  into	  HEK293	  cells.	  
Box	  plots	  are	  presented	  as	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  
points.	  	  At	  1mM	  and	  2mM	  caffeine,	  statistically	  significant	  increases	  in	  calcium	  release	  were	  observed	  between	  
all	  variants	  and	  wild	  type.	  	  At	  1mM	  caffeine,	  the	  p.G3990V	  variant	  also	  produced	  a	  statistically	  significant	  
increase	  in	  calcium	  release	  as	  compared	  to	  cells	  transfected	  with	  the	  p.E3104K	  and	  p.V4849I	  constructs.	  	  No	  
statistically	  significant	  difference	  was	  observed	  between	  the	  responses	  at	  20mM	  caffeine.	  *	  p,0.05,	  **	  p<0.01,	  
***	  p<0.001	  
	  
4.3.2.3	  Expression	  analysis	  of	  HEK293	  cells	  transfected	  with	  pcRYR1	  constructs	  
HEK293	   cells	   were	   seeded	   onto	   6-­‐well	   plates	   and	   when	   at	   80%	   confluence	   were	  
transiently	  transfected	  with	  wild	  type	  and	  mutant	  pcRYR1	  constructs.	   	  48	  hours	  post-­‐
transfection,	  whole	  protein	  was	  extracted	   from	  the	  HEK293	  cells,	  quantified	  and	   ran	  
on	   a	   4%	   and	   8%	   SDS	   polyacrylamide	   gel.	   	   For	   stable	   HEK293	   cell	   lines,	   cells	   were	  
allowed	   to	   grow	   to	   confluence	   on	   a	   10cm	   dish	   before	   extracting	   whole	   protein.	  	  
Proteins	   on	   the	   gel	   were	   blotted	   onto	   a	   PVDF	   membrane	   and	   probed	   with	   anti-­‐
ryanodine	   receptor	   (34C)	   and	   anti-­‐alpha	   tubulin	   antibodies	   before	   detection	   using	   a	  
secondary	   HRP-­‐conjugated	   antibody	   (Figure	   4.11	   and	   Figure	   4.12).	   	   No	   RYR1	  
expression	  was	  detected	  in	  protein	  extracts	  isolated	  from	  untransfected	  HEK293	  cells.	  	  
Alpha	   tubulin	  was	   used	   as	   a	   loading	   control	   for	   all	   protein	   samples	   ran	   on	   the	   gels.	  	  
Expression	  of	  RYR1	  was	  normalised	  with	   alpha	   tubulin	   set	   as	   the	   relative	  maximum.	  	  
The	   level	   of	   RYR1	   expression	   detected	   in	   each	   of	   the	   transfected	   samples	   was	   not	  
different	  from	  each	  other	  (n=3).	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Figure	  4.11	  –	  Western	  blot	  analysis	  of	  HEK293	  cells	  transiently	  transfected	  with	  wild	  type	  and	  mutant	  pcRYR1	  
constructs	  
Protein	  extracts	  were	  run	  on	  a	  SDS-­‐PAGE	  gel	  followed	  by	  blotting	  onto	  a	  PVDF	  membrane	  and	  probed	  using	  anti-­‐
ryanodine	  receptor	  and	  anti-­‐alpha	  tubulin	  primary	  antibodies.	  	  Proteins	  were	  detected	  using	  a	  secondary	  HRP-­‐
conjugated	  antibody.	  	  RYR1	  was	  detected	  in	  all	  stably	  transfected	  samples	  with	  no	  apparent	  difference	  in	  




Figure	  4.12	  –	  Western	  blot	  analysis	  of	  HEK293	  cells	  transiently	  transfected	  with	  wild	  type	  and	  mutant	  pcRYR1	  
constructs	  
Protein	  extracts	  were	  run	  on	  a	  SDS-­‐PAGE	  gel	  followed	  by	  blotting	  onto	  a	  PVDF	  membrane	  and	  probed	  using	  anti-­‐
ryanodine	  receptor	  and	  anti-­‐alpha	  tubulin	  primary	  antibodies.	  	  Proteins	  were	  detected	  using	  a	  secondary	  HRP-­‐
conjugated	  antibody.	  	  No	  RYR1	  protein	  was	  detected	  in	  untransfected	  HEK293	  cells.	  	  RYR1	  was	  detected	  in	  all	  
transfected	  samples	  with	  no	  apparent	  difference	  in	  expression	  between	  constructs.	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4.3.3	  Comparison	  of	  stable	  and	  transient	  transfection	  of	  HEK293	  cells	  
For	   the	  wild	   type	  and	  p.G3990V	  pcRYR1	   constructs	  experiments	  were	  carried	  out	  on	  
stable	   and	   transiently	   transfected	   cells.	   	   Results	   from	   both	   sets	   of	   experiments	   are	  
plotted	   in	  parallel	   in	   Figure	  4.13	   and	   Figure	  4.14.	   	   For	   each	   analysis	   performed	  n=6.	  	  
The	  caffeine	  dose-­‐response	  curves	  of	  cells	  stably	  and	  transiently	  transfected	  with	  both	  
wild	   type	   and	   p.G3990V	   cells	   share	   very	   similar	   curves	   (Figure	   4.13A).	   	   The	   EC50	  
calculated	   for	  each	  construct	  and	  each	   transfection	  method	   is	   listed	   in	  Figure	  4.13C.	  	  
Stably	  transfected	  cells	  with	  wild	  type	  pcRYR1	  produced	  an	  EC50	  of	  4.099mM	  compared	  
with	  3.209mM	  for	  transiently	  transfected	  cells.	   	  This	  was	  found	  not	  to	  be	  statistically	  
significantly	  different	   (p=0.2376).	   	  The	  same	  was	  seen	   for	  cells	  stably	  and	  transiently	  
transfected	   with	   p.G3990V	   pcRYR1	   constructs.	   	   The	   EC50	   of	   1.414mM	   (stable)	   and	  
1.252mM	  (transient)	  was	  not	  significantly	  different	  (p=0.2276).	  	  At	  1mM	  caffeine,	  cells	  
transiently	   transfected	   with	   p.G3990V	   constructs	   produced	   a	   statistically	   significant	  
higher	   response	   as	   a	   percentage	   of	   its	   maximum	   as	   compared	   with	   cells	   stably	  
transfected	  with	  p.G3990V	  constructs	  (p=0.0032).	  	  There	  was	  no	  significant	  difference	  
in	   response	   for	   cells	   transfected	   either	   stably	   or	   transiently	   with	   wild	   type	   pcRYR1	  
constructs	   at	   1mM.	   	   At	   2mM,	   cells	   transiently	   transfected	   with	   wild	   type	   pcRYR1	  
produced	   a	   statistically	   significantly	   larger	   response	   than	   stably	   transfected	   cells	  
(p=0.0092).	   	   Cells	   stably	   or	   transiently	   transfected	   with	   p.G3990V	   constructs	   had	  
reached	   a	   response	   close	   to	   the	   maximum	   at	   2mM	   caffeine	   and	   no	   significant	  
difference	  was	  observed	  between	  the	  two	  transfection	  methods.	   	  At	  20mM	  caffeine,	  
all	   cells	   either	   stably	   or	   transiently	   transfected	   with	   either	   wild	   type	   or	   p.G3990V	  
constructs	   had	   reached	   a	  maximum	   response	   and	   so	   no	   statistical	   differences	  were	  
observed.	  
AUC	   measurements	   taken	   at	   corresponding	   caffeine	   concentrations	   were	   also	  
comparable	   for	   cells	   stably	   and	   transiently	   transfected.	   	   No	   statistically	   significant	  
differences	  were	  observed	  at	  any	  caffeine	  concentration	  between	  either	  transfection	  
method	   (stable	   and	   transient	   transfection).	   	   There	   was	   a	   trend	   for	   cells	   stably	  
transfected	  with	  p.G3990V	  to	  have	  a	  larger	  and	  more	  varied	  response	  at	  1mM	  caffeine	  
	   129	  
(938.6	   ±	   180.7	   FU)	   and	   2mM	   caffeine	   (1326	   ±	   334.4	   FU)	   	   compared	   to	   transient	  
transfections	  (486.6	  ±	  58.66	  FU	  and	  667.5	  ±	  76.47	  FU	  respectively).	  	  The	  opposite	  was	  
observed	  with	  wild	  type	  transfected	  cells.	  	  Stably	  transfected	  cells	  produced	  a	  smaller	  
calcium	  transient	  at	  both	  1mM	  caffeine	  (24.81	  ±	  8.537	  FU)	  and	  2mM	  caffeine	  (124.1	  ±	  
57.1	   FU)	   than	   transiently	   transfected	   cells	   (80.95	   ±	   31.11	   FU	   and	   285.8	   ±	   100.8	   FU	  
respectively).	  	  Cells	  stably	  or	  transiently	  transfected	  with	  either	  wild	  type	  or	  p.G3990V	  
constructs	  all	  produced	  a	  similar	  response	  at	  20mM.	  	  Cells	  transiently	  transfected	  with	  
wild	   type	   pcRYR1	   did	   have	   a	   slightly	   lower	   amount	   of	   calcium	   release	   at	   20mM	  
compared	   to	   stably	   transfected	  wild	   type	  cells	   as	  well	   as	  both	   stably	  and	   transiently	  
transfected	  p.G3990V	  cells,	  but	  this	  was	  not	  statistically	  significant.	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Figure	  4.13	  –	  Comparison	  of	  the	  EC50	  of	  HEK293	  cells	  stably	  or	  transiently	  transfected	  with	  wild	  type	  and	  
p.G3990V	  pcRYR1	  constructs.	  	  	  
(A)	  	  Caffeine	  dose-­‐response	  for	  HEK293	  cells	  stably	  (solid	  lines)	  or	  transiently	  (dashed	  lines)	  transfected	  with	  wild	  
type	  (blue)	  or	  p.G3990V	  (magenta)	  pcRYR1	  constructs.	  	  All	  points	  are	  shown	  as	  the	  mean	  plus	  or	  minus	  the	  
standard	  error	  of	  the	  mean.	  	  (B)	  Graph	  showing	  the	  %	  of	  the	  maximal	  response	  reached	  at	  1mM,	  2mM	  and	  20mM	  
for	  cells	  either	  stably	  or	  transiently	  transfected	  with	  wild	  type	  or	  p.G3990V	  RYR1	  constructs.	  	  Data	  are	  presented	  
as	  the	  mean	  plus	  or	  minus	  the	  standard	  error	  of	  the	  mean.	  	  At	  1mM	  there	  was	  no	  significant	  difference	  between	  
wild	  type	  constructs	  but	  there	  was	  for	  cells	  either	  stably	  or	  transiently	  transfected	  with	  p.G3990V	  constructs	  
(p=0.0032).	  	  At	  2mM	  there	  was	  a	  significant	  difference	  observed	  between	  the	  wild	  type	  constructs	  (p=0.0092)	  but	  
no	  difference	  was	  seen	  between	  cells	  stably	  or	  transiently	  transfected	  with	  p.G3990V.	  	  No	  differences	  were	  
observed	  at	  20mM.	  (C-­‐D)	  	  No	  statistically	  significant	  difference	  between	  the	  EC50	  of	  cells	  stably	  or	  transiently	  
transfected	  with	  wild	  type	  pcRYR1	  or	  p.G3990V	  pcRYR1.	  	  Box	  plots	  are	  the	  median,	  the	  upper	  and	  lower	  quartiles	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Figure	  4.14	  –	  Comparison	  of	  the	  area	  under	  the	  curve	  responses	  for	  cells	  either	  transiently	  or	  stably	  transfected	  
with	  wild	  type	  or	  p.G3990V	  pcRYR1	  cDNA	  constructs.	  	  	  
Box	  plots	  are	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  No	  
statistically	  significant	  difference	  was	  observed	  between	  cells	  stably	  or	  transiently	  transfected	  with	  either	  wild	  




The	   data	   presented	   above	   is	   supportive	   of	   the	   p.R2336H,	   p.E3104K,	   p.G3990V	   and	  
p.V4948I	   variants	   to	   be	   added	   to	   the	   genetic	   diagnostic	   panel	   for	  MH.	   	   Cells	   either	  
stably	   or	   transiently	   transfected	  with	   each	   of	   these	   variants	   produced	   a	   statistically	  
significantly	  reduced	  EC50	  as	  compared	  to	  wild	  type	  transfected	  cells	  as	  well	  as	  a	  trend	  
to	  have	  a	  higher	  amount	  of	  calcium	  release	  and	  a	  higher	  percentage	  of	  their	  maximum	  
response	  was	  elicited	  at	  lower	  doses	  of	  caffeine.	  	  In	  addition	  to	  this,	  data	  is	  presented	  
that	   indicates	  that	  the	  p.D3986E	  variant	   is	  not	  causative	  of	  MH	  in	  the	  four	  families	   it	  
has	  been	  identified	  in.	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4.4.1	  p.R2336H	  
The	   p.R2336H	  mutation	   produced	   the	  most	   severe	   response	   out	   of	   all	   the	   variants	  
tested	  in	  this	  chapter.	  	  The	  EC50	  was	  reduced	  by	  the	  most	  with	  a	  caffeine	  concentration	  
of	   less	   than	   1mM	   required	   to	   produce	   half	   of	   the	   maximal	   response	   (0.91mM).	  	  
Furthermore,	   at	   1mM	   caffeine	   the	   amount	   of	   calcium	   released	  was	  massively	  more	  
than	  any	  other	  variant	  under	   investigation	   (p<0.001).	   	  A	  maximum	  response	  for	  cells	  
transfected	  with	  this	  variant	  was	  reached	  very	  early.	   	  At	  1mM	  caffeine,	  60.7%	  of	  the	  
maximum	  response	  had	  been	  achieved	  and	  this	  increased	  to	  87.68%	  at	  2mM	  caffeine.	  	  	  
The	  data	   from	   the	   literature	   is	   a	   little	   less	   supportive	  of	   the	  p.R2336H	  variant	  being	  
added	   to	   the	   genetic	   diagnostic	   panel	   for	   MH.	   	   Lymphoblastoid	   cells	   isolated	   from	  
patients	   carrying	   this	   variant	   only	   produced	   an	  MH	   phenotype	  when	   exposed	   to	   4-­‐
CmC.	  	  The	  response	  obtained	  from	  these	  cells	  when	  they	  were	  exposed	  to	  caffeine	  was	  
similar	   to	   that	   of	   wild	   type	   familial	   control	   samples	   in	   all	   7	   families	   investigated	  
(Levano	  et	  al.,	  2009).	  	  The	  data	  obtained	  in	  this	  chapter,	  however,	  gives	  clear	  evidence	  
of	  the	  variant’s	  role	  in	  the	  MH	  phenotype.	  	  As	  previously	  discussed,	  the	  use	  of	  patient	  
samples	   for	   functional	   experiments	  may	  not	  be	   the	  best	  method	  due	   to	  unforeseen	  
genetic	  background	  issues.	  	  In	  Levano	  et	  al.	  (2009),	  this	  problem	  may	  be	  compounded	  
by	  the	  use	  of	  cells	  in	  which	  RYR1	  does	  not	  carry	  out	  its	  primary	  function	  meaning	  the	  
results	  obtained	  in	  that	  study	  are	  a	  reflection	  of	  the	  experimental	  model	  used,	  rather	  
than	  the	  pathogenicity	  of	  the	  p.R2336H	  variant.	   	  The	  variant	  has	  been	  identified	   in	  7	  
UK	  families	  and	  a	  further	  7	  worldwide.	  	  It	  cosegregates	  with	  disease	  and	  is	  absent	  from	  
control	   samples.	   	   	   Combined	   with	   the	   functional	   data	   obtained	   in	   this	   chapter,	   the	  
p.R2336H	  variant	  can	  be	  added	  to	  the	  genetic	  diagnostic	  panel	  for	  MH.	  
	  
4.4.2	  p.E3104K	  
The	  p.E3104K	  variant	  produced	  a	   response	   that	   is	   consistent	  with	  being	  causative	  of	  
MH.	   	  The	  EC50	  was	  significantly	   reduced	   to	  1.74mM	  (compared	   to	  4.099mM	  for	  wild	  
type	   transfected	   cells).	   	   At	   both	   1mM	   and	   2mM	   caffeine	   a	   statistically	   significant	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increase	  in	  calcium	  release	  was	  observed	  as	  compared	  to	  wild	  type.	  	  At	  1mM	  caffeine,	  
however,	   this	   response	   was	   not	   significantly	   different	   to	   wild	   type	   in	   terms	   of	   the	  
percentage	  of	  the	  maximum.	  	  At	  2mM	  caffeine,	  a	  significant	  difference	  was	  observed	  
in	  terms	  of	  percentage	  of	  the	  maximum.	  	  The	  variant	  has	  been	  identified	  in	  4	  families,	  
all	   of	  which	   are	   in	   the	  UK.	   	   It	   cosegregates	  with	   disease	   and	   is	   absent	   from	   control	  
samples.	   	  Combined	  with	   the	   functional	  data	  presented	  above,	   the	  p.E3104K	  variant	  
should	  be	  added	  to	  the	  genetic	  diagnostic	  panel	  for	  MH.	  
	  
4.4.3	  p.G3990V	  
The	  p.G3990V	  variant	  was	  both	   stably	   and	   transiently	   transfected	   into	  HEK293	   cells.	  	  
Both	   sets	   of	   experiments	   showed	   that	   cells	   transfected	   with	   p.G3990V	   had	   a	  
significantly	  reduced	  EC50	  (stable	  =	  1.44mM	  and	  transient	  =	  1.252mM)	  as	  compared	  to	  
wild	  type	  transfected	  cells	  (stable	  =	  3.209mM	  and	  transient	  =	  4.099mM).	  	  These	  values	  
were	   not	   significantly	   different	   from	  each	   other	   indicating	   that	   the	   data	   obtained	   is	  
consistent	  regardless	  of	  the	  method	  of	  transfection.	  	  Both	  sets	  of	  experiments	  showed	  
a	  significantly	   increased	  calcium	  release	  at	  both	  1mM	  and	  2mM	  caffeine.	   	   	  However,	  
only	   in	   the	   transient	  experiments	  was	   this	  determined	  to	  be	  significantly	  higher	  as	  a	  
percentage	  of	  the	  overall	  maximum	  response	  for	  1mM	  caffeine.	  	  The	  reason	  for	  this	  is	  
unclear	   but	   may	   be	   due	   to	   the	   nature	   of	   the	   transient	   experiments.	   	   For	   stable	  
transfections	   an	   individual	   cell	   is	   selected	   and	   expanded	   for	   future	   experiments.	  	  
Transient	  transfections	  will	  inherently	  have	  more	  variability	  in	  them	  due	  to	  differential	  
uptake	   of	   the	   plasmid	   between	   experiments.	   	   It	   is	   feasible	   that	   this	   variability	   has	  
caused	  the	  differences	  seen,	  however,	  another	  explanation	  is	  that	  this	  measurement	  is	  
not	  representative	  of	  the	  overall	  causality	  of	  the	  variant	  under	  investigation.	  	  The	  EC50	  
of	   cells	   either	   stably	   or	   transiently	   transfected	   with	   this	   variant	   was	   unchanged	   in	  
terms	  of	  being	  significantly	  reduced	  compared	  to	  wild	  type,	  regardless	  of	  the	  result	  of	  
that	   measurement.	   	   	   The	   p.G3990V	   variant	   has	   been	   identified	   in	   10	   families	  
worldwide,	  all	  of	  which	  are	  in	  the	  UK.	  	  It	  cosegregates	  with	  disease	  and	  is	  not	  found	  in	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control	  chromosomes.	   	  This	  knowledge	  combined	  with	  the	  functional	  data	  presented	  
above	   strongly	   suggests	   that	   the	   p.G3990V	   variant	   should	   be	   added	   to	   the	   genetic	  
diagnostic	  panel	  for	  MH.	  
	  
4.4.4	  p.D3986E	  
The	  p.D3986E	  variant	  was	  found	  to	  have	  an	  EC50	  not	  significantly	  different	  to	  wild	  type	  
and	  a	  comparable	  calcium	  release	  when	  exposed	  to	  all	  doses	  of	  caffeine.	  	  Based	  on	  this	  
data	   it	  could	  be	  concluded	  that	  the	  p.D3986E	  variant	  may	  not	  be	  causative	  of	  MH	  in	  
the	   4	   UK	   families	   it	   has	   been	   identified	   in.	   	   At	   1mM	   and	   2mM	   caffeine,	   cells	  
transfected	  with	  p.D3986E	  did	  produce	  a	   response	   that	  was	   significantly	  higher	   as	   a	  
percentage	  of	  its	  maximum	  as	  compared	  to	  wild	  type	  without	  altering	  the	  overall	  EC50	  
of	  the	  cells,	  however,	  as	  discussed	  in	  terms	  of	  the	  p.G3990V	  variant,	  this	  measurement	  
may	  not	  be	  representative	  of	  the	  functional	  consequences	  of	  the	  variant.	  	  Despite	  this,	  
because	  of	  this	  seemingly	  exaggerated	  response	  at	  1mM	  and	  2mM	  caffeine,	  the	  EC10	  
and	   EC25	   of	   the	   cells	   containing	  wild	   type	   and	   the	   p.D3986E	   variant	  were	  measured	  
from	  the	  same	  dose-­‐response	  curve	  as	  the	  EC50.	  	  Cells	  transfected	  with	  p.D3986E	  were	  
found	  to	  have	  a	  statistically	  significantly	  decreased	  EC10	  as	  compared	  to	  wild	  type	  but	  
the	  EC25	  was	  not	  significantly	  lowered	  despite	  being	  substantially	  lower	  than	  the	  wild	  
type	  cells	  (p=0.07).	  	  	  
Although	   there	   is	   evidence	   to	   suggest	   that	   MH	   can	   be	   triggered	   when	   a	   certain	  
threshold	  has	  been	  achieved	  (Jiang	  et	  al.,	  2008)	  it	  seems	  unlikely	  that	  an	  altered	  EC10	  
would	  be	  enough	  to	  trigger	  an	  MH	  reaction	  in	  these	  individuals.	  	  Moreover,	  individuals	  
carrying	  the	  p.D3986E	  variant	  have	  been	  found	  to	  have	  a	  stronger	  IVCT	  reaction	  than	  
most	   other	   patients	   carrying	   a	   number	   of	   causative	   or	   uncharacterised	   RYR1	  
mutations,	   which	   could	   not	   be	   explained	   through	   a	   reduction	   in	   the	   EC10	   of	   the	  
p.D3986E	  variant	  (Carpenter	  et	  al.,	  2009c).	  	  A	  total	  of	  22	  RYR1	  variants	  were	  screened	  
for	  in	  the	  UK	  MH	  population	  followed	  by	  correlating	  genotyping	  data	  with	  quantitative	  
data	   obtained	   through	   the	   IVCT	   tests.	   	   The	   p.D3986E	   variant	   produced	   a	   caffeine	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contracture	  that	  was	  significantly	  higher	   than	  most	  other	  RYR1	  variants	   investigated.	  	  
Furthermore,	   individuals	   carrying	   the	   p.D3986E	   had	   a	   higher	  mean	   static	   halothane	  
contracture	  than	  all	  other	  variants	  under	  investigation	  in	  this	  chapter.	  
Despite	   individuals	   carrying	   the	   p.D3986E	   RYR1	   variant	   appearing	   to	   have	   a	   more	  
severe	   IVCT	   reaction	   than	   most	   other	   variants	   the	   data	   presented	   in	   this	   chapter	  
indicates	  that	  it	  may	  be	  a	  polymorphism	  that	  is	  segregating	  with	  MH	  phenotype.	  	  The	  
families	  in	  which	  the	  p.D3986E	  variant	  has	  been	  identified	  have	  had	  the	  entire	  coding	  
sequence	  of	  RYR1	  and	  CACNA1S	  sequenced	  which	  rules	  out	   the	  presence	  of	  another	  
variant	   within	   the	   coding	   regions	   of	   these	   genes,	   which	   has	   been	   seen	   before	   in	   a	  
number	  of	  families	  (Monnier	  et	  al.,	  2002).	  	  An	  additional,	  as	  yet	  unidentified	  variant	  in	  
another	   gene	   that	   is	   in	   linkage	   disequilibrium	  with	   the	   p.D3986E	   variant	   cannot	   be	  
ruled	  out.	  	  Recent	  evidence	  has	  suggested	  that	  individuals	  who	  share	  an	  RYR1	  variant	  
also	  possess	  a	  common	  ‘high-­‐risk’	  haplotype	  that	  is	  associated	  with	  MH	  (Carpenter	  et	  
al.,	   2009a).	   	   Based	   on	   this,	   the	   families	   in	   which	   the	   p.D3986E	   variant	   has	   been	  
identified	  may	  be	  good	  starting	  points	  to	  look	  for	  additional	  variants	  in	  other	  genes	  as	  
causative	  agents	  or	  potential	  modifiers	  to	  the	  MH	  phenotype.	  	  	  
	  
4.4.5	  p.V4849I	  	  
The	   p.V4948I	   variant	   also	   had	   an	   EC50	   that	   was	   significantly	   reduced	   (1.711mM)	   as	  
compared	  to	  wild	  type	  (4.099mM).	  	  At	  1mM	  caffeine,	  no	  significant	  increase	  in	  calcium	  
release	  was	  observed	  when	  compared	  with	  wild	   type.	   	  At	  2mM	  caffeine,	  however,	  a	  
significant	  increase	  was	  observed.	  	  At	  20mM	  caffeine,	  there	  appeared	  to	  be	  a	  reduced	  
response	   as	   a	   percentage	   of	   the	   maximum	   for	   cells	   transfected	   with	   the	   p.V4849I	  
variant	   as	   compared	   to	  wild	   type	   controls.	   	   The	   p.V4849I	   variant	   has	   been	   found	   in	  
both	  MH	  and	  CCD	  patients	  (Jungbluth	  et	  al.,	  2002,	  Monnier	  et	  al.,	  2005,	  Levano	  et	  al.,	  
2009,	  Ducreux	  et	  al.,	  2006)	  and	  although	  a	  clear	  conclusion	  cannot	  be	  drawn	  directly	  
from	   this	   result,	   the	   reduction	   in	   response	  may	   hint	   at	   a	   smaller	   calcium	   store	   as	   a	  
result	  of	  the	  CCD	  phenotype.	  	  It	  has	  been	  previously	  reported	  that	  CCD	  mutations	  can	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have	  a	  decreased	  EC50	  but	  still	  present	  in	  the	  patients	  as	  a	  myopathy	  (Tong	  et	  al.,	  1997,	  
Yang	  et	  al.,	  2003).	  	  The	  p.V4849I	  variant	  appears	  to	  be	  a	  classic	  MH	  mutation	  in	  terms	  
of	  the	  EC50	  result	  and	  there	  are	  hints	  that	  the	  same	  variant	  is	  responsible	  for	  the	  CCD	  
phenotype	   seen	   in	   the	   patients.	   	   The	   p.V4849I	   variant	   has	   been	   identified	   in	   12	  
families	  worldwide,	  8	  of	  which	  are	  in	  the	  UK.	  	  The	  mutation	  cosegregates	  with	  disease	  
and	   is	   absent	   from	   control	   chromosomes.	   	   	   This	   information	   coupled	   with	   the	  
functional	   data	   obtained	   in	   this	   chapter	   indicates	   that	   the	   p.V4849I	   variant	   can	   be	  
added	  to	  the	  genetic	  diagnostic	  panel	  for	  MH.	  	  However,	  further	  investigations	  should	  
be	  carried	  out	  to	  truly	  ascertain	  the	  role	  this	  variant	  plays	  in	  the	  CCD	  phenotype.	  	  The	  
easiest	   way	   in	   which	   this	   could	   be	   ascertained	   is	   through	   measuring	   the	   resting	  
intracellular	  calcium	  level	  of	  cells	  carrying	  this	  variant	  on	  a	  defined	  genetic	  background	  
to	  see	  if	  the	  result	  is	  consistent	  with	  other	  CCD	  variants.	  
	  
4.4.6	  Stable	  vs.	  Transient	  transfection	  
In	  this	  chapter,	  stable	  HEK293	  cell	  lines	  were	  generated	  carrying	  wild	  type	  pcRYR1	  and	  
the	   p.R2336H,	   p.D3986E	   and	   p.G3990V	   variants.	   	   Additionally,	   the	   p.E3104K	   and	  
p.V4849I	  variants	  were	  transiently	   transfected	   into	  HEK293	  cells.	   	  The	  p.G3990V	  was	  
also	  transiently	  transfected	   into	  HEK293	  cells	   in	  preliminary	  experiments	  designed	  to	  
generate	  a	  firm	  protocol	  for	  calcium	  imaging	  and	  data	  analysis	  before	  the	  stable	  clones	  
had	   been	   generated.	   	   No	   obvious	   differences	   were	   observed	   between	   cells	   either	  
stably	   or	   transiently	   transfected	   with	   wild	   type	   and	   p.G3990V	   pcRYR1	   constructs	  
indicating	   that	   both	   methods	   are	   equally	   viable	   and	   comparable	   for	   these	  
experiments.	   	   There	   were	   slight	   discrepancies	   in	   the	   percentage	   of	   the	   maximum	  
response	  generated	  at	  1mM	  and	  2mM	  caffeine	  for	  p.G3990V	  and	  wild	  type	  constructs	  
respectively	  but	  this	  had	  no	  effect	  on	  the	  EC50	  or	  amount	  of	  calcium	  released	  at	  these	  
doses	   of	   caffeine,	   further	   supporting	   the	   notion	   that	   these	   measurements	   are	  
misleading.	  	  There	  was	  a	  trend	  for	  cells	  transfected	  transiently	  with	  p.G3990V	  to	  have	  
a	   less	  varied	  calcium	  release	  when	  AUC	  measurements	  were	  taken.	   	   It	   is	  not	  directly	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clear	  as	  to	  why	  this	  might	  be.	   	  We	  would	  have	  expected	  that	  it	  would	  have	  been	  the	  
stable	  clones	   that	  produced	  a	  more	  consistent	   result	  as	   they	  were	  generated	   from	  a	  
single	  HEK293	  cell	  containing	  p.G3990V.	  	  This	  may	  be	  just	  due	  to	  differential	  loading	  of	  
the	   fluorescent	   calcium	   indicator	   Fluo-­‐4	   AM.	   	   	   Fluo-­‐4	   is	   a	   non-­‐ratiometric	   calcium	  
indicator	   meaning	   that	   the	   concentration	   of	   calcium	   released	   cannot	   be	   directly	  
quantified.	   Differences	   in	   loading	   of	   the	   indicator	   can	   lead	   to	   differences	   in	   the	  
observed	   calcium	   concentration	   present	   in	   the	   cells.	   	   Instead,	   the	   calculations	   are	  
made	  relative	  to	  a	  maximum	  meaning	  the	  EC50	  can	  be	  calculated	  but	  the	  concentration	  
of	  calcium	  achieved	  at	  this	  dose	  cannot.	  	  Ratiometric	  calcium	  indicators	  such	  as	  fura-­‐2	  
utilise	  two	  different	  excitation	  and	  emission	  wavelengths	  to	  create	  a	  ratio	  that	  can	  be	  
converted	   into	   a	   concentration	   of	   calcium	   present.	   	   However,	   in	   this	   study,	   it	   was	  
sufficient	  to	  see	  a	  trend	  of	  an	  increased	  calcium	  release	  at	  low	  doses	  of	  caffeine	  from	  
the	  mutant	  RYR1	  variants.	  	  
All	  RYR1	  variants	  under	   investigation	   in	  this	  chapter,	  with	  the	  exception	  of	  p.D3986E	  
that	   was	   discussed	   earlier,	   produced	   a	   statistically	   significantly	   increased	   calcium	  
release	  at	  1mM	  and	  2mM	  caffeine.	  	  	  	  Furthermore,	  at	  20mM	  caffeine	  when	  all	  variants	  
had	   reached	   a	   maximum	   response	   as	   deduced	   from	   the	   dose-­‐response	   curves,	   no	  
significant	  differences	  were	  observed	  between	  any	  construct	  under	  investigation.	  	  This	  
suggests	  that	  the	  size	  of	  the	  calcium	  store	  is	  not	  greatly	  affected	  by	  the	  introduction	  of	  
either	  wild	  type	  or	  mutant	  RYR1	  channels.	  	  This	  was	  a	  consistent	  finding	  that	  indicates	  
that	  any	  differences	  in	  Fluo-­‐4	  loading	  are	  not	  significantly	  altering	  the	  data	  obtained.	  	  	  
	  
4.4.7	  G418	  selection	  of	  stable	  HEK293	  cell	  lines	  expressing	  pcRYR1	  constructs	  
An	  antibiotic	  kill	  curve	  was	  produced	  as	  a	  means	  to	  deduce	  the	  correct	  concentration	  
of	  G418	  to	  use	  in	  the	  selective	  growth	  medium	  for	  HEK293	  cells	  stably	  transfected	  with	  
pcRYR1	  constructs.	   	  After	   the	  10-­‐day	   selection	  experiment	  on	  untransfected	  HEK293	  
cells	  98%	  of	  cells	  were	  dead.	  	  Based	  on	  this,	  1mg/ml	  G418	  was	  chosen	  for	  the	  initial	  10	  
day	   selection	   after	   transfection.	   	   In	   the	   kill	   curve	   experiment,	   88%	   of	   untransfected	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HEK293	   cells	   had	   been	   killed	   after	   exposure	   to	   1mg/ml	   G418	   for	   10	   days.	   	   In	   the	  
preliminary	  selection	  of	  stable	  clones,	  this	  concentration	  allowed	  for	  a	  high	  percentage	  
of	  untransfected	  HEK293	  cells	   to	  be	  killed	  without	  going	  as	   far	  as	  98%	  meaning	   that	  
those	  that	  were	  transfected	  had	  a	  chance	  to	  produce	  the	  resistance	  gene	  before	  being	  
killed	   rapidly	  by	   the	  high	  antibiotic	   concentration.	   	  After	   the	   initial	   10	  day	   selection,	  
the	   concentration	   of	   G418	   in	   the	   growth	   medium	   was	   reduced	   to	   0.8mg/ml	   for	   a	  
further	  10	  days	  to	  allow	  for	  a	  high	  level	  of	  selection	  to	  be	  maintained	  but	  also	  gave	  the	  
transfected	  cells	  a	  chance	  to	  start	  to	  thrive.	  
	  
4.4.8	  Measurement	  of	  HEK293	  cell	  background	  
HEK293	  cells	  are	  a	  non-­‐native	  cell	  type	  for	  RYR1	  to	  be	  transfected	  into.	  	  Although	  any	  
endogenous	  level	  of	  RYR1	  is	  below	  the	  detection	  capabilities	  of	  western	  blotting,	  there	  
may	   be	   other	   caffeine-­‐sensitive	   calcium	   channels	   present	   such	   as	   the	   inositol	  
triphosphate	  sensitive	  calcium	  channels.	  	  Because	  of	  this,	  a	  background	  rate	  of	  calcium	  
release	  was	  determined	  before	  the	  calcium	  release	  assays	  were	  performed.	  Tong	  et	  al.	  
(1999b)	  have	  previously	  reported	  that	  6	  out	  of	  200	  HEK293	  cells	  responded	  at	  20mM	  
caffeine	  resulting	  in	  an	  estimated	  background	  rate	  of	  3%.	  	  No	  other	  paper	  reports	  any	  
background	   effect	   seen	   from	   HEK293	   cells	   and	   in	   fact,	   many	   report	   that	   there	   was	  
either	   no	   response	   seen	   at	   all	   upon	   exposure	   to	   high	   concentrations	   of	   caffeine	   or	  
make	  no	  reference	  to	  any	  control	  experiments	  carried	  out	  (Lynch	  et	  al.,	  1999,	  Du	  et	  al.,	  
2001,	  Monnier	  et	  al.,	  2005,	  Migita	  et	  al.,	  2009).	   	  A	  calcium	  release	  assay	  was	  carried	  
out	  on	  untransfected	  cells	  using	  the	  same	  caffeine	  series	  that	  would	  be	  used	  for	  the	  
experiments	   involving	  RYR1.	   	  Calcium	  release	  was	  observed	  at	  high	  doses	  of	  caffeine	  
(8mM-­‐20mM).	   	   Ten	   independent	   experiments	   were	   analysed	   using	   ImageJ	   to	   count	  
the	   total	   number	   of	   cells	   in	   the	   field	   of	   vision	   as	   well	   as	   those	   that	   responded	   to	  
caffeine.	   	   An	   average	   background	   response	   of	   4.02%	   was	   deduced	   from	   the	   10	  
experiments,	  which	  was	  close	  to	  the	  background	  rate	  observed	  in	  Tong	  et	  al.	  (1999b).	  	  
Based	   on	   this,	   when	   analysing	   data	   obtained	   from	   the	   transfection	   of	   HEK293	   cells	  
with	  RYR1	  constructs,	  cells	  that	  only	  responded	  to	  8mM-­‐20mM	  caffeine	  were	  excluded	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from	   the	   analysis	   and	   assumed	   to	   be	   untransfected.	   	   Even	   though	   stable	   cell	   lines	  
should	   consist	  of	  entirely	   transfected	   cells	   this	  methodology	  was	  also	  applied	   to	   the	  
stable	  HEK293	  cell	   lines	  as	  a	  precautionary	  measure	  to	  remove	  the	  possibility	  of	  any	  
untransfected	  cells	  entering	  the	  analysis.	  
	  
4.4.9	  The	  calcium	  transient	  videos	  
The	  calcium	  release	  experiments	  were	  performed	  using	  an	  8	  channel	  injector	  system.	  	  
Throughout	   the	   course	   of	   the	   experiments	   being	   carried	   out,	   one	   or	   more	   of	   the	  
channels	   became	   unavailable	   for	   use	  meaning	   the	   caffeine	   series	   had	   to	   be	   altered	  
accordingly.	   	  When	   all	   8	   channels	  were	   available	   caffeine	   concentrations	   of	   0.2mM,	  
0.5mM,	  1mM,	  2mM,	  5mM,	  10mM	  and	  20mM	  were	  used.	  	  The	  series	  had	  to	  be	  altered	  
when	   two	  channels	  were	  out	  of	   service.	   	  Based	  on	   the	  data	  already	  obtained	   it	  was	  
decided	   that	   0.2mM	   caffeine	   was	   unnecessary	   as	   no	   cells	   responded	   at	   caffeine	  
concentrations	   so	   low	  and	  by	  5mM,	   cells	   transfected	  with	  mutant	  RYR1	   had	  already	  
reached	   a	  maximum	  meaning	   that	   10mM	   could	   also	   be	   removed.	   	   This	  was	   altered	  
further	  when	  one	  of	  the	  channels	  became	  available	  again	  resulting	   in	  a	  final	  caffeine	  
series	   of	   0.5mM,	   1mM,	   2mM,	   4mM,	   8mM	   and	   20mM.	   	   In	   spite	   of	   the	   change	   in	  
caffeine	   series	   no	   significant	   differences	   were	   observed	   between	   the	   wild	   type	  
transfected	  cells	  in	  each	  caffeine	  series	  giving	  us	  confidence	  that	  all	  the	  mutant	  results	  
are	  accurate.	  
	  
4.5	  Future	  work	  
Future	  work	  will	   focus	   on	   expanding	   the	   number	   of	  RYR1	   variants	   put	   through	   this	  
experimental	  system.	  	  The	  use	  of	  the	  mutations	  under	  investigation	  in	  this	  chapter	  has	  
allowed	   us	   to	   develop	   a	   protocol	   that	   is	   highly	   replicable	   and	   relatively	  
straightforward.	  	  Coupled	  with	  the	  cloning	  work	  carried	  out	  in	  the	  previous	  chapter,	  a	  
production	  line	  of	  RYR1	  variants	  transfected	  into	  HEK293	  cells	  and	  put	  through	  these	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experiments	   is	  a	  real	  possibility	  allowing	  us	  to	  heavily	  expand	  the	  current	  number	  of	  
RYR1	  variants	  approved	  for	  genetic	  diagnosis.	  
In	   the	   current	   study,	   only	   one	   RYR1	   channel	   agonist	   was	   used	   to	   test	   the	   RYR1	  
variants.	   	   Future	   work	   will	   expand	   this	   current	   protocol	   to	   include	   known	   channel	  
agonists	  such	  as	  halothane,	  4-­‐CmC	  and	  ryanodine.	   	  All	  of	  these	  have	  been	  previously	  
used	   to	   investigate	   the	   functional	   consequences	  of	  RYR1	   variants	   (Tong	  et	   al.,	   1997,	  
Lynch	  et	  al.,	  1999,	  Yang	  et	  al.,	  2003,	  Migita	  et	  al.,	  2009,	  Sato	  et	  al.,	  2010,	  Sato	  et	  al.,	  
2013).	   	   Halothane	   is	   by	   far	   the	  most	   clinically	   relevant	   channel	   agonist	   for	   RYR1	   in	  
terms	  of	  the	  MH	  phenotype.	  	  However,	  the	  volatility	  of	  halothane	  has	  made	  it	  difficult	  
to	  use	  in	  such	  experiments.	  	  The	  exact	  concentration	  of	  halothane	  reaching	  the	  cells	  is	  
difficult	  to	  ascertain	  accurately.	  	  Despite	  this,	  retesting	  the	  variants	  under	  investigation	  
in	   this	   study	  with	  halothane	   is	  of	   interest,	  especially	  with	   reference	   to	   the	  p.D3986E	  
variant	   that	   responded	   in	   a	   similar	   way	   to	   wild	   type	   RYR1.	   	   The	   likelihood	   of	   the	  
p.D3986E	   responding	   in	   a	   way	   similar	   to	   other	   causative	   variants	   when	   exposed	   to	  
halothane	   remains	   unclear,	   especially	   when	   considering	   the	   fact	   that	   IVCT	   data	  
obtained	  from	  patients	  carrying	  the	  same	  variant	  responded	  in	  a	  very	  severe	  manner	  
when	  exposed	  to	  caffeine.	  
In	   this	   chapter,	   crude	   data	   were	   presented	   as	   a	   comparison	   between	   the	   results	  
obtained	   from	   either	   stably	   or	   transiently	   transfecting	   the	   wild	   type	   or	   p.G3990V	  
variants	   into	   HEK293	   cells.	   	   No	   discernable	   difference	   was	   seen	   between	   the	   two	  
methods	   leading	   to	   the	   conclusion	   that	  whether	   or	   not	   the	   experiments	   are	   carried	  
out	  on	  stably	  or	  transiently	  transfected	  cells	  is	  not	  important.	  	  Although	  this	  conclusion	  
was	  drawn	   from	  testing	  only	   two	  constructs	   it	   seems	  highly	   likely	   that	   it	   is	  accurate.	  	  	  
Based	   on	   the	   simplicity	   and	   speed	   of	   transiently	   transfecting	   HEK293	   cells	   with	   the	  
constructs	  future	  experiments	  are	  likely	  to	  rely	  heavily	  on	  this	  method.	  	  
By	  far	  the	  most	  important	  direction	  of	  future	  work	  based	  on	  this	  chapter	  would	  be	  the	  
introduction	   of	   these	   variants	   into	   a	  more	   native	   cell	   environment.	   	  Our	   experience	  
with	  utilising	  a	  viral	  method	  of	   transducing	  a	  muscle-­‐like	  cell	   line	   that	   is	  a	   functional	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knock-­‐out	   for	   RYR1	   will	   be	   discussed	   in	   the	   next	   chapter.	   	   Although	   it	   is	   widely	  
accepted	  that	  ideally	  these	  experiments	  would	  be	  carried	  out	  in	  a	  cellular	  environment	  
more	  fitting	  for	  the	  functional	  purpose	  of	  RYR1,	  it	  remains	  unclear	  as	  to	  whether	  there	  
would	   be	   a	   functional	   difference	   based	   on	   the	   cellular	   environment	   of	   the	   channel.	  	  
With	   the	   exception	   of	   the	   p.D3986E	   variant,	   an	   exaggerated	   response	   from	  mutant	  
RYR1	  channels	   is	  consistently	  elicited	  from	  experiments	  carried	  out	   in	  non-­‐native	  cell	  
types	  such	  as	  HEK293	  cells	  used	  in	  this	  study	  and	  others.	  	  	  However,	  we	  still	  feel	  that	  
confirming	   that	   there	   is	   no	   difference	   between	   the	   responses	   seen	   in	   different	   cell	  
types	  is	  important	  for	  the	  future	  of	  functional	  studies	  of	  MH	  variants.	  	  It	  is	  conceivable	  
that	   for	   the	   p.D3986E	   variant	   to	   display	   a	   pathogenic	   phenotype,	   it	   requires	   the	  
interaction	  with	  any	  one	  of	  a	  number	  of	  accessory	  proteins	  that	  are	  not	  expressed	  in	  
HEK293	  cells.	  	  	  
	  
4.6	  Conclusions	  
Based	   on	   the	   data	   obtained	   in	   this	   chapter,	   it	   seems	   clear	   that	   the	   p.R2336H,	  
p.E3104K,	  p.G3990V	  and	  p.V4849I	  RYR1	  variants	  are	  the	  causative	  mutation	  of	  MH	  in	  
the	  families	  they	  have	  been	  identified	  in.	  	  They	  all	  produced	  a	  response	  that	  has	  now	  
long	  been	  recognised	  as	  the	  hallmark	  of	  a	  causative	  MH	  mutation,	  that	   is,	  a	  reduced	  
EC50	   when	   exposed	   to	   channel	   agonists,	   in	   this	   case	   caffeine.	   	   Furthermore,	   a	   clear	  
trend	  in	  increased	  calcium	  release	  was	  observed	  at	  1mM	  and	  2mM	  caffeine	  which	  was	  
closer	  to	  its	  maximum	  response	  than	  wild	  type	  transfected	  cells.	  
The	  role	  of	  the	  p.D3986E	  variant	  remains	  unclear.	  	  Based	  on	  the	  data	  obtained	  in	  this	  
chapter,	  there	  is	  an	  argument	  for	  excluding	  this	  variant	  as	  the	  causative	  factor	  of	  MH	  
in	  the	  four	  families	   it	  has	  been	  identified	  in.	   	  However,	  the	  fact	  that	   it	  has	  only	  been	  
identified	   in	   MH	   patients,	   to	   cosegregate	   perfectly	   with	   disease	   and	   that	   patients	  
carrying	  this	  variant	  have	  a	  stronger	  caffeine	  contracture	  during	  the	  IVCT	  test	  cannot	  
be	  ignored.	  	  These	  four	  families	  that	  possess	  this	  variant	  may	  be	  good	  starting	  points	  
for	   further	   investigations	   into	  new	  causative	  variants	  associated	  with	  MH.	   	  Recently,	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our	  group	  has	  begun	  sequencing	  the	  exome	  of	  patients	  for	  which	  no	  causative	  variant	  
has	  been	  identified.	  	  These	  families	  would	  be	  ideal	  candidates	  for	  such	  experiments	  on	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Chapter	  Five -­‐	  Functional	  analysis	  of	  genetic	  variants	  in	  the	  RYR1	  gene	  associated	  
with	  malignant	  hyperthermia	  in	  1B5	  cells.	  
5.1	  Introduction	  
5.1.1	  EMHG	  Guidelines	  and	  the	  use	  of	  non-­‐native	  cells	  for	  functional	  analysis	  
As	  has	  been	  discussed	  in	  previous	  chapters,	  the	  majority	  of	  the	  functional	  analysis	  of	  
genetic	  variants	   in	  the	  RYR1	  gene	  has	  been	  carried	  out	  using	  cells	   in	  which	  RYR1	  and	  
other	   EC	   coupling	   accessory	   proteins	   are	   not	   expressed.	   	   Some	   researchers	   have	  
differentiated	  primary	  myoblasts	   isolated	  from	  patients	  carrying	  previously	   identified	  
RYR1	  variants	  in	  functional	  studies.	  	  Such	  experiments	  are	  therefore	  performed	  in	  the	  
correct	   cellular	   environment	   for	   RYR1	   with	   all	   accessory	   proteins	   required	   for	   EC	  
coupling	  also	  being	  present.	   	  However,	   cells	   isolated	   from	  patients	  do	  not	  possess	  a	  
defined	  genetic	  background	  meaning	  that	  the	  data	  obtained	  is	  insufficient	  for	  inclusion	  
onto	  the	  genetic	  diagnostic	  panel	  for	  MH	  unless	  experiments	  are	  carried	  out	  on	  more	  
than	  one	  family	  that	  possess	  the	  variant	  in	  question	  (Wehner	  et	  al.,	  2004,	  Kaufmann	  et	  
al.,	   2012).	   	   According	   to	   Robinson	   et	   al.	   (2006),	   106	   families	   possess	   a	   unique	  RYR1	  
variant,	  ruling	  out	  the	  possibility	  for	  genetic	  testing	  for	  these	  families	  if	  the	  primary	  cell	  
method	   were	   to	   be	   used	   alone.	   	   Currently,	   using	   either	   a	   non-­‐native	   cellular	  
environment	   of	   defined	   genetic	   background	   or	  myotubes	   isolated	   from	  patients	   are	  
both	  acceptable	  according	  to	  the	  EMHG	  guidelines,	  however	  the	  use	  of	  a	  muscle	  cell	  
line	   of	   defined	   genetic	   background	   would	   provide	   the	   most	   scientifically	   accurate	  
method	  of	  carrying	  out	  functional	  analysis.	  
	  
5.1.2	  The	  development	  of	  a	  dyspedic	  myoblast	  cell	  line	  for	  use	  in	  functional	  studies	  
of	  RYR1	  variants	  
Attempts	  have	  been	  made	  to	  use	  a	  mouse	  myoblast	  cell	  line	  as	  a	  means	  of	  functionally	  
assessing	  genetic	  variants	  in	  RYR1	  (Otsu	  et	  al.,	  1994).	  	  C2C12	  cells,	  a	  mouse	  muscle	  cell	  
line,	  were	  transfected	  using	  conventional	  lipid	  based	  methods	  and	  a	  difference	  in	  the	  
functional	  consequences	  of	  the	  genetic	  variants	  compared	  to	  wild	  type	  was	  observed	  
	   144	  
in	   terms	  of	   sensitivity	   to	   channel	   agonists.	   	  However,	   no	  difference	   in	   expression	  of	  
RYR1	  was	   observed	   in	   protein	   extracts	  when	   compared	  with	   untransfected	   controls	  
making	  the	  estimation	  of	  the	  transfection	  efficiency	  of	  the	  experiment	  impossible,	  as	  
C2C12	  cells	  possess	  endogenous	  RYR1,	  and	  the	  resulting	  analysis	  difficult.	  
A	   muscle-­‐like	   cell	   line	   has	   been	   developed	   for	   use	   in	   functional	   studies	   of	   RYR1	  
variants	  (Moore	  et	  al.,	  1998).	   	  Mouse	  embryonic	  stem	  cells	  null	  for	  both	  RYR1	  alleles	  
were	   injected	   subcutaneously	   into	   an	   immunodeficient	   mouse	   causing	  
teratocarcinoma	   formation.	   	   Fibroblast	   cells	   isolated	   from	   the	   tumour	   were	  
transduced	  down	  the	  muscle	  differentiation	  pathway	  with	  myoD	  resulting	  in	  a	  cell	  line,	  
termed	  1B5	  cells,	  that	  was	  deficient	  in	  all	  RYR	  isoforms,	  expressed	  all	  the	  key	  skeletal	  
muscle	  triadic	  proteins	  and	  had	  the	  ability	  to	  form	  multinucleated	  myotubes.	  
	  
5.1.2.1	  Development	  of	  a	  viral	  method	  of	  transducing	  dyspedic	  myotubes	  with	  RYR1	  
variants	  for	  functional	  studies	  
Following	   on	   from	   the	   development	   of	   the	   1B5	   cell	   line,	   a	   viral	  method	  of	   infecting	  
differentiating	  myotubes	  with	  wild	   type	  and	  mutant	  RYR1	   constructs	  was	  developed	  
for	  functional	  experiments	  (Cunningham	  and	  Davison,	  1993,	  Fraefel	  et	  al.,	  1996,	  Wang	  
et	  al.,	  2000,	  Yang	  et	  al.,	  2003).	  	  The	  entire	  HSV-­‐1	  genome	  was	  inserted	  into	  a	  set	  of	  five	  
cosmids	  for	  functional	  studies	  of	  HSV-­‐1	  genes	  before	  Fraefel	  et	  al.	  (1996)	  modified	  the	  
cosmid	  set	  by	  removing	  the	  packaging	  and	  cleavage	  signals	   from	  two	  of	   the	  cosmids	  
and	  placing	  them	  into	  a	  modified	  pUC	  vector	  (pHSVPrPUC).	  	  Rabbit	  RyR1	  was	  inserted	  
into	   the	   pHSVPrPUC	   vector	   creating	   a	   highly	   efficient	   gene	   delivery	   system	   for	   1B5	  
cells.	  	  HSV-­‐1	  infection	  efficiencies	  of	  up	  to	  90%	  were	  seen	  compared	  to	  almost	  0%	  for	  
standard	   lipofectamine	   transfection	  methods	   (Wang	   et	   al.,	   2000,	   Yang	   et	   al.,	   2003).	  	  
1B5	   cells	   expressing	   rabbit	   RYR1	   variants	   displayed	   an	   increased	   sensitivity	   to	  
traditional	  channel	  agonists	  such	  as	  caffeine,	  halothane	  and	  4-­‐CmC	  as	  well	  as	  KCl.	  	  The	  
increase	   in	   sensitivity	   to	   KCl	   indicates	   that	  MH	   variants	   also	   result	   in	   a	   defect	   in	   EC	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coupling.	   	   Since	   the	   development	   and	   validation	   of	   this	   system,	   no	   further	   genetic	  
variants	  in	  RYR1	  have	  been	  functionally	  characterised	  utilising	  this	  method.	  
	  
5.1.3	  Potential	  differences	  between	  HEK293	  cells	  and	  1B5	  cells	  
HEK293	  cells	  have	  been	   the	  primary	   functional	   characterisation	  system	  employed	  by	  
researchers	  examining	  the	  effects	  of	  RYR1	  variants	  in	  vitro.	  	  However,	  there	  is	  a	  huge	  
difference	   in	   both	   the	   structure	   and	   function	   of	   HEK293	   cells	   and	   skeletal	   muscle	  
myotubes.	   	   Firstly,	   no	   report	   to	   date	   has	   been	   able	   to	   detect	   any	   RYR	   isoform	   in	  
HEK293	  cells.	  	  	  Whilst	  it	  is	  this	  characteristic,	  along	  with	  ease	  of	  transfection	  that	  made	  
HEK293	  cells	  an	  attractive	  choice	  for	  functional	  experiments,	  other	  key	  skeletal	  muscle	  
triadic	  proteins	  are	  also	  not	  expressed	  (Nakai	  et	  al.,	  1996).	  	  Perhaps	  most	  importantly,	  
Cav1.1	  is	  not	  expressed	  in	  HEK293	  cells.	  	  RYR1	  interacts	  directly	  with	  Cav1.1	  (encoded	  
by	  CACNA1S)	  to	  initiate	  calcium	  release	  in	  skeletal	  muscle	  after	  excitation	  contraction	  
coupling.	   	   Additionally,	   skeletal	   muscle	   also	   possesses	   a	   highly	   organised	   and	  
specialised	   structure,	   which	   allows	   efficient	   calcium	   release	   and	   reuptake.	   	   Such	  
organisation	   is	  not	  present	   in	  non-­‐native	   (i.e.	  non-­‐muscle)	  cell	   types	  such	  as	  HEK293	  
cells.	  
Although	   no	   obvious	   differences	   have	   been	   observed	   between	   the	   dose-­‐response	  
generated	   by	  RYR1	   variants	   expressed	   in	   1B5	   cells	   and	   HEK293	   cells	   in	   response	   to	  
caffeine,	   halothane	   and	   4-­‐CmC	   (Yang	   et	   al.,	   2006),	   evidence	   is	   mounting	   that	   the	  
resting	   calcium	   levels	  may	  differ	  when	   the	   same	  RYR1	   variants	   are	   expressed	   in	   the	  
two	  cell	  lines.	  	  Tong	  et	  al.	  (1999b)	  expressed	  15	  RYR1	  mutations	  previously	  associated	  
with	  MH	  or	  CCD	  in	  HEK293	  cells	  and	  found	  that	  only	  those	  mutations	  associated	  with	  
the	  myopathy	   produced	   a	   resting	   calcium	   level	   that	  was	   elevated	   compared	   to	  wild	  
type	  controls	  as	  well	  as	  all	  MH	  mutations	  under	  investigation.	  	  This	  directly	  contradicts	  
work	   carried	   out	   on	   MHS	   swine	   (Lopez	   et	   al.,	   1987a),	   human	   muscle	   preparations	  
(Lopez	   et	   al.,	   1987b,	   Lopez	   et	   al.,	   2005)	   and	   dyspedic	   myotubes	   expressing	   RYR1	  
variants	  (Yang	  et	  al.,	  2007).	  	  In	  Yang	  et	  al.	  (2007),	  all	  MH	  variants	  expressed	  in	  1B5	  cells	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produced	   a	   resting	   calcium	   level	   significantly	   higher	   than	   that	   of	  wild	   type	   controls,	  
two	  of	  which	   had	  been	  previously	   expressed	   in	  HEK293	   cells	   and	   resulted	   in	   a	   level	  
similar	   to	   wild	   type	   (Tong	   et	   al.,	   1999b).	   	   One	   of	   the	   variants,	   p.R615C,	   is	   the	  MH	  
mutation	  in	  swine	  that	  also	  produced	  a	  significantly	  higher	  resting	  calcium	  level	  in	  the	  
two	  studies	  by	  Lopez	  and	  colleagues	  (Lopez	  et	  al.,	  2005,	  Lopez	  et	  al.,	  1987b).	  
The	   results	   obtained	   in	   these	   studies	   hint	   at	   a	   fundamental	   difference	   between	   the	  
biology	   of	   HEK293	   cells	   and	   1B5	   cells	   when	   expressing	   RYR1	   variants.	   	   This	   is	   not	  
surprising	  given	  that	  myotubes	  are	  highly	  specialised	  to	  express	  RYR1	  and	  release	  and	  
sequester	   calcium.	   	   	   Myotubes	   have	   a	   specialised	   SR	   designed	   for	   calcium	   storage,	  
release	  and	  reuptake	  and	  specific	  cellular	  structure	  for	  the	  use	  of	  calcium.	  	  Conversely,	  
HEK293	   cells	   are	   largely	   nuclear	   and	   small	   in	   comparison	   to	   fused,	   multinucleated	  
myotubes	   and	   possess	   a	   non-­‐specialised	   endoplasmic	   reticulum.	   	   In	   spite	   of	   these	  
differences,	  another	  factor	  that	  may	  contribute	  to	  the	  difference	  in	  results	  obtained	  by	  
the	  above	  studies	  is	  the	  method	  of	  measuring	  resting	  calcium.	  	  The	  studies	  on	  muscle	  
fibres	   and	   cells	   utilise	   calcium-­‐sensitive	   microelectrodes	   specifically	   designed	   and	  
calibrated	  for	  the	  measurement	  of	  resting	  intracellular	  calcium	  levels.	  	  In	  comparison,	  
Tong	  et	  al.	  (1999b)	  utilised	  the	  ratiometric	  calcium	  dye	  fura-­‐2	  to	  estimate	  the	  resting	  
calcium	  concentration.	   	  Whilst	  fura-­‐2	  has	  the	  ability	  to	  measure	  intracellular	  calcium,	  
the	   previously	   mentioned	   differences	   in	   cell	   structure	   may	   make	   accurately	   taking	  
these	  measurements	  problematic.	  	  This	  is	  hinted	  at	  in	  a	  study	  by	  Wehner	  et	  al.	  (2004)	  
in	  which	   fura-­‐2	  was	  used	   to	  measure	   the	   resting	   calcium	   level	   of	  myotubes	   isolated	  
from	   patients	   carrying	   RYR1	   variants.	   	   Two	   out	   of	   the	   three	   variants	   tested	   had	   a	  
significantly	   higher	   resting	   calcium	   level	   as	   compared	   to	  MHN	   controls.	   	  Whilst	   the	  
possibility	  of	  different	  RYR1	  mutations	  producing	  different	  levels	  of	  resting	  calcium	  or	  
the	  effect	  of	  unknown	  genetic	  contributors	  from	  the	  patient	  samples	  can	  not	  be	  ruled	  
out,	   the	   results	  highlight	   the	  possible	  disadvantages	  of	  using	   fura-­‐2	   as	   a	  measure	  of	  
resting	  calcium.	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5.1.4	  Variants	  in	  pHSVRYR1	  
Two	   RYR1	   variants	   and	   the	   wild	   type	   construct	   were	   shuttled	   into	   the	   pHSVPrPUC	  
vector	  as	  described	   in	  chapter	  3.	   	  The	  two	  variants	  successfully	   transferred	  were	  the	  
p.R2336H	   and	   the	   p.D3986E	   constructs.	   	  Whilst	   the	   intention	   of	   this	   project	  was	   to	  
shuttle	  all	  variants	  under	  investigation	  in	  this	  thesis	  into	  pHSVPrPUC,	  the	  only	  available	  
method	   of	   transfer	   was	   cloning	   the	   entire	   15kb	   RYR1	   coding	   sequence	   in	   a	   non-­‐
directional	  manner,	  which	   limited	  the	  success	  of	   transfer.	   	   In	  spite	  of	   this,	   these	  two	  
variants	   are	   ideal	   candidates	   for	   further	   study	   in	   1B5	   cells.	   	   The	   p.R2336H	   variant	  
produced	   the	   strongest	   result	   in	   HEK293	   cells	   and	   can	   act	   as	   a	   positive	   control	   to	  
observe	   increased	   sensitivity	   in	   the	   myotubes	   system	   compared	   to	   wild	   type.	   	   The	  
p.D3986E	  variant	  has	  been	  identified	  in	  4	  UK	  families	  and	  has	  been	  associated	  with	  a	  
stronger	  caffeine	  contracture	  than	  other	  MH	  variants.	  	  However,	  in	  the	  HEK293	  system	  
utilised	   in	   chapter	   4,	   the	   p.D3986E	   variant	   produced	   a	   response	   that	   was	  
indistinguishable	  from	  wild	  type	  transfected	  cells.	  	  Of	  particular	  interest	  in	  this	  chapter	  
is	  the	  results	  obtained	  from	  1B5	  cells	  infected	  with	  p.D3986E	  HSV-­‐1	  virions,	  allowing	  a	  
direct	  comparison	  with	  the	  results	  obtained	  in	  chapter	  4	  and	  forming	  the	  basis	  of	  an	  
evaluation	  of	  the	  use	  of	  HEK293	  cells	  as	  a	  system	  for	  the	  functional	  analysis	  of	  genetic	  
variants	  in	  RYR1.	  
	  
5.2	  Aims	  of	  the	  chapter	  
The	  primary	  aim	  of	  this	  chapter	  was	  to	  express	  wild	  type	  and	  mutant	  RYR1	  constructs	  
in	  the	  dyspedic	  myoblast	  cell	   line	  and	  examine	  the	  functional	  consequences	  of	  these	  
variants	  in	  the	  native	  muscle	  environment.	  	  The	  data	  obtained	  from	  this	  chapter	  would	  
form	  the	  basis	  of	  an	  assessment	  on	  the	  use	  of	  HEK293	  cells	  as	  a	  viable	  system	  for	  the	  
functional	  analysis	  of	  genetic	  variants	  in	  the	  RYR1	  gene	  associated	  with	  MH.	  
Additionally,	   expressing	   genetic	   variants	   of	   RYR1	   in	   1B5	   cells	   would	   allow	   us	   to	  
measure	   the	   intracellular	   resting	   calcium	   concentration	   using	   calcium-­‐sensitive	  
microelectrodes.	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5.3	  Results	  
5.3.1	  Titration	  of	  HSV-­‐1	  virions	  
5.3.1.1	  Titration	  using	  immunofluorescence	  
Titration	   experiments	   were	   carried	   out	   to	   determine	   the	   concentration	   of	   HSV-­‐1	  
virions	   harvested	   after	   viral	   packaging.	   	   Monkey	   Vero	   (2-­‐2)	   cells	   were	   infected	  
overnight	   with	   1µl,	   5µl	   and	   20µl	   of	   harvested	   HSV-­‐1	   virions	   before	   immunostaining	  
specific	  for	  RYR1	  	  (Figure	  5.1).	  	  A	  small	  amount	  of	  background	  staining	  was	  observed	  in	  
uninfected	   2-­‐2	   cells	   and	   a	   similar	   pattern	   was	   observed	   in	   wild	   type	   and	   p.R2336H	  
infected	   cells.	   	   The	   amount	   of	   Cy3	   (RYR1)	   staining	   observed	   for	   wild	   type	   and	  
p.R2336H-­‐infected	   cells	   was	   indistinguishable	   from	   the	   background	   staining	   seen	   in	  
uninfected	  controls.	   	  Additionally,	   the	  p.D3986E	   infected	  cells	   showed	  no	  visible	  Cy3	  
staining	  indicating	  the	  absence	  of	  RYR1	  from	  the	  cell	  samples.	  
	  
Figure	  5.1	  –	  Titration	  of	  harvested	  wild	  type,	  p.R2336H	  and	  p.D3986E	  HSV-­‐1	  virions	  using	  immunocytochemistry	  
on	  2-­‐2	  cells.	  
2-­‐2	  cells	  were	  infected	  with	  harvested	  HSV-­‐1	  virions	  containing	  wild	  type,	  p.R2336H	  and	  p.D3986E	  pHSVRYR1	  
constructs.	  	  Cells	  were	  infected	  overnight	  before	  the	  removal	  of	  the	  virions	  and	  incubation	  in	  growth	  medium	  for	  
a	  further	  24	  hours.	  	  Cells	  were	  fixed	  with	  ice-­‐cold	  methanol	  before	  staining	  with	  DAPI	  (blue)	  and	  34C	  anti-­‐
ryanodine	  receptor	  antibody	  (red).	  	  Some	  background	  was	  observed	  in	  the	  negative	  control,	  uninfected	  2-­‐2	  cells	  
that	  were	  not	  distinguishable	  from	  the	  wild	  type	  or	  p.R2336H	  infected	  cells.	  	  Furthermore,	  the	  p.D3986E	  infected	  
cells	  showed	  no	  RYR1	  staining.	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5.3.1.2	  Titration	  using	  calcium	  release	  assays	  
Due	  to	  the	  immunocytochemistry	  experiments	  showing	  no	  apparent	  RYR1	  expression,	  
the	  harvested	  virions	  were	  also	  titrated	  using	  differentiated	  1B5	  cells	  exposed	  to	  1mM,	  
5mM	  and	  20mM	  caffeine	  (Figure	  5.2).	  	  Differentiating	  1B5	  cells	  were	  exposed	  to	  20µl,	  
50µl	   and	   100µl	   of	   harvested	   HSV-­‐1	   virions	   overnight	   before	   the	   addition	   of	   fresh	  
medium	   and	   a	   further	   24-­‐hour	   incubation	   before	   the	   calcium	   release	   assay	   was	  
performed.	  	  None	  of	  the	  infected	  cells	  responded	  to	  1mM	  or	  5mM	  caffeine,	  however,	  
all	   wild	   type	   and	   p.R2336H	   infected	   cells	   released	   calcium	  when	   exposed	   to	   20mM	  
caffeine.	   	   Wild	   type	   infected	   cells	   appeared	   to	   respond	   with	   a	   larger	   increase	   in	  
fluorescence	  upon	  exposure	  to	  caffeine.	  	  	  The	  number	  of	  cells	  infected	  was	  calculated	  
from	   the	   field	   of	   view	   used	   for	   the	   calcium	   measurements	   and	   the	   percentage	   of	  
responding	   cells	   at	   20mM	   was	   plotted	   in	   Table	   5.1.	   	   When	   infected	   with	   20µl	   of	  
virions,	   80%	   of	   the	   wild	   type	   myotubes	   in	   the	   field	   of	   view	   responded	   to	   20mM	  
caffeine	  compared	  with	  50%	  for	  myotubes	  infected	  with	  the	  p.R2336H	  virions.	   	   	  Only	  
10%	   of	   myotubes	   were	   successfully	   infected	   with	   RYR1	   when	   the	   virion	   volume	  
increased	  to	  50µl	  and	  100µl	  for	  the	  p.R2336H	  construct.	  	  Wild	  type	  infection	  efficiency	  
stayed	   relatively	   constant	   throughout	   the	   concentration	   range.	   	   Although	   the	  
efficiency	  dropped	  to	  40%	  when	  50µl	  of	  virions	  was	  used,	  it	  returned	  to	  80%	  for	  100µl.	  	  
For	   both	   constructs,	   as	   the	   virion	   concentration	   increased,	   so	   did	   the	   amount	   of	  
cellular	  debris	  visible	  on	  the	  cells.	   	  For	  cells	   infected	  with	  the	  p.D3986E	  construct,	  no	  
response	  was	  seen	  from	  any	  of	  the	  infected	  myotubes	  at	  any	  caffeine	  concentration.	  	  
Similarly	  to	  the	  wild	  type	  and	  p.R2336H	  constructs,	  cellular	  debris	  severely	   increased	  
as	   the	   concentration	   of	   the	   p.D3986E	   virions	   increased.	   	   Cells	   that	   did	   respond	   to	  
caffeine	  produced	  a	   typical	   calcium	   release	   response	   from	  myotubes.	   The	  myotubes	  
responded	   by	   contracting,	   releasing	   calcium	   as	   indicated	   by	   an	   increase	   in	  
fluorescence	  followed	  by	  sequestration	  back	  into	  the	  intracellular	  stores	  (Figure	  5.3).	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Construct	   Concentration	  of	  virions	   Percentage	  of	  cells	  responding	  at	  20mM	  caffeine	  
Wild	  Type	   20µl	   80	  
50µl	   40	  
100µl	   80	  
p.R2336H	   20µl	   50	  
50µl	   10	  
100µl	   10	  
p.D3986E	   20µl	   0	  
	   	   50µl	   0	  
100µl	   0	  
Table	  5.1	  –	  Calculation	  of	  the	  efficiency	  of	  infection	  of	  wild	  type	  and	  p.R2336H	  pHSVRYR1	  virions.	  
For	  both	  the	  wild	  type	  and	  p.R2336H	  pHSVRYR1	  virions,	  the	  best	  infection	  efficiency	  was	  observed	  at	  the	  lowest	  
concentration	  of	  virions.	  	  For	  wild	  type	  virions,	  the	  same	  efficiency	  was	  observed	  at	  100µl	  virions,	  however	  the	  
cellular	  debris	  generated	  from	  this	  concentration	  was	  higher.	  	  As	  the	  virion	  concentration	  increased	  for	  the	  
p.R2336H	  construct,	  the	  infection	  efficiency	  dropped	  dramatically	  to	  10%	  for	  both	  50µl	  and	  100µl.	  	  Myotubes	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Figure	  5.2	  –	  Titration	  of	  HSV-­‐1	  virions	  using	  1B5	  cells	  exposed	  to	  caffeine.	  
1B5	  cells	  were	  plated	  onto	  96-­‐well	  plates	  and	  differentiated	  for	  3	  days	  before	  infection	  with	  incremental	  
amounts	  of	  harvested	  wild	  type,	  p.R2336H	  and	  p.D3986E	  virions.	  	  Infection	  was	  carried	  out	  overnight	  before	  the	  
virions	  were	  removed	  and	  replaced	  with	  differentiation	  medium	  and	  cultured	  for	  a	  further	  2	  days.	  	  Calcium	  
measurements	  were	  carried	  out	  using	  1mM,	  5mM	  and	  20mM	  caffeine.	  	  No	  infected	  cells	  responded	  to	  1mM	  or	  
5mM	  caffeine.	  	  Cells	  infected	  with	  wild	  type	  or	  p.R2336H	  HSV-­‐1	  virions	  produced	  a	  calcium	  release	  at	  20mM	  
regardless	  of	  the	  virion	  concentration	  used.	  	  Cells	  infected	  with	  p.D3986E	  virions	  did	  not	  respond	  to	  any	  caffeine	  







	   152	  
	  
Figure	  5.3	  –	  Time	  lapse	  image	  of	  1B5	  myotubes	  releasing	  calcium	  upon	  exposure	  to	  20mM	  caffeine.	  
1B5	  cells	  were	  infected	  with	  wild	  type	  pHSVRYR1	  virions	  and	  exposed	  to	  20mM	  caffeine.	  	  Upon	  exposure	  to	  
caffeine	  the	  1B5	  cells	  contracted	  and	  released	  calcium	  as	  visualised	  by	  a	  temporary	  increase	  in	  fluorescence	  
before	  sequestration	  back	  into	  the	  calcium	  stores	  and	  fluorescence	  returned	  to	  the	  baseline.	  
	  
	  
5.3.2	  Caffeine-­‐induced	  calcium	  release	  of	  1B5	  myotubes	  infected	  with	  HSV-­‐1	  virions	  
Based	   on	   the	   results	   obtained	   in	   the	   caffeine-­‐induced	   calcium	   release	   titration	  
experiments,	   20µl	   of	   harvested	   HSV-­‐1	   virions	  were	   added	   to	   1B5	   cells	   before	   being	  
exposed	   to	   a	   more	   thorough	   caffeine	   series	   for	   functional	   assays	   (Figure	   5.4).	  	  
Unfortunately,	  the	  infection	  efficiency	  seen	  in	  the	  original	  titration	  experiments	  could	  
not	   be	   repeated	   throughout	   the	   caffeine-­‐induced	   calcium	   release	   experiments.	   	   On	  
occasion	  (Figure	  5.4	  A-­‐B),	  a	  calcium	  release	  event	  was	  observed	  in	  a	  similar	  manner	  to	  
the	  original	  titration	  experiments.	  	  A	  response	  was	  only	  ever	  observed	  twice	  out	  of	  10	  
experiments	   and	   only	   at	   20mM	   caffeine,	   which	   was	   insufficient	   for	   a	   thorough	  
functional	   examination	   of	   the	   genetic	   variants	   in	   RYR1	   under	   investigation	   in	   this	  
chapter.	  	  The	  vast	  majority	  of	  experiments	  produced	  no	  calcium	  release	  at	  any	  caffeine	  
concentration	  used	  (Figure	  5.4C).	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Figure	  5.4	  –	  Caffeine-­‐induced	  calcium	  release	  experiments	  on	  1B5	  cells	  infected	  with	  HSV-­‐1	  virions	  containing	  
wild	  type	  or	  p.R2336H	  RYR1	  
Displayed	  are	  examples	  of	  the	  caffeine-­‐induced	  calcium	  release	  experiments	  carried	  out	  on	  1B5	  cells	  infected	  
with	  HSV-­‐1	  virions	  containing	  RYR1	  constructs.	  	  (A-­‐B)	  	  On	  occasion,	  calcium	  release	  events	  were	  observed	  at	  
20mM	  caffeine	  for	  wild	  type	  RYR1	  (A)	  and	  p.R2336H	  RYR1	  (B).	  	  This	  was,	  however,	  a	  rare	  event	  and	  the	  two	  
occasions	  it	  occurred	  are	  displayed	  above.	  (C)	  A	  representative	  trace	  from	  a	  caffeine-­‐induced	  calcium	  release	  
experiment	  performed	  on	  differentiated	  1B5	  cells	  infected	  with	  HSV-­‐1	  virions	  containing	  RYR1	  constructs.	  	  No	  
calcium	  release	  was	  observed	  at	  any	  caffeine	  concentration.	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5.3.3	  Control	  experiments	  to	  test	  the	  ability	  of	  2-­‐2	  cells	  and	  the	  cosmid	  set	  to	  
package	  HSV-­‐1	  virions	  
To	  test	  the	  possibility	  that	  the	  anti-­‐RYR1	  antibody	  was	  not	  working	  efficiently,	  C2C12	  
cells	  were	   also	  differentiated	   and	   stained	  with	   the	   anti-­‐ryanodine	   receptor	   antibody	  
(Figure	   5.5).	   	   Panel	   A	   shows	   multinucleated	   myotubes	   clearly	   showing	   Cy3	  
fluorescence,	   indicating	   the	   presence	   of	   RYR1.	   	   To	   probe	   the	   possibility	   that	   the	  
constructs	  generated	  in	  chapter	  3	  were	  not	  being	  packaged	  properly	  due	  to	  a	  fault	  in	  
the	   plasmid,	   a	   pHSVRyR1	   plasmid	   with	   a	   green	   fluorescent	   protein	   (GFP)	   tag	   was	  
packaged	  into	  HSV-­‐1	  virions	  using	  the	  same	  protocol	  that	  was	  used	  for	  the	  pHSVRYR1	  
constructs	  generated	   in	   this	   thesis.	   	  The	  pHSVRyR1-­‐GFP	  plasmid	  had	  previously	  been	  
successfully	  packaged	  into	  HSV-­‐1	  virions,	  which	  had	  subsequently	  been	  used	  to	  infect	  
1B5	   cells.	   	   Figure	   5.5	   B	   shows	   differentiated	   1B5	   cells	   infected	   with	   pHSVRyR1-­‐GFP	  
HSV-­‐1	   virions.	   	   	   No	   specific	  GFP	   staining	  was	   observed	   indicating	   that	  RyR1	   had	   not	  
been	  packaged	  into	  the	  virions.	  
	  
	  
Figure	  5.5	  –	  Control	  experiments	  carried	  out	  to	  test	  the	  34C	  antibody	  and	  the	  packaging	  protocol	  
(A)	  C2C12	  cells	  fixed	  and	  stained	  with	  the	  anti-­‐ryanodine	  receptor	  antibody.	  	  Clear	  red	  (Cy3)	  staining	  was	  
observed	  in	  all	  multi-­‐nuclear	  myotubes	  examined.	  	  (B)	  GFP	  fluorescence	  of	  myotubes	  infected	  with	  RYR1-­‐GFP	  
HSV-­‐1	  virions.	  	  No	  specific	  GFP	  staining	  was	  observed	  in	  the	  myotubes.	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5.3.4	  Use	  of	  conventional	  transfection	  agents	  on	  1B5	  dyspedic	  myotubes	  
As	  well	  as	  using	  viral	  methods,	  1B5	  cells	  were	  transfected	  with	  wild	  type	  pcRYR1	  using	  
two	   conventional	   transfection	   reagents;	   LF2000	   and	   Xfect	   polymer	   in	   an	   attempt	   to	  
obtain	  sufficiently	  high	  enough	  RYR1	  expression	  for	  thorough	  caffeine-­‐induced	  calcium	  
release	   experiments	   	   (Figure	   5.6).	   	   Titration	   using	   caffeine-­‐induced	   calcium	   release	  
appeared	   to	   give	   a	   more	   clear	   indication	   of	   the	   presence	   of	   RYR1	   as	   compared	   to	  
immunocytochemistry	   so	   this	   method	   was	   chosen	   as	   the	   means	   of	   testing	   the	  
conventional	   transfection	   reagents.	   	   1B5	   cells	  were	   transfected	   and	   then	   allowed	   to	  
differentiate	  for	  3	  or	  4	  days.	  	  Additionally,	  cells	  were	  differentiated	  for	  4	  days	  at	  both	  
low	  and	  high	  cell	  density.	   	  A	   further	  experiment	  was	  carried	  out	   in	  which	  cells	  were	  
transfected	   midway	   through	   a	   4-­‐day	   differentiation	   period.	   	   Cells	   were	   exposed	   to	  
20mM	   caffeine	   followed	   by	   40mM	  KCl	   to	   ascertain	  whether	   or	   not	  RYR1	   was	   being	  
expressed	   in	   the	  cells.	   	  No	  cells	   transfected	  with	  either	  LF2000	  or	   the	  Xfect	  polymer	  
responded	  when	  exposed	  to	  20mM	  caffeine.	  	  Cells	  transfected	  using	  the	  Xfect	  polymer	  
suffered	  a	  mild	  quench	  in	  fluorescence	  when	  exposed	  to	  caffeine.	  	  A	  similar	  but	  milder	  
response	  was	  seen	  in	  some	  of	  the	  experiments	  utilising	  LF2000.	  	  Cells	  transfected	  using	  
LF2000	   did	   not	   respond	   to	   40mM	   KCl	   whereas	   cells	   transfected	   using	   the	   Xfect	  
polymer	  experienced	  a	  mild	  calcium	  release,	  which	  was	  slowly	  sequestered	  back	  into	  
the	  intracellular	  stores.	  	  Neither	  LF2000	  or	  Xfect	  were	  able	  to	  produce	  a	  high	  enough	  
transfection	   efficiency	   for	   thorough	   functional	   analysis	   so	   subsequent	   experiments	  
using	  mutant	  pcRYR1	  constructs	  were	  not	  performed.	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Figure	  5.6	  –	  Traces	  of	  dyspedic	  myotubes	  transfected	  with	  wild	  type	  pcRYR1	  using	  LF2000	  and	  Xfect	  polymer.	  
Transfections	  were	  carried	  out	  24	  hours	  prior	  to	  the	  infection	  of	  myoblast	  differentiation.	  	  Cells	  were	  also	  plated	  
at	  high	  and	  low	  density	  and	  differentiated	  for	  4	  days.	  	  Some	  cells	  were	  transfected	  midway	  through	  a	  4-­‐day	  
differentiation	  period.	  	  No	  cells	  responded	  when	  exposed	  to	  20mM	  caffeine.	  	  There	  appeared	  to	  be	  some	  
quenching	  of	  fluorescence	  when	  caffeine	  was	  added.	  	  This	  was	  more	  prominent	  in	  cells	  transfected	  using	  the	  
Xfect	  polymer.	  	  Cells	  transfected	  using	  LF2000	  did	  not	  respond	  to	  40mM	  KCl	  whereas	  cells	  transfected	  using	  the	  
Xfect	  polymer	  did	  have	  a	  mild	  calcium	  release	  that	  was	  slowly	  sequestered	  back	  into	  the	  intracellular	  stores.	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5.4	  Discussion	  
Although	   the	   data	   presented	   in	   this	   chapter	   does	   not	   add	   to	   the	   knowledge	   of	   the	  
difference	  between	  HEK293	  cells	  and	  1B5	  cells	  as	  a	  functional	  experimental	  system,	  it	  
does	   highlight	   the	   difficulties	   encountered	   by	   expressing	   not	   only	   large	   cDNA	  
constructs	   in	   cell	   lines	   but	   also	   more	   specifically	   in	   expressing	   these	   constructs	   in	  
skeletal	   muscle	   cells.	   	   In	   this	   chapter,	   almost	   no	   reliable	   expression	   of	   RYR1	   was	  
observed	   in	   1B5	   cells	   either	   infected	   with	   HSV-­‐1	   virions	   or	   transfected	   using	   the	  
conventional	  methods	  of	  LF2000	  and	  the	  Xfect	  polymer.	  
	  
5.4.1	  Difficulties	  in	  generating	  a	  high	  titre	  of	  HSV-­‐1	  virions	  containing	  wild	  type	  and	  
mutant	  RYR1	  constructs	  
The	  primary	  reason	  for	  the	   inability	  to	  generate	  data	   in	  1B5	  cells	   in	  this	  chapter	  was	  
the	  difficulties	  associated	  with	  generating	  a	  high	  titre	  of	  HSV-­‐1	  virions	  containing	  wild	  
type	  and	  mutant	  RYR1	  constructs.	  	  Several	  attempts	  were	  made	  at	  packaging	  the	  wild	  
type,	   p.R2336H	   and	   p.D3986E	   pHSVRYR1	   constructs	   into	   HSV-­‐1	   virions.	   	   Caffeine-­‐
induced	  calcium	  release	  was	  selected	  as	  the	  primary	  method	  of	  titrating	  the	  viral	  titre	  
obtained	   in	   the	  packaging	  experiments	  due	   to	   technical	  difficulties	  experienced	  with	  
immunocytochemistry.	   	  No	  response	  was	  seen	  for	  any	  of	   the	  constructs	  packaged	  at	  
1mM	  or	  5mM	  caffeine.	  	  However,	  a	  response	  was	  observed	  in	  wild	  type	  and	  p.R2336H	  
infected	   cells	   upon	   exposure	   to	   20mM	   caffeine.	   	   The	   response	   was	   specific	   to	   the	  
addition	  of	   the	  caffeine	  and	   followed	  a	  pattern	  of	  calcium	  release	  and	  sequestration	  
similar	   to	   that	   reported	   previously	   for	   1B5	   cells	   (Yang	   et	   al.,	   2003).	   	   For	   wild	   type	  
infected	  cells,	  up	  to	  80%	  of	  cells	  responded	  to	  20mM	  caffeine.	  	  This	  was	  observed	  at	  a	  
low	   viral	   infection	   volume	   (20μl	   of	   the	   harvested	   virions)	   as	   well	   as	   a	   high	  
concentration	  of	  virions	  (100μl	  of	  the	  harvested	  virions).	   	  For	  p.R2336H	  infected	  cells	  
the	  efficiency	  was	  not	  as	  high	  and	  at	  its	  peak	  reached	  50%,	  which	  was	  obtained	  at	  the	  
lowest	  virus	  concentration	  (20μl	  of	  the	  harvested	  virions).	  	  For	  p.D3986E	  infected	  cells,	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no	   response	   was	   observed	   at	   any	   caffeine	   concentration	   or	   viral	   infection	  
concentration.	  
For	   all	   constructs,	   as	   the	   viral	   concentration	   increased	   so	  did	   the	  amount	  of	   cellular	  
debris	  visible	  under	  the	  microscope.	   	  This	   is	   likely	  due	  to	  an	   increase	   in	  not	  only	  any	  
potential	   virions	   in	   the	   solution	   infecting	   and	  possibly	   killing	   the	   cells	   being	   infected	  
but	   also	   an	   increase	   in	   cellular	   debris	   left	   over	   from	   the	  harvesting	  of	   the	  packaged	  
virions.	  	  Ideally,	  this	  would	  be	  reduced	  by	  having	  a	  high	  viral	  titre	  from	  the	  packaging	  
experiments	  therefore	  reducing	  the	  need	  for	   increased	  volumes	  of	  harvested	  virions.	  	  
Based	  on	  the	  titration	  experiments	  20μl	  of	  virus	  was	  added	  to	  differentiating	  1B5	  cells	  
for	   more	   comprehensive	   functional	   experiments	   involving	   a	   wider	   caffeine	   series.	  	  
Unfortunately,	   the	   efficiency	   observed	   in	   the	   original	   titration	   experiments	   was	   not	  
reproduced	  and	  almost	  no	  calcium	  release	  was	  observed	  at	  any	  caffeine	  concentration	  
in	   any	   of	   the	   experiments.	   A	   total	   of	   2	   responses	   were	   seen	   throughout	   the	  
experiments,	   however,	   these	   were	   always	   at	   high	   doses	   of	   caffeine	   and	   were	   not	  
reproduced	   in	   different	   wells	   of	   the	   same	   experiment	   meaning	   no	   comprehensive	  
functional	  experiments	  were	  completed.	  
The	  reason	  for	  the	  extremely	  low	  viral	  titre	  is	  unclear.	  	  All	  materials	  used	  for	  the	  viral	  
packaging	  experiments	  were	  obtained	  from	  Professor	  Paul	  Allen’s	  laboratory	  and	  had	  
been	  used	  successfully	  to	  package	  pHSVRyR1	  virions	  previously.	  	  The	  only	  difference	  to	  
the	  materials	  was	  the	  insertion	  of	  the	  human	  RYR1	  cDNA	  constructs	  generated	  in	  this	  
project.	   	  The	  possibility	  that	  RYR1	  was	  not	  being	  packaged	  properly	  and	  expressed	  in	  
the	  dyspedic	  myotubes	  was	  examined	  through	  the	  use	  of	  a	  positive	  control	  pHSVRyR1-­‐
GFP	  tagged	  construct	  that	  had	  been	  successfully	  packaged	  previously.	  	  	  The	  pHSVRyR1-­‐
GFP	   construct	  was	   packaged	   into	  HSV-­‐1	   virions	   along	   side	   the	   pHSVRYR1	   constructs	  
generated	   in	   this	   project.	   	   No	   GFP-­‐positive	   cells	   were	   observed	   upon	   examination	  
under	   fluorescence	   microscopy	   indicating	   that	   the	   defect	   may	   be	   occurring	   in	   the	  
packaging	  process	   rather	   than	   the	  pHSVRYR1	   constructs,	  possibly	   though	  a	  defect	   in	  
one	  of	   the	   five	  cosmids	   that	  contains	   the	  entire	  HSV-­‐1	  genome	  minus	   the	  packaging	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signals.	   	   It	   is	   noteworthy	   that	   the	   original	   laboratory	   in	   which	   the	   material	   was	  
acquired	  from	  is	  also	  currently	  having	  difficulties	  successfully	  packaging	  HSV-­‐1	  virions.	  
	  
5.4.2	  The	  use	  of	  conventional	  transfection	  methods	  on	  dyspedic	  myotubes	  
Conventional	   transfection	  methods	  were	   also	   used	   in	   this	   chapter	   as	   an	   attempt	   to	  
generate	  high	  enough	  transfection	  efficiencies	  for	  functional	  experiments.	  	  LF2000	  is	  a	  
standard	  lipid	  based	  transfection	  reagent	  that	  has	  been	  repeatedly	  used	  in	  functional	  
experiments	  of	  RYR1	  variants	  using	  HEK293	  cells	  as	  well	  as	   in	  this	  thesis	   (Tong	  et	  al.,	  
1997,	  Tong	  et	  al.,	  1999a,	  Lynch	  et	  al.,	  1999,	  Tong	  et	  al.,	  1999b).	  	  A	  second	  transfection	  
reagent,	  Xfect,	  was	  also	  used	  due	   to	  claims	   that	  muscle	   cells	  and	  primary	  myoblasts	  
had	   been	   previously	   transfected	   successfully	   using	   it.	   	   Unfortunately,	   neither	  
transfection	   method	   produced	   high	   enough	   transfection	   efficiencies	   for	   functional	  
experiments.	   	   Based	   on	   the	   findings	   of	   Neuhuber	   et	   al.	   (2002)	   that	   suggested	   an	  
increased	  transfection	  efficiency	  when	  transfecting	  primary	  myoblasts	  compared	  with	  
differentiating	   myotubes,	   several	   time	   points	   during	   myotubes	   differentiation	   were	  
used	   for	   the	   transfection	  of	  pcRYR1	   into	  1B5	  cells	  as	  well	  as	  different	  differentiation	  
durations.	   	  Transfections	  were	  carried	  out	  prior	   to	  differentiation	  periods	  of	  3	  and	  4	  
days.	  	  Furthermore,	  the	  effect	  of	  cell	  density	  was	  examined	  by	  carrying	  out	  the	  4-­‐day	  
differentiation	  transfections	  at	  a	   low	  and	  a	  high	  cell	  density.	   	  A	  final	  experiment	  was	  
set	   up	  mimicking	   the	   infection	  method	  of	   the	  HSV-­‐1	   virions	   by	   transfecting	   the	   1B5	  
cells	  mid-­‐differentiation.	  	  	  
No	  obvious	  differences	  were	  observed	  between	  any	  of	  the	  times	  of	  transfection.	  	  For	  
cells	   transfected	   using	   LF2000,	   no	   responses	   were	   observed	   when	   challenged	   with	  
20mM	   caffeine	   or	   40mM	   KCl.	   	   Cells	   transfected	   using	   the	   Xfect	   polymer	   did	   not	  
respond	   to	   20mM	   caffeine,	   however	   a	   slight	   calcium	   release	   was	   observed	   upon	  
exposure	   to	   40mM	  KCl.	   	   The	   reason	   that	   the	   cells	   responded	   to	   40mM	  KCl	   but	   not	  
20mM	  caffeine	  is	  not	  immediately	  clear.	  	  It	  is	  unlikely	  to	  be	  a	  background	  effect	  seen	  
in	  1B5	  cells	  as	  untransfected	  cells	  or	  cells	   transfected	  with	  LF2000	  did	  not	  share	  this	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response	   and,	   as	   reported	   by	   Yang	   et	   al.	   (2003),	   1B5	   cells	   do	   not	   respond	   to	   any	  
traditional	  RYR1	   channel	   agonist.	   	  Whatever	   the	   reason,	   the	   response	  was	  not	   large	  
enough	  for	  a	  comprehensive	  functional	  characterisation	  experiment.	  	  	  
The	   data	   obtained	   using	   conventional	   transfection	   methods	   in	   this	   chapter	   is	  
consistent	   with	   data	   previously	   presented	   by	   several	   studies	   (Wang	   et	   al.,	   2000,	  
Campeau	  et	  al.,	  2001,	  Neuhuber	  et	  al.,	  2002).	   	  Wang	  et	  al.	   (2000)	  showed	  that	  using	  
standard	   transfection	  methods	  was	   significantly	   less	  efficient	   that	   the	  HSV-­‐1	   system.	  	  
The	   largest	  plasmid	   tested	   in	  Campeau	  et	   al.	   (2001)	  was	  17kb,	  3kb	   smaller	   than	   the	  
pHSVRYR1	   and	   pcRYR1	   plasmids	   constructed	   in	   this	   project	   and	   perhaps	  
unsurprisingly,	  the	  efficiency	  generated	  in	  this	  chapter	  was	  much	  lower.	  
	  
5.5	  Future	  work	  
Periodically,	   companies	   produce	   transfection	   reagents	   that	   claim	   to	   be	   able	   to	  
transfect	   muscle	   cells	   with	   high	   efficiency.	   	   In	   spite	   of	   this	   there	   is	   a	   wealth	   of	  
literature	  showing	  that	  different	  transfection	  reagents	  are	  unsuccessful	  at	  transfecting	  
muscle	   cells	   to	   a	   high	   efficiency.	   	   The	   problem	   is	   exacerbated	   when	   the	   gene	   of	  
interest	   is	   large	  as	   transfection	  efficiency	  dramatically	  drops	  as	   the	   size	  of	   the	  cDNA	  
construct	   increases.	   	   Previous	   reports	   have	   obtained	   up	   to	   90%	   infection	   efficiency	  
using	   the	   HSV-­‐1	   system	   described	   above	   and	   future	   work	   should	   be	   aimed	   at	  
reproducing	  this	  success.	   	   If	  this	  were	  possible	  it	  would	  allow	  a	  thorough	  comparison	  
to	  be	  carried	  out	  between	  the	  responses	  of	  genetic	  variants	  of	  RYR1	  in	  non-­‐native	  cell	  
types	   and	   1B5	   cells	   and	   an	   argument	   could	   be	  made	   for	   the	   exclusion	   of	   the	   non-­‐
native	   cell	   types	   from	   the	  EMHG	  guidelines.	   	   If	   the	  protocol	   could	  be	  made	   simpler,	  
more	   reliable	   and	   quicker	   there	   would	   also	   be	   the	   possibility	   of	   switching	   to	   a	  
guideline	   protocol	   that	   only	   used	  muscle	   cells	   for	   the	   functional	   characterisation	   of	  
genetic	  variants	  in	  the	  RYR1	  gene.	  
An	  alternative	  method	  of	  expressing	  RYR1	  variants	  in	  dyspedic	  muscle	  cells	  is	  the	  use	  
of	   microinjection.	   	   Experiments	   have	   been	   successfully	   carried	   out	   on	   dysgenic	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(CACNA1S	  null)	  myotubes	   for	   functional	  assays	  of	  Cav1.1	   (Bannister	  and	  Beam,	  2009,	  
Eltit	  et	  al.,	  2012a).	   	  Utilising	  this	  technique	  for	  the	  functional	  assays	   involved	  in	  RYR1	  
variants	  may	  avoid	   the	  need	   for	   viral	   packaging,	  potentially	  making	   the	  experiments	  
safer	  as	  it	  would	  not	  require	  HSV-­‐1	  virions.	  	  However,	  the	  number	  of	  cells	  that	  would	  
need	   to	   be	  manually	   injected	   using	   this	   process	   would	   be	   high	  making	   the	   process	  
potentially	   less	   efficient	   and	   more	   time	   intensive	   than	   if	   the	   HSV-­‐1	   system	   was	  
properly	  optimised.	  	  	  
The	   use	   of	   murine	   models	   of	   MH	   is	   increasing.	   	   To	   date,	   3	   different	   MH	   RYR1	  
mutations	  have	  been	   knocked	   in	   to	   a	  mouse	  model	   as	  well	   as	   1	  CACNA1S	  mutation	  
(Yang	  et	  al.,	  2006,	  Chelu	  et	  al.,	  2006,	  Zvaritch	  et	  al.,	  2007,	  Eltit	  et	  al.,	  2012b).	  	  Although	  
it	   is	   still	   not	   practical	   to	  make	   a	  mouse	  model	   of	   every	  MH	  mutation,	   it	  may	   be	   of	  
interest	   to	   select	   individual	   mutations	   of	   interest.	   	   For	   example,	   in	   the	   previous	  
chapter,	  the	  p.D3986E	  variant	  responded	  in	  a	  way	  that	  was	  indistinguishable	  from	  wild	  
type.	  	  If	  the	  p.D3986E	  variant	  still	  responds	  in	  a	  similar	  way	  to	  wild	  type	  in	  the	  muscle-­‐
like	  system,	  it	  would	  be	  of	  interest	  to	  examine	  the	  effects	  of	  this	  mutation	  in	  vivo.	  
Finally,	  successful	  expression	  of	  these	  genetic	  variants	  in	  myotubes	  would	  facilitate	  the	  
possibility	  of	  measuring	   resting	   intracellular	   calcium	  concentrations	  of	  wild	   type	  and	  
mutant	  channels	  that,	  unfortunately,	  could	  not	  be	  carried	  out	  in	  this	  chapter.	  
	  
5.6	  Conclusions	  
The	  work	  presented	  in	  this	  chapter	  supports	  a	  large	  body	  of	  literature	  highlighting	  the	  
difficulties	   associated	   with	   expressing	   genes	   of	   interest	   in	   muscle	   cells.	   	   These	  
problems	   were	   compounded	   by	   the	   size	   of	   RYR1,	   which,	   even	   in	   more	   easily	  
transfected	  cells	  has	  low	  transfection	  efficiency	  due	  to	  its	  15kb	  coding	  sequence.	  	  Until	  
the	   issues	   surrounding	   expressing	   large	   cDNA	   constructs	   in	   muscle	   cells	   are	   fully	  
resolved	   it	  will	  be	   impossible	  to	  comprehensively	  deduce	  whether	  there	   is	  a	  need	  to	  
stop	  the	  use	  of	  non-­‐native	  cell	  types	  for	  the	  functional	  characterisation	  experiments	  of	  
genetic	  variants	  in	  the	  RYR1	  gene.	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To	  date,	  the	  majority	  of	  the	  experiments	  carried	  out	  on	  RYR1	  variants	  have	  been	  dose-­‐
response	   experiments	   involving	   known	   channel	   agonists	   such	   as	   caffeine,	   4-­‐CmC,	  
halothane	  and	  ryanodine	   (Tong	  et	  al.,	  1997,	  Yang	  et	  al.,	  2003).	   	  Further	  experiments	  
have	   involved	   measuring	   the	   intracellular	   resting	   calcium	   of	   cells	   and	   muscle	  
specimens	   known	   to	   be	   carrying	   variants	   in	  RYR1	   (Lopez	   et	   al.,	   1985a,	   Lopez	   et	   al.,	  
1985b,	  Lopez	  et	  al.,	  1986,	  Lopez	  et	  al.,	  1987a,	  Lopez	  et	  al.,	  1988,	  Tong	  et	  al.,	  1999b,	  
Lopez	  et	  al.,	  2005,	  Yang	  et	  al.,	  2007).	   	  No	  experiment	  has	   looked	  at	   the	  effect	  of	  an	  
increased	   or	   decreased	   expression	   of	   mutant	   RYR1	   in	   terms	   of	   its	   effect	   on	   the	  
sensitivity	  to	  channel	  agonists	  despite	  a	  growing	  body	  of	  evidence	  suggesting	  that	  the	  
expression	   level	  of	  RYR1	  may	  play	  a	   role	   in	  MH	  pathogenesis.	   	   	  Grievink	  and	  Stowell	  
(2010),	   carried	   out	   allele	   specific	   PCR	   on	   immortalised	   lymphoblastoid	   cells	   carrying	  
known	   RYR1	   variants.	   	   It	   was	   found	   that	   patients	   carrying	   the	   RYR1	   variants	   had	   a	  
higher	  expression	  from	  the	  wild	  type	  allele,	  possibly	  as	  a	  compensatory	  mechanism	  to	  
protect	  against	  the	  defective	  allele.	  	  This	  increase	  in	  expression	  may	  represent	  some	  of	  
the	  variation	  seen	  in	  the	  clinical	  presentation	  of	  patients	  undergoing	  anaesthesia	  with	  
the	   same	   variant	   but	   largely	   differing	   phenotypes.	   	   Perez	   et	   al.	   (2005)	   carried	   out	   a	  
study	  examining	  the	  effect	  of	  increasing	  the	  expression	  of	  RYR1	  in	  dyspedic	  myotubes.	  	  
The	  resting	  calcium	  level	  of	  myotubes	  expressing	  wild	  type	  RYR1	  was	  not	  significantly	  
increased	   when	   expression	   level	   was	   increased	   by	   up	   to	   20-­‐fold.	   	   Similarly,	   no	  
statistically	   significant	   effect	   on	   caffeine	   sensitivity	   was	   observed	   within	   this	  
expression	  range.	  	  Interestingly,	  when	  RYR3	  was	  over-­‐expressed	  in	  the	  same	  range,	  the	  
resting	  calcium	  level	  continuously	  increased	  and	  was	  elevated	  when	  compared	  to	  wild	  
type	   at	   the	   lowest	   expression	   level	   used.	   	   The	   caffeine	   sensitivity	   of	   RYR3	   also	  
increased	  as	   the	  expression	   level	   increased,	  hinting	  at	   the	   importance	  of	   the	   role	  of	  
elevated	  resting	  calcium	  in	  the	  sensitivity	  of	  RYR1	  to	  channel	  agonists.	  	  Unfortunately,	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no	  variants	  of	  RYR1	  were	  examined	  in	  this	  study.	  	  It	  has,	  however,	  long	  been	  suggested	  
that	   patients	   with	   MH	   have	   an	   elevated	   baseline	   resting	   calcium	   level	   in	   skeletal	  
muscle	  (Lopez	  et	  al.,	  1985a)	  and	  more	  specifically,	  MH-­‐associated	  RYR1	  and	  CACNA1S	  
variants	  have	  been	  shown	  to	  produce	  a	  higher	  resting	  calcium	  level	  in	  myotubes	  (Yang	  
et	  al.,	  2007,	  Eltit	  et	  al.,	  2012a).	   	   Furthermore,	   it	  has	  been	  shown	   that	   correcting	   the	  
resting	  calcium	   level	  of	  cells	  expressing	  RYR1	  variants	   to	  a	  wild	  type	   level	   lowers	  the	  
sensitivity	   of	   MHS	   muscle	   (Lopez	   et	   al.,	   2005).	   	   Reducing	   this	   resting	   calcium	   level	  
resulted	  in	  muscle	  that	  responded	  in	  a	  similar	  way	  to	  wild	  type,	  indicating	  that	  the	  MH	  
response	   seen	   in	   patients	   may	   be,	   at	   least	   in	   part,	   due	   to	   the	   chronically	   elevated	  
resting	  calcium	  observed	  in	  susceptible	  individuals.	  
To	  facilitate	  experiments	  aimed	  at	  examining	  the	  effect	  of	  an	  increased	  expression	  of	  
RYR1	  variants	  on	  caffeine	  sensitivity	  of	  transfected	  HEK293	  cells,	  RYR1	  constructs	  were	  
cloned	   into	   a	   pTUNE	   inducible	   expression	   vector	   as	   described	   in	   chapter	   3.	   	   The	  
p.D1056H,	  p.R2355W	  and	  p.D3986E	  RYR1	  variants	  were	  cloned	  into	  the	  pTUNE	  vector.	  	  
These	  variants	  have	  been	  identified	  in	  a	  total	  of	  13	  families	  in	  the	  UK.	  	  The	  p.R2355W	  
variant	  has	  also	  been	  identified	  in	  2	  additional	  families	  worldwide.	  
	  
6.1.1	  p.D1056H	  
The	  Leeds	  MH	  diagnostic	  centre	  recently	  sent	  patient	  samples	  in	  which	  no	  potentially	  
causative	   genetic	   variant	   had	   been	   identified	   for	   whole	   exome	   sequencing.	   	   In	   one	  
family,	   a	   novel	   c.3166	   C>T	   (p.D1056H)	   RYR1	   variant	   was	   identified	   that	   had	   been	  
missed	   using	   conventional	   Sanger	   sequencing.	   	   Subsequent	   screening	   in	   this	   family	  
found	  that	  the	  variant	  cosegregated	  with	  the	  MH	  phenotype	  in	  all	  the	  family	  members	  
available	  for	  screening.	  	  Furthermore,	  upon	  routine	  screening	  of	  the	  rest	  of	  the	  UK	  MH	  
population	   for	   the	   p.D1056H	   variant,	   it	   was	   also	   identified	   in	   a	   patient	   who	  
experienced	  an	  EHS	  reaction.	  	  The	  individual	  was	  a	  member	  of	  the	  British	  military	  and	  
on	  a	  training	  exercise	  suffered	  dizziness,	  excessive	  sweating	  and	  although	  he	  did	  not	  
lose	  consciousness,	  he	  had	  a	  temperature	  of	  38.9°C	  upon	  examination.	  	  Heat	  tolerance	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tests	  repeatedly	  showed	  excessive	  heat	  production	  and	  he	  was	  subsequently	  referred	  
for	  MH	  testing	  at	  the	  Leeds	  diagnostic	  centre.	  	  The	  IVCT	  test	  diagnosed	  the	  patient	  as	  
MHN	  and	  no	  further	  family	  members	  were	  tested.	  
	  
6.1.1.1	  Exertional	  heat	  stroke	  and	  MH	  
EHS	   is	   a	  disorder	   in	  which	  exercise,	   usually	   in	  warm	  climates	   triggers	   excessive	  heat	  
production	  in	  susceptible	  individuals	  that	  exceeds	  their	  body’s	  capability	  to	  remove.	  	  It	  
has	   long	  been	  suggested	   that	   there	   is	  a	  genetic	   link	  between	  MH	  and	  EHS,	  primarily	  
due	   to	   the	   similarity	   in	   the	   symptoms	   involved	   in	   both	   disorders	   (Hopkins,	   2007,	  
Muldoon	  et	  al.,	  2004,	  Muldoon	  et	  al.,	  2008)	  as	  well	  as	  the	  tendency	  of	  animal	  models	  
of	  MH	  to	  display	  EHS	  symptoms	  when	  exposed	  to	  an	  increased	  ambient	  temperature.	  	  
Early	  porcine	  models	  of	  MH	  all	  displayed	  an	  EHS-­‐like	  phenotype	  termed	  PSS	  in	  which	  
pigs	   that	   possess	   a	   variant	   in	   the	   porcine	   RYR1	   undergo	   a	   hypermetabolic	   reaction	  
when	  stressed	  before	  slaughter	  (Heffron	  et	  al.,	  1982,	  Otsu	  et	  al.,	  1994).	  	  More	  recently,	  
murine	   models	   of	   MH	   have	   all	   displayed	   an	   EHS	   phenotype	   when	   the	   ambient	  
temperature	  has	  been	  elevated	  to	  42°C	  (Yang	  et	  al.,	  2006,	  Chelu	  et	  al.,	  2006,	  Yuen	  et	  
al.,	  2012,	  Lanner	  et	  al.,	  2012).	  	  	  
In	   recent	   years,	   RYR1	   variants	   have	   been	   identified	   in	   a	   number	   of	   heat-­‐related	  
illnesses	   (see	   table	   1.2	   in	   chapter	   1).	   	  Wappler	   et	   al.	   (2001)	   reported	   three	   families	  
containing	   an	  RYR1	   variant	   in	   association	  with	   exertional	   rhabdomyolysis	   as	   well	   as	  
MH.	   	   Additionally,	   a	   common	   RYR1	   variant	   was	   identified	   in	   three	   New	   Zealand	  
families	   with	   exertional	   rhabdomyolysis	   (Davis	   et	   al.,	   2002)	   as	   well	   as	   two	   variants	  
found	  associated	  with	  a	  fatal	  episode	  of	  stress-­‐induced	  MH	  in	  two	  children	  (Groom	  et	  
al.,	  2011).	  	  Most	  significantly,	  an	  RYR1	  variant	  has	  also	  been	  found	  in	  association	  with	  a	  
classic	   EHS	  episode	   (Tobin	  et	   al.,	   2001).	   	  A	  12-­‐year-­‐old	  boy	   suffered	  an	  MH	   reaction	  
when	   undergoing	   surgery	   but	   recovered	   without	   complications	   only	   to	   die	   several	  
months	   later	  of	  an	  EHS	  episode	  whilst	  playing	   football.	   	  Genetic	  analysis	   identified	  a	  
p.R163C	  RYR1	  mutation	  that	  has	  been	  consistently	  associated	  with	  MH	  and	  has	  been	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found	   to	   be	   functionally	   relevant	   in	   both	   the	   HEK293	   (Tong	   et	   al.,	   1997)	   and	   1B5	  
systems	  (Yang	  et	  al.,	  2003).	  
A	   recent	   study	   on	   an	  MH	  mouse	   carrying	   the	   p.Y524S	   RYR1	   variant	   found	   that	   pre-­‐
treatment	  with	  AICAR,	  a	  drug	  that	  imitates	  the	  effect	  of	  AMP	  in	  the	  activation	  of	  AMPK	  
that	   has	   previously	   been	   shown	   to	  mimic	   the	   effects	   of	   exercise	   in	   sedentary	  mice	  
(Narkar	   et	   al.,	   2008),	   completely	   protected	   the	   mice	   against	   the	   EHS	   phenotype	  
normally	   associated	   with	   MH	   mice	   (Lanner	   et	   al.,	   2012).	   	   Treatment	   with	   AICAR	  
lowered	  the	  baseline	  resting	  calcium	  in	  the	  MH	  mice	  to	  a	  level	  similar	  to	  that	  of	  wild	  
type	   littermates.	   	   It	   was	   postulated	   that	   this	   reduction	   in	   resting	   calcium	   was	  
responsible	  for	  the	  protection	  against	  the	  EHS	  phenotype,	  leading	  to	  the	  suggestion	  of	  
the	   use	   of	   AICAR	   as	   a	   prophylactic	   treatment	   for	   individuals	  who	   are	   susceptible	   to	  
EHS.	   	  Unfortunately,	  no	  experiments	  were	  carried	  out	  on	   the	  effect	  of	  AICAR	  on	   the	  




The	  p.R2355W	  variant	  has	  been	  identified	  in	  nine	  families	  worldwide,	  seven	  of	  which	  
are	  in	  the	  UK.	  	  The	  variant	  has	  been	  found	  to	  segregate	  with	  MH	  phenotype	  and	  was	  
absent	   from	   a	   panel	   of	   control	   chromosomes.	   	   Wehner	   et	   al.	   (2004)	   differentiated	  
primary	   myoblasts	   isolated	   from	   patients	   carrying	   this	   variant	   into	   myotubes	   and	  
exposed	   them	   to	   incremental	   doses	   of	   caffeine,	   4-­‐CmC	   and	   halothane	   as	   well	   as	  
measuring	   the	   resting	   calcium	   level	   of	   the	   myotubes	   in	   comparison	   with	   wild	   type	  
controls.	   	   Surprisingly	   for	   cells	   carrying	   an	  MH	  variant,	   the	   resting	   calcium	   level	  was	  
not	  found	  to	  be	  significantly	  higher	  than	  that	  of	  wild	  type	  controls.	  	  However,	  the	  EC50	  
of	  myotubes	  containing	  the	  p.R2355W	  variant	  was	  consistently	  significantly	  lower	  than	  
that	  of	   familial	  wild	   type	  controls.	   	  However,	   as	  only	  one	   family	  was	   tested,	  no	   firm	  
conclusions	   could	   be	  made	   on	   the	   causality	   of	   the	   variant	   as	   outlined	   in	   the	   EMHG	  
guidelines	  for	  functional	  analysis.	  	  It	  cannot	  be	  conclusively	  ruled	  out	  that	  an	  additional	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variant	   unknown	   to	   the	   investigators	   is	   contributing	   to	   the	   MH	   phenotype	   in	   this	  
family.	  	  Functional	  analysis	  of	  this	  variant	  in	  the	  HEK293	  cell	  system	  established	  in	  this	  
thesis	  would	  be	  able	  to	  conclusively	  state	  whether	  or	  not	  the	  p.R2355W	  variant	  should	  
be	  added	  to	  the	  genetic	  diagnostic	  panel	  of	  MH.	  
	  
6.1.3	  p.D3986E	  
Data	   was	   obtained	   for	   the	   p.D3986E	   variant	   in	   chapter	   4	   that	   suggested	   that	   the	  
p.D3986E	   variant	   responds	   in	   a	   similar	  way	   to	  wild	   type	  when	   expressed	   in	  HEK293	  
cells.	  Based	  on	  this,	  the	  p.D3986E	  variant	  was	  cloned	  into	  the	  pTUNE	  inducible	  vector	  
to	   further	   probe	   its	   functional	   consequences	   through	   over-­‐	   or	   under-­‐expression.	  	  
Furthermore,	   the	   p.D3986E	   variant	   is	   in	   a	   region	   of	   RYR1	   that	   is	   important	   for	   the	  
maintenance	   of	   resting	   calcium	   (Claudio	   Perez,	   personal	   communication).	   	   When	  
chimeric	  RYR	  proteins	  were	  expressed	  in	  dyspedic	  myotubes	  containing	  a	  fragment	  of	  
RYR3	  that	  spans	  the	  area	  of	  the	  p.D3986E	  variant,	  resting	  calcium	  levels	   increased	  to	  
levels	  similar	  to	  wild	  type	  RYR3	  channels	  and	  were	  significantly	  higher	  than	  wild	  type	  
RYR1	   expressing	   cells.	   	   Perez	   et	   al.	   (2005)	   have	   previously	   demonstrated	   that	   an	  
increase	   in	   RYR3	   expression	   results	   in	   an	   increase	   in	   sensitivity	   to	   channel	   agonists	  
such	  as	  caffeine.	  	  Experiments	  performed	  in	  this	  chapter	  will	  allow	  us	  to	  examine	  the	  
effect	  of	  an	  increase	  in	  the	  p.D3986E	  variant	  on	  the	  sensitivity	  of	  transfected	  HEK293	  
cells	  to	  caffeine.	  
	  
6.2	  Aims	  of	  the	  chapter	  
The	  aims	  of	  this	  chapter	  were	  to	  functionally	  assess	  the	  p.D1056H	  and	  p.R2355W	  RYR1	  
variants	   to	   support	   their	   inclusion	   onto	   the	   genetic	   diagnostic	   panel	   for	   MH.	   	   The	  
p.D1056H	   has	   been	   associated	   with	   both	   MH	   and	   EHS	   and	   functional	   data	   would	  
further	   support	   the	   link	  between	   the	   two	  conditions.	   	  Additionally,	  using	   the	  pTUNE	  
inducible	  expression	  vector,	   functional	  studies	  were	  carried	  out	  on	  a	  defined	  genetic	  
background	   as	  well	   as	  with	   consistent	   expression	   levels,	   allowing	   us	   to	   examine	   the	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effect	   of	  RYR1	  expression	   on	   the	   sensitivity	   of	   transfected	   cells	   to	   caffeine.	   	   Finally,	  
dose-­‐response	   experiments	   were	   carried	   out	   on	   transfected	   cells	   pre-­‐treated	   with	  
AICAR,	   a	   compound	   previously	   found	   to	   be	   fully	   preventative	   of	   an	   EHS	   reaction	  
developing	   in	  MH	  mice.	   	   In	   these	   experiments,	  we	   examined	  whether	   or	   not	   AICAR	  
acted	  by	  reducing	  the	  sensitivity	  of	  mutant	  transfected	  cells	  to	  caffeine.	  
	  
6.3	  Results	  
6.3.1	  Caffeine-­‐induced	  calcium	  release	  
HEK293	   cells	   were	   transfected	   with	   full-­‐length	   wild	   type,	   p.D1056H,	   p.R2355W	   and	  
p.D3986E	   pTUNERYR1	   variants.	   	   Expression	   of	   RYR1	   was	   induced	   using	   IPTG	   at	   a	  
standard	  concentration	  of	  25µM.	   	  72	  hours	  post-­‐transfection,	  cells	  were	   loaded	  with	  
Fluo-­‐4	   AM,	   a	   fluorescent	   calcium	   indicator,	   and	   exposed	   to	   incremental	   doses	   of	  
caffeine	  (0.5mM,	  1mM,	  2mM,	  4mM,	  8mM	  and	  20mM).	  	  The	  increase	  and	  subsequent	  
decrease	   in	   fluorescence	   was	   measured	   using	   confocal	   microscopy	   and	   the	  
fluorescence	  data	  was	  plotted	  in	  Prism6.	  	  The	  background	  rate	  of	  4.02%	  estimated	  in	  
chapter	   4	   was	   used	   again	   for	   these	   experiments.	   	   Cells	   that	   were	   untransfected	   or	  
transfected	  but	  not	  exposed	  to	  IPTG	  were	  also	  measured.	  	  No	  difference	  was	  observed	  
between	   the	   two,	   confirming	  no	  endogenous	  RYR1	  was	  being	  expressed	   (Figure	   6.1).	  
Representative	   traces	   from	   each	   construct	   transfected	   are	   presented	   in	   (Figure	   6.2).	  	  
No	  cells	  responded	  to	  0.5mM	  caffeine.	  	  All	  cells	  responded	  to	  1mM	  caffeine	  but	  there	  
was	  a	  trend	  for	  a	  larger	  response	  in	  cells	  transfected	  with	  p.D1056H.	  	  At	  2mM	  caffeine,	  
cells	   transfected	   with	   p.D1056H	   once	   again	   produced	   a	   much	   larger	   response	  
compared	  to	  cells	  transfected	  with	  wild	  type,	  p.R2355W	  and	  p.D3986E	  constructs.	  	  At	  
4mM	   caffeine,	   cells	   transfected	   with	   the	   p.D1056H	   and	   p.R2355W	   constructs	  
appeared	  to	  reach	  a	  maximum	  response	  that	  was	  maintained	  when	  exposed	  to	  8mM	  
and	   20mM	   caffeine.	   	   Wild	   type	   and	   p.D3986E	   transfected	   cells	   did	   not	   reach	   a	  
maximum	  until	  they	  were	  exposed	  to	  8mM	  caffeine.	   	  At	  20mM	  caffeine,	  all	  cells	  had	  
reached	  a	  maximum	  response	  and	  produced	  a	  large	  calcium	  transient.	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Figure	  6.1	  –	  Untransfected	  HEK293	  cells	  and	  uninduced	  pTUNE	  constructs	  in	  HEK293	  cells.	  	  	  
(A)	  Untransfected	  HEK293	  cells	  only	  responded	  to	  high	  doses	  of	  caffeine	  (8mM-­‐20mM).	  	  (B)	  HEK293	  cells	  
transfected	  with	  wild	  type	  pTUNERYR1	  but	  not	  exposed	  to	  any	  IPTG	  were	  indistinguishable	  from	  untransfected	  
HEK293	  cells.	  	  They	  also	  only	  responded	  to	  8mM	  and	  20mM	  caffeine.	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Figure	  6.2	  –	  Representative	  traces	  of	  HEK293	  cells	  transfected	  with	  different	  pTUNERYR1	  constructs	  releasing	  
calcium	  when	  exposed	  to	  incremental	  doses	  of	  caffeine.	  	  	  
All	  transfected	  cells	  were	  induced	  to	  express	  RYR1	  using	  25µM	  IPTG.	  	  Wild	  type	  transfected	  cells	  responded	  
minimally	  to	  1mM	  caffeine	  and	  had	  an	  increased	  response	  as	  the	  concentration	  of	  caffeine	  increased.	  	  A	  
maximum	  response	  appeared	  to	  be	  reached	  at	  around	  8mM	  caffeine.	  Cells	  transfected	  with	  p.D3986E	  responded	  
in	  a	  similar	  way	  to	  wild	  type.	  	  Cells	  transfected	  with	  p.D1056H	  and	  p.R2355W	  reached	  a	  maximum	  response	  at	  
around	  4mM	  caffeine	  and	  tended	  to	  have	  a	  more	  exaggerated	  response	  at	  doses	  of	  caffeine	  lower	  than	  this.	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Experiments	  were	  normalised	  with	  the	  peak	  fluorescence	  obtained	  in	  each	  experiment	  
defined	  as	  100%	  and	   the	   initial	  baseline	   fluorescence	  as	  0%.	   	   The	  peak	   fluorescence	  
generated	  at	  each	  caffeine	  concentration	  was	  taken	  for	  each	  experiment	  and	  plotted	  
on	   a	   logarithmic	   scale.	   	   A	   dose-­‐response	   curve	   was	   fitted	   using	   the	   non-­‐linear	  
regression	   function	   in	  Prism6	  (Figure	  6.3).	   	  For	   the	  p.D1056H	  and	  p.R2355W	  variants,	  
the	  dose	  response	  curve	  was	  shifted	  to	  the	  left	  indicating	  an	  increase	  in	  sensitivity	  to	  
caffeine.	   	   The	   p.D3986E	   variant	   produced	   a	   similar	   response	   to	   wild	   type,	   which	   is	  
consistent	   with	   the	   results	   obtained	   in	   chapter	   4	   (Figure	   6.3	   A-­‐C).	   	   The	   EC50	   of	   the	  
p.D1056H	   (1.834mM,	   SEM	   =	   0.278,	   95%	   CI	   =	   1.36-­‐2.792)	   and	   p.R2355W	   (1.378mM,	  
SEM	  =	  0.6186,	  95%	  CI	  =	  0.02-­‐2.298)	  variants	  were	  statistically	  significantly	  reduced	  as	  
compared	  to	  wild	  type	  (3.804mM,	  SEM	  =	  0.586,	  95%	  CI	  =	  2.525-­‐5.392)	  (p=0.0191,	  n=7	  
and	  p=0.0477,	  n=4	  respectively)	  (Figure	  6.3	  D-­‐E).	  	  Consistent	  with	  the	  results	  obtained	  
in	  chapter	  4,	  the	  EC50	  of	  cells	  transfected	  with	  the	  p.D3986E	  variant	  was	  similar	  to	  wild	  
type	  and	  was	  not	  statistically	  significantly	  different	  (4.667mM,	  SEM	  =	  0.494,	  95%	  CI	  =	  
2.744-­‐5.889;	  p=0.6901,	  n=4).	  	  Furthermore,	  cells	  transfected	  with	  either	  the	  p.D1056H	  
or	   p.R2355W	   variant	   had	   an	   EC50	   that	   was	   statistically	   significantly	   lower	   than	   cells	  
transfected	   with	   the	   p.D3986E	   variant	   (p=0.0027	   and	   p=0.0243	   respectively.	   n=4).	  	  
Cells	  transfected	  with	  the	  p.D1056H	  and	  p.R2355W	  variants	  had	  an	  EC50	  that	  was	  not	  
significantly	   different	   from	   each	   other	   (p=0.837,	   n=4).	   	   The	   percentage	   of	   the	  
maximum	  response	  generated	  at	  each	  caffeine	  concentration	  for	  each	  construct	  under	  
investigation	   in	   this	   chapter	   was	   also	   plotted	   and	   analysed	   (Figure	   6.3	   F).	   	   At	   1mM	  
caffeine,	  no	  statistically	  significant	  differences	  were	  observed	  between	  each	  construct	  
under	   investigation.	   	   However,	   there	   was	   a	   trend	   for	   cells	   transfected	   with	   the	  
p.D1056H	   and	   p.R2355W	   variants	   to	   produce	   a	   response	   that	  was	   higher	   than	  wild	  
type	  or	  p.D3986E	  transfected	  cells.	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Figure	   6.3	   –	   Caffeine	   dose-­‐response	   analysis	   of	   cells	   transfected	   with	   wild	   type,	   p.D1056H,	   p.R2355W	   and	  
p.D3986E	  pTUNERYR1	  constructs.	  	  	  
All	  transfected	  cells	  were	  induced	  to	  express	  RYR1	  using	  25µM	  IPTG.	  (A-­‐C)	  Dose-­‐response	  curves	  for	  the	  three	  
RYR1	  variants	  under	  investigation	  in	  this	  chapter	  plotted	  with	  the	  response	  from	  cells	  transfected	  with	  wild	  type	  
pTUNERYR1.	  	  Data	  points	  are	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  the	  mean.	  	  For	  cells	  transfected	  with	  
p.D1056H	  and	  p.R2355W	  the	  curve	  was	  shifted	  to	  the	  left	  indicating	  an	  increase	  in	  sensitivity	  to	  caffeine.	  	  Cells	  
transfected	  with	  p.D3986E	  pTUNERYR1	  produced	  a	  dose-­‐response	  curve	  similar	  to	  wild	  type	  transfected	  cells.	  	  (D-­‐
E)	  	  The	  EC50	  was	  calculated	  for	  all	  constructs.	  	  Box	  plots	  are	  presented	  as	  the	  median,	  the	  upper	  and	  lower	  
quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  Cells	  transfected	  with	  p.D1056H	  and	  p.R2355W	  
constructs	  had	  a	  statistically	  significantly	  reduced	  EC50	  as	  compared	  to	  wild	  type	  (p<0.05).	  	  Cells	  transfected	  with	  
p.D3986E	  pTUNERYR1	  had	  an	  EC50	  similar	  to	  wild	  type	  transfected	  cells	  and	  was	  not	  statistically	  significantly	  
different	  (p=0.6901).	  	  Furthermore,	  cells	  transfected	  with	  p.D1056H	  and	  p.R2355W	  constructs	  had	  an	  EC50	  that	  
was	  statistically	  significantly	  lower	  than	  cells	  transfected	  with	  p.D3986E	  (p=0.0044	  and	  p=0.0243	  respectively).	  	  
(F)	  Dose	  response	  analysis	  at	  each	  caffeine	  concentration	  that	  produced	  a	  response	  from	  the	  transfected	  cells.	  	  
Data	  are	  presented	  as	  the	  mean	  plus	  or	  minus	  the	  standard	  error	  of	  the	  mean.	  	  At	  2mM	  and	  4mM	  caffeine,	  cells	  
transfected	  with	  p.D1056H	  and	  p.R2355W	  produced	  a	  statistically	  significantly	  increased	  response	  as	  a	  
percentage	  of	  the	  maximum	  as	  compared	  to	  wild	  type.	  	  At	  2mM	  caffeine,	  the	  response	  produced	  by	  p.D1056H	  
transfected	  cells	  was	  also	  significantly	  higher	  than	  cells	  transfected	  with	  p.D3986E.	  	  	  *p<0.05,	  **p<0.01.	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At	   2mM	   caffeine,	   cells	   transfected	   with	   both	   the	   p.D1056H	   and	   p.R2355W	   variants	  
produced	  a	  response	  that	  was	  statistically	  significantly	  greater	  as	  a	  percentage	  of	  their	  
maximum	  as	  compared	  to	  wild	  type.	  	  Cells	  transfected	  with	  p.D1056H	  and	  p.R2355W	  
had	   a	   mean	   response	   of	   60.5%	   ±	   13.95	   and	   58.37%	   ±	   20.85	   respectively	   of	   the	  
maximum	   compared	   to	   27.78%	   ±	   11.39	   for	   wild	   type	   (p=0.0471	   and	   p=0.0476	  
respectively).	   	  Cells	   transfected	  with	   the	  p.D3986E	  construct	  produced	  a	   response	  of	  
13.34%	   ±	   2.012	   which	   was	   not	   statistically	   significantly	   different	   to	   wild	   type	  
(p=0.4494).	  	  At	  4mM,	  once	  again	  cells	  transfected	  with	  the	  p.D1056H	  (81.69%	  ±	  10.87)	  
and	   the	   p.R2355W	   (80.64%	   ±	   16.37)	   constructs	   produced	   a	   response	   that	   was	  
statistically	  significantly	  higher	  than	  the	  wild	  type	  response	  (53.37%	  ±	  11.56;	  p=0.0498	  
and	   p=0.0441	   respectively).	   	   The	   p.D3986E	   transfected	   cells	   did	   not	   produce	   a	  
response	  that	  was	  significantly	  different	  to	  wild	  type	  (46.32%	  ±	  10.04;	  p=0.7510).	  	  For	  
all	  analyses	  of	  the	  percentage	  of	  the	  maximum	  response	  n=4.	  
	  
6.3.2	  EC10	  and	  EC25	  of	  HEK293	  cells	  transfected	  with	  the	  p.D3986E	  variant	  
In	   chapter	   4,	   it	   was	   observed	   that	   cells	   transfected	   with	   the	   p.D3986E	   variant	   in	  
pcRYR1	   had	   an	   EC10	   that	   was	   statistically	   significantly	   lower	   than	   that	   of	   wild	   type	  
transfected	   cells.	   	   The	   EC25	   of	   p.D3986E	   transfected	   cells	   was	   also	   substantially	  
reduced	  as	  compared	  to	  wild	  type.	  	  The	  same	  analysis	  was	  carried	  out	  on	  HEK293	  cells	  
transiently	   transfected	   with	   wild	   type	   and	   p.D3986E	   pTUNERYR1	   constructs	   (Figure	  
6.4).	   	  The	  EC10	  of	  HEK293	  cells	   transfected	  with	  wild	   type	  pTUNERYR1	  was	  2.769mM	  
compared	   with	   2.502mM	   for	   p.D3986E	   transfected	   cells.	   	   This	   was	   not	   statistically	  
significantly	  different	   (p=0.7489).	   	   Similar	   results	  were	  observed	   for	   the	  EC25	  of	   cells	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Figure	  6.4	  –	  EC10	  and	  EC25	  analysis	  of	  cells	  transfected	  with	  wild	  type	  and	  p.D3986E	  pTUNERYR1.	  	  	  
All	  cells	  were	  induced	  to	  express	  RYR1	  using	  25µM	  	  IPTG.	  	  (A)	  Box	  plots	  showing	  wild	  type	  (blue)	  and	  p.D3986E	  
(orange)	  EC10	  and	  EC25.	  Unlike	  cells	  transfected	  with	  wild	  type	  and	  p.D3986E	  pcRYR1,	  cells	  transfected	  with	  the	  
pTUNERYR1	  equivalent	  constructs	  showed	  no	  difference	  in	  either	  EC10	  or	  EC25.	  	  Box	  plots	  are	  presented	  as	  the	  
median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  (B)	  The	  EC10	  of	  wild	  type	  was	  
2.769mM	  compared	  to	  2.502mM	  for	  p.D3986E	  transfected	  cells	  (p=0.749).	  Similarly,	  the	  EC25	  of	  cells	  transfected	  




6.3.3	  Area	  under	  the	  curve	  measurements	  of	  HEK293	  cells	  transfected	  with	  
pTUNERYR1	  constructs	  
AUC	  measurements	  were	  taken	  from	  the	  fluorescence	  traces	  obtained	  in	  the	  caffeine-­‐
induced	   calcium	   release	   assays	   as	   an	   indirect	   measure	   of	   how	   much	   calcium	   was	  
released	   at	   each	   caffeine	   concentration	   (Figure	   6.5).	   	   For	   each	   experiment	   (n=4	   for	  
each	   construct),	   the	   baseline	   was	   independently	   ascertained	   by	   looking	   at	   the	  
fluorescence	  before	   the	  addition	  of	  any	  caffeine.	   	  At	  1mM	  caffeine,	  cells	   transfected	  
with	  the	  p.D1056H	  and	  p.R2355W	  variants	  produced	  a	  statistically	  significantly	  higher	  
calcium	  release	  than	  cells	  transfected	  with	  wild	  type	  pTUNERYR1.	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Figure	   6.5	   –	   Area	   under	   the	   curve	   measurements	   of	   HEK293	   cells	   transfected	   with	   pTUNERYR1	   constructs,	  
induced	  with	  25µM	  IPTG	  for	  72	  hours	  and	  exposed	  to	  incremental	  doses	  of	  caffeine.	  	  	  
At	  1mM	  and	  2mM	  caffeine,	  cells	  transfected	  with	  the	  p.D1056H	  and	  p.R2355W	  variants	  had	  a	  statistically	  
significantly	  higher	  amount	  of	  calcium	  release	  than	  cells	  transfected	  with	  wild	  type	  pTUNERYR1.	  	  Furthermore,	  
cells	  transfected	  with	  the	  p.R2355W	  variant	  had	  a	  statistically	  significantly	  higher	  amount	  of	  calcium	  release	  than	  
either	  of	  the	  other	  two	  variants	  under	  investigation	  in	  this	  chapter.	  	  At	  4mM-­‐20mM	  caffeine,	  no	  significant	  
difference	  in	  calcium	  release	  was	  observed	  between	  any	  of	  the	  constructs	  under	  investigation	  in	  this	  chapter.	  	  
Box	  plots	  are	  shown	  as	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  
*p<0.05,	  **p<0.01,	  ***p<0.001.	  	  
	  
Cells	   transfected	   with	   the	   p.D1056H	   and	   p.R2355W	   variants	   produced	   a	   calcium	  
release	  of	  	  133	  FU	  ±	  32.6	  	  and	  295.9	  FU	  ±	  34.04	  compared	  with	  45.66	  FU	  ±	  15.87	  for	  
cells	   transfected	  with	   the	  wild	   type	   construct	   (p=0.0310	   and	  p=0.0002	   respectively).	  	  
Furthermore,	   cells	   transfected	   with	   the	   p.R2355W	   variant	   had	   a	   statistically	  
significantly	   higher	   calcium	   release	   at	   1mM	   caffeine	   than	   the	   p.D1056H	   variant	  
(p=0.0105).	   	  Cells	   transfected	  with	   the	  p.D3986E	  variant	  behaved	   in	  a	   similar	  way	   to	  
wild	   type	   transfected	   cells,	   just	   as	   they	   did	   in	   chapter	   4.	   	   The	   p.D3986E	   transfected	  
cells	   produced	   a	   calcium	   release	   of	   68.23	   FU	   ±	   4.582	   which	   was	   not	   statistically	  
significantly	  different	  from	  the	  wild	  type	  response	  (p=	  0.2605).	   	   	  The	  response	  of	  the	  
p.D3986E	  transfected	  cells	  was	  also	  statistically	  significantly	  lower	  than	  the	  p.R2355W	  
response	  (p=0.0006)	  but	  not	  the	  p.D1056H	  response	  (p=0.1772).	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A	  2mM	  caffeine,	  once	  again	  the	  p.D3986E	  transfected	  cells	  did	  not	  produce	  a	  response	  
significantly	  different	  from	  wild	  type	  (258.9	  FU	  ±	  85.19	  and	  186	  FU	  ±80.43	  respectively;	  
p=0.5636).	   	   Cells	   transfected	   with	   the	   p.D1056H	   and	   p.R2355W	   variants	   both	  
produced	   a	   calcium	   release	   that	  was	   statistically	   significantly	   different	   to	  wild	   type.	  	  
p.D1056H	   transfected	   cells	   produced	   a	   response	   of	   765.3	   FU	   ±	   273.7	   (p=0.0408	  
compared	   to	  wild	   type)	  and	  cells	   transfected	  with	   the	  p.R2355W	  variant	  produced	  a	  
response	   of	   807.5	   FU	   ±	   358.1	   (p=0.0362	   compared	   to	   wild	   type).	   	   At	   the	   caffeine	  
concentrations	  of	  4mM,	  8mM	  and	  20mM,	  no	  statistically	  significantly	  different	  amount	  
of	  calcium	  release	  was	  observed	  between	  any	  of	  the	  constructs	  under	  investigation	  in	  
this	  chapter.	  	  
	  
6.3.4	  Differential	  expression	  of	  pTUNERYR1	  constructs	  
Experiments	  were	  performed	  to	  examine	  the	  sensitivity	  of	  RYR1	  variants	  at	  lower	  and	  
higher	  expression	  levels.	   	  The	  expression	  level	  of	  RYR1	  was	   induced	  to	  a	   lower	  and	  a	  
higher	  expression	  level	  than	  that	  used	  in	  the	  initial	  experiments	  by	  using	  2.5µM	  IPTG	  
and	  250µM	   IPTG	   respectively.	   	   For	  each	   IPTG	  concentration	  and	  construct	  examined	  
n=4.	   	   Cells	   expressing	   RYR1	   at	   a	   higher	   and	   lower	   level	   were	   exposed	   to	   the	   same	  
caffeine	   series	   as	   cells	   transfected	   with	   pTUNERYR1	   and	   induced	   with	   25µM	   ITPG.	  	  
Dose	   response	   curves	   were	   created	   in	   the	   same	   way	   as	   before	   and	   the	   EC50	   was	  
calculated	   for	   each	   expression	   level	   (Figure	   6.6).	   	   The	   increase	   or	   decrease	   in	  
expression	  for	  cells	  transfected	  with	  wild	  type	  pTUNERYR1	  had	  no	  effect	  on	  the	  EC50.	  	  
The	  EC50	  of	  cells	  transfected	  and	  induced	  with	  25µM	  IPTG	  was	  3.804mM.	  	  The	  EC50	  did	  
increase	  slightly	  to	  4.328mM	  (SEM	  =	  0.871,	  95%	  CI	  =	  1.349-­‐6.893)	  when	  the	  cells	  were	  
induced	   with	   2.5µM	   IPTG	   and	   decrease	   to	   3.05mM	   (SEM	   =	   0.273,	   95%	   CI	   =	   2.427-­‐
3.943)	  when	   the	   cells	  were	   induced	  with	   250µM	   IPTG	   but	   neither	   of	   these	   reached	  
statistical	   significance	   (p=0.876	   and	   p=0.3197	   respectively).	   	   Similar	   results	   were	  
observed	   for	  cells	   transfected	  with	   the	  p.D1056H	  variant.	   	  The	  EC50	   for	  cells	   induced	  
with	  25µM	  IPTG	  was	  1.834mM	  compared	  with	  1.914mM	  (SEM	  =	  0.144,	  95%	  CI	  =	  1.618-­‐
2.358)	  with	  2.5µM	  IPTG	  induction	  and	  2.344mM	  (SEM	  =	  0.392,	  95%	  CI	  =	  1.86-­‐3.87)	  for	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250µM	  IPTG.	  	  Once	  again,	  these	  were	  not	  statistically	  significantly	  different	  (p=0.7846	  
and	  p=0.1304	  respectively).	  	  Cells	  transfected	  with	  the	  p.R2355W	  variant	  and	  induced	  
with	  25µM	  IPTG	  had	  an	  EC50	  of	  1.378mM	  compared	  with	  3.87mM	  (SEM	  =	  0.731,	  95%	  
CI	  =	  2.237-­‐6.891)	  for	  an	  induction	  level	  of	  2.5µM	  and	  2.842mM	  (SEM	  =	  0.242,	  95%	  CI	  =	  
2.09-­‐3.34)	  for	  250µM	  IPTG.	  	  The	  EC50	  of	  cells	  induced	  with	  2.5µM	  IPTG	  was	  statistically	  
significantly	   higher	   than	   cells	   induced	  with	   25µM	   IPTG	   (p=0.0342)	   and	   250µM	   IPTG	  
(p=0.0222).	   	  An	   increase	   in	  expression	   level	  of	   the	  p.R2355W	  variant	   from	  the	  25µM	  
IPTG	  level	  had	  no	  significant	  effect	  on	  EC50	  (p=0.2184).	  	  The	  opposite	  occurred	  for	  cells	  
transfected	   with	   the	   p.D3986E	   variant.	   	   A	   decrease	   in	   expression	   (2.5µM	   IPTG	  
induction)	   resulted	   in	   no	   significant	   difference	   in	   EC50	  when	   compared	   to	   the	   25µM	  
IPTG	  induction	  (EC50	  =	  3.762mM	  and	  4.667mM	  respectively;	  p=0.3713.	  	  For	  the	  2.5µM	  
induction	   the	   SEM	   =	   0.105	   and	   95%	  CI	   =	   3.49-­‐4.16).	   	   Conversely,	   cells	   induced	  with	  
250µM	  IPTG	  had	  an	  EC50	  of	  2.724mM	  (SEM	  =	  0.211,	  95%	  CI	  =	  2.069-­‐3.412),	  which	  was	  
statistically	  significantly	   lower	  than	  for	  both	  the	  2.5µm	  IPTG	  level	  (p=0.0036)	  and	  the	  
25µM	  IPTG	  level	  (p=0.0261).	  
The	   EC50	   of	   cells	   transfected	   with	   wild	   type	   pTUNERYR1	   and	   induced	   with	   2.5µM,	  
25µM	  and	  250µM	  IPTG	  was	  not	  statistically	  significantly	  different	  than	  the	  EC50	  of	  cells	  
transfected	   with	   the	   p.R2355W	   variant	   and	   induced	   with	   2.5µM	   IPTG.	   (p=0.7102,	  
p=0.541	   and	   p=0.943	   respectively)	   (Figure	   6.7).	   	   Furthermore,	   the	   decreased	  
expression	   level	   of	   the	   p.R2355W	   variant	   produced	   an	   EC50	   that	   was	   statistically	  
significantly	  higher	  than	  cells	  expressing	  the	  p.D1056H	  variant	  at	  the	  2.5µM	  and	  25µM	  
IPTG	   induction	   levels	   (p=0.002	   and	   p=0.0061	   respectively)	   as	   well	   as	   being	  
substantially	  lower	  than	  cells	  induced	  at	  the	  highest	  level	  (p=0.0556).	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Figure	  6.6	  –	  The	  effect	  of	  increased	  and	  decreased	  expression	  on	  the	  EC50	  of	  cells	  transfected	  with	  pTUNERYR1	  
constructs.	  	  	  
(A-­‐B)	  The	  EC50	  of	  cells	  transfected	  with	  wild	  type	  pTUNERYR1.	  	  The	  increase	  in	  expression	  through	  increased	  IPTG	  
induction	  of	  pTUNE	  constructs	  had	  no	  effect	  on	  the	  EC50	  of	  cells	  transfected	  with	  wild	  type	  pTUNERYR1.	  	  (C-­‐D)	  	  
The	  EC50	  of	  cells	  transfected	  with	  p.D1056H	  pTUNERYR1.	  	  The	  increase	  in	  expression	  had	  no	  effect	  on	  the	  EC50	  of	  
cells	  transfected	  with	  the	  p.D1056H	  construct.	  	  (E-­‐F)	  	  The	  EC50	  of	  cells	  transfected	  with	  p.R2355W	  pTUNERYR1.	  	  
An	  increased	  expression	  of	  the	  p.R2355W	  variant	  had	  no	  effect	  on	  the	  EC50	  of	  the	  transfected	  cells.	  	  However,	  a	  
decrease	  in	  expression	  (2.5µM	  IPTG	  induction)	  resulted	  in	  an	  EC50	  that	  was	  statistically	  significantly	  higher	  than	  
cells	  induced	  with	  25µM	  and	  250µM	  IPTG.	  	  (G-­‐H)	  	  The	  EC50	  of	  cells	  transfected	  with	  p.D3986E	  pTUNERYR1.	  	  A	  
decreased	  expression	  of	  the	  p.D3986E	  variant	  had	  no	  effect	  on	  the	  EC50	  of	  transfected	  cells.	  	  However,	  an	  
increase	  in	  expression	  (250	  µM	  IPTG	  induction)	  resulted	  in	  an	  EC50	  that	  was	  statistically	  significantly	  lower	  than	  
cells	  induced	  with	  2.5µM	  and	  25µM	  IPTG.	  	  For	  the	  dose-­‐response	  graphs,	  data	  points	  are	  mean	  plus	  and	  minus	  
the	  standard	  error	  of	  the	  mean.	  	  Box	  plots	  are	  presented	  as	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  
maximum	  and	  minimum	  data	  points.	  	  *p<0.05,	  **p<0.01.	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Cells	  transfected	  with	  the	  p.D3986E	  variant	  and	  induced	  to	  a	  higher	  level	  of	  expression	  
through	   exposure	   to	   250µM	   IPTG	   produced	   an	   EC50	   that	   was	   similar	   to	   the	   value	  
observed	   for	   causative	   MH	   mutations.	   	   The	   EC50	   dropped	   to	   2.724mM	   which	   was	  
statistically	   significantly	   lower	   than	   cells	   transfected	  with	  wild	   type	   pTUNERYR1	   and	  
induced	   with	   25µM	   IPTG	   (p=0.0398).	   	   The	   EC50	   of	   cells	   transfected	   with	   p.D3986E	  
pTUNERYR1	  induced	  with	  250µM	  IPTG	  was	  not	  statistically	  significantly	  different	  from	  
the	  p.D1056H	  and	  p.R2355W	  variants	  (p=0.1233	  and	  p=0.2713	  respectively).	  
	  
Figure	  6.7	  –	  Differential	  expression	  of	  the	  p.R2355W	  and	  p.D3986E	  variants	  and	  the	  subsequent	  EC50.	  	  	  
(A)	  Lowering	  the	  expression	  level	  of	  the	  p.R2355W	  variant	  causes	  the	  EC50	  to	  increase	  to	  a	  level	  similar	  to	  wild	  
type	  and	  p.D3986E	  transfected	  cells.	  	  (B)	  Increasing	  the	  expression	  level	  of	  the	  p.D3986E	  variant	  causes	  the	  EC50	  
to	  decrease	  to	  a	  level	  similar	  to	  MH	  mutations.	  	  Box	  plots	  are	  shown	  as	  the	  median,	  the	  upper	  and	  lower	  
quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  
	  
	  
6.3.5	  Area	  under	  the	  curve	  measurements	  of	  HEK293	  cells	  expressing	  wild	  type	  and	  
mutant	  RYR1	  at	  different	  levels	  
Area	  under	   the	   curve	  measurements	  were	   taken	   from	   the	   traces	  obtained	   from	   the	  
caffeine-­‐induced	  calcium	  release	  experiments	  carried	  out	  on	  HEK293	  cells	   transiently	  
transfected	  with	  pTUNERYR1	   and	   induced	  with	  either	  2.5µM	  or	  250µM	   IPTG	   (Figure	  
6.8).	  	  Cells	  transfected	  with	  wild	  type	  pTUNERYR1	  had	  a	  trend	  to	  release	  more	  calcium	  
at	  every	  caffeine	  concentration	  when	  they	  were	  induced	  with	  250µM	  IPTG.	  	  However,	  
at	   the	   1mM	   and	   2mM	   doses	   of	   caffeine,	   the	   increase	   in	   calcium	   release	   was	   not	  
statistically	  significantly	  higher	  (p=0.348	  and	  p=0.2434	  respectively).	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Figure	   6.8	   –	   Area	   under	   the	   curve	   measurements	   of	   HEK293	   cells	   transiently	   transfected	   with	   pTUNERYR1	  
constructs	  and	  induced	  to	  differing	  levels	  of	  expression.	  	  	  
(A)	  Wild	  type	  pTUNERYR1	  induced	  with	  2.5µM	  and	  250µM	  IPTG.	  	  The	  increase	  in	  RYR1	  expression	  had	  no	  effect	  
on	  the	  amount	  of	  calcium	  release	  at	  1mM	  and	  2mM	  caffeine.	  	  However,	  at	  both	  4mM	  and	  8mM	  caffeine,	  a	  
statistically	  significantly	  higher	  amount	  of	  calcium	  release	  was	  observed	  in	  cells	  expressing	  RYR1	  to	  a	  higher	  level.	  	  
This	  effect	  was	  not	  seen	  at	  20mM	  caffeine.	  	  (B-­‐D)	  Cells	  transfected	  with	  the	  mutant	  pTUNERYR1	  constructs	  did	  
not	  display	  a	  statistically	  significant	  amount	  of	  calcium	  release	  at	  any	  caffeine	  concentration	  when	  expression	  
was	  increased	  with	  250µM	  IPTG.	  	  Box	  plots	  are	  shown	  as	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  
maximum	  and	  minimum	  data	  points.	  	  *p<0.05.	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However,	   at	   4mM	   and	   8mM	   caffeine,	   a	   statistically	   significant	   increase	   in	   calcium	  
release	  was	  observed	  as	  expression	  level	  increased.	  	  At	  4mM	  caffeine,	  the	  amount	  of	  
calcium	  released	  by	  wild	  type	  transfected	  cells	  increased	  from	  129.1	  FU	  ±	  34.94	  to	  290	  
FU	  ±	  50.9	  (p=0.0396).	  	  At	  8mM	  caffeine,	  the	  amount	  of	  calcium	  released	  by	  wild	  type	  
transfected	  cells	  increased	  from	  223.3	  FU	  ±	  26.46	  to	  483.9	  FU	  ±	  85.26	  (p=0.0267).	  	  This	  
trend	   for	   increased	   calcium	   release	  was	   not	  maintained	   at	   20mM	   caffeine,	  where	   a	  
maximum	  amount	  of	  calcium	  release	  appeared	  to	  have	  been	  reached	  (p=0.1770).	  	  For	  
the	  p.D1056H	  transfected	  cells,	  there	  appeared	  to	  be	  a	  trend	  of	  more	  calcium	  release	  
in	   cells	   induced	   with	   2.5µM	   IPTG	   although	   this	   did	   not	   reach	   significance	   at	   any	  
caffeine	   concentration	   investigated	   in	   this	   experiment.	   	   Cells	   transfected	   with	  
p.D1056H	   and	   induced	   with	   2.5µM	   IPTG	   also	   appeared	   to	   have	   a	   much	   more	  
consistent	   response.	   	   At	   2mM	   and	   4mM	   caffeine	   the	   range	   of	   calcium	   release	   was	  
from	  99.1	  FU	  and	  198.09	  FU	  respectively	  compared	  with	  198.09	  FU	  and	  220.5	  FU	  for	  
cells	  induced	  with	  250µM	  IPTG.	  	  For	  cells	  transfected	  with	  the	  p.R2355W	  variant	  there	  
was	   once	   again	   a	   trend	   for	   cells	   induced	   with	   250µM	   IPTG	   to	   have	   an	   increase	   in	  
calcium	  release	  compared	  to	  cells	  induced	  with	  only	  2.5µM	  IPTG,	  although	  this	  did	  not	  
reach	   statistical	   significance	   at	   any	   caffeine	   concentration	   used	   in	   this	   experiment.	  	  
Cells	  transfected	  with	  the	  p.D3986E	  variant	  did	  not	  appear	  to	  have	  a	  clear	  trend	  in	  the	  
amount	   of	   calcium	   released	   depending	   on	   the	   level	   of	   induction.	   	   At	   each	   caffeine	  
concentration,	   no	   significant	   difference	   was	   observed	   between	   cells	   induced	   with	  
either	   2.5µM	   or	   250µM	   IPTG.	   	   However,	   similarly	   to	   cells	   transfected	   with	   the	  
p.D1056H	   variant,	   cells	   induced	   with	   2.5µM	   IPTG	   appeared	   to	   have	   a	   much	   more	  
consistent	  calcium	  release	  at	  4mM	  and	  8mM	  caffeine	  when	  compared	  to	  cells	  induced	  
with	   250µM	   IPTG.	   	   At	   4mM	  caffeine,	   cells	   induced	  with	   2.5µM	   IPTG	  had	   a	   range	   of	  
calcium	  release	  of	  133.52	  FU	  compared	  with	  224.5	  FU	  for	  the	  250µM	  IPTG.	  	  Similarly,	  
at	   8mM	  caffeine,	   cells	   induced	  with	  2.5µM	   IPTG	  had	  a	   range	  of	   498.7	   FU	   compared	  
with	  870.7	  FU	  for	  cells	  induced	  with	  250µM	  IPTG.	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6.3.6	  The	  effect	  of	  AICAR	  on	  the	  sensitivity	  of	  HEK293	  cells	  transfected	  with	  
pTUNERYR1	  constructs	  to	  caffeine	  
Experiments	  were	  performed	  to	  examine	  the	  effect	  of	  AICAR	  on	  the	  caffeine	  sensitivity	  
of	  the	  RYR1	  variants	  under	  investigation	  in	  this	  chapter.	  	  HEK293	  cells	  were	  transfected	  
with	  pTUNERYR1	   constructs	  and	   induced	  with	  25µM	   IPTG.	   	  Some	  wells	  of	   cells	  were	  
treated	  with	  1mM	  AICAR	  overnight	  at	  37°C	  and	  5%	  CO2.	  	  For	  each	  construct	  n=4	  with	  
and	   without	   treatment	   with	   AICAR.	   Transfected	   cells	   were	   exposed	   to	   the	   same	  
caffeine	   series	   as	  with	   previous	   experiments	   to	   examine	   the	   effect	   of	   AICAR	   on	   the	  
caffeine	  sensitivity	  of	  the	  various	  RYR1	  constructs	  under	  investigation	  in	  this	  chapter.	  	  
Dose-­‐response	   curves	  were	   plotted	   and	   the	   EC50	   of	   the	   transfected	  were	   calculated	  
(Figure	  6.9).	   	  There	  appeared	  to	  be	  no	  significant	  effect	  of	  AICAR	  on	  cells	  transfected	  
with	  wild	   type	   pTUNERYR1	   with	   the	   EC50	   of	   untreated	   cells	   being	   3.881mM	   (SEM	   =	  
0.626,	  95%	  CI	  =	  2.14-­‐6.128)	  compared	  with	  4.179mM	  (SEM	  =	  0.546,	  95%	  CI	  =	  2.333-­‐
5.811)	  for	  cells	  exposed	  to	  AICAR	  overnight	  (p=0.943).	  	  	  
All	  MH	  mutations	  were	  statistically	  significantly	  affected	  by	  the	  presence	  of	  AICAR	   in	  
the	   culture	   medium	   overnight.	   	   The	   EC50	   of	   cells	   transfected	   with	   the	   p.D1056H	  	  
variant	   increased	   from	   1.872mM	   (SEM	   =	   0.159,	   95%	   CI	   =	   1.511-­‐2.527)	   to	   8.684mM	  
(SEM	  =	  0.764,	  95%	  CI	  =	  6.518-­‐11.38)	  upon	  exposure	  to	  AICAR	  (p=0.001).	  	  Similarly,	  the	  
EC50	  of	  cells	  transfected	  with	  the	  p.R2355W	  variant	  was	  4.516mM	  (SEM	  =	  0.29,	  95%	  CI	  
=	  3.918-­‐4.832)	  when	  exposed	  to	  AICAR	  compared	  with	  1.34mM	  (SEM	  =	  0.619,	  95%	  CI	  =	  
0.02-­‐2.987)	   for	   untreated	   controls	   (p=0.0284).	   	   Finally,	   cells	   transfected	   with	   the	  
p.D3986E	  RYR1	  variant	  had	  an	  EC50	  of	  4.667mM	  (SEM	  =	  0.494,	  95%	  CI	  =	  2.744-­‐5.889)	  
when	   cultured	   in	  AICAR-­‐free	   conditions	   compared	  with	   an	   EC50	   of	   9.961mM	   (SEM	  =	  
1.182,	  95%	  CI	  5.255-­‐12.78)	  in	  the	  presence	  of	  AICAR.	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Figure	  6.9	  –	  The	  effect	  of	  AICAR	  on	  the	  EC50	  of	  cells	  transfected	  with	  pTUNERYR1	  constructs.	  	  	  
(A-­‐B)	  No	  statistically	  significant	  difference	  was	  observed	  between	  cells	  transfected	  with	  wild	  type	  pTUNERYR1	  
with	  or	  without	  pre-­‐treatment	  of	  AICAR.	  The	  EC50	  of	  cells	  not	  treated	  with	  AICAR	  was	  3.881mM	  compared	  with	  
4.179mM	  with	  treatment	  (p=0.943).	  	  (C-­‐H)	  	  The	  treatment	  of	  any	  of	  the	  MH	  variants	  under	  investigation	  in	  this	  
chapter	  with	  AICAR	  resulted	  in	  a	  statistically	  significant	  increase	  in	  EC50	  as	  compared	  with	  untreated	  controls.	  	  
The	  most	  dramatic	  difference	  was	  seen	  in	  cells	  transfected	  with	  the	  p.D1056H	  variant	  where	  the	  EC50	  increased	  
from	  1.872mM	  to	  8.684mM	  (p=0.0001).	  	  The	  EC50	  of	  cells	  transfected	  with	  the	  p.R2355W	  variant	  increased	  to	  
4.516mM	  from	  1.340mM	  (p=0.0284)	  when	  treated	  with	  AICAR	  and	  cells	  transfected	  with	  the	  p.D3986E	  variant	  
and	  treated	  with	  AICAR	  saw	  the	  EC50	  increase	  from	  4.667mM	  to	  9.961mM	  (p=0.0105).	  	  For	  the	  dose-­‐response	  
graphs,	  the	  data	  points	  shown	  are	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  the	  mean.	  	  Box	  plots	  are	  shown	  
as	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  	  *p<0.05,	  ***p<0.001.	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6.3.7	  Viability	  stain	  of	  HEK293	  cells	  transfected	  with	  pTUNERYR1	  and	  treated	  with	  
IPTG	  and	  AICAR	  
To	  ensure	  that	  the	  presence	  of	  AICAR	  in	  the	  culture	  medium	  was	  not	  causing	  the	  effect	  
seen	  by	  killing	  the	  cells	  a	  mutant	  pTUNERYR1	  construct	  was	  transfected	   into	  HEK293	  
cells	  and	  exposed	  to	  either	  0µM,	  25µM	  or	  250µM	  IPTG	  for	  72	  hours.	  	  48	  hours	  into	  the	  
experiment	   some	   cells	   were	   treated	   with	   1mM	   AICAR	   overnight	   in	   a	   repeat	   of	   the	  
conditions	  used	   for	   the	  caffeine-­‐induced	  calcium	  release	  experiments.	   	  After	   the	  72-­‐
hour	  incubation,	  cells	  were	  pelleted,	  resuspended	  in	  PBS	  and	  exposed	  to	  a	  trypan	  blue	  
viability	   stain	   (Figure	  6.10).	   	   There	  were	  no	   significant	  differences	  between	   the	   total	  
numbers	   of	   cells	   counted	   for	   each	   of	   the	   experimental	   treatments	   and	   there	   was	  
always	  substantially	  more	  living	  cells	  as	  compared	  to	  dead	  cells.	  	  The	  total	  percentage	  
of	  cells	  alive	  did	  appear	  to	  decrease	  with	  the	   increasing	  severity	  of	   the	  experimental	  
treatments	  with	  83.45%	  of	  cells	  alive	  when	  untransfected	  and	  untreated	  however	  the	  
lowest	  percentage	  of	   alive	   cells	  was	  only	  77%	   for	   the	   transfected,	  250µM	  and	  1mM	  
AICAR	   conditions.	   	   Experiments	   were	   performed	   in	   triplicate	   and	   no	   statistically	  
significant	   differences	   were	   observed	   between	   any	   of	   the	   experimental	   conditions	  
applied.	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Figure	  6.10	  –	  Viability	  stain	  of	  cells	  transfected	  with	  pTUNERYR1	  and	  treated	  with	  IPTG	  and	  AICAR.	  	  	  
HEK293	  cells	  were	  transfected	  with	  wild	  type	  pTUNERYR1.	  	  	  Some	  cells	  were	  induced	  at	  a	  level	  of	  25µM	  IPTG,	  
some	  were	  induced	  with	  250µM	  IPTG.	  	  Some	  cells	  were	  also	  exposed	  to	  1mM	  AICAR	  overnight	  before	  
measurements	  were	  taken.	  	  72	  hours	  post-­‐transfection	  and	  induction	  with	  IPTG	  cells	  were	  exposed	  to	  a	  trypan	  
blue	  viability	  stain	  and	  the	  number	  of	  living	  and	  dead	  cells	  counted	  with	  a	  haemocytometer	  (panel	  A	  and	  B).	  
There	  was	  a	  much	  greater	  number	  of	  living	  cells	  compared	  to	  dead	  cells	  in	  all	  experimental	  conditions	  and	  no	  
significant	  difference	  between	  any	  of	  experimental	  conditions	  in	  terms	  of	  numbers	  of	  living	  or	  dead	  cells.	  	  	  
Transfection	  of	  the	  pTUNERYR1	  construct	  resulted	  in	  a	  slight	  decrease	  in	  the	  total	  number	  of	  cells	  which	  was	  
further	  reduced	  upon	  exposure	  to	  either	  IPTG	  or	  AICAR	  although	  the	  difference	  was	  not	  significant	  (panel	  C).	  
Panel	  D	  shows	  the	  percentage	  of	  cells	  that	  were	  living	  after	  the	  various	  treatments.	  	  Although	  there	  was	  a	  trend	  
to	  have	  fewer	  cells	  alive	  as	  the	  treatments	  became	  more	  extreme	  this	  was	  not	  statistically	  significantly	  different.	  	  
When	  cells	  were	  transfected,	  exposed	  to	  250µM	  IPTG	  and	  AICAR,	  77%	  of	  cells	  were	  still	  alive.	  	  Data	  are	  presented	  
as	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  the	  mean.	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6.3.8	  Comparison	  between	  cells	  transfected	  with	  pcRYR1	  and	  pTUNERYR1	  cDNA	  
constructs	  
The	  dose-­‐response	   curves	   generated	   in	   chapter	  4	   and	   this	   chapter	   for	   the	  wild	   type	  
and	   p.D3986E	   variants	   in	   the	   pcDNA	   and	   pTUNE	   expression	   vectors	   are	   plotted	  
together	   in	   Figure	   6.11	   to	   examine	   whether	   there	   are	   any	   differences	   in	   response	  
between	  the	  two	  expression	  vectors.	  	  The	  EC50	  of	  the	  wild	  type	  and	  p.D3986E	  variants	  
in	   both	   the	   pcDNA	   and	   pTUNE	   expression	   vectors	   were	   not	   significantly	   different.	  	  
Furthermore,	  the	  EC50	  was	  not	  significantly	  different	  between	  the	  expression	  vectors.	  	  
There	  was	  a	  trend	  for	  both	  the	  pTUNERYR1	  constructs	  to	  have	  a	  slightly	  elevated	  EC50	  
but	  this	  was	  not	  significantly	  different	  (p=0.1213	  for	  the	  wild	  types	  and	  p=0.1781	  for	  
the	  p.D3986E	  constructs).	  	  There	  was	  also	  no	  difference	  between	  the	  pcDNA	  wild	  type	  




Figure	  6.11	  –	  A	  comparison	  of	  the	  response	  of	  wild	  type	  and	  p.D3986E	  RYR1	  in	  the	  pcDNA	  and	  pTUNE	  expression	  
vectors.	  	  	  
(A)	  The	  dose	  response	  curves	  of	  wild	  type	  and	  p.D3986E	  RYR1	  in	  both	  the	  pTUNE	  and	  pcDNA	  expression	  vectors.	  	  
Data	  points	  are	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  the	  mean.	  	  (B)	  Box	  plots	  of	  the	  EC50	  of	  each	  of	  the	  
wild	  type	  and	  p.D3986E	  RYR1	  constucts	  in	  the	  pTUNE	  and	  pcDNA	  expression	  vectors.	  	  No	  statistically	  significant	  
difference	  in	  EC50	  was	  observed	  between	  the	  two	  wild	  type	  constructs	  or	  the	  two	  p.D3986E	  constructs	  in	  either	  
expression	  vector.	  	  Box	  plots	  are	  presented	  as	  the	  median,	  the	  upper	  and	  lower	  quartiles	  and	  the	  maximum	  and	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6.3.9	  Detection	  of	  RYR1	  expression	  through	  western	  blotting	  
HEK293	   cells	   were	   transfected	   and	   induced	   using	   the	   same	   concentrations	   of	   IPTG	  
used	  for	  the	  functional	  experiments.	  	  Whole	  protein	  was	  extracted	  from	  HEK293	  cells	  
72	  hours	  post-­‐transfection	  with	   all	   pTUNERYR1	   constructs.	   	  Western	  blot	   analysis	   of	  
the	   detection	   of	   RYR1	   at	   the	   various	   IPTG	   doses	   is	   shown	   in	   Figure	   6.12	   and	   Figure	  
6.13.	   	  Western	   blots	  were	   repeated	   in	   triplicate	   each	  with	   a	   new	  harvested	   protein	  
sample.	   	   Figure	   6.12A	   shows	   a	   representative	   western	   blot	   of	   RYR1	   and	   tubulin	  
expression	   when	   HEK293	   cells	   were	   transiently	   transfected	   with	   pTUNERYR1	  
constructs	  and	  induced	  with	  the	  incremental	  doses	  of	  IPTG	  used	  in	  this	  study.	  	  Panel	  B	  
shows	   the	   relative	   intensity	   of	   the	   RYR1	   bands	   detected	   in	   comparison	   to	   the	  
‘standard’	  25μM	   induction	   level	  used	   in	   the	   initial	  experiments.	   	  When	   induced	  with	  
2.5μM	  IPTG,	  RYR1	  detection	  was	   lowered.	   	  Similarly,	  when	  250μM	  IPTG	  was	  used	  to	  
induce	  the	  cells,	  expression	  was	  increased.	  	  
	  
	  
Figure	  6.12	  –	  Western	  blot	  analysis	  of	  HEK293	  cells	  transiently	  transfected	  with	  pTUNERYR1	  constructs	  
(A)	  Representative	  western	  blot	  image	  of	  HEK293	  cells	  transiently	  transfected	  with	  pTUNERYR1	  and	  induced	  with	  
incremental	  doses	  of	  IPTG.	  	  Proteins	  were	  run	  on	  a	  8%	  polyacrylamide	  gel	  and	  blotted	  overnight	  onto	  a	  PVDF	  
membrane.	  	  The	  membrane	  was	  probed	  for	  RYR1	  (upper	  panel)	  and	  alpha	  tubulin	  (lower	  panel)	  using	  
monoclonal	  antibodies.	  	  (B)	  After	  determining	  that	  equal	  amounts	  of	  protein	  were	  run	  using	  the	  alpha	  tubulin	  
control,	  the	  relative	  intensities	  of	  the	  RYR1	  protein	  bands	  were	  determined	  using	  Image	  Lab	  software	  with	  the	  
25μM	  IPTG	  set	  as	  the	  comparison	  band.	  	  All	  pTUNERYR1	  constructs	  induced	  with	  2.5μM	  IPTG	  were	  expressed	  at	  a	  
lower	  level	  compared	  with	  25μM	  IPGT	  and	  all	  constructs	  induced	  250μM	  IPTG	  were	  expressed	  at	  a	  higher	  level.	  	  
No	  statistically	  significant	  difference	  in	  protein	  expression	  was	  observed	  between	  any	  of	  the	  constructs	  when	  
induced	  with	  the	  same	  amount	  of	  IPGT.	  	  Data	  are	  presented	  as	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  
the	  mean.	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Figure	  6.13	  shows	  the	  combined	  data	  for	  all	  pTUNERYR1	  constructs	  pooled	  according	  
to	   the	   level	  of	   IPTG	  used	   to	   induce	  RYR1	  expression.	   	  Cells	   induced	  with	  25μM	   IPTG	  
were	  used	  as	   the	   reference	  band	   to	   relatively	  quantify	   the	  cells	   induced	  with	  2.5μM	  
and	   250μM	   IPTG.	   	  When	   induced	  with	   2.5μM	   IPTG,	   a	   statistically	   significantly	   lower	  
amount	   of	   RYR1	   was	   detected	   as	   compared	   to	   both	   25μM	   and	   250μM	   IPTG	  
(p<0.0001).	   	   Similarly,	   cells	   induced	   with	   250μM	   IPTG	   produced	   a	   statistically	  
significantly	  higher	  amount	  of	  RYR1	  compared	  with	  both	  2.5μM	  and	  25μM	  IPTG.	  	  Pre-­‐
treatment	  with	  1mM	  AICAR	  overnight	  had	  no	  affect	  on	  RYR1	  expression	  in	  transfected	  




Figure	  6.13	  –	  Relative	  quantity	  of	  RYR1	  when	  pTUNERYR1	  constructs	  are	  pooled	  into	  their	  respective	  IPTG	  
concentrations.	  
The	  data	  obtained	  from	  the	  western	  blots	  on	  all	  pTUNERYR1	  constructs	  were	  pooled	  according	  to	  the	  
concentration	  of	  ITPG	  used	  to	  induce	  expression.	  	  25μM	  IPTG	  was	  used	  as	  the	  band	  for	  relative	  quantification	  of	  
the	  2.5μM	  and	  250μM	  IPTG	  inductions.	  	  Cells	  induced	  with	  2.5μM	  IPTG	  produced	  a	  statistically	  significantly	  lower	  
amount	  of	  RYR1	  in	  comparison	  to	  both	  25μM	  and	  250μM	  IPTG	  (p<0.0001).	  Cells	  induced	  with	  250μM	  IPTG	  
produced	  a	  statistically	  significantly	  higher	  amount	  of	  RYR1	  in	  comparison	  to	  both	  2.5μM	  and	  25μM	  IPTG.	  	  Data	  
points	  are	  presented	  as	  the	  mean	  plus	  or	  minus	  the	  standard	  error	  of	  the	  mean.	  ****p<0.0001.	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Figure	  6.14	  –	  Western	  blot	  analysis	  of	  HEK293	  cells	  transiently	  transfected	  with	  pTUNERYR1	  constructs	  and	  
exposed	  to	  AICAR.	  
Representative	  western	  blot	  image	  of	  HEK293	  cells	  transiently	  transfected	  with	  pTUNERYR1,	  induced	  with	  25μM	  
IPTG	  and	  incubated	  with	  1mM	  AICAR	  overnight.	  	  Proteins	  were	  run	  on	  a	  8%	  polyacrylamide	  gel	  and	  blotted	  
overnight	  onto	  a	  PVDF	  membrane.	  	  The	  membrane	  was	  probed	  for	  RYR1	  (upper	  panel)	  and	  alpha	  tubulin	  (lower	  
panel)	  using	  monoclonal	  antibodies.	  	  RYR1	  expression	  was	  not	  affected	  by	  the	  overnight	  incubation	  with	  1mM	  
AICAR.	  	  Additionally,	  the	  presence	  of	  1mM	  AICAR	  had	  no	  affect	  on	  untransfected	  cells.	  
	  
	  
6.3.9	  Comparison	  of	  wild	  type	  RYR1	  in	  pcDNA	  and	  pTUNE	  expression	  vectors	  	  
All	   of	   the	   dose	   response	   experiments	   that	   involved	   wild	   type	   RYR1	   were	   plotted	  
together	   to	   examine	   any	   differences	   between	   the	   different	   wild	   type	   constructs	  
(Figure	  6.15).	   	  No	  statistically	  significant	  difference	  was	  observed	  between	  any	  of	  the	  
wild	  type	  constructs	  under	   investigation	   in	  this	  project	   (HEK293	  cells	  both	  stably	  and	  
transiently	   transfected	   with	   wild	   type	   pcRYR1,	   HEK293	   cells	   transiently	   transfected	  
with	   wild	   type	   pTUNERYR1	   and	   HEK293	   cells	   transiently	   transfected	   with	   wild	   type	  
pTUNERYR1	  induced	  to	  differing	  levels	  of	  expression.	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Figure	  6.15	  –	  A	  comparison	  of	  all	  wild	  type	  RYR1	  constructs	  and	  conditions	  used	  in	  this	  thesis.	  	  	  
(A)	  Dose	  response	  curve	  for	  all	  the	  wild	  type	  constructs	  and	  conditions	  used.	  	  	  	  The	  EC50	  of	  the	  various	  wild	  types	  
ranged	  from	  3.05mM	  to	  4.328mM.	  	  Data	  points	  are	  the	  mean	  plus	  and	  minus	  the	  standard	  error	  of	  the	  mean.	  	  (B)	  
Box	  plots	  showing	  the	  EC50	  of	  all	  wild	  type	  constructs	  used	  in	  this	  thesis.	  	  No	  statistically	  significantly	  different	  
response	  was	  seen	  between	  any	  wild	  type	  used.	  	  Box	  plots	  are	  shown	  as	  the	  median,	  the	  upper	  and	  lower	  
quartiles	  and	  the	  maximum	  and	  minimum	  data	  points.	  
	  
6.4	  Discussion	  
One	  of	  the	  primary	  goals	  of	  this	  chapter	  was	  to	  functionally	  assess	  the	  consequences	  
of	  three	  genetic	  variants	   in	  the	  RYR1	  gene	  that	  have	  been	  associated	  with	  MH.	   	  One	  
variant,	  the	  p.D1056H	  was	  selected	  for	  study	  based	  on	  the	  occurrence	  of	  the	  mutation	  
in	  an	  individual	  who	  had	  suffered	  an	  EHS	  reaction	  but	  upon	  MH	  testing	  proved	  to	  have	  
a	  normal	  IVCT	  response.	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Additionally,	  the	  use	  of	  the	  pTUNE	  inducible	  expression	  vector	  allowed	  us	  to	  carry	  out	  
experiments	  examining	  the	  effect	  of	  an	  increase	  or	  decrease	  in	  wild	  type	  and	  mutant	  
RYR1	  expression	  on	  the	  sensitivity	  of	  transfected	  cells	  to	  caffeine.	  	  This	  follows	  on	  from	  
an	  accumulation	  of	  recent	  data	  suggesting	  that	  the	  expression	  level	  of	  RYR1	  may	  play	  a	  
role	  in	  the	  variability	  of	  MH	  responses	  seen	  in	  the	  population.	  
Finally,	   in	   this	   chapter,	   the	   effect	   of	   AICAR	   on	   the	   sensitivity	   of	   transfected	   cells	   to	  
caffeine	  was	  also	   investigated.	   	  AICAR	  has	  recently	  become	  a	  potential	  candidate	   for	  
the	  prophylactic	  treatment	  of	  EHS	  and	  has	  been	  proven	  to	  play	  a	  role	  in	  the	  reduction	  
of	   baseline	   resting	   calcium	   levels	   that	   has	   previously	   been	   implicated	   as	   a	   large	  
contributor	  to	  the	  MH	  response.	  
	  
6.4.1	  p.D1056H	  
The	  p.D1056H	  RYR1	  variant	  has	  been	  associated	  with	  both	  MH	  and	  EHS.	  	  Interestingly,	  
the	  patient	  who	  suffered	  an	  EHS	  reaction	  was	  tested	  for	  MH	  and	  diagnosed	  as	  MHN.	  	  
However,	   in	   the	  HEK293	   cell	   system	  established	   in	   this	   thesis,	   the	  p.D1056H	   variant	  
responds	   in	  a	   typically	  MH	   fashion.	   	  The	  EC50	  of	   cells	   transfected	  with	   the	  p.D1056H	  
variant	  and	  induced	  at	  a	   level	  of	  25µM	  IPTG	  was	  1.834mM	  compared	  with	  3.804mM	  
for	  wild	   type	  transfected	  cells	   (p=0.0191).	   	  At	  2mM	  and	  4mM	  caffeine,	   the	  response	  
generated	  from	  p.D1056H	  transfected	  cells	  as	  a	  percentage	  of	  the	  maximum	  response	  
was	  statistically	  significantly	  higher	  than	  the	  equivalent	  wild	  type	  response	  (p=0.0471	  
and	   p=0.0498	   respectively).	   	   Additionally,	   the	   amount	   of	   calcium	   released	   at	   both	  
1mM	   and	   2mM	   caffeine	   was	   statistically	   significantly	   higher	   than	   the	   wild	   type	  
response.	   	   The	   above	   data	   is	   indicative	   of	   a	   causative	  MH	   variant	   and	   it	   appears	   as	  
though	  it	  should	  be	  added	  to	  the	  genetic	  diagnostic	  panel	  for	  MH.	  	   It	   is	  possible	  that	  
there	  is	  an	  additional	  genetic	  variant	  within	  the	  EHS	  patient	  either	  preventing	  the	  full	  
MH	  phenotype	  becoming	  apparent	  or	  driving	   the	  phenotype	  down	  a	  specifically	  EHS	  
route.	  	  The	  RYR1	  variant	  was	  identified	  through	  exome	  sequencing,	  the	  full	  results	  of	  
any	   potential	   additional	   genetic	   variants	   that	   may	   be	   responsible	   for	   the	   EHS	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phenotype	   are	   still	   pending	   but	   may	   contribute	   to	   further	   understanding	   the	  
differences	   between	   EHS	   and	   MH.	   	   A	   further	   possibility	   is	   that	   the	   MH	   family	  
containing	   this	   variant	   may	   have	   an	   additional	   genetic	   variant	   that	   pushes	   the	  
phenotype	   towards	   full	   MH	   however,	   due	   to	   the	   fact	   that	   on	   a	   defined	   genetic	  
background,	   the	   p.D1056H	   variant	   produces	   a	   distinct	   MH	   phenotype	   this	   seems	  
unlikely.	   	  When	   the	   expression	   level	   of	   p.D1056H	   RYR1	  was	   increased	   or	   decreased	  
compared	  with	  the	  initial	  experiments,	  no	  differences	  were	  observed	  in	  either	  the	  EC50	  
or	   the	   amount	   of	   calcium	   released,	   ruling	   out	   differential	   expression	   as	   a	   potential	  
cause	  in	  the	  variability	  observed	  in	  EHS	  and	  MH	  phenotypic	  presentation.	  
	  
6.4.2	  p.R2355W	  
Cells	   transfected	   with	   the	   p.R2355W	   RYR1	   variant	   and	   induced	   with	   25µM	   IPTG	  
produced	  a	   typical	  MH	  phenotype.	   	  The	  EC50	  of	  cells	   transfected	  with	   the	  p.R2355W	  
variant	   was	   1.378mM	   compared	   with	   3.804mM	   for	   wild	   type	   transfected	   cells	  
(p=0.047).	   	   At	   2mM	   caffeine,	   the	   response	   produced	   by	   the	   p.R2355W	   transfected	  
cells	   was	   statistically	   significantly	   higher	   as	   a	   percentage	   of	   the	  maximum	   response	  
than	  wild	  type	  transfected	  cells.	  	  Furthermore,	  the	  amount	  of	  calcium	  released	  at	  1mM	  
and	  2mM	  caffeine	  was	   statistically	   significantly	   higher	   than	   the	  equivalent	  wild	   type	  
response.	   Based	   on	   this	   data,	   it	   is	   clear	   that	   the	   p.R2355W	   variant	   is	   the	   causative	  
factor	  of	  MH	  in	  the	  14	  families	   it	  has	  been	  identified	   in.	   	  Data	  previously	  obtained	  in	  
primary	  cells	  isolated	  from	  muscle	  biopsy	  specimens	  carrying	  this	  variant	  had	  strongly	  
hinted	  that	  this	  variant	  was	  causative	  of	  MH	  but	  failed	  to	  place	  the	  p.R2355W	  variant	  
onto	   the	   genetic	   diagnostic	   panel	   for	  MH	   because	   cells	   from	   only	   one	   family	   were	  
available	   for	   testing	   (Wehner	   et	   al.,	   2004).	   	   Cells	   isolated	   from	  patients	   carrying	   the	  
mutation	   displayed	   an	   increased	   sensitivity	   to	   caffeine,	   halothane	   and	   4-­‐CmC	   but	  
without	   a	   second	   family	   to	   test	   this	  was	   insufficient	   for	   the	   inclusion	   of	   this	   variant	  
onto	  the	  genetic	  diagnostic	  panel.	   	  No	  such	  problems	  exist	  for	  the	  work	  presented	  in	  
this	  chapter	  due	  to	  the	  use	  of	  a	  recombinant	  system	  on	  a	  defined	  genetic	  background	  
	   192	  
and	  therefore,	  the	  work	  presented	  meets	  the	  EMHG	  criteria	  for	  adding	  the	  p.R2355W	  
variant	  to	  the	  genetic	  diagnostic	  panel	   for	  MH.	   	  Cells	  transfected	  with	  the	  p.R2355W	  
variant	  displayed	  no	  difference	  when	   induced	  to	  a	  higher	  expression	   level	  with	   IPTG,	  
however,	   when	   induced	   with	   a	   smaller	   concentration	   of	   IPTG,	   the	   EC50	   reached	   a	  
statistically	  significantly	  higher	  level	  which	  was	  in	  line	  with	  the	  wild	  type	  responses	  at	  
all	   IPTG	  concentrations.	   	  The	  reason	   for	   this	   is	  unclear	  but	  may	  be	  supportive	  of	   the	  
hypothesis	  put	  forward	  by	  Grievink	  and	  Stowell	  (2010).	  	  If	  a	  decrease	  in	  the	  p.R2355W	  
variant	  can	  cause	  the	  sensitivity	  of	  the	  cells	  expressing	  it	  to	  decrease,	  then	  an	  increase	  
in	  wild	   type	   expression	   as	   a	   compensatory	  mechanism	  may	  provide	   a	   similar	   effect.	  	  
Such	  an	  effect	  would	  result	  in	  variability	  seen	  between	  patients	  carrying	  the	  p.R2355W	  
variant	  based	  on	  the	  expression	  level	  of	  each	  allele.	  
	  
6.4.3	  p.D3986E	  
The	  data	  obtained	   from	  cells	   transfected	  with	   the	  p.D3986E	  pTUNERYR1	   variant	  and	  
induced	  with	  25µM	   IPTG	   is	   consistent	  with	   the	  data	  obtained	   in	  chapter	  4	  using	   the	  
pcRYR1	  construct.	  	  The	  EC50	  of	  cells	  transfected	  with	  the	  p.D3986E	  variant	  was	  similar	  
to	   data	   obtained	   from	   wild	   type	   transfected	   cells.	   	   The	   p.D3986E	   had	   an	   EC50	   of	  
4.667mM	   compared	   with	   3.804mM	   for	   wild	   type	   transfected	   cells	   (p=0.6901).	   	   At	  
every	   caffeine	   concentration	   used	   in	   these	   experiments,	   the	   amount	   of	   calcium	  
released	   from	   p.D3986E	   transfected	   cells	   was	   not	   statistically	   significantly	   different	  
from	  wild	  type	  transfected	  cells.	  	  	  
Unlike	  the	  data	  obtained	  in	  chapter	  4,	  cells	  transfected	  with	  the	  p.D3986E	  pTUNERYR1	  
construct	   did	   not	   produce	   a	   significantly	   different	   response	   as	   a	   percentage	   of	   the	  
maximum	   when	   compared	   to	   wild	   type.	   	   HEK293	   cells	   stably	   transfected	   with	   the	  
p.D3986E	   pcRYR1	   construct	   had	   displayed	   a	   significantly	   different	   increase	   in	   the	  
response	  as	  a	  percentage	  of	  the	  maximum	  response	  at	  both	  1mM	  and	  2mM	  caffeine	  
(p=0.046	   and	   p=0.0033	   respectively)	   compared	   to	   wild	   type	   transfected	   cells.	   	   This	  
increase	  in	  response	  at	  1mM	  and	  2mM	  caffeine	  resulted	  in	  the	  EC25	  of	  cells	  transfected	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with	  the	  p.D3986E	  variant	   to	  be	  dramatically	   reduced	  and	  the	  EC10	   to	  be	  statistically	  
significantly	   reduced.	   	   This	   was	   not	   the	   case	   in	   cells	   transfected	  with	   the	   p.D3986E	  
pTUNERYR1	  construct.	  	  Both	  the	  EC10	  (2.502mM)	  and	  EC25	  (4.297mM)	  were	  similar	  to	  
cells	  transfected	  with	  the	  wild	  type	  pTUNERYR1	  construct	  (EC10	  =	  2.769mM;	  p=	  0.7849	  
and	  EC25	   =	   3.441mM;	  p=0.5126).	   	   The	   reason	   for	   the	  difference	   in	   EC10	   and	  EC25	   for	  
cells	   transfected	  with	  either	   the	  pcRYR1	  or	   the	  pTUNERYR1	   construct	   is	  not	  clear.	   	   It	  
may	   be	   due	   to	   differences	   generated	   in	   the	   cellular	   environment	   caused	   by	   stable	  
expression	   of	   the	   mutant	   RYR1	   gene.	   	   Evidence	   suggests	   that	   the	   MH	   response	   is	  
exacerbated	  by	  a	  chronic	   increase	   in	  basal	   resting	  calcium	   levels.	   	  A	  HEK293	  cell	   line	  
stably	  expressing	  a	  RYR1	  variant	  may	  have	  an	   increased	   resting	   calcium	   level	  due	   to	  
the	  prolonged	  expression	  over	  time.	  
A	  decrease	  in	  expression	  level	  for	  cells	  transfected	  with	  the	  p.D3986E	  variant	  had	  no	  
effect	   on	   the	   cells’	   sensitivity	   to	   caffeine.	   	   However,	   an	   increase	   in	   induction	   of	  
expression	   level	   resulted	   in	   a	   statistically	   significant	   decrease	   in	   EC50.	   	   Interestingly,	  
this	  decrease	   in	  EC50	  brought	   it	   in	   line	  with	  that	  of	  clear	  causative	  MH	  variants.	   	  The	  
data	   obtained	   from	   these	   experiments	   may,	   at	   least	   in	   part,	   explain	   how	   patients	  
carrying	   the	   p.D3986E	   variant	   can	   still	   be	   MHS	   despite	   the	   variant	   appearing	   to	  
produce	   a	   wild	   type	   phenotype	   in	   HEK293	   cells	   as	   well	   as	   further	   support	   the	  
suggestion	  that	  expression	   levels	  of	  specific	  alleles	  of	  RYR1	   can	  result	   in	   the	  variable	  
responses	  seen	  in	  patients.	  
	  
6.4.5	  The	  effect	  of	  AICAR	  on	  the	  sensitivity	  of	  RYR1	  channels	  
Recently,	  AICAR,	  was	  found	  to	  be	  fully	  protective	  of	  the	  heat-­‐induced	  EHS	  phenotype	  
seen	  in	  MH	  mice	  (Lanner	  et	  al.,	  2012).	  The	  protective	  effect	  observed	  was	  attributed	  to	  
a	  decrease	   in	   the	   resting	  calcium	   level	   in	   the	   skeletal	  muscle	   fibres	  of	   the	  MH	  mice.	  	  
AICAR	   was,	   however,	   seen	   to	   have	   no	   effect	   on	   the	   anaesthesia-­‐induced	   MH	  
phenotype	   in	   the	  RYR1	  mutant	  mice.	   	   In	   Lanner	   et	   al.	   (2012),	   no	   experiments	  were	  
carried	   out	   to	   examine	   the	   effect	   of	   AICAR	   on	   the	   sensitivity	   of	   the	   mutant	   RYR1	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channels.	   	   In	   this	  project,	  HEK293	  cells	  were	   transfected	  with	  pTUNERYR1	   constructs	  
and	  induced	  with	  25µM	  IPTG.	  	  Cells	  were	  incubated	  with	  1mM	  AICAR	  overnight,	  prior	  
to	   caffeine-­‐induced	  calcium	  release	  experiments.	   	  AICAR	  appeared	   to	  have	  no	  effect	  
on	   cells	   transfected	  with	   the	  wild	   type	   pTUNERYR1	   construct,	   as	   the	   EC50	   remained	  
statistically	   unchanged.	   	   However,	   for	   all	   the	   mutant	   pTUNERYR1	   constructs,	   a	  
statistically	  significant	  increase	  in	  EC50	  was	  observed.	  	  AICAR	  has	  been	  found	  to	  protect	  
against	  EHS	  so	   it	   is	  perhaps	  not	  surprising	  that	  the	  most	  dramatic	  effect	  was	  seen	   in	  
cells	   transfected	  with	   the	  p.D1056H	  variant,	  which	  has	  been	   implicated	   in	  EHS.	   	   The	  
EC50	   of	   cells	   transfected	   with	   p.D1056H	   increased	   from	   1.872mM	   to	   8.684mM.	   A	  
milder,	   yet	   still	   substantial	   response	   was	   observed	   in	   cells	   transfected	   with	   the	  
p.R2355W	   variant.	   	   The	   EC50	   of	   these	   cells	   increased	   from	   1.34mM	   to	   4.516mM,	   a	  
value	  very	  similar	   to	  wild	   type	   transfected	  cells.	   	   	   Interestingly,	  Wehner	  et	  al.	   (2004)	  
reported	   that	   this	   variant	  did	  not	  have	   a	   resting	   calcium	   level	   higher	   than	  wild	   type	  
when	  primary	  cells	  were	  tested.	  	  Although	  this	  apparently	  normal	  resting	  calcium	  level	  
may	   have	   been	   observed	   due	   to	   the	   measurement	   method	   employed,	   the	   result	  
obtained	   by	   Wehner	   et	   al.	   (2004)	   may	   help	   explain	   why	   the	   p.R2355W	   variant	  
responded	  in	  a	  slightly	  milder	  manner	  to	  the	  other	  variants	  under	  investigation	  in	  this	  
project.	   	  Although	  wild	  type	  transfected	  cells	  appeared	  to	  have	  no	  response,	  viability	  
experiments	  were	  carried	  out	  to	  show	  that	  IPTG	  and	  AICAR	  were	  not	  killing	  the	  cells,	  
resulting	   in	   the	  decrease	   in	   sensitivity	  observed.	   	  Furthermore,	  western	  blot	  analysis	  
showed	  that	  the	  level	  of	  expression	  of	  RYR1	  was	  not	  affected	  by	  AICAR.	  
Perhaps	   most	   surprising	   was	   the	   result	   obtained	   from	   cells	   transfected	   with	   the	  
p.D3986E	   variant.	   	   The	   addition	   of	   AICAR	   to	   cells	   still	   resulted	   in	   a	   statistically	  
significant	   increase	   in	   EC50	   from	   4.667mM	   to	   9.961mM	   even	   though	   the	   initial	  
experiments	   indicated	   that	   this	   variant	   responded	   in	   a	   similar	   way	   to	   wild	   type	  
transfected	   cells.	   	   This	   result,	   combined	   with	   the	   data	   obtained	   from	   an	  
overexpression	  of	  the	  p.D3986E	  variant	  through	  induction	  with	  250µM	  IPTG	  suggests	  
that	  the	  p.D3986E	  variant	  may	  have	  a	  more	  complicated	  role	  in	  MH	  pathogenesis	  than	  
was	  first	  suspected	  from	  the	  initial	  experiments.	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One	  possibility	  is	  that,	  although	  the	  p.D3986E	  possesses	  a	  seemingly	  mild	  sensitivity	  to	  
caffeine	  when	  compared	  to	  other	  MH	  variants,	  the	  resting	  calcium	  of	  cells	  expressing	  
this	  variant	  is	  still	  elevated.	  	  This	  theory	  is	  supported	  by	  data	  obtained	  from	  the	  Perez	  
laboratory	   that	  has	  hinted	   that	   the	   region	   that	   the	  p.D3986E	  variant	   sits	   in	   is	   highly	  
relevant	  to	  the	  maintenance	  of	  normal	  resting	  calcium.	  	  Previous	  data	  published	  by	  the	  
same	  group	  has	   shown	   that	   an	   increase	   in	  RYR3	   expression	   results	   in	   an	   increase	   in	  
resting	   calcium	   whereas	   as	   RYR1	   expression	   increases,	   the	   resting	   calcium	   remains	  
constant	   (Perez	  et	  al.,	  2005).	   	  Subsequent	  experiments	  using	  chimeric	  channels,	  with	  
sections	   of	   RYR3	   inserted	   into	   the	   RYR1	   coding	   sequence,	   identified	   a	   region	  
containing	  the	  3986	  residue	  as	  key	  for	  maintaining	  the	  resting	  calcium.	  	  	  
A	   mutation	   in	   this	   region	   could	   feasibly	   cause	   RYR1	   to	   start	   behaving	   in	   a	   similar	  
fashion	  to	  RYR3,	  resulting	  in	  elevated	  resting	  calcium.	  	  This	  is	  further	  supported	  by	  the	  
data	  obtained	   in	  this	  chapter	  regarding	  the	  expression	   level	  of	   the	  p.D3986E	  variant.	  	  
Only	   the	   p.D3986E	   variant	   produced	   an	   increased	   sensitivity	   to	   caffeine	   as	   the	  
expression	  level	   increased,	  which	  is	  analogous	  to	  the	  data	  obtained	  from	  the	  original	  
Perez	  study	  on	  RYR3.	  	  An	  increase	  in	  the	  expression	  of	  this	  variant	  may	  be	  causing	  the	  
resting	  calcium	  level	  to	  increase	  therefore	  predisposing	  the	  cells	  to	  be	  more	  sensitive	  
to	  caffeine.	  	  Previous	  studies	  have	  hinted	  that	  if	  the	  resting	  calcium	  level	  is	  corrected	  
then	  sensitivity	   to	  channel	  agonists	   such	  as	  caffeine	  are	   reduced	  also.	   	  By	   increasing	  
the	   resting	   calcium	   level	   through	   overexpression,	   the	   p.D3986E	   variant	   may	   be	  
predisposing	  the	  cells	  to	  respond	  in	  an	  ‘MH	  positive’	  manner	  meaning	  that	  this	  variant	  
may	  yet	  be	  the	  cause	  of	  MH	  in	  the	  families	  it	  has	  been	  identified	  in.	  Data	  obtained	  in	  
this	   chapter	   shows	   that	   an	   increase	   in	   expression	   level	   of	   all	   constructs	   under	  
investigation	  did	  not	  result	  in	  a	  significant	  increase	  in	  calcium	  release	  meaning	  that	  the	  
increase	   in	   sensitivity	   of	   the	   p.D3986E	   variant	   is	   being	   achieved	   through	   a	   different	  
mechanism,	  possibly	  an	  elevated	  resting	  calcium	  level.	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6.4.6	  Wild	  types	  and	  p.D3986E	  in	  pcRYR1	  and	  pTUNERYR1.	  
With	   the	   addition	   of	   the	   data	   obtained	   from	   all	   induction	   levels	   of	   wild	   type	  
pTUNERYR1	   transfected	  cells,	  a	   total	  of	   five	  different	  experiments	  have	  been	  carried	  
out	  using	  a	  wild	  type	  RYR1	  construct.	  	  The	  data	  obtained	  for	  all	  of	  these	  experiments	  
was	  plotted	  together	  in	  this	  chapter	  and	  no	  significant	  differences	  were	  observed.	  	  This	  
data	   confirms	   the	   reproducibility	   of	   these	   experiments	   regardless	   of	   the	   expression	  
vector	   that	   wild	   type	   RYR1	   is	   in	   or	   the	   level	   of	   expression	   produced	   in	   the	   cells.	  	  
Coupled	   with	   the	   fact	   that	   the	   data	   obtained	   on	   the	   p.D3986E	   variant	   in	   the	  
pTUNERYR1	   construct	   (at	   a	   standard	   25µM	   IPTG	   induction	   level)	   was	   also	   not	  
statistically	   significantly	   different	   from	   that	   obtained	   in	   the	   pcRYR1	   experiments	  
suggests	   that	   the	   systems	   utilised	   in	   this	   thesis	   is	   robust	   and	   reliable.	   	   However,	   as	  
demonstrated	  through	  the	  results	  obtained	  in	  cells	  expressing	  p.R2355W	  at	  a	  low	  level	  
and	   p.D3986E	   at	   a	   high	   level,	   it	   is	   important	   to	   follow	   up	   such	   experiments	   with	  
expression	  analysis	  through	  western	  blotting.	  
	  
6.5	  Future	  work	  
The	   work	   presented	   above	   represents	   a	   first	   step	   into	   examining	   the	   effect	   of	   the	  
expression	  level	  of	  wild	  type	  and	  mutant	  RYR1	  on	  the	  sensitivity	  to	  caffeine	  in	  HEK293	  
cells.	  	  Three	  RYR1	  variants	  have	  been	  studied	  in	  this	  chapter	  and	  the	  obvious	  next	  step	  
is	  to	  expand	  this	  to	  as	  many	  RYR1	  variants	  as	  possible	  to	  get	  a	  better	  understanding	  of	  
the	   role	  of	   the	  expression	   level	   of	  RYR1	   in	  MH	  pathogenesis.	   	   The	  p.D3986E	   variant	  
was	   the	   only	   mutation	   that	   showed	   an	   increase	   in	   sensitivity	   to	   caffeine	   as	   the	  
expression	  level	  increased.	  An	  obvious	  next	  step	  for	  this	  work	  would	  be	  to	  examine	  the	  
expression	  level	  of	  the	  p.D3986E	  allele	  in	  the	  patients	  it	  has	  been	  identified	  in.	  	  Allele-­‐
specific	  PCR	  has	  previously	  been	  used	  to	  assess	  the	  expression	  level	  of	  each	  RYR1	  allele	  
and	   the	   same	   could	   be	   done	   with	   this	   variant	   (Grievink	   and	   Stowell,	   2010).	   	   As	  
explained	  above,	  the	  resting	  calcium	  level	  of	  this	  variant	  is	  of	  particular	  interest	  to	  us	  
due	  to	  the	  proximity	  of	  this	  variant	  to	  an	  identified	  region	  of	  RYR1	  implicated	  in	  resting	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calcium	  levels	  combined	  with	  the	  data	  outlined	  above.	  	  It	  would	  be	  of	  interest	  to	  see	  if	  
all	   MH-­‐associated	   variants	   within	   this	   region	   also	   cause	   the	   sensitivity	   of	   RYR1	   to	  
increase,	   including	   the	  p.G3990V	   variant	   for	  which	   functional	   data	  was	  presented	   in	  
chapter	   4.	   	   	   Future	   work	   using	   the	   pTUNE	   inducible	   vector	   could	   also	   focus	   on	  
measuring	   the	   resting	   intracellular	  calcium	   level	  of	  all	   variants	  under	   investigation	   in	  
this	   thesis	   to	   allow	   us	   to	   get	   a	   clearer	   picture	   of	   the	   role	   of	   resting	   calcium	   in	  MH	  
pathogenesis.	  	  Of	  particular	  interest	  would	  be	  the	  results	  of	  cells	  expressing	  p.R2355W	  
at	  high	  and	  low	  levels	  to	  examine	  whether	  this	  is	  the	  reason	  for	  the	  reduced	  sensitivity	  
to	  caffeine.	  
The	  measurement	  of	  resting	  calcium	  levels	  in	  HEK293	  cells	  is	  difficult	  to	  ascertain	  and	  
conflicting	   results	   are	  present	   in	   the	   literature	   regarding	   the	   resting	   calcium	   level	   of	  
the	   same	  MH	  variants	  depending	  on	  whether	   they	   are	  expressed	   in	  HEK293	   cells	   or	  
muscle	  cells	  (Tong	  et	  al.,	  1999b,	  Lopez	  et	  al.,	  2005).	  	  Also,	  an	  assumption	  was	  made	  in	  
this	  chapter	  that	  AICAR	  is	  still	  acting	  on	  HEK293	  cells	  in	  the	  same	  way	  observed	  in	  the	  
Lanner	   et	   al.	   (2012)	   study.	   Experiments	   measuring	   resting	   calcium	   levels	   should	   be	  
performed	   with	   and	   without	   AICAR	   treatment	   to	   confirm	   this	   assumption.	   	   Ideally,	  
these	   variants	   should	   be	   transferred	   to	   the	  pHSVPrPUC	  expression	   vector,	   packaged	  
into	   HSV-­‐1	   virions	   and	   expressed	   in	   dyspedic	   myotubes	   to	   obtain	   a	   more	   accurate	  
resting	  calcium	  level.	  
	  
6.6	  Conclusions	  
Based	  on	  the	  data	  presented	  in	  this	  chapter,	  the	  p.D1056H	  and	  p.R2355W	  variant	  can	  
be	  added	  to	  the	  genetic	  diagnostic	  panel	  for	  MH.	  	  The	  p.R2355W	  variant	  has	  long	  been	  
suggested	   as	   causative	   of	   MH	   as	   it	   has	   been	   found	   in	   association	   with	   the	   MHS	  
phenotype	  in	  7	  families	  in	  the	  UK	  and	  a	  total	  of	  9	  families	  worldwide.	  	  The	  functional	  
data	   presented	   in	   this	   chapter	   supports	   work	   already	   carried	   out	   by	  Wehner	   et	   al.	  
(2004)	  and	  confirms	  its	  functional	  role	  in	  MH.	  	  	  The	  p.D1056H	  variant	  has	  what	  appears	  
to	   be	   a	   more	   complicated	   role	   in	   MH.	   	   The	   functional	   data	   presented	   above	   is	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supportive	  of	  the	  variant	  being	  added	  to	  the	  genetic	  diagnostic	  panel	  for	  MH	  and	  the	  
variant	   is	   almost	   certainly	   the	   cause	   of	   MH	   in	   the	   family	   it	   has	   been	   identified	   in.	  	  
However,	  the	  presence	  of	  this	  variant	  in	  an	  individual	  who	  suffered	  an	  EHS	  reaction	  yet	  
was	   diagnosed	   as	   MHN	   highlights	   the	   complicated	   genetic	   nature	   of	   MH	   and	  
strengthens	  the	  link	  between	  RYR1	  variants	  and	  EHS.	  
The	   work	   presented	   in	   this	   chapter	   also	   supports	   the	   growing	   body	   of	   evidence	   to	  
suggest	  that	  the	  expression	  level	  of	  RYR1,	  at	  least	  in	  part,	  contributes	  to	  the	  variability	  
seen	  in	  the	  MH	  experience	  of	  susceptible	  patients.	  	  Variations	  in	  the	  expression	  of	  the	  
p.R2355W	  and	  p.D3986E	  variants	  were	  shown	  to	  alter	  the	  EC50	  of	  	  transfected	  HEK293	  
cells	  when	  exposed	  to	  caffeine.	  	  Reduced	  expression	  of	  the	  p.R2355W	  variant	  resulted	  
in	   an	   EC50	   that	   decreased	   from	  an	   ‘MH-­‐like’	   range	   to	   one	   that	  was	   indistinguishable	  
from	  the	  wild	  type	  response.	  	  Conversely,	  the	  p.D3986E	  variant	  had	  been	  responding	  
in	  a	  wild	   type	  manner	  until	   the	  expression	   level	  was	   increased.	   	   This	   resulted	   in	   the	  
sensitivity	   of	   transfected	   cells	   to	   caffeine	   to	   increase	   as	   seen	   by	   the	   significant	  
decrease	  in	  EC50.	  
The	  work	  presented	  also	  adds	  to	  recent	  work	  on	  the	  role	  of	  AICAR	  on	  the	  sensitivity	  of	  
mutant	  RYR1	  channels.	  	  AICAR	  caused	  a	  significant	  decrease	  in	  caffeine	  sensitivity	  for	  
all	  variants	  under	   investigation	   in	  this	  chapter.	   	  The	  effect	  of	  AICAR	  on	  the	  p.D3986E	  
was	  perhaps	  the	  most	  surprising	  given	  the	  fact	   that	   it	  had	  previously	  responded	   in	  a	  
wild	   type	   manner.	   	   AICAR	   works	   by	   reducing	   calcium	   leak	   from	   mutant	   channels,	  
hinting	  that	  the	  resting	  calcium	  level	  of	  patients	  carrying	  the	  p.D3986E	  variant	  may	  still	  
be	  elevated	  and	  contributing	  to	  the	  MH	  phenotype.	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Chapter	  Seven -­‐	  Final	  discussion	  
7.1	  Introduction	  
Since	  the	  introduction	  of	  the	  EMHG	  guidelines	  for	  the	  inclusion	  of	  variants	  in	  the	  RYR1	  
gene	  onto	  a	  genetic	  diagnostic	  panel	  for	  MH,	  one	  of	  the	  main	  focuses	  of	  research	  has	  
been	  the	  functional	  analysis	  of	  the	  variants	  found	  in	  patients.	  	  In	  over	  ten	  years,	  only	  
31	  variants	  have	  met	  the	  criteria	  set	  out	  in	  the	  guidelines	  (Urwyler	  et	  al.,	  2001).	  	  One	  
of	  the	  primary	  reasons	  for	  this	  are	  the	  difficulties	  associated	  with	  cloning,	  subcloning,	  
performing	  mutagenesis	  and	  expressing	   large	  genes	   in	  vitro.	   	   In	   this	   thesis,	  a	  cloning	  
strategy	   was	   employed	   that	   resulted	   in	   the	   creation	   of	   two	   subclones	   of	   RYR1	  
containing	   the	  entire	   coding	   sequence	  between	   them.	   	   Furthermore,	   a	  protocol	  was	  
developed	   for	   the	   efficient	   mutagenesis	   of	   these	   subclones	   meaning	   that	   only	   one	  
subcloning	   step	   is	   required	   for	   the	   creation	   of	   full-­‐length	   mutant	   RYR1	   constructs	  
when	  previously,	   subclones	  as	   small	  as	  4,500bp	  have	  been	  required	   for	  mutagenesis	  
(Tong	  et	  al.,	  1997).	  	  A	  total	  of	  seven	  variants	  were	  generated	  and	  expressed	  in	  HEK293	  
cells,	   six	   of	  which	  were	   proven	   to	   be	   causative	   of	  MH.	   	  One	   variant,	   p.D3986E,	  was	  
found	   to	   be	   indistinguishable	   from	  wild	   type	  RYR1.	   	   However,	   when	   the	   expression	  
level	  of	  this	  variant	  increased,	  so	  did	  the	  caffeine	  sensitivity	  of	  transfected	  cells	  hinting	  
at	  a	  more	  complicated	  role	  in	  MH	  pathogenesis	  than	  was	  first	  apparent.	  	  Finally,	  in	  this	  
thesis,	   functional	   analysis	   of	   an	  RYR1	   variant	   associated	  with	  both	  MH	  and	  EHS	  was	  
performed.	   	   This	   variant,	   p.D1056H,	   was	   identified	   through	   exome	   sequencing	   of	  
patients	   in	   which	   no	   variant	   had	   previously	   been	   identified	   and	   was	   subsequently	  
identified	   in	  an	  EHS	  patient	  who	  had	  tested	  negative	   for	  MH.	   	  The	  p.D1056H	  variant	  
responded	  in	  the	  same	  way	  as	  other	  MH	  variants	  did	  to	  caffeine	  stimulation	  indicating	  
its	  role	  as	  the	  causative	  genetic	  variant	  of	  MH	  in	  the	  family	  in	  which	  it	  was	  identified.	  	  
The	   reason	  behind	   the	  MHN	  diagnosis	  upon	   testing	  with	   the	   IVCT	   is	  unclear	  but	   the	  
results	  generated	  in	  this	  thesis	  highlight	  the	  link	  between	  the	  two	  conditions	  and	  the	  
importance	  of	  referring	  EHS	  patients	  for	  MH	  testing.	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7.1.1	  Cloning	  and	  mutagenesis	  
244	  RYR1	  variants	  are	  listed	  on	  the	  EMHG	  website,	  only	  31	  of	  which	  are	  available	  for	  
use	   in	   genetic	   diagnosis	   partly	   due	   to	   the	   difficulties	   associated	   with	   manipulating	  
large	   cDNA	   constructs.	   	   In	   this	   thesis,	   MEGAWHOP	  mutagenesis	   was	   performed	   on	  
subclones	   of	   11,128bp	   and	   12,523bp	   in	   size.	   	   Although	   MEGAWHOP	   has	   been	  
previously	   used	   for	   the	   mutagenesis	   of	   large	   cDNA	   templates,	   the	   largest	   reported	  
plasmid	  successfully	  mutated	  using	  MEGAWHOP	  is	  6,000bp	  (Sato	  et	  al.,	  2010,	  Sato	  et	  
al.,	   2013).	   	   The	   ability	   to	   perform	  mutagenesis	   on	   such	   large	   plasmids	   negated	   the	  
need	   to	   produce	   further	   subclones,	   which,	   with	   the	   lack	   of	   unique	   restriction	   sites	  
within	   the	   RYR1	   coding	   sequence,	   would	   have	   been	   problematic.	   	   An	   overall	  
mutagenesis	   efficiency	   of	   52.9%,	   although	   seemingly	   low,	   is	   high	   for	   successfully	  
mutating	   large	  cDNA	  constructs.	   	  The	  production	  and	  highly	  efficient	  mutagenesis	  of	  
two	  subclones	  of	  RYR1	  that	  accounts	  for	  the	  entire	  RYR1	  coding	  sequence	  means	  that	  
future	   functional	   studies	   can	   be	   performed	   without	   the	   need	   for	   subcloning	   RYR1	  
before	  being	  able	  to	  perform	  mutagenesis.	  	  With	  so	  many	  as	  yet	  uncharacterised	  RYR1	  
variants	   found	   in	   association	   with	   MH,	   the	   development	   of	   a	   reliable	   and	   robust	  
cloning	  and	  mutagenesis	  protocol	  was	  essential.	  
	  
7.1.2	  Causative	  MH	  variants	  
In	  this	  thesis,	  the	  p.D1056H,	  p.R2336H,	  p.R2355W,	  p.E3104K,	  p.G3990V	  and	  p.V4849I	  
variants	   have	   been	   proven	   to	   be	   causative	   of	   MH	   by	   assessing	   their	   functional	  
consequences	  in	  an	  in	  vitro,	  recombinant	  expression	  system.	  	  HEK293	  cells	  transfected	  
with	  each	  of	   these	   variants	   responded	   in	   a	   typically	  MH	   fashion.	   	   They	  displayed	  an	  
increased	   sensitivity	   to	   caffeine	   as	   indicated	   by	   a	   statistically	   significant	   decrease	   in	  
EC50,	   a	   measurement	   in	   which	   the	   dose	   required	   to	   obtain	   half	   of	   the	   maximal	  
response	   is	   calculated.	   Furthermore,	   the	   mutant	   constructs	   resulted	   in	   a	   higher	  
amount	  of	  intracellular	  calcium	  release	  at	  lower	  doses	  of	  caffeine	  when	  compared	  to	  
wild	  type	  controls.	  	  It	  is	  the	  conclusion	  of	  this	  thesis	  that	  these	  variants	  can	  be	  added	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to	  the	  genetic	  diagnostic	  panel	  of	  MH,	  negating	  the	  need	  for	  the	  IVCT	  in	  patients	  found	  
to	  be	  carrying	  these	  mutations.	  
	  
7.1.3	  The	  role	  of	  the	  p.D3986E	  variant	  in	  MH	  pathogenesis	  
The	  caffeine	  sensitivity	  of	  the	  p.D3986E	  variant	  was	  no	  different	  from	  that	  of	  wild	  type	  
transfected	   cells.	   	   Furthermore,	   the	   amount	  of	   calcium	   released	  at	   low	  doses	   (1mM	  
and	   2mM)	   of	   caffeine	   was	   not	   significantly	   higher	   than	   that	   observed	   in	   wild	   type	  
expressing	  cells.	   	  Based	  purely	  on	   this	  data	   it	  would	  appear	  as	   though	   the	  p.D3986E	  
variant	   is	  not	  the	  causative	  mutation	  of	  MH	  in	  the	  four	   families	   in	  which	   it	  has	  been	  
identified.	   	  Whilst	  we	  cannot	  be	  certain	  that	  there	  is	  not	  another,	  as	  yet	  unidentified	  
variant	  in	  these	  patients	  it	  is	  important	  to	  note	  that	  as	  a	  group,	  patients	  carrying	  this	  
variant	  have	  been	  found	  to	  have	  a	  caffeine	  contracture	  that	  is	  significantly	  larger	  than	  
that	  of	  patients	  carrying	  other	  causative	  MH	  mutations	  during	  the	  IVCT	  (Carpenter	  et	  
al.,	   2009c).	   	   Patients	   carrying	   this	   variant	  have	  had	   the	  entire	  RYR1	  gene	   sequenced	  
and	  no	  additional	  variant	  was	  identified,	  however,	  there	  may	  be	  an	  additional	  variant	  
segregating	  with	  this	  mutant	  allele	  through	  linkage	  disequilibrium,	  potentially	  as	  part	  
of	  a	  ‘high	  risk’	  haplotype	  that	  is	  contributing	  to	  the	  MH	  phenotype	  as	  a	  modifier	  of	  the	  
overall	  phenotype	  (Carpenter	  et	  al.,	  2009a).	  	  	  
The	   EC10	   of	   cells	   stably	   transfected	   with	   the	   p.D3986E	   variant	   was	   statistically	  
significantly	  higher	  than	  that	  of	  wild	  type	  transfected	  cells	  (see	  section	  4.3.1.3).	  	  Whilst	  
this	   result	  was	   not	   repeated	   in	   cells	   transiently	   transfected	  with	   p.D3986E	   and	  wild	  
type	  RYR1	   in	   the	   pTUNE	   expression	   vector,	   it	   hints	   at	   the	   possibility	   of	   this	   variant	  
contributing,	  at	  least	  in	  part	  to	  the	  overall	  MH	  phenotype.	  	  	  
It	  has	  long	  been	  established	  that	  RYR1	  variants	  that	  result	  in	  MH	  also	  confer	  a	  higher	  
baseline	   resting	   calcium	   level	   in	   cells	   expressing	   the	   mutation	   (Tong	   et	   al.,	   1999b,	  
Lopez	  et	  al.,	  2005,	  Yang	  et	  al.,	  2007).	   	  The	  work	  presented	  in	  chapter	  6	  suggests	  that	  
the	  p.D3986E	  variant	  may	   still	   result	   in	  a	  higher	   resting	   calcium	   level	   than	  wild	   type	  
transfected	   cells	   (see	   section	   6.3.6).	   	   Treatment	  with	  AICAR,	   a	   compound	  proven	   to	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lower	   baseline	   resting	   calcium	   levels	   in	   muscle	   fibres	   of	   MH	   mice,	   resulted	   in	   a	  
significant	   decrease	   in	   sensitivity	   to	   caffeine	   that	   was	   consistent	   with	   other	   MH	  
mutations	  but	  not	  wild	  type	  RYR1.	  	  The	  suggestion	  that	  the	  p.D3986E	  variant	  confers	  a	  
higher	  baseline	  resting	  calcium	  level	  may	  be	  consistent	  with	  work	  being	  performed	  by	  
Claudio	   Perez’s	   laboratory	   in	   which	   a	   300	   amino	   acid	   region	   of	   RYR1	   has	   been	  
identified	   to	  be	   important	   in	   the	  maintenance	  of	   resting	  calcium	   levels	   (unpublished	  
observations).	  	  Substitution	  of	  this	  region	  with	  the	  equivalent	  region	  of	  RYR3	  results	  in	  
an	   elevated	   resting	   calcium	   level	   in	   line	   with	   normal	   RYR3	   levels.	   	   Interestingly,	  
previous	  work	  from	  the	  same	  laboratory	  suggests	  that	  an	  increase	  in	  RYR3	  expression	  
results	   in	  both	  an	  elevated	   resting	  calcium	   level	  and	   increased	  sensitivity	   to	  caffeine	  
(Perez	  et	  al.,	  2005).	  	  Similar	  results	  were	  obtained	  from	  the	  experiments	  in	  chapter	  6	  
looking	   at	   the	   effect	   of	   an	   increase	   in	   mutant	   RYR1	   expression.	   	   An	   increase	   in	  
p.D3986E	   expression	   resulted	   in	   a	   significant	   increase	   in	   sensitivity	   to	   caffeine	   (see	  
section	   6.3.4).	   	   Whilst	   a	   clear	   answer	   cannot	   be	   given	   yet	   on	   what	   the	   p.D3986E	  
variant	  is	  doing	  to	  the	  normal	  resting	  calcium	  level	  of	  transfected	  cells,	  it	  is	  interesting	  
that	  this	  variant	  falls	  in	  a	  region	  so	  important	  to	  resting	  calcium	  levels.	  	  Looking	  at	  all	  
the	  data	  obtained	  on	  the	  p.D3986E	  variant	  in	  this	  thesis,	  it	  is	  apparent	  that	  the	  role	  of	  
this	  variant	  in	  MH	  is	  not	  as	  clear	  as	  first	  suspected.	  	  Initially	  it	  appeared	  as	  though	  this	  
variant	   was	   not	   the	   causative	   mutation	   in	   the	   families	   it	   has	   been	   identified	   in.	  	  
However,	   coupled	   with	   the	   data	   on	   increased	   expression	   levels	   and	   pre-­‐treatment	  
with	  AICAR,	  there	  are	  suggestions	  that	  this	  variant	  may	  still	  play	  a	  role.	  	  Future	  work	  on	  
this	   variant	   will	   focus	   on	   expressing	   it	   in	  myotubes	   to	   see	   if	   a	  more	   native	   cellular	  
environment	  and	  structure	  for	  RYR1	  enhance	  the	  seemingly	  mild	  phenotype	  observed	  
in	  HEK293	  cells.	  	  Furthermore,	  the	  families	  in	  which	  this	  variant	  has	  been	  identified	  are	  
ideal	  candidates	  for	  exome	  sequencing	  to	  attempt	  to	  identify	  potential	  modifying	  loci	  
that	  could	  result	  in	  the	  full	  MH	  phenotype.	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7.1.4	  p.D1056H,	  EHS	  and	  MH	  
In	  chapter	  6,	  functional	  analysis	  of	  the	  p.D1056H	  RYR1	  variant	  was	  presented.	  	  Taken	  
alone,	  the	  data	  obtained	  indicate	  a	  classic	  MH	  mutation.	  	  The	  sensitivity	  of	  transfected	  
cells	   to	   caffeine	   was	   statistically	   significantly	   reduced	   and	   the	   amount	   of	   calcium	  
released	   at	   lower	   doses	   of	   caffeine	  were	   significantly	   higher	  when	   compared	   to	   the	  
equivalent	   experiment	   performed	   on	   wild	   type	   transfected	   cells	   (see	   sections	   6.3.1	  
and	  6.3.3	  respectively).	  	  Additionally,	  this	  variant	  has	  been	  found	  to	  cosegregate	  with	  
MH	  susceptibility	  in	  the	  family	  it	  was	  identified	  in.	  	  However,	  on	  subsequent	  screening	  
of	   the	   entire	   UK	   MH	   population,	   this	   variant	   was	   also	   found	   in	   an	   individual	   who	  
suffered	  an	  EHS	  reaction	  whilst	  undergoing	  a	  military	  training	  exercise	  in	  a	  hot	  climate.	  	  
The	   individual	  was	  referred	  for	  MH	  testing	  as	  per	  the	  widely	  accepted	  procedure	  for	  
EHS	  patients	  but	  was	  diagnosed	  as	  MHN	  after	  undergoing	  the	  IVCT.	  	  	  
The	   reason	   for	   the	   discrepancy	   between	   the	   EHS	   and	   MH	   phenotype	   is	   unknown,	  
however,	  reports	  of	  genotype/phenotype	  discordance	  between	  MH	  diagnosis	  through	  
the	  IVCT	  and	  the	  presence	  of	  an	  RYR1	  variant	  proven	  to	  be	  causative	  of	  MH	  have	  been	  
known	   (Deufel	   et	   al.,	   1995,	   Fagerlund	   et	   al.,	   1997,	   Robinson	   et	   al.,	   2003b).	   	   The	  
reasons	  for	  discordance	  are	  unclear	  but	  are	  likely	  to	  involve	  the	  role	  of	  other	  genetic	  
factors	   that	  push	   the	  overall	  phenotype	  one	  way	  or	   the	  other.	   	  There	   is	  evidence	   to	  
suggest,	   at	   least	   in	  MH	   susceptibility	   and	  presumably	   therefore	   in	   EHS	   susceptibility	  
also,	  that	  multiple,	  interacting	  gene	  products	  are	  responsible	  for	  disease	  (Robinson	  et	  
al.,	  2003a,	  Robinson	  et	  al.,	  2000).	  	  Regardless	  of	  the	  exact	  reason,	  the	  work	  presented	  
in	   this	   thesis	  unequivocally	   links	   an	  RYR1	   variant	   found	   in	   association	  with	  both	  MH	  
and	  EHS.	   	  Furthermore,	  this	  variant	  has	  been	  proven	  to	  be	  the	  causative	  mutation	  of	  
MH	  through	  the	  functional	  studies	  performed	  in	  this	  project.	   	  Whilst	  the	  relative	  lack	  
of	  RYR1	  variants	  found	   in	  association	  with	  EHS	  may	  be	  due	  to	  the	   limited	  number	  of	  
studies	   aimed	   at	   identifying	   genetic	   variants	   responsible	   for	   the	   disease,	   the	   EHS	  
phenotype	   is,	   similarly	   to	   MH,	   likely	   to	   be	   a	   result	   of	   a	   number	   of	   genes	   and	  
environmental	   factors.	   	   The	  MHN/EHS	   patient	   described	   in	   this	   thesis	   would	   be	   an	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ideal	   candidate	   for	   exome	   sequencing	   to	   identify,	   not	   only	   potential	   contributing	  
genes	  to	  the	  EHS	  phenotype	  but	  also	  for	  modifying	  genes	  of	  the	  MH	  phenotype.	  
	  
7.2	  Future	  work	  
7.2.1	  Functional	  characterisation	  of	  further	  genetic	  variants	  
Since	   the	   introduction	   of	   the	   EMHG	   guidelines	   for	   the	   inclusion	   of	   variants	   in	  RYR1	  
onto	  the	  genetic	  diagnostic	  panel	   for	  MH	  over	  10	  years	  ago,	  only	  31	  mutations	  have	  
met	   the	   criteria.	   	   With	   244	   variants	   listed	   on	   the	   EMHG	   website	   as	   potentially	  
causative	   of	   MH,	   the	   focus	   of	   future	   work	   will	   be	   the	   further	   expansion	   of	   the	  
availability	   of	   genetic	   diagnosis.	   	   The	   work	   carried	   out	   in	   this	   project	   has	   provided	  
suitable	  subclones	  of	  RYR1	  and	  a	  mutagenesis	  protocol	  that	  can	  be	  used	  to	  generate	  
any	  RYR1	  variant	  associated	  with	  MH	  for	  functional	  studies.	  	  Currently,	  the	  majority	  of	  
individuals	  being	   referred	   for	  MH	  testing	  are	  still	   required	   to	  undergo	   the	   IVCT	   for	  a	  
conclusive	  diagnosis,	  however,	  with	  suitable	   resources	   in	  place	   for	   the	  generation	  of	  
cDNA	   constructs	   for	   the	   functional	   analysis	   of	  many	  RYR1	   variants,	   it	  will	   eventually	  
mean	  that	  genetic	  diagnosis	  is	  the	  primary	  method	  of	  diagnosis	  for	  MH.	  
	  
7.2.2	  Native	  vs.	  non-­‐native	  environment	  for	  functional	  studies	  
The	  only	  project	  goal	  that	  was	  unfulfilled	  in	  this	  thesis	   is	  the	  successful	  expression	  of	  
the	  RYR1	  variants	  generated	  in	  dyspedic	  myotubes.	  	  	  	  Several	  issues	  were	  encountered	  
during	   this	  project,	   the	   first	  of	  which	  was	   the	   lack	  of	   suitable	   restriction	   sites	   in	   the	  
original	  pcRYR1	  plasmid	   for	  efficient	  and	  simple	   transfer	   into	   the	  pHSVPrPUC	  vector.	  
Due	  to	  the	  fact	  that	  there	  was	  only	  one	  suitable	  restriction	  site,	  non-­‐directional	  cloning	  
of	  the	  full	  15kb	  coding	  sequence	  was	  required,	  making	  ligation	  efficiency	  in	  the	  correct	  
orientation	  remarkably	  low.	  	  Nevertheless,	  three	  constructs	  were	  successfully	  shuttled	  
into	   the	  pHSVPrPUC	  vector;	   however,	   sufficiently	   high	   viral	   titres	  were	  not	  obtained	  
for	   any	   of	   the	   constructs	   meaning	   thorough	   functional	   experiments	   could	   not	   be	  
performed.	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One	   of	   the	   main	   focuses	   of	   future	   work	   will	   be	   to	   successfully	   express	   the	   RYR1	  
variants	  generated	  in	  this	  project	  in	  dyspedic	  myotubes	  to	  thoroughly	  evaluate	  the	  use	  
of	   non-­‐native	   cell	   types	   for	   functional	   studies.	   	   As	   discussed	   above,	   of	   particular	  
interest	  are	  the	  results	  obtained	  from	  the	  p.D3986E	  variant.	   	  This	  variant	  produced	  a	  
response	   that	   was	   similar	   to	   wild	   type	   in	   the	   experiments	   in	   chapter	   4,	   however	  
increasing	  the	  expression	  of	  this	  variant	  produced	  a	  statistically	  significant	  increase	  in	  
caffeine	  sensitivity.	  	  Furthermore,	  experiments	  involving	  AICAR	  hinted	  at	  the	  possibility	  
that	   this	   variant	   still	   confers	   a	   high	   resting	   calcium	   level	   on	   transfected	   cells.	  	  
Functional	   analysis	   of	   this	   variant	   in	   myotubes	   will	   allow	   us	   to	   further	   probe	   the	  
consequences	   of	   this	   mutation	   in	   relation	   to	   MH.	   	   Additionally,	   expressing	   these	  
variants	  in	  myotubes	  will	  allow	  the	  measurement	  of	  intracellular	  resting	  calcium	  levels,	  
allowing	  us	   to	  confirm	  the	  hypothesis	   that	  expression	  of	   the	  p.D3986E	  variant	   is	   still	  
resulting	  in	  a	  larger	  baseline	  resting	  calcium	  level	  which	  may	  be	  contributing	  to	  the	  MH	  
phenotype.	  
	  
7.3	  Final	  conclusions	  
The	  work	  presented	  in	  this	  thesis	  is	  supportive	  of	  the	  p.D1056H,	  p.R2336H,	  p.R2355W,	  
p.E3104K,	  p.G3990V	  and	  p.V4849I	  RYR1	  variants	  to	  be	  added	  to	  the	  genetic	  diagnostic	  
panel	  for	  MH.	  	  The	  inclusion	  of	  these	  variants	  expands	  the	  availability	  of	  initial	  genetic	  
diagnosis	   for	   MH	   by	   19.35%,	   negating	   the	   need	   for	   the	   invasive	   muscle	   biopsy	  
associated	  with	  the	  IVCT.	  	  The	  six	  variants	  proven	  to	  be	  causative	  of	  MH	  in	  this	  thesis	  
have	  been	  identified	  in	  52	  families	  worldwide	  and	  represent	  a	  quarter	  of	  the	  families	  
that	  posses	  an	  as	  yet	  uncharacterised	  RYR1	  variant	  in	  the	  UK.	  	  Furthermore,	  the	  work	  
presented	  in	  this	  thesis	   lays	  the	  groundwork	  for	  the	  further	  expansion	  of	  the	  genetic	  
diagnostic	   panel	   through	   the	   production	   of	   suitable	   RYR1	   subclones	   covering	   the	  
entire	   coding	   sequence	   of	   the	   gene	   as	   well	   as	   the	   development	   of	   a	   robust	  
mutagenesis	   protocol	   that	   reliably	   produces	   the	   desired	   mutation.	   	   On	   top	   of	   the	  
primary	  goal	  of	  expanding	   the	  genetic	  diagnostic	  panel	   for	  MH,	  work	  was	  presented	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that	  further	  supports	  the	  genotypic	  link	  between	  EHS	  and	  MH.	  	  The	  functional	  analysis	  
of	  the	  p.D1056H	  variant	  highlighted	  the	  potential	  causal	  role	  of	  RYR1	  variants	   in	  EHS	  
whilst	  also	  suggesting	  that	  additional	  variants	  are	  required	  to	  either	  augment	  the	  MH	  
reaction	   or	   protect	   against	   the	   EHS	   phenotype.	   	   These	   findings	   can	   guide	   future	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